<SEC-DOCUMENT>0001640334-16-001933.txt : 20161109
<SEC-HEADER>0001640334-16-001933.hdr.sgml : 20161109
<ACCEPTANCE-DATETIME>20161109164951
ACCESSION NUMBER:		0001640334-16-001933
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		47
CONFORMED PERIOD OF REPORT:	20160930
FILED AS OF DATE:		20161109
DATE AS OF CHANGE:		20161109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nemus Bioscience, Inc.
		CENTRAL INDEX KEY:			0001516551
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				450692882
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-55136
		FILM NUMBER:		161984890

	BUSINESS ADDRESS:	
		STREET 1:		600 ANTON BLVD, SUITE 1100
		CITY:			COSTA MESA
		STATE:			CA
		ZIP:			92626
		BUSINESS PHONE:		(949) 396-0330

	MAIL ADDRESS:	
		STREET 1:		600 ANTON BLVD, SUITE 1100
		CITY:			COSTA MESA
		STATE:			CA
		ZIP:			92626

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LOAD GUARD LOGISTICS, INC.
		DATE OF NAME CHANGE:	20121107

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LOAD GUARD TRANSPORTATION, INC.
		DATE OF NAME CHANGE:	20110324
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>nmus_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<html><head><title>nmus_10q.htm</title><!--Document Created by EDGARMaster--></head><BODY spellcheck="true" style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN; MARGIN: 0px 7%" scroll="yes"><p style="MARGIN: 0px"><div style="FONT-SIZE: 1px; WIDTH: 100%; BORDER-BOTTOM: #000000 4px solid; MARGIN: 0px"></div><div style="FONT-SIZE: 1pt; WIDTH: 100%; BORDER-BOTTOM: #000000 1px solid; MARGIN-TOP: 2px"></div><p style="MARGIN: 0px"><p style="COLOR: black; MARGIN: 0px" align="center">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b><font size="3">UNITED STATES</font></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b><font size="3">SECURITIES AND EXCHANGE COMMISSION</font></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b><font size="3">Washington, D.C. 20549</font></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b><font size="5">FORM 10-Q</font></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">(Mark One)</p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><b><font style="FONT-FAMILY: Wingdings">x </font>QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px" align="center">For the quarterly period ended <strong>September 30, 2016</strong></p><p style="MARGIN: 0px" align="center">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>or</b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p><p style="MARGIN: 0px 0px 0px 27pt; TEXT-INDENT: -27pt" align="justify"><font style="FONT-FAMILY: Wingdings">o </font>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="center">For the transition period from _______ to ________</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="right">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center">Commission File Number: <u><strong>000-55136</strong></u></p><p style="MARGIN: 0px">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="left"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cols="1" cellpadding="0" width="55%" align="center" border="0" >    <tr><td style="BORDER-BOTTOM: black 1px solid"><p style="MARGIN: 0px" align="center"><font size="5"><strong>Nemus Bioscience, Inc.</strong></font></p></td></tr><tr><td><p style="MARGIN: 0px" align="center">(Exact name of registrant as specified in its charter)</p></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="85%" align="center" border="0" >    <tr height="15"><td style="BORDER-BOTTOM: black 1px solid" valign="top" width="45%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><strong>Nevada</strong></p></td><td width="10%"><p style="MARGIN: 0px" align="center"><strong></strong>&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="top" width="45%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><strong>45-0692882</strong></p></td></tr><tr height="15"><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center">(State or other jurisdiction of incorporation or organization)</p></td><td><p style="MARGIN: 0px" align="center">&nbsp;</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center">(I.R.S. Employer Identification No.)</p></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0" >    <tr height="15"><td valign="top" width="100%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b><u>600 Anton Blvd., Suite 1100, Costa Mesa, CA 92626</u></b></p></td></tr><tr height="15"><td valign="top" width="100%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center">(Address of principal executive offices) (Zip Code)</p></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0" >    <tr height="15"><td valign="top" width="100%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b><u>(949) 396-0330</u></b></p></td></tr><tr height="15"><td valign="top" width="100%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center">(Registrant's telephone number, including area code)</p></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b><u>650 Town Center Drive, Suite 1770, Costa Mesa, CA 92626</u></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center">(Former name or former address, if changed since last report)</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p><p style="COLOR: black; MARGIN: 0px">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&nbsp;<font style="FONT-FAMILY: Wingdings">x</font> Yes&nbsp;&nbsp;&nbsp;&nbsp; <font style="FONT-FAMILY: Wingdings">&#168;</font> No</p><p style="COLOR: black; MARGIN: 0px">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&nbsp;<font style="FONT-FAMILY: Wingdings">x</font> Yes&nbsp;&nbsp; <font style="FONT-FAMILY: Wingdings">&#168;</font> No</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="right">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">Indicate by check mark whether the registrant is a large accelerated file, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.</p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="85%" align="center" border="0" >    <tr height="15"><td valign="top" width="25%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">Large accelerated filer</p></td><td valign="top" width="5%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><font style="FONT-FAMILY: Wingdings">&#168;</font></p></td><td valign="top" width="40%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p></td><td valign="top" width="25%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">Accelerated filer</p></td><td valign="top" width="5%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><font style="FONT-FAMILY: Wingdings">&#168;</font></p></td></tr><tr height="15"><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">Non-accelerated filer</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><font style="FONT-FAMILY: Wingdings">&#168;</font></p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">(Do not check if a smaller reporting company)</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">Smaller reporting company</p></td><td valign="top"><p style="MARGIN: 0px"><font style="FONT-FAMILY: Wingdings"><font style="FONT-FAMILY: Wingdings">x</font></font></p></td></tr></table></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="right">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;<font style="FONT-FAMILY: Wingdings">&#168;</font> Yes&nbsp;&nbsp; <font style="FONT-FAMILY: Wingdings">x</font> No</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="right">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">As of November 8, 2016, there were&nbsp;20,798,163 shares of the issuer's common stock, par value $0.001 per share, issued and outstanding.</p><p style="COLOR: black; MARGIN: 0px">&nbsp;</p><p style="COLOR: black; MARGIN: 0px"><p style="MARGIN: 0px"><div style="FONT-SIZE: 1pt; WIDTH: 100%; BORDER-BOTTOM: #000000 1px solid; MARGIN: 0px"></div><div style="MARGIN-BOTTOM: -12px; FONT-SIZE: 1pt; WIDTH: 100%; BORDER-BOTTOM: #000000 4px solid; MARGIN-TOP: 2px"></div><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><table class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0" >    <tr><td class="hpbhr">&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr></tr><tr><td><div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr><tr><td>&nbsp;</td></tr></table></p><p style="MARGIN: 0px" align="center"><a name="toc">&nbsp;<b>TABLE OF CONTENTS</b></a></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0" >    <tr height="15"><td colspan="5"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b><a href="#PART I - FINANCIAL INFORMATION">PART I&nbsp;<b>&#8211;&nbsp;</b>FINANCIAL INFORMATION</a></b></p></td></tr><tr height="15"><td width="9%"></td><td width="80%"></td><td width="1%"></td><td width="9%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p></td><td width="1%"></td></tr><tr height="15" bgcolor="#cceeff"><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><a href="#Item 1. Financial Statements">Item 1.</a></p></td><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><a href="#Item 1. Financial Statements">Financial Statements:</a></p></td><td></td><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="right">4</p></td><td></td></tr><tr height="15" bgcolor="#ffffff"><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p></td><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><a href="#CONSOLIDATED BALANCE SHEETS">Consolidated Balance Sheets as of September 30, 2016 (Unaudited) and December 31, 2015</a></p></td><td></td><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="right">4</p></td><td></td></tr><tr height="15" bgcolor="#cceeff"><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p></td><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><a href="#CONSOLIDATED STATEMENTS OF OPERATIONS">Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2016 and 2015 (Unaudited)</a></p></td><td></td><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="right">5</p></td><td></td></tr><tr height="15" bgcolor="#ffffff"><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p></td><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><a href="#CONSOLIDATED STATEMENTS OF CASH FLOWS">Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2016 and 2015 (Unaudited)</a></p></td><td></td><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="right">6</p></td><td></td></tr><tr height="15" bgcolor="#cceeff"><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p></td><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><a href="#Notes">Notes to the Unaudited Consolidated Financial Statements</a></p></td><td></td><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="right">&nbsp;7</p></td><td></td></tr><tr height="15" bgcolor="#ffffff"><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><a href="#Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.">Item 2.</a></p></td><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><a href="#Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</a></p></td><td></td><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="right">22</p></td><td></td></tr><tr height="15" bgcolor="#cceeff"><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><a href="#Item 3. Quantitative and Qualitative Disclosures about Market Risk.">Item 3.</a></p></td><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><a href="#Item 3. Quantitative and Qualitative Disclosures about Market Risk.">Quantitative and Qualitative Disclosures about Market Risk</a></p></td><td></td><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="right">26</p></td><td></td></tr><tr height="15" bgcolor="#ffffff"><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><a href="#Item 4. Controls and Procedures.">Item 4.</a></p></td><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><a href="#Item 4. Controls and Procedures.">Controls and Procedures</a></p></td><td></td><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="right">26</p></td><td></td></tr><tr height="15" bgcolor="#ffffff"><td></td><td></td><td></td><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p></td><td></td></tr><tr height="15" bgcolor="#ffffff"><td colspan="5"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b><a href="#PART II - OTHER INFORMATION">PART II &#8211; OTHER INFORMATION</a></b></p></td></tr><tr height="15" bgcolor="#ffffff"><td></td><td></td><td></td><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p></td><td></td></tr><tr height="15" bgcolor="#cceeff"><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><a href="#Item 1. Legal Proceeding">Item 1.</a></p></td><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><a href="#Item 1. Legal Proceeding">Legal Proceedings</a></p></td><td></td><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="right">27</p></td><td></td></tr><tr height="15" bgcolor="#ffffff"><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><a href="#Item 1A. Risk Factors.">Item 1A.</a></p></td><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><a href="#Item 1A. Risk Factors.">Risk Factors</a></p></td><td></td><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="right">27</p></td><td></td></tr><tr height="15" bgcolor="#cceeff"><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><a href="#Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.">Item 2.</a></p></td><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><a href="#Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.">Unregistered Sales of Equity Securities and Use of Proceeds</a></p></td><td></td><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="right">27</p></td><td></td></tr><tr height="15" bgcolor="#ffffff"><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><a href="#Item 3. Defaults Upon Senior Securities.">Item 3.</a></p></td><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><a href="#Item 3. Defaults Upon Senior Securities.">Defaults Upon Senior Securities</a></p></td><td></td><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="right">27</p></td><td></td></tr><tr height="15" bgcolor="#cceeff"><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><a href="#Item 4. Mine Safety Disclosures.">Item 4.</a></p></td><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><a href="#Item 4. Mine Safety Disclosures.">Mine Safety Disclosures</a></p></td><td></td><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="right">27</p></td><td></td></tr><tr height="15" bgcolor="#ffffff"><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><a href="#Item 5. Other Information.">Item 5.</a></p></td><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><a href="#Item 5. Other Information.">Other Information</a></p></td><td></td><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="right">27</p></td><td></td></tr><tr height="15" bgcolor="#cceeff"><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><a href="#Item 6. Exhibits.">Item 6.</a></p></td><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><a href="#Item 6. Exhibits.">Exhibits</a></p></td><td></td><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="right">28</p></td><td></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><table id="pagebreak4babe619-6373-4740-81f3-28bd88df3ed4" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">    <tr><td class="hpbhr">&nbsp;</td></tr><tr><td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">2</td></tr><tr></tr><tr><td><div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr><tr><td>&nbsp;</td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>FORWARD-LOOKING STATEMENTS</b></p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p><p style="MARGIN: 0px">Statements in this Quarterly Report on Form 10-Q that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, you can identify forward-looking statements by terminology including "anticipates," "believes," "can," "continue," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "should," "will," "would" or the negative of these terms or other comparable terminology. Factors that could cause actual results to differ materially from those currently anticipated include those set forth in Part I, Item 1A. &ldquo;Risk Factors&rdquo; of our Annual Report on Form 10-K for the year ended December 31, 2015 and Part II, Item 1A. &ldquo;Risk Factors&rdquo; of this Quarterly Report on Form 10-Q, including, without limitation, risks relating to:</p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px" align="left"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0" >    <tr><td width="4%"></td><td valign="top" width="4%"><font style="FONT-FAMILY: Symbol">&#183;</font></td><td valign="top">the results of our research and development activities, including uncertainties relating to the discovery of potential product candidates and the preclinical and clinical testing of our product candidates;</td></tr><tr><td></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><tr><td></td><td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td><td valign="top">the early stage of our product candidates presently under development;</td></tr><tr><td></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><tr><td></td><td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td><td valign="top">our need for substantial additional funds in order to continue our operations, and the uncertainty of whether we will be able to obtain the funding we need;</td></tr><tr><td></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><tr><td></td><td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td><td valign="top">our ability to obtain and, if obtained, maintain regulatory approval of our current product candidates, and any of our other future product candidates, and any related restrictions, limitations, and/or warnings in the label of any approved product candidate;</td></tr><tr><td></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><tr><td></td><td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td><td valign="top">our ability to retain or hire key scientific or management personnel;</td></tr><tr><td></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><tr><td></td><td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td><td valign="top">our ability to protect our intellectual property rights that are valuable to our business, including patent and other intellectual property rights;</td></tr><tr><td></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><tr><td></td><td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td><td valign="top">our dependence on the University of Mississippi, third-party manufacturers, suppliers, research organizations, testing laboratories and other potential collaborators;</td></tr><tr><td></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><tr><td></td><td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td><td valign="top">our ability to develop successful sales and marketing capabilities in the future as needed;</td></tr><tr><td></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><tr><td></td><td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td><td valign="top">the size and growth of the potential markets for any of our approved product candidates, and the rate and degree of market acceptance of any of our approved product candidates;</td></tr><tr><td></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><tr><td></td><td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td><td valign="top">competition in our industry; and</td></tr><tr><td></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><tr><td></td><td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td><td valign="top">regulatory developments in the United States and foreign countries.</td></tr></tr></tr></tr></tr></tr></tr></tr></tr></tr></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">We operate in a rapidly-changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. The forward-looking statements included in this report speak only as of the date hereof, and except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to actual results or to changes in our expectations.</p><p style="COLOR: black; MARGIN: 0px">&nbsp;</p><p style="COLOR: black; MARGIN: 0px"><table id="pagebreak08784a23-527f-4998-99ef-7ffb3dbd2f5e" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">    <tr><td class="hpbhr">&nbsp;</td></tr><tr><td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">3</td></tr><tr></tr><tr><td><div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr><tr><td><a href="#toc">Table of Contents</a></td></tr></table></p><p style="MARGIN: 0px">&nbsp;&nbsp;</p><p style="MARGIN: 0px" align="center"><b><a name="PART I - FINANCIAL INFORMATION">PART I - FINANCIAL INFORMATION</a></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><b><u><a name="Item 1. Financial Statements">Item 1. Financial Statements</a></u></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>NEMUS BIOSCIENCE, INC. AND SUBSIDIARY</b></p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b><a name="CONSOLIDATED BALANCE SHEETS">CONSOLIDATED BALANCE SHEETS</a></b></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><table style="WIDTH: 100%; TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0" >    <tr><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td id="hdcell" valign="bottom" colspan="2" align="center"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>(unaudited)</b></p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td id="hdcell" valign="bottom" colspan="2" align="center"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td id="hdcell" valign="bottom" colspan="2" align="center"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>September 30,</b></p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td id="hdcell" valign="bottom" colspan="2" align="center"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>December 31,</b></p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" colspan="2" align="center"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>2016</b></p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" colspan="2" align="center"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>2015</b></p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr height="15"><td colspan="9"><p style="MARGIN: 0px" align="center"><strong>ASSETS</strong></p></td></tr><tr><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><b>Current assets</b></p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" colspan="2" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" colspan="2" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN: 0px 0px 0px 15px">Cash and cash equivalents </p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%">$</td><td id="ffcell" valign="bottom" width="9%" align="right">319,930</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%">$</td><td id="ffcell" valign="bottom" width="9%" align="right">3,221,209</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN: 0px 0px 0px 15px">Restricted cash </p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">37,500</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">37,500</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN: 0px 0px 0px 15px">Prepaid expenses </p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">249,193</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">158,946</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN: 0px 0px 0px 15px">Other current assets </p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">28,626</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">36,126</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN: 0px 0px 0px 30px">Total current assets </p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">635,249</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">3,453,781</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><b>Property and equipment, net </b></p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">12,994</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">13,383</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><b>Other assets </b></p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN: 0px 0px 0px 15px">Deposits and other assets </p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">43,884</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">43,884</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN: 0px 0px 0px 30px">Total other assets </p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">43,884</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">43,884</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN: 0px 0px 0px 30px">Total assets </p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 3px double" valign="bottom" width="1%">$</td><td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign="bottom" width="9%" align="right">692,127</td><td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 3px double" valign="bottom" width="1%">$</td><td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign="bottom" width="9%" align="right">3,511,048</td><td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top" colspan="9"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><strong>LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED<br></strong><b>STOCK AND STOCKHOLDERS' DEFICIT </b></p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><b>Current liabilities </b></p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN: 0px 0px 0px 15px">Accounts payable </p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%">$</td><td id="ffcell" valign="bottom" width="9%" align="right">387,373</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%">$</td><td id="ffcell" valign="bottom" width="9%" align="right">125,357</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN: 0px 0px 0px 15px">Accrued payroll and related expenses </p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">71,802</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">46,268</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN: 0px 0px 0px 15px">Accrued license and patent reimbursement fees </p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">80,000</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">97,500</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN: 0px 0px 0px 15px">Accrued expenses </p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">135,381</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">228,645</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN: 0px 0px 0px 15px">Provision for conversion of Series B preferred stock </p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">166,718</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">84,090</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN: 0px 0px 0px 30px">Total current liabilities </p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">841,274</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">581,860</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><b>Noncurrent liabilities </b></p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN: 0px 0px 0px 15px">Deferred rent </p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">-</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">3,233</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN: 0px 0px 0px 15px">Series B warrants </p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">869,990</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">2,454,959</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN: 0px 0px 0px 30px">Total noncurrent liabilities </p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">869,990</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">2,458,192</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN: 0px 0px 0px 30px">Total liabilities </p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">1,711,264</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">3,040,052</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><b>Commitments and contingencies </b></p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN: 0px 0px 0px 15px">(Note 3) </p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr height="15" bgcolor="#ffffff"><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN: 0px 0px 0px 15px" align="left">Redeemable Convertible Series B Preferred Stock, $0.001 par value, 20 million shares authorized; 4,492 issued and outstanding as of September 30, 2016 and 4,500 issued and outstanding as of December 31, 2015, net of $493,770 of issuance costs; $4.5 million liquidation preference as of September 30, 2016 </p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">1,359,899</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">1,363,200</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><b>Stockholders&rsquo; deficit </b></p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN: 0px 0px 0px 15px" align="left">Common stock, $0.001 par value; 236 million shares authorized; 19,913,163 issued and outstanding as of September 30, 2016 and 19,903,163 issued and outstanding as of December 31, 2015 </p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">19,913</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">19,903</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN: 0px 0px 0px 15px">Additional paid-in-capital </p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">6,635,345</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">6,086,987</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN: 0px 0px 0px 15px">Warrants </p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">781,811</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">759,386</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN: 0px 0px 0px 15px">Accumulated deficit </p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">(9,816,105</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">)</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">(7,758,480</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">)</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN: 0px 0px 0px 30px">Total stockholders&rsquo; deficit </p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">(2,379,036</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">)</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">(892,204</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">)</p></td></tr><tr height="15" bgcolor="#cceeff"><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN: 0px 0px 0px 30px">Total liabilities and stockholders&rsquo; deficit </p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 3px double" valign="bottom" width="1%">$</td><td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign="bottom" width="9%" align="right">692,127</td><td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 3px double" valign="bottom" width="1%">$</td><td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign="bottom" width="9%" align="right">3,511,048</td><td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr></table></p><p style="MARGIN: 0px" align="center"><br>See accompanying notes to the unaudited consolidated financial statements.</p><p style="MARGIN: 0px" align="center">&nbsp;</p><p style="MARGIN: 0px" align="center"><table id="pagebreak1d4639cf-a4ef-46dd-b826-2958bd20e6c8" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">    <tr><td class="hpbhr">&nbsp;</td></tr><tr><td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">4</td></tr><tr></tr><tr><td><div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr><tr><td><a href="#toc">Table of Contents</a></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>NEMUS BIOSCIENCE, INC. AND SUBSIDIARY</b></p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b><a name="CONSOLIDATED STATEMENTS OF OPERATIONS">CONSOLIDATED STATEMENTS OF OPERATIONS</a></b></p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>(unaudited)</b></p><p style="MARGIN: 0px" align="center">&nbsp;</p><p style="MARGIN: 0px"><table style="WIDTH: 100%; TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0" >    <tr><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td id="hdcell" valign="bottom" colspan="2" align="center"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>Three Months</b></p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td id="hdcell" valign="bottom" colspan="2" align="center"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>Three Months</b></p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td id="hdcell" valign="bottom" colspan="2" align="center"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>Nine Months</b></p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td id="hdcell" valign="bottom" colspan="2" align="center"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>Nine Months</b></p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td id="hdcell" valign="bottom" colspan="2" align="center"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>Ended</b></p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td id="hdcell" valign="bottom" colspan="2" align="center"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>Ended</b></p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td id="hdcell" valign="bottom" colspan="2" align="center"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>Ended</b></p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td id="hdcell" valign="bottom" colspan="2" align="center"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>Ended</b></p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td id="hdcell" valign="bottom" colspan="2" align="center"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>September 30,</b></p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td id="hdcell" valign="bottom" colspan="2" align="center"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>September 30,</b></p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td id="hdcell" valign="bottom" colspan="2" align="center"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>September 30,</b></p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td id="hdcell" valign="bottom" colspan="2" align="center"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>September 30,</b></p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>2016</b></p></td><td style="PADDING-BOTTOM: 1px" valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>2015</b></p></td><td style="PADDING-BOTTOM: 1px" valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>2016</b></p></td><td style="PADDING-BOTTOM: 1px" valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>2015</b></p></td><td style="PADDING-BOTTOM: 1px" valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr><td><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" colspan="2" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" colspan="2" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" colspan="2" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" colspan="2" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><b>Operating expenses</b></p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" colspan="2" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" colspan="2" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" colspan="2" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" colspan="2" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN: 0px 0px 0px 15px">Research and development</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%">$</td><td id="ffcell" valign="bottom" width="9%" align="right">80,525</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%">$</td><td id="ffcell" valign="bottom" width="9%" align="right">152,288</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%">$</td><td id="ffcell" valign="bottom" width="9%" align="right">675,840</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%">$</td><td id="ffcell" valign="bottom" width="9%" align="right">232,862</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN: 0px 0px 0px 15px">General and administrative</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">775,623</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">744,004</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">2,882,682</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">2,929,799</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN: 0px 0px 0px 30px">Total operating expenses</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">856,148</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">896,292</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">3,558,522</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">3,162,661</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><b>Operating loss</b></p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">(856,148</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">(896,292</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">(3,558,522</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">(3,162,661</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td></tr><tr bgcolor="#cceeff"><td><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><b>Other expense (income)</b></p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN: 0px 0px 0px 15px">Change in fair value of warrant liability</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">27,665</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">-</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">(1,584,969</td><td valign="bottom" width="1%">)</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">-</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN: 0px 0px 0px 15px">Change in fair value of conversion rights of Series A preferred stock</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">-</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">286,000</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">-</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">986,000</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN: 0px 0px 0px 15px">Change in fair value of conversion rights of Series B preferred stock</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">61,058</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">-</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">82,872</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">-</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><b>Net loss before income taxes</b></p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">(944,871</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">(1,182,292</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">(2,056,425</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">(4,148,661</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td></tr><tr bgcolor="#ffffff"><td><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN: 0px 0px 0px 15px">Provision for income taxes</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">400</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">500</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">1,200</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">1,316</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><b>Net loss</b></p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td><td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">(945,271</td><td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td><td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">(1,182,792</td><td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td><td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">(2,057,625</td><td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td><td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">(4,149,977</td><td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td></tr><tr bgcolor="#ffffff"><td><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><b>Basic and diluted loss </b><strong>per common share</strong></p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td><td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">(0.05</td><td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td><td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">(0.07</td><td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td><td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">(0.10</td><td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td><td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">(0.25</td><td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td></tr><tr bgcolor="#ffffff"><td><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><b>Shares used in computing basic </b><strong>and diluted loss per share</strong></p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">19,913,163</td><td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">17,062,366</td><td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">19,910,426</td><td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">16,519,854</td><td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px" align="center">See accompanying notes to the unaudited consolidated financial statements.</p><p style="MARGIN: 0px" align="center">&nbsp;</p><p style="MARGIN: 0px" align="left"><table id="pagebreakf31e2a5a-d541-4542-af0f-a4eb70a25b0b" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">    <tr><td class="hpbhr">&nbsp;</td></tr><tr><td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">5</td></tr><tr></tr><tr><td><div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr><tr><td><a href="#toc">Table of Contents</a></td></tr></table></p><p style="MARGIN: 0px" align="center">&nbsp;</p><p style="MARGIN: 0px"><b><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>NEMUS BIOSCIENCE, INC. AND SUBSIDIARY</b></p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b><a name="CONSOLIDATED STATEMENTS OF CASH FLOWS">CONSOLIDATED STATEMENTS OF CASH FLOWS</a></b></p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>(unaudited)</b></p><p style="MARGIN: 0px">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><table style="WIDTH: 100%; TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0" >    <tr><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td id="hdcell" valign="bottom" colspan="2" align="center"><strong>Nine Months</strong></td><td valign="bottom"><p style="MARGIN: 0px"><strong></strong>&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px"><strong></strong>&nbsp;</p></td><td id="hdcell" valign="bottom" colspan="2" align="center"><strong>Nine Months</strong></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td id="hdcell" valign="bottom" colspan="2" align="center"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>Ended</b></p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td id="hdcell" valign="bottom" colspan="2" align="center"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>Ended</b></p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td id="hdcell" valign="bottom" colspan="2" align="center"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>September 30,</b></p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td id="hdcell" valign="bottom" colspan="2" align="center"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>September 30,</b></p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>2016</b></p></td><td style="PADDING-BOTTOM: 1px" valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>2015</b></p></td><td style="PADDING-BOTTOM: 1px" valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr><td><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" colspan="2" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" colspan="2" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><b>Cash flows from operating activities:</b></p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" colspan="2" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" colspan="2" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN: 0px 0px 0px 15px">Net loss </p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%">$</td><td id="ffcell" valign="bottom" width="9%" align="right">(2,057,625</td><td valign="bottom" width="1%">)</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%">$</td><td id="ffcell" valign="bottom" width="9%" align="right">(4,149,977</td><td valign="bottom" width="1%">)</td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN: 0px 0px 0px 15px">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN: 0px 0px 0px 30px">Depreciation</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">11,505</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">7,290</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN: 0px 0px 0px 30px">Stock-based compensation expense</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">544,823</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">263,985</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN: 0px 0px 0px 30px">Amortization of warrants and stock issued for services (1) (2)</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">51,539</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">529,016</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN: 0px 0px 0px 30px">Change in fair value of conversion rights of Series A preferred stock</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">-</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">986,000</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN: 0px 0px 0px 30px">Change in fair value of conversion rights of Series B preferred stock</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">82,872</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">-</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN: 0px 0px 0px 30px">Change in fair value of warrant liabilities</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">(1,584,969</td><td valign="bottom" width="1%">)</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">-</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN: 0px 0px 0px 30px">Changes in assets and liabilities:</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN: 0px 0px 0px 45px">Restricted cash</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">-</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">(37,500</td><td valign="bottom" width="1%">)</td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN: 0px 0px 0px 45px">Prepaid expenses (1)</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">(119,361</td><td valign="bottom" width="1%">)</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">25,800</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN: 0px 0px 0px 45px">Other current assets</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">7,500</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">5,470</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN: 0px 0px 0px 45px">Accounts payable (2)</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">262,016</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">(267,264</td><td valign="bottom" width="1%">)</td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN: 0px 0px 0px 45px">Accrued payroll and related expenses</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">25,534</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">99,157</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN: 0px 0px 0px 45px">Accrued license and patent reimbursement fees</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">(17,500</td><td valign="bottom" width="1%">)</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">(29,212</td><td valign="bottom" width="1%">)</td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN: 0px 0px 0px 45px">Stock subscription liability</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">-</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">(100,000</td><td valign="bottom" width="1%">)</td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN: 0px 0px 0px 45px">Accrued expenses and other liabilities</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">(96,497</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">52,899</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN: 0px 0px 0px 60px">Net cash used in operating activities</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">(2,890,163</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">(2,614,336</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><b>Cash flows from investing activities:</b></p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN: 0px 0px 0px 15px">Purchases of property and equipment</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">(11,116</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">(1,982</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN: 0px 0px 0px 60px">Net cash used in investing activities</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">(11,116</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">(1,982</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><b>Cash flows from financing activities:</b></p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN: 0px 0px 0px 15px">Proceeds from common stock issuance, net of $3,920 issuance costs</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">-</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">721,069</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN: 0px 0px 0px 15px">Proceeds from Series A preferred stock issuance, net of $7,700 issuance costs</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">-</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">1,442,302</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN: 0px 0px 0px 15px">Proceeds from Series B preferred stock issuance, net of $411,661 issuance costs</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">-</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">4,588,339</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN: 0px 0px 0px 60px">Net cash provided by financing activities</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">-</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">6,751,710</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><b>Net increase (decrease) in cash and cash equivalents</b></p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">(2,901,279</td><td valign="bottom" width="1%">)</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">4,135,392</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><b>Cash and cash equivalents</b>,<b> beginning of period</b></p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">3,221,209</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">207,330</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><b>Cash and cash equivalents, end of period</b></p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 3px double" valign="bottom" width="1%">$</td><td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign="bottom" width="9%" align="right">319,930</td><td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 3px double" valign="bottom" width="1%">$</td><td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign="bottom" width="9%" align="right">4,342,722</td><td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><i>Supplemental disclosures of cash-flow information:</i></p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">Cash paid during the period for:</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN: 0px 0px 0px 15px">Interest</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 3px double" valign="bottom" width="1%">$</td><td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign="bottom" width="9%" align="right">-</td><td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 3px double" valign="bottom" width="1%">$</td><td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign="bottom" width="9%" align="right">-</td><td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN: 0px 0px 0px 15px">Income taxes</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 3px double" valign="bottom" width="1%">$</td><td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign="bottom" width="9%" align="right">-</td><td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 3px double" valign="bottom" width="1%">$</td><td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign="bottom" width="9%" align="right">116</td><td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p></b><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><em>Supplemental disclosures of non-cash financing and investing activities: </em></p><b><p style="MARGIN: 0px">&nbsp;</p></b><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0" >    <tr style="MARGIN: 0px"><td valign="top" width="4%">(1)</td><td valign="top"><p style="MARGIN: 0px">During the nine months ended September 30, 2015, the Company issued warrants of our common stock for consulting services. The warrants were valued at $417,875 and were recorded as a Prepaid expense and are being amortized over the service period.</p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px">During the nine months ended September 30, 2015, the Company also issued shares of common stock for consulting services valued at $168,000. Such amounts were recorded as a Prepaid expense and are being amortized over the service period.</p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px">During the nine months ended September 30, 2016, warrants issued to service providers for consulting services were valued at $22,425 and recorded as a Prepaid expense and are being amortized over the service period.</p></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0" >    <tr><td valign="top" width="4%">(2)</td><td valign="top">During the nine months ended September 30, 2015, the Company issued warrants of our common stock to a service provider in exchange for extinguishment of $10,000 of trade accounts payable owed to this vendor.</td></tr></table></p><p style="MARGIN: 0px" align="center">&nbsp;</p><p style="MARGIN: 0px" align="center">See accompanying notes to the unaudited consolidated financial statements.</p><b><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;</p></b><p style="COLOR: black; MARGIN: 0px" align="justify"><b><table id="pagebreakb087f423-83d0-40b5-949b-6dbe2f4d6cdb" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">    <tr><td class="hpbhr">&nbsp;</td></tr><tr><td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">6</td></tr><tr></tr><tr><td><div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr><tr><td><a href="#toc">Table of Contents</a></td></tr></table><p style="MARGIN: 0px"><p style="MARGIN: 0px">&nbsp;</p></b><p style="COLOR: black; MARGIN: 0px" align="justify"><b><a name="Notes">1.&nbsp;Nature of Operations, Business Activities and Summary of Significant Accounting Policies</a></b></p><p style="COLOR: black; MARGIN: 0px" align="justify"><strong></strong>&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b style="MARGIN: 0px"><i>Nature of Operations and Basis of Presentation</i></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><strong><em></em></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Nemus Bioscience, Inc. is a biopharmaceutical company that plans to develop and commercialize therapeutics from cannabinoids through a partnership with the University of Mississippi. The University of Mississippi ("UM") is federally permitted and licensed to cultivate cannabis for research and commercial purposes. Unless otherwise specified, references in these Notes to the Unaudited Consolidated Financial Statements to the "Company," "we" or "our" refer to Nemus Bioscience, Inc., a Nevada corporation formerly known as Load Guard Logistics, Inc. ("LGL"), together with its wholly-owned subsidiary, Nemus, a California corporation ("Nemus"). Nemus became the wholly owned subsidiary of Nemus Bioscience, Inc. through the Merger (as defined below).</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Nemus Bioscience, Inc. (formerly LGL) was incorporated in Nevada on March 16, 2011. Nemus was incorporated in California on July 17, 2012. Our headquarters are located in Costa Mesa, California.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">As of September 30, 2016, the Company has devoted substantially all of its efforts to securing product licenses, raising capital, and building infrastructure, and has not realized revenue from its planned principal operations.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 0.5in" align="justify">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b style="MARGIN: 0px"><i>Business Activities</i></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><strong><em></em></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">On October 31, 2014, pursuant to an Agreement and Plan of Merger, dated October 17, 2014 (the "Merger Agreement"), LGL, Nemus Acquisition Corp. ("Acquisition Sub"), Nemus Bioscience, Inc. ("Name Change Merger Sub"), and Nemus Acquisition Sub merged with and into Nemus and Nemus survived as a wholly-owned subsidiary of LGL (the "Merger"). Immediately after the Merger, LGL changed its name to "Nemus Bioscience, Inc." by merging with Name Change Merger Sub. At the closing of the Merger and pursuant to the Merger Agreement, Nemus issued an aggregate of 3,120,000 shares of its common stock to the former stockholders of LGL in exchange for all of the outstanding shares of LGL's capital stock, which when combined with the 12,880,000 shares of Nemus common stock outstanding, amounted to 16,000,000 total shares outstanding upon completion of the merger.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The Merger is being accounted for as a reverse-merger and recapitalization. Nemus is the acquirer for financial reporting purposes and LGL is the acquired company. Consequently, the assets and liabilities and the operations that will be reflected in the historical consolidated financial statements prior to the Merger will be those of Nemus and will be recorded at the historical cost basis of Nemus, and the consolidated financial statements after completion of the Merger will include the assets and liabilities of LGL and Nemus, the historical operations of Nemus and the operations of the Nemus from and after the closing date of the Merger.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 0.5in" align="justify">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b style="MARGIN: 0px"><i>Use of Estimates</i></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><strong><em></em></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles ("U.S. GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of our financial statements include estimates as to the appropriate carrying value of certain assets and liabilities which are not readily apparent from other sources.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 0.5in" align="justify">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b style="MARGIN: 0px"><i>Liquidity and Going Concern</i></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><strong><em></em></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The Company has incurred operating losses and negative cash flows from operations since our inception. As of September 30, 2016, we had cash and cash equivalents of $319,930. In October 2016, we raised an additional $500,000 (see note 8) to be utilized to fund operations. The Company anticipates that it will continue to incur net losses into the foreseeable future as it continues to advance and develop a number of potential drug candidates into preclinical development activities and expands its corporate infrastructure which includes the costs associated with being a public company. Without additional funding, management believes that the Company will not have sufficient funds to meet its obligations within one year after the date the consolidated financial statements are issued. These conditions give rise to substantial doubt as to the Company's ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><table id="pagebreak99f739fd-7723-4db4-8193-9ca5d84d6db2" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">    <tr><td class="hpbhr">&nbsp;</td></tr><tr><td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">7</td></tr><tr></tr><tr><td><div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr><tr><td><a href="#toc">Table of Contents</a></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The Company plans to continue to fund its operations and capital funding needs through public or private equity or debt financings, strategic collaborations, licensing arrangements, asset sales, government grants or other arrangements. However, the Company cannot be sure that such additional funds will be available on reasonable terms, or at all. If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result. If the Company is unable to secure adequate additional funding, the Company may be forced to make a reduction in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 0.5in" align="justify">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b style="MARGIN: 0px"><i>Cash and Cash Equivalents</i></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><strong><em></em></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The carrying value of those investments approximates their fair market value due to their short maturity and liquidity. Cash and cash equivalents include cash on hand and amounts on deposit with financial institutions, which amounts may at times exceed federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 0.5in" align="justify">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b style="MARGIN: 0px"><i>Restricted Cash</i></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><strong><em></em></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">A deposit of $37,500 as of September 30, 2016 and December 31, 2015 was restricted from withdrawal and held by a bank in the form of a certificate of deposit. This certificate serves as collateral for payment of the Company's credit cards.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b style="MARGIN: 0px"><i>Fair Value Measurements</i></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><strong><em></em></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last is considered unobservable, is used to measure fair value:&nbsp;</p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0" >    <tr height="15"><td valign="top" width="4%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p></td><td valign="top" width="6%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">Level 1:</p></td><td valign="top" width="90%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities.</p></td></tr><tr height="15"><td valign="top"></td><td valign="top"></td><td valign="top"></td></tr><tr height="15"><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">Level 2:</p></td><td valign="top"><p style="MARGIN: 0px">Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</p></td></tr><tr height="15"><td valign="top"></td><td valign="top"></td><td valign="top"></td></tr><tr height="15"><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">Level 3:</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</p></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The carrying values of our financial instruments, including, cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses approximate their fair value due to the short maturities of these financial instruments. The Series B warrant liability and the conversion liability for the Series B preferred stock were valued utilizing Level 3 inputs primarily from a third party independent appraisal conducted as of September 30, 2016.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 0.5in" align="justify">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b style="MARGIN: 0px"><i><table id="pagebreakc4f7bc44-0e4f-4cf7-8de7-bb894fe5df78" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">    <tr><td class="hpbhr">&nbsp;</td></tr><tr><td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">8</td></tr><tr></tr><tr><td><div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr><tr><td><a href="#toc">Table of Contents</a></td></tr></table><p style="MARGIN: 0px"></i></b><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b style="MARGIN: 0px"><i></i></b>&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b style="MARGIN: 0px"><i>Property and Equipment, Net</i></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><strong><em></em></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">As of September 30, 2016, property and equipment, net, was $12,994, consisting primarily of computers and equipment. The Company had $13,383 of property and equipment, net, as of December 31, 2015. Expenditures for additions, renewals and improvements will be capitalized at cost. Depreciation will generally be computed on a straight-line method based on the estimated useful life of the related assets currently ranging from two to three years. Maintenance and repairs that do not extend the life of assets are charged to expense when incurred. When properties are disposed of, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is reported in the period the transaction takes place.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount exceeds its estimated future undiscounted cash flows, an impairment charge is recognized by the amount by which the carrying amount exceeds the fair value of the asset.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, will be charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where there is an identified alternative future use. No cost associated with the use of licensed technologies has been capitalized to date.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 0.5in" align="justify">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b style="MARGIN: 0px"><i>Income Taxes</i></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><strong><em></em></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The Company accounts for our deferred income tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities, and net operating loss carry forwards (the "NOLs") and other tax credit carry forwards. These items are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period that includes the enactment date. Any interest or penalties would be recorded in the Company's statement of operations in the period incurred.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The Company records a valuation allowance to reduce the deferred income tax assets to the amount that is more likely than not to be realized. In making such determinations, management considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. As a result, there are no income tax benefits reflected in the statement of operations to offset pre-tax losses.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The Company recognizes a tax benefit from uncertain tax positions when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 0.5in" align="justify">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b style="MARGIN: 0px"><i>Revenue Recognition</i></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><strong><em></em></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The Company has not begun planned principal operations and has not generated any revenue since inception.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 0.5in" align="justify">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b style="MARGIN: 0px"><i>Research and Development Expenses</i></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><strong><em></em></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Research and development ("R&amp;D") costs are expensed when incurred. These costs may consist of external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants; license fees; employee-related expenses, which include salaries, benefits and stock-based compensation for the personnel involved in our preclinical and clinical drug development activities; and facilities expense, depreciation and other allocated expenses; and equipment and laboratory supplies.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 0.5in" align="justify">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b style="MARGIN: 0px"><i><table id="pagebreak948b2b3d-d501-421f-aca6-af7dc7dbb43d" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">    <tr><td class="hpbhr">&nbsp;</td></tr><tr><td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">9</td></tr><tr></tr><tr><td><div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr><tr><td><a href="#toc">Table of Contents</a></td></tr></table></i></b><p style="MARGIN: 0px"><b style="MARGIN: 0px"><i></i></b>&nbsp;</p><p style="MARGIN: 0px"><b style="MARGIN: 0px"><i>Stock-Based Compensation Expenses</i></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><strong><em></em></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Stock-based compensation cost is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period. We use the Black-Scholes option pricing model for estimating the grant date fair value of stock options and warrants using the following assumptions:</p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0" >    <tr height="15"><td width="4%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p></td><td valign="top" width="4%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">Exercise price - We determined the exercise price based on valuations using the best information available to management at the time of the valuations.</p></td></tr><tr height="15"><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr height="15"><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">Volatility&nbsp;- We estimate the stock price volatility based on industry peers who are also in the early development stage given the limited market data available in the public arena.</p></td></tr><tr height="15"><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr height="15"><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">Expected term - The expected term is based on a simplified method which defines the life as the average of the contractual term of the options and warrants and the weighted-average vesting period for all open awards.</p></td></tr><tr height="15"><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr height="15"><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">Risk-free rate - The risk-free interest rate for the expected term of the option or warrant is based on the average market rate on U.S. treasury securities in effect during the period in which the awards were granted.</p></td></tr><tr height="15"><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr height="15"><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">Dividends - The dividend yield assumption is based on our history and expectation of paying no dividends.</p></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b style="MARGIN: 0px"><i>Stock-Based Compensation for Non-Employees</i></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><strong><em></em></strong>&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px; TEXT-INDENT: 33.75pt" align="justify">The Company accounts for warrants and options issued to non-employees under Financial Accounting Standards Board (&ldquo;FASB&rdquo;) Accounting Standards Codification (&ldquo;ASC&rdquo;) No. 505-50, <i>Equity - Equity Based Payments to Non-Employees,</i> using the Black-Scholes option-pricing model. The value of such non-employee awards is periodically re-measured over the vesting terms and at each quarter end.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 0.5in" align="justify">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b style="MARGIN: 0px"><i>Segment Information</i></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><strong><em></em></strong>&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px; TEXT-INDENT: 33.75pt" align="justify">FASB ASC No. 280, <i>Segment Reporting</i>, establishes standards for reporting information about reportable segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group ("CODM"), in deciding how to allocate resources and in assessing performance. The CODM evaluates revenues and gross profits based on product lines and routes to market. Based on the early development stage of our operation, we operate in a single reportable segment.</p><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b style="MARGIN: 0px"><i>Comprehensive Income (Loss)</i></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><strong><em></em></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company is required to record all components of comprehensive income (loss) in the consolidated financial statements in the period in which they are recognized. Net income (loss) and other comprehensive income (loss), net of their related tax effect, arrived at a comprehensive income (loss). For the three and nine months ended September 30, 2016, the comprehensive income (loss) was equal to the net income (loss).</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 0.5in" align="justify">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b style="MARGIN: 0px"><i>Earnings per share</i></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><strong><em></em></strong>&nbsp;</p><p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">The Company applies FASB ASC No. 260, <i>Earnings per Share</i>. Basic earnings (loss) per share is computed by dividing earnings (loss) available to common stockholders by the weighted-average number of shares of common stock outstanding. Diluted earnings or loss per share would include the dilutive effect of&nbsp;outstanding warrants and awards granted to employees under stock-based compensation plans.&nbsp; Potential shares of the Company's common stock are excluded from the calculation of diluted loss per common share because their effect would be anti-dilutive for the periods presented.&nbsp; For the three and nine month period ending September 30, 2016, 10,879,500 warrants and 1,142,500 stock options outstanding at the end of the period are excluded from the calculation of diluted loss per common share.&nbsp; For the three and nine month&nbsp; period ended September 30, 2015, 10,759,500 warrants and 1,151,000 stock options outstanding at the end of the period are excluded from the calculation of diluted loss per common share.</p><p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px"><table id="pagebreak429e994f-ad67-4e71-899d-3894dd8e4f5f" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">    <tr><td class="hpbhr">&nbsp;</td></tr><tr><td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">10</td></tr><tr></tr><tr><td><div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr><tr><td><a href="#toc">Table of Contents</a></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b style="MARGIN: 0px"><i>Recent accounting pronouncements</i></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><strong><em></em></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">In February 2016, the FASB issued ASU No. 2016-02 <i>Leases</i> (Topic 842) intended to improve financial reporting around leasing transactions. The ASU affects all companies and other organizations that lease assets such as real estate, airplanes, and manufacturing equipment. The ASU will require organizations that lease assets - referred to as "lessees"- to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. For public companies, the standard is effective for fiscal years beginning after December 15, 2018 and interim periods therein. Earlier adoption is permitted for any annual or interim period for which consolidated financial statements have not yet been issued. The Company is currently evaluating the potential impact that the adoption of ASU No. 2016-02 may have on its consolidated financial statements.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 0.5in" align="justify">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b>2. University of Mississippi Agreements</b></p><strong></strong><p style="COLOR: black; MARGIN: 0px" align="justify"><strong></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">In July 2013, the Company entered into a Memorandum of Understanding (MOU) with UM to engage in joint research of extracting, manipulating, and studying cannabis in certain forms to develop intellectual property (IP) with the intention to create and commercialize therapeutic medicines. Nemus will own all IP developed solely by its employees and will jointly own all IP developed jointly between Nemus and UM employees. The term of the MOU agreement is five years and the parties agree to negotiate separate research agreements upon the identification of patentable technologies as well as any deemed to be a trade secret. The agreement may be terminated by either party with three months&rsquo; written notice to the other party.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 0.5in" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><u>UM 5050 pro-drug agreements</u>:</p><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">On September 29, 2014, the Company executed three license agreements with UM pursuant to which UM granted us exclusive, perpetual, worldwide licenses, including the right to sublicense, to intellectual property related to UM 5050, a pro-drug formulation of tetrahydrocannabinol, or THC for products administered through each of ocular, oral or rectal delivery. The license agreement for the field of oral delivery also includes rights to UM 1250, a bio-adhesive hot melt extruded film for topical and mucosal adhesion application and drug delivery. The license agreements contain certain milestone and royalty payments, as defined therein. There is an annual fee of $25,000 per license agreement, payable on the anniversary of each effective date. The aggregate milestone payments under the license agreements, if the milestones are achieved, is $2.1 million. These licenses also require the Company to reimburse UM for patent costs incurred related to these products under license. The agreements will terminate upon expiration of the patents, breach or default of the license agreements, or upon 60 days&rsquo; written notice by the Company to UM.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px; TEXT-INDENT: 33.75pt" align="justify">On October 15, 2014, we signed a renewable option agreement for the rights to explore other routes of delivery of UM5050 not yet agreed upon and/or in combination with other cannabinoids or other compatible compounds. There was a one-time up-front option payment of $10,000 for a six-month option period that has subsequently been renewed under the same financial terms and conditions. The most recent renewal occurred for the period from October 1, 2016 to December 14, 2016 to coincide with the renewals of the UM 8930 license discussed below. The option payment for this shortened period is $2,500 due and payable on October 31, 2016.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><u>UM 8930 pro-drug agreements:</u></p><p style="COLOR: black; MARGIN: 0px" align="justify"><u></u>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">On December 14, 2015, the Company executed two license agreements with UM pursuant to which UM granted us exclusive, perpetual, worldwide licenses, including the right to sublicense, to intellectual property related to UM 8930, a pro-drug formulation of cannabidiol ("CBD") for products administered through each of ocular or rectal delivery. The license agreements contain certain milestone and royalty payments, as defined therein. There is a one-time upfront payment of $65,000 per license agreement, payable in four equal monthly installments that started on December 15, 2015. There is an annual fee of $25,000 per license agreement, payable on the anniversary of each effective date. The aggregate milestone payments under the license agreements, if the milestones are achieved, is $1.4 million. These licenses also require the Company to reimburse UM for patent costs incurred related to these products under license. These license agreements will terminate upon expiration of the patents, breach or default of the license agreements, or upon 60 days&rsquo; written notice by the Company to UM.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">On December 14, 2015, we signed a renewable option agreement for the rights to explore other routes of delivery of UM8930 not yet agreed upon and/or in combination with other cannabinoids or other compatible compounds. There was a one-time up-front option payment of $10,000 for an option period ending March 31, 2016. This option was subsequently renewed for the period October 1, 2016 to December 14, 2016 to coincide with the UM8930 annual license renewal. The option payment for this shortened period is $2,500 due and payable on October 31, 2016.</p><p style="COLOR: black; MARGIN: 0px" align="justify"><b></b>&nbsp;</p><b><p style="COLOR: black; MARGIN: 0px" align="justify"><table id="pagebreak3003146d-b280-45aa-bf6c-d45c239d2173" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">    <tr><td class="hpbhr">&nbsp;</td></tr><tr><td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">11</td></tr><tr></tr><tr><td><div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr><tr><td><a href="#toc">Table of Contents</a></td></tr></table></p><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"></b><b>3. Commitments and Contingencies</b></p><p style="COLOR: black; MARGIN: 0px" align="justify"><strong></strong>&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b style="MARGIN: 0px"><i>Lease Commitments</i></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><strong><em></em></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">On September 1, 2014, the Company signed an operating lease for laboratory and office space at the Innovation Hub, Insight Park located on the University of Mississippi campus. The lease term commenced on October 1, 2014 and expires on December 31, 2017. There is annual escalating rent provisions and two months of free rent in the agreement. The total cash payments over the life of the lease are divided by the total number of months in the lease period and the average rent will be charged to expense each month during the lease period. The monthly amount charged to rent expense is $9,267.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">In October 2014, we signed a lease agreement for our corporate office headquarters that consists of approximately 4,087 square feet located at 650 Town Center Drive, Suite 1770, Costa Mesa, CA 92626. The lease expired on October 31, 2016 and our monthly rent was $5,373, payable in equal monthly installments with annual escalations. There was no subsequent renewal upon expiration of this lease.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">In November 2015, the Company entered into an operating lease for its office and lab furnishings both in Costa Mesa and the Innovation Hub laboratory. The lease expires on November 3, 2017 and the monthly lease payments are $7,559.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Total net rent expense related to our operating leases for the three months ended September 30, 2016 and 2015, was $79,771 and $56,680, respectively. For the nine months ended September 30, 2016 and 2015, total net rent expense from operating leases was $240,746 and $170,931 respectively.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Future minimum payments under the non-cancelable portion of our operating leases as of September 30, 2016 are as follows:</p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="85%" align="center" border="0" >    <tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">2016</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%">$</td><td id="ffcell" valign="bottom" width="9%" align="right">56,671</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">2017</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">161,963</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">2018</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">-</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">2019</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">-</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">2020</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">-</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">Thereafter</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">-</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">Total</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td><td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">218,634</td><td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b style="MARGIN: 0px"><i>Legal Matters</i></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><strong><em></em></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><i>General Litigation and Disputes</i></p><p style="COLOR: black; MARGIN: 0px" align="justify"><em></em>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">On August 3, 2016, John B. Hollister filed to dismiss his complaint against the Company and its Executive Chairman, and the Company and its Executive Chairman filed to dismiss their complaint against Hollister filed on January 25, 2016 containing claims against him for defamation, false light, unfair competition, breach of contract, breach of fiduciary duty and fraud.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Hollister's employment as the Company's Chief Executive Officer was terminated by the Company on August 24, 2015 for good and lawful reasons by the Company's Board of Directors as the Company decided to go in a different direction. As stated in the Company's December 28, 2015 Form 8-K, the Company maintains that Hollister's complaint and subsequent pleadings were grossly inaccurate and his claims were entirely without merit alleging various causes of action arising out of his termination, including a breach of contract claim.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Neither the Company nor its Executive Chairman made any payment to Hollister to resolve the lawsuit or otherwise.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">According to the Orange County Superior Court's online case records posted on August 11, 2016, the court entered the order for dismissal of the entire action with prejudice effective as of the&nbsp;August 3, 2016 filing date.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 0.5in" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 0.5in" align="justify"><table id="pagebreak60f71632-d1a4-4a8d-adb1-6b9f6a83985b" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">    <tr><td class="hpbhr">&nbsp;</td></tr><tr><td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">12</td></tr><tr></tr><tr><td><div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr><tr><td><a href="#toc">Table of Contents</a></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><i>Government Proceedings</i></p><p style="COLOR: black; MARGIN: 0px" align="justify"><em></em>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Like other companies in the pharmaceutical industry, we are subject to extensive regulation by national, state and local government agencies in the United States. As a result, interaction with government agencies occurs in the normal course of our operations. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from any government investigation or proceeding. As of September 30, 2016, the Company had no current proceedings or inquiries.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 0.5in" align="justify">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b style="MARGIN: 0px"><i>Change in Control Severance Plan</i></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><strong><em></em></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">In February 2015, we adopted a change in control severance plan, in which our named executive officers participate, that provides for the payment of severance benefits if the executive's service is terminated within twelve months following a change in control, either due to a termination without cause or upon a resignation for good reason (as each term is defined in the plan).</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">In either such event, and provided the executive timely executes and does not revoke a general release of claims against the Company, he or she will be entitled to receive: (i) a lump sum cash payment equal to at least six months of the executive's monthly compensation, plus an additional month for each full year of service over six years, (ii) Company-paid premiums for continued health insurance for a period equal to length of the cash severance period or, if earlier, when executive becomes covered under a subsequent employer's healthcare plan, and (iii) full vesting of all then-outstanding unvested stock options and restricted stock awards.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 0.5in" align="justify">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b style="MARGIN: 0px"><i>Contract Manufacturing Organization ("CMO") Agreement</i></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><strong><em></em></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">On February 5, 2016, the Company entered into a letter agreement ("Agreement") with a third party contract manufacturing organization ("CMO") pursuant to which the CMO is to provide services to Nemus for process development and analytical method development and qualification for Nemus' prodrug of tetrahydrocannabinol, or THC, as well as for sample production and a stability study.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Pursuant to the terms of the Agreement, Nemus will pay an estimated $154,000 to $183,000 in fees and expenses for the initial evaluation and development of a process for the production of Nemus' pro-drug of THC to ensure reproducibility, quality and safety and an estimated $142,900 for analytical method development and qualification. The Company recognized $18,896 and $225,244 respectively as research and development expense towards these fees for the three and nine months ended September 30, 2016. After the initial evaluation and development, Nemus has agreed to pay additional fees and expenses for sample production of Nemus' pro-drug of THC and a stability study, as well as possible extensions to or modifications of the aforementioned projects.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Nemus may at any time cancel or delay any project under the Agreement prior to the scheduled start date. Nemus must reimburse the CMO for costs incurred prior to and including the date of cancellation plus any reasonable and foreseeable costs associated with stopping work on any project, including the CMO's loss of revenue incurred as the result of reserving production facilities for Nemus' exclusive use. Nemus may terminate the Agreement in whole or in part at any time upon 30 days' written notice.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 0.5in" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><b>4. Stockholders' Deficit and Redeemable Convertible Series B Preferred Stock</b></p><p style="COLOR: black; MARGIN: 0px" align="justify"><strong></strong>&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b style="MARGIN: 0px"><i>Common Stock</i></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><strong><em></em></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">In June 2014, the Company sold 1,800,000 shares of common stock with no par value and warrants for a purchase price of $900,000 (the "June 2014 Stock Purchase Agreement") to a group of private investors. See additional discussion on warrants below.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><table id="pagebreakb0abf1bb-941a-4bf6-acc9-fc4656b8239f" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">    <tr><td class="hpbhr">&nbsp;</td></tr><tr><td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">13</td></tr><tr></tr><tr><td><div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr><tr><td><a href="#toc">Table of Contents</a></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="left">In August 2014, the Company sold 2,200,000 shares of common stock with no par value and warrants for a purchase price of $1,100,000 to a group of private investors. See additional discussion on warrants below.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 135px" align="left">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="left">In October 2014, the Company issued 1,110,000 shares of common stock with no par value to eighteen individual investors that had participated in a prior entity founded by Nemus' then current president. Such entity has been insolvent and not operating since the inception date of Nemus. The issuance of these shares was in exchange for the signing of a release of claims against the Company, its President, and the former entity. The Company recorded a general and administrative expense of $466,200 in the fourth quarter of 2014 to reflect the fair market value of the common stock issued in exchange for the release of claims. The fair market value of the common stock issued was determined via an independent third-party valuation conducted as of October 31, 2014.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 135px" align="left">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="left">In January 2015, the Company sold 241,663 shares of common stock with par value of $0.001 for a purchase price of $724,989 to a group of private investors.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 135px" align="left">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="left">In March 2015, the Company issued 24,000 shares of common stock with par value of $0.001 to a third party in exchange for services to be performed related to raising additional capital. The Company recorded a prepaid expense of $168,000 in the first quarter of 2015 to reflect the fair market value of the common stock issued and is amortizing this expense over the contract service period which is one year. The fair market value was determined utilizing the Company's closing stock price as of the commencement date of the contract service period. For three months ended March 31, 2016, the Company amortized $12,194 to general and administrative expense which represented the completion of this agreement.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 135px" align="left">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="left">In August 2015, in conjunction with the Series B Preferred Stock sale (discussed below), the Company raised $5.0 million at $1,000 per share resulting in the automatic conversion of the Series A Preferred Stock to common stock. This resulted in the conversion of 580,000 shares of Series A Preferred Stock at $2.50 per share to the equivalent of 1,812,500 shares of common stock.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 135px" align="left">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="left">In December 2015, a Series B Preferred Stockholder converted 500 shares of its preferred stock to common stock as allowed under the Series B Stock Agreement (discussed below), resulting in the issuance of 625,000 shares of common stock at an effective price of $0.80 per share.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 135px" align="left">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="left">In March 2016, another Series B Preferred Stockholder converted 8 shares of&nbsp;its preferred stock to common stock, resulting in the issuance of 10,000 shares of common stock at an effective price of $0.80 per share.</p><p style="COLOR: black; MARGIN: 0px" align="left">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b style="MARGIN: 0px"><i>Preferred Stock</i></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><strong><em></em></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The Company has authorized 20,000,000 shares of preferred stock with a par value of $0.001 per share.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><u>Series A Preferred Stock:</u> In April 2015, the Company sold 250,000 shares of Series A preferred stock with par value of $0.001 and 50,000 warrants to purchase the Company's common stock for an aggregate purchase price of $625,000, or $2.50 per share to a group of private investors. The shares of preferred stock automatically convert to shares of common stock either at (i) a subsequent equity financing of at least $1,000,000 or (ii) October 1, 2015, whichever is earlier. The warrants are exercisable at a price of $5.00 per share and expire five years from the issuance date. In May 2015, the Company sold 150,000 shares and 30,000 warrants and in July 2015, the Company sold 180,000 shares and 36,000 warrants under the same terms and conditions.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The Series A preferred stock issued also has a "down-round" protection feature provided to the investors if the Company subsequently issues or sells any shares in a round of equity financing of at least $1,000,000 prior to October 1, 2015 in which the shares of common stock to be acquired are at a price less than $2.50 per share. The Company is required to issue additional shares of common stock to the investors in an amount such that the subscription price paid, when divided by the total number of shares issued will result in an actual price paid per share of common stock equal to such lower price. This conversion occurred as discussed above in conjunction with the Series B Preferred Stock financing totaling $5.0 million and resulted in the conversion of 580,000 shares of Series A Preferred Stock at to 1,812,500 shares of common stock.</p><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><table id="pagebreak8620827e-869a-4a3b-b918-0697a075b27c" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">    <tr><td class="hpbhr">&nbsp;</td></tr><tr><td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">14</td></tr><tr></tr><tr><td><div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr><tr><td><a href="#toc">Table of Contents</a></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><u>Redeemable Convertible Series B Preferred Stock:</u> In August 2015, the Company sold 5,000 shares of Series B Convertible Preferred Stock and warrants to purchase 6,250,000 shares of the Company's common stock for an aggregate purchase price of $1,000 per share resulting in gross proceeds of $5.0 million. Each share of preferred stock is convertible into 1,250 shares of common stock which results in an effective conversion price of $0.80 per common share and can be converted by the holder at any time. The Series B preferred stock issued also has a "down-round" protection feature provided to the investors if the Company subsequently issues or sell any shares of common stock, stock options, or convertible securities at a price less than the conversion price of $0.80 per common share. The conversion price is automatically adjusted down to the price of the instrument being issued. See additional discussion in Note 5 below. The Series B shares have liquidation preference over other preferred shares and common stock and have voting rights equal to the number of common shares into which each holder's preferred stock is convertible as of the record date. The preferred stock has no dividend rights. If dividends are declared on the common stock, the holders of the preferred stock shall be entitled to participate in such dividends on an as-if converted basis. The warrants are exercisable at a price of $1.15 per share and expire five years from the issuance date. See additional discussion regarding these warrants in Note 6 below.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary, Series B preferred stockholders receive an amount per share equal to the conversion price of $0.80, subject to down-round adjustment, multiplied by the as-if converted share amount of 5,615,000 common shares, totaling $4.5 million. If upon the liquidation, the assets are insufficient to permit payments to the Series B holders, all assets legally available will be distributed in a pro rata basis among the Series B holders in proportion to the full amounts they would otherwise be entitled to receive. Any remaining assets are distributed pro rata among the common stockholders.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Subject to certain trigger events occurring, the Series B preferred stock holders have the right to force the Company to redeem the shares of preferred stock at a price per preferred share equal to the greater of (A) 115% of the conversion amount and (B) the product of (1) the conversion rate in effect at such time and (2) the greatest closing sale price of the Common Stock during the period beginning on the date immediately preceding such triggering event and ending on the date such holder delivers the notice of redemption. Such triggering events include:</p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0" >    <tr height="15"><td width="4%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p></td><td valign="top" width="4%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td><td valign="top" width="92%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">Failure of the Series B Registration Statement to be declared effective by the SEC on or prior to the date that is ninety days after the Effectiveness Deadline;</p></td></tr><tr height="15"><td></td><td></td><td></td></tr><tr height="15"><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">Suspension of the Company's common stock from trading for a period of (2) consecutive trading days;</p></td></tr><tr height="15"><td></td><td></td><td></td></tr><tr height="15"><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">Failure of the Company to deliver all the shares of the common stock or make the appropriate cash payments in a timely manner upon conversion of the Series B Preferred;</p></td></tr><tr height="15"><td></td><td></td><td></td></tr><tr height="15"><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">Any default of indebtedness;</p></td></tr><tr height="15"><td></td><td></td><td></td></tr><tr height="15"><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">Any filing of voluntary or involuntary bankruptcy by the Company;</p></td></tr><tr height="15"><td></td><td></td><td></td></tr><tr height="15"><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">A final judgment in excess of $100,000 rendered against the Company;</p></td></tr><tr height="15"><td></td><td></td><td></td></tr><tr height="15"><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">Breach of representations and warranties in the Stock Purchase Agreement;</p></td></tr><tr height="15"><td></td><td></td><td></td></tr><tr height="15"><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">Failure to comply with the Series B Certificate of Designation or Rule 144 requirements.</p></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">As certain of these triggering events are considered to be outside the control of the Company, the Series B preferred stock is considered to be contingently redeemable convertible and as a result, has been classified as mezzanine equity in the Company's balance sheet.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">In December 2015, a Series B Preferred Stock holder converted 500 shares of its preferred stock to common stock at the conversion rate of 1,250:1 resulting in the issuance of 625,000 shares of common stock. In March 2016, another Series B Preferred Stockholder converted 8 shares of its preferred stock to common stock at the same ratio resulting in the issuance of 10,000 shares of common stock. As a result of these conversions, the liquidation preference for the Series B Preferred Stock has been reduced to $4.5 million at both September 30, 2016 and December 31, 2015.</p><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><table id="pagebreak8c06d180-478c-4cde-a5e3-bd2ca280d5d9" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">    <tr><td class="hpbhr">&nbsp;</td></tr><tr><td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">15</td></tr><tr></tr><tr><td><div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr><tr><td><a href="#toc">Table of Contents</a></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><b style="MARGIN: 0px"><i>Warrants</i></b></p><p style="COLOR: black; MARGIN: 0px" align="justify"><strong><em></em></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">On July 17, 2012, the Company issued warrants to purchase up to 3,000,000 shares of our common stock to its founders and two advisors in consideration for services provided in the start-up of operations. The warrants are exercisable at a price of $1.00 per share and expire on June 20, 2023. The Company valued these warrants utilizing the Black-Scholes valuation model and they were determined to be of nominal value given the start-up nature of the Company's operations at the time of grant.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">In conjunction with the June 2014 Stock Purchase Agreement, the Company issued warrants to purchase up to 450,000 shares of common stock to a group of private investors. The warrants are exercisable at a price of $1.00 per share and expire on June 12, 2020. The Company valued these warrants at $85,500. This amount was recorded as warrants and was reclassified from the total consideration received for both the common stock and warrants purchased.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">In August 2014 as part of the June 2014 Stock Purchase Agreement, the Company issued warrants to purchase up to 550,000 shares of common stock with an exercise price of $1.00 per share that expire in August 2020. The Company valued these warrants at $104,500. This amount was recorded as warrants and was reclassified from the total consideration received for both the common stock and warrants purchased.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">In March 2015, the Company entered into an agreement with a financial advisory and public relations consulting firm which included the issuance of warrants to purchase up to 90,000 shares of common stock with an exercise price of $2.50 per share with a term of five years and vest quarterly over one year. These warrants were in exchange for services performed beginning in the first quarter and were subsequently issued in April 2015. The Company estimated the vested warrant value to be $85,950 utilizing the Black Scholes option pricing model and amortized $5,145 for services provided for the nine months ended September 30, 2016 and $46,810 for the nine months ended September 30, 2015.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">In April 2015, the Company entered into an agreement with one of its investors to provide advisory services on all matters including financing. In conjunction with this agreement, the Company issued warrants that vest immediately to purchase 100,000 shares of common stock with an exercise price of $5.00 per share with a term of ten years. The Company estimated the warrant value to be $326,000 utilizing the Black Scholes option pricing model and recorded this amount to general and administrative expense for the quarter due to the immediate vesting.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">In April 2015, the Company issued to a former service provider in exchange for payment of its outstanding invoice warrants that vest immediately to purchase 6,000 shares of common stock with an exercise price of $2.50 per share. The Company estimated the warrant value to be $10,000 which represented the value of the trade debt extinguished.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">In April 2015, the Company issued 50,000 warrants to purchase the Company's common stock in conjunction with its Series A Preferred Stock financing. The warrants are exercisable at a price of $5.00 per share and expire five years from the issuance date. In May 2015, the Company issued 30,000 warrants and in July 2015, 36,000 warrants under the same terms and conditions.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">In June 2015, the Company issued to a service provider in exchange for consulting services warrants that vest immediately to purchase 10,000 shares of common stock with an exercise price of $5.00 per share with a term of five years. The Company estimated the warrant value to be $14,700 utilizing the Black Scholes option pricing model.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">In August 2015, the Company issued 6,250,000 warrants to purchase common stock in conjunction with its Series B Preferred Stock financing. See further discussion in Note 6 below.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">In August 2015, the Company issued 187,500 warrants to purchase common stock to its investment banker in exchange for services rendered in conjunction with the Series B Preferred Stock financing. The warrants vest immediately and have an exercise price of $1.15 per share. The Company estimated the value of the warrants to be $86,250 utilizing the Black Scholes option pricing model and recorded this amount to offering costs.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">In November 2015, the Company entered into an agreement with a financial advisory and public relations consulting firm which included the issuance of warrants to purchase up to 120,000 shares of common stock with an exercise price of $1.15 per share with a term of five years. These warrants are in exchange for services to be performed from November 25, 2015 to May 25, 2016 and 60,000 shares vest immediately with the remainder in one quarter. The Company estimated the warrant value of vested warrants to be $42,000 utilizing the Black Scholes option pricing model and amortized $7,800 during the fiscal year ended December 31, 2015 and $34,200 in the nine months ended September 30, 2016.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><table id="pagebreak99d2b016-08e3-4528-ac70-59d1c41c7610" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">    <tr><td class="hpbhr">&nbsp;</td></tr><tr><td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">16</td></tr><tr></tr><tr><td><div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr><tr><td><a href="#toc">Table of Contents</a></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The Company's board of directors considered various objective and subjective factors, along with input from management, to determine the fair value of the warrants, including:&nbsp;</p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0" >    <tr height="15"><td width="4%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p></td><td valign="top" width="4%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">Contemporaneous valuation prepared by an independent third-party valuation specialist effective as of April 1, 2015, August 20, 2015, December 31, 2015, March 31, 2016, June 30, 2016, and September 30, 2016,</p></td></tr><tr height="15"><td></td><td></td><td></td></tr><tr height="15"><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">Its results of operations, financial position and the status of research and development efforts and achievement of enterprise milestones,</p></td></tr><tr height="15"><td></td><td></td><td></td></tr><tr height="15"><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">The composition of, and changes to, the Company's management team and board of directors,</p></td></tr><tr height="15"><td></td><td></td><td></td></tr><tr height="15"><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">The lack of liquidity of its common stock as a newly public company,</p></td></tr><tr height="15"><td></td><td></td><td></td></tr><tr height="15"><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">The Company's stage of development, business strategy and the material risks related to its business and industry,</p></td></tr><tr height="15"><td></td><td></td><td></td></tr><tr height="15"><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">The valuation of publicly-traded companies in the biotechnology sectors,</p></td></tr><tr height="15"><td></td><td></td><td></td></tr><tr height="15"><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">External market conditions affecting the biotechnology industry sectors,</p></td></tr><tr height="15"><td></td><td></td><td></td></tr><tr height="15"><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">The likelihood of achieving a liquidity event for the holders of its common stock, such as an initial public offering, or IPO, or a sale of the Company, given prevailing market conditions, and</p></td></tr><tr height="15"><td></td><td></td><td></td></tr><tr height="15"><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">The state of the IPO market for similarly situated biotechnology companies,</p></td></tr><tr height="15"><td></td><td></td><td></td></tr><tr height="15"><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">Discussions held with bankers, potential investors, and preliminary term sheets received as part of management's capital raise efforts.</p></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">There are significant judgments and estimates inherent in the determination of the fair value of the Company's warrants. These judgments and estimates included the assumptions regarding its future operating performance, the time to completing an IPO or other liquidity event and the determination of the appropriate valuation methods. If the Company had made different assumptions, its warrant valuation could have been significantly different.</p><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><b style="MARGIN: 0px"><i>Stock Option Plans: 2014 Omnibus Incentive Plan</i></b></p><p style="COLOR: black; MARGIN: 0px" align="justify"><strong><em></em></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The 2014 Omnibus Incentive Plan (the "2014 Plan") was adopted to provide a means by which officers, non-employee directors, and employees of and consultants to the Company and its affiliates could be given an opportunity to acquire an equity interest in the Company. All officers, non-employee directors, and employees of and consultants to the Company are eligible to participate in the 2014 Plan.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">On October 31, 2014, after the closing of the Merger, our Board of Directors approved the 2014 Plan. The 2014 Plan reserved 3,200,000 shares for future grants. As of September 30, 2016, options (net of canceled or expired options) covering an aggregate of 1,142,500 shares of the Company's common stock had been granted under the 2014 Plan, and the Company had 1,142,500 options outstanding and 857,500 shares available for future grants under the 2014 Plan.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Options granted under the 2014 Plan expire no later than 10 years from the date of grant. Options granted under the 2014 Plan may be either incentive or non-qualified stock options. For incentive and non-qualified stock option grants, the option price shall be at least 100% of the fair value on the date of grants, as determined by the Company's Board of Directors. If at any time the Company grants an option, and the optionee directly or by attribution owns stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, the option price shall be at least 110% of the fair value and shall not be exercisable more than five years after the date of grant.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><table id="pagebreak39390a96-cbf6-4c19-9e09-d88ac5747615" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">    <tr><td class="hpbhr">&nbsp;</td></tr><tr><td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">17</td></tr><tr></tr><tr><td><div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr><tr><td><a href="#toc">Table of Contents</a></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Options granted under the 2014 Plan may be immediately exercisable if permitted in the specific grant approved by the Board of Directors and, if exercised early may be subject to repurchase provisions. The shares acquired generally vest over a period of five years from the date of grant. The Company granted options to purchase 1,142,500 shares net of cancellations through September 30, 2016, under the 2014 Plan.</p><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The following is a summary of activity under the 2014 Plan as of September 30, 2016:</p><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;   <p style="MARGIN: 0px"><table  style="WIDTH: 100%; TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">    <tr><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td id="hdcell" valign="bottom" colspan="2" align="center"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" colspan="10" align="center"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>Options Outstanding</b></p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td id="hdcell" valign="bottom" colspan="2" align="center"><strong>Shares</strong></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td id="hdcell" valign="bottom" colspan="2" align="center"></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td id="hdcell" valign="bottom" colspan="2" align="center"></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td id="hdcell" valign="bottom" colspan="2" align="center"><strong>Weighted</strong></td><td valign="bottom"><p style="MARGIN: 0px"><strong>&nbsp;</strong></p></td></tr><tr><td valign="bottom"><p style="MARGIN: 0px"><strong>&nbsp;</strong></p></td><td valign="bottom"><p style="MARGIN: 0px"><strong>&nbsp;</strong></p></td><td id="hdcell" valign="bottom" colspan="2" align="center"><p style="MARGIN: 0px" align="center"><strong>&nbsp;Available</strong></p><p style="MARGIN: 0px" align="center"><strong>for Grant of</strong></p></td><td valign="bottom"><p style="MARGIN: 0px"><strong>&nbsp;</strong></p></td><td valign="bottom"><p style="MARGIN: 0px"><strong>&nbsp;</strong></p></td><td id="hdcell" valign="bottom" colspan="2" align="center"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><strong>Number of</strong></p></td><td valign="bottom"><p style="MARGIN: 0px"><strong>&nbsp;</strong></p></td><td valign="bottom"><p style="MARGIN: 0px"><strong>&nbsp;</strong></p></td><td id="hdcell" valign="bottom" colspan="2" align="center"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><strong>Price per</strong></p></td><td valign="bottom"><p style="MARGIN: 0px"><strong>&nbsp;</strong></p></td><td valign="bottom"><p style="MARGIN: 0px"><strong>&nbsp;</strong></p></td><td id="hdcell" valign="bottom" colspan="2" align="center"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><strong>Average</strong></p><strong>Exercise</strong></td><td valign="bottom"><p style="MARGIN: 0px"><strong>&nbsp;</strong></p></td></tr><tr><td valign="bottom"><p style="MARGIN: 0px"><strong>&nbsp;</strong></p></td><td valign="bottom"><p style="MARGIN: 0px"><strong>&nbsp;</strong></p></td><td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" colspan="2" align="center"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><strong>Options &amp; Shares</strong></p></td><td valign="bottom"><p style="MARGIN: 0px"><strong>&nbsp;</strong></p></td><td valign="bottom"><p style="MARGIN: 0px"><strong>&nbsp;</strong></p></td><td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" colspan="2" align="center"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><strong>Shares</strong></p></td><td valign="bottom"><p style="MARGIN: 0px"><strong>&nbsp;</strong></p></td><td valign="bottom"><p style="MARGIN: 0px"><strong>&nbsp;</strong></p></td><td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" colspan="2" align="center"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><strong>Share</strong></p></td><td valign="bottom"><p style="MARGIN: 0px"><strong>&nbsp;</strong></p></td><td valign="bottom"><p style="MARGIN: 0px"><strong>&nbsp;</strong></p></td><td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" colspan="2" align="center"><strong>Price</strong></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr height="15"><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><b>Balance at December&nbsp;31, 2015</b></p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"></td><td id="ffcell" valign="bottom" width="9%" align="right">2,020,000</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"></td><td id="ffcell" valign="bottom" width="9%" align="right">1,180,000</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td>$ </td><td><p style="MARGIN: 0px" align="right">0.42-3.00</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%">$</td><td id="ffcell" valign="bottom" width="9%" align="right">0.63</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">Shares used for restricted stock awards (see discussion below)</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">(1,200,000</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><b>Subtotal</b></p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">820,000</td><td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">Options granted</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">-</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">-</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%">$</td><td id="ffcell" valign="bottom" width="9%" align="right">-</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%">$</td><td id="ffcell" valign="bottom" width="9%" align="right">-</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">Options exercised</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">-</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">-</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%">$</td><td id="ffcell" valign="bottom" width="9%" align="right">-</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%">$</td><td id="ffcell" valign="bottom" width="9%" align="right">-</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">Options cancelled</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">37,500</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">(37,500</td><td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%">$</td><td id="ffcell" valign="bottom" width="9%" align="right">1.15</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%">$</td><td id="ffcell" valign="bottom" width="9%" align="right">1.15</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><b>Balance at September 30, 2016</b></p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 3px double" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign="bottom" width="9%" align="right">857,500</td><td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td style="BORDER-BOTTOM: black 3px double" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign="bottom" width="9%" align="right">1,142,500</td><td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td>$ </td><td><p style="MARGIN: 0px" align="right">0.42-3.00</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%">$</td><td id="ffcell" valign="bottom" width="9%" align="right">0.61</td><td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The weighted average remaining contractual life in years of the options outstanding as of September 30, 2016 was 8.15 years.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Aggregate intrinsic value is the sum of the amounts by which the quoted market price of the Company's stock exceeded the exercise price of the stock options at September 30, 2016 for those stock options for which the quoted market price was in excess of the exercise price ("in-the-money options"). As of September 30, 2016, the aggregate intrinsic value of options outstanding was $52,500. As of September 30, 2016, 238,500 options to purchase shares of common stock were exercisable.</p><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><b style="MARGIN: 0px"><i>Restricted Stock Awards</i></b></p><p style="COLOR: black; MARGIN: 0px" align="justify"><strong><em></em></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Restricted stock awards ("RSAs") are granted to our board of directors and members of senior management and are issued pursuant to the Company's 2014 Omnibus Incentive Plan. On October 20, 2015, a total of 1,200,000 RSAs were granted to members of the Company's senior management and board of directors with a fair market value of approximately $900,000. These RSAs vest from one to three years from the grant date as services are rendered to the Company. For the three and nine months ended September 30, 2016, the Company recorded $93,750 and $281,250 respectively in stock-based compensation expense related to these awards. (See discussion below).</p><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><b style="MARGIN: 0px"><i><table id="pagebreak32f674c6-5a14-4543-a781-2db36c99bbf7" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">    <tr><td class="hpbhr">&nbsp;</td></tr><tr><td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">18</td></tr><tr></tr><tr><td><div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr><tr><td><a href="#toc">Table of Contents</a></td></tr></table><p style="MARGIN: 0px"></i></b><p style="COLOR: black; MARGIN: 0px" align="justify"><b style="MARGIN: 0px"><i></i></b>&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><b style="MARGIN: 0px"><i>Stock Based Compensation Expense</i></b></p><p style="COLOR: black; MARGIN: 0px" align="justify"><strong><em></em></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The Company recognizes stock-based compensation expense based on the fair value of that portion of stock options that are ultimately expected to vest during the period. Stock-based compensation expense recognized in the consolidated statements of operations includes compensation expense for stock-based awards based on the estimated grant date fair value over the requisite service period. For the three and nine months ended September 30, 2016, the Company recognized stock-based compensation expense of $181,608 and $544,823 (including compensation expense for RSAs discussed above) which was recorded as a general and administrative expense in the consolidated statements of operations. For the three and nine months ended September 30, 2015, stock-based compensation expense was $4,286 and $263,985, respectively.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The total amount of unrecognized compensation cost related to non-vested stock options was $1,109,963 as of September 30, 2016. This amount will be recognized over a weighted average period of 3.14 years.</p><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><b style="MARGIN: 0px"><i>Valuation Assumptions</i></b></p><p style="COLOR: black; MARGIN: 0px" align="justify"><strong><em></em></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The fair value of options was estimated at the date of grant using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company's common stock for similar terms. The expected term was estimated using the simplified method as permitted under SAB No. 110, since the Company has no recent exercise or forfeiture history that is representative of options granted during the year. The expected term represents the estimated period of time that stock options are expected to be outstanding, which is less than the contractual term which is generally ten years. The risk-free interest rate is based on the U.S. Treasury yield. The expected dividend yield is zero, as the Company does not anticipate paying dividends in the near future. There were no options granted in the nine months ended September 30, 2016; the assumptions for options granted in the nine months ended September 30, 2015 are as follows:</p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><table style="WIDTH: 100%; TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0" >    <tr><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" colspan="4" align="center"><p style="MARGIN: 0px 0px 0px 1.9pt" align="center"><b>Nine Months Ended September 30,</b></p></td><td valign="bottom"><p style="MARGIN: 0px" align="center">&nbsp;</p></td></tr><tr><td valign="bottom"><p style="MARGIN: 0px" align="center">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px" align="center">&nbsp;</p></td><td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="center"><p style="MARGIN: 0px 0px 0px 0.4pt" align="center"><b>2016</b></p></td><td valign="bottom"><p style="MARGIN: 0px" align="center">&nbsp;</p></td><td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center"><p style="MARGIN: 0px 0px 0px 0.9pt" align="center"><b>2015</b></p></td><td style="PADDING-BOTTOM: 1px" valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr height="15"><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td colspan="2"><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">Dividend yield</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="COLOR: black; MARGIN: 0px" align="right">NA</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">0.00</td><td valign="bottom" width="1%">%</td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">Volatility factor</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="COLOR: black; MARGIN: 0px" align="right">NA</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px" align="right">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">75.00</td><td valign="bottom" width="1%">%</td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">Risk-free interest rate</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="COLOR: black; MARGIN: 0px" align="right">NA</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td colspan="2"><p style="MARGIN: 0px" align="right">1.65-1.85</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">%</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">Expected term (years)</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="COLOR: black; MARGIN: 0px" align="right">NA</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td colspan="2"><p style="COLOR: black; MARGIN: 0px" align="right">6.25-6.50</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">Weighted-average fair value of options granted during the periods</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="COLOR: black; MARGIN: 0px" align="right">NA</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%">$</td><td id="ffcell" valign="bottom" width="9%" align="right">2.69</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><b>5. Provision for Conversion of Preferred Stock</b></p><p style="COLOR: black; MARGIN: 0px" align="justify"><strong></strong>&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b style="MARGIN: 0px"><i>Series A Preferred Stock Conversion Liability</i></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><strong><em></em></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">In connection with the Series A preferred stock financing, the Company recorded a liability related to down-round protection provided to the stockholders in the event that the Company does another offering of common stock greater than $1,000,000 at a price below $2.50 per share. The down-round provision expires at the closing of a subsequent financing round or October 1, 2015 whichever is earlier. With the assistance of a third-party valuation specialist, the Company valued the conversion liability pursuant to the accounting guidance of ASC 820-10, <i>Fair Value Measurements</i>, as of the closing date of the first round of financing which was April 1, 2015.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">As of June 30, 2015, the Company re-evaluated the likelihood and valuation of a potential down-round given that management has been actively pursuing capital raising efforts. In the absence of any definitive agreement, the Company calculated the fair value of the conversion feature to be $700,000 by determining the highest probability of a per share price in the next anticipated round of financing, after considering all discussions with bankers, potential investors, and preliminary term sheets. This amount was booked as a current liability as of June 30, 2015 and was charged as a non-operating expense for the period.</p><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><table id="pagebreak2cb34c8a-140a-4847-9248-664d55aef00a" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">    <tr><td class="hpbhr">&nbsp;</td></tr><tr><td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">19</td></tr><tr></tr><tr><td><div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr><tr><td><a href="#toc">Table of Contents</a></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">In July 2015, the Company increased its down-round provision by $286,000 based on the closing of an additional round of 180,000 Series A shares by determining the highest probability of a per share price in the next anticipated round of financing, after considering all discussions with bankers, potential investors, and preliminary term sheets. This amount was charged to non-operating expense for the three months ended September 30, 2015.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">As of August 21, 2015, upon the closing of the Series B Preferred Stock sale with proceeds totaling $5.0 million, the Company issued 1,232,000 additional shares of common stock at $0.80 per share thereby eliminating this liability of $986,000 and offsetting it to Additional Paid-in-Capital. This amount was calculated by determining the difference in per share pricing between the Series A Preferred Stock financing of $2.50 per share and the Series B Preferred Stock Financing of $0.80 per share multiplied by the 580,000 total shares included in the Series A offering.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 0.5in" align="justify">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b style="MARGIN: 0px"><i>Series B Preferred Stock Conversion Liability</i></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><strong><em></em></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">As of August 20, 2015, in connection with the Series B preferred stock financing, the Company recorded a liability related to down-round protection provided to the stockholders in the event that the Company does another sale or issuance of common stock, stock options or convertible securities where the share price is below $0.80 per share. With the assistance of a third-party valuation specialist, the Company valued the conversion liability pursuant to the accounting guidance of ASC 820-10, <i>Fair Value Measurement</i>s, as of the closing date of the financing. The Company also performed a review of the conversion liability in conjunction with ASC 815, <i>Derivatives and Hedging/Contracts in Entity's Own Equity</i>, and determined that the liability requires bifurcation and re-measurement to fair market value at the end of each reporting period. The value of this embedded derivative was determined utilizing a with and without method by valuing the preferred stock with and without the down round protection.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">As of September 30, 2016, the Company engaged a third-party valuation specialist to re-measure the conversion liability to fair market value as of that date utilizing the same methodology previously performed. The derivative which was classified as a current liability was adjusted to $166,718 as of September 30, 2016. The change in fair market value was recorded as non-operating expense of $61,058 for the three months ended September 30, 2016 and $82,872 as non-operating expense for the nine months ended September 30, 2016.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 0.5in" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><b>6. Series B Warrants</b></p><p style="COLOR: black; MARGIN: 0px" align="justify"><strong></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">In conjunction with the Series B Preferred Stock financing, the Company issued 6,437,500 common stock warrants that are exercisable at a price of $1.15 per share and expire five years from the issuance date. The warrants were initially valued at $2,935,800 utilizing the Black-Scholes pricing model. The warrants are exercisable in cash or through a cashless exercise provision. The Series B warrants also have a "down-round" protection feature provided to the investors if the Company subsequently issues or sells any shares of common stock, stock options, or convertible securities at a price less than the exercise price of $1.15 per each warrant. The conversion price is automatically adjusted down to the price of the instrument being issued. The Company reviewed the classification of the warrants as liabilities or equity under the guidance of ASC 480-10, <i>Distinguishing Liabilities from Equity</i>, and concluded that the Series B warrants should be classified as a liability. The Company then applied the fair value allocation methodology for allocating the proceeds of $5.0 million received from the Series B financing between the conversion liability and the warrants with the residual amount being allocated to the Preferred Stock. The Company also performed the same valuation as of September 30, 2016 utilizing the Black-Scholes pricing model and the following assumptions:</p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><table style="WIDTH: 100%; TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0" >    <tr><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" colspan="6" align="center"><p style="MARGIN: 0px 0px 0px 2.4pt" align="center"><b>Nine Months</b></p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>Ended September 30,</b></p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center"><p style="MARGIN: 0px 0px 0px 0.9pt" align="center"><b>2016</b></p></td><td style="PADDING-BOTTOM: 1px" valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td><td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center"><p style="MARGIN: 0px 0px 0px 0.4pt" align="center"><b>2015</b></p></td><td style="PADDING-BOTTOM: 1px" valign="bottom"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">Dividend yield</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">0.00</td><td valign="bottom" width="1%">%</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">0.00</td><td valign="bottom" width="1%">%</td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">Volatility factor</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">70.00</td><td valign="bottom" width="1%">%</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">70.00</td><td valign="bottom" width="1%">%</td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">Risk-free interest rate</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td colspan="2"><p style="COLOR: black; MARGIN: 0px" align="right">1.11 - 1.29</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">1.75</td><td valign="bottom" width="1%">%</td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">Expected term (years)</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td colspan="2"><p style="COLOR: black; MARGIN: 0px" align="right">3.89-3.90</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td id="ffcell" valign="bottom" width="9%" align="right">4.61</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">Weighted-average fair value of warrants</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%">$</td><td id="ffcell" valign="bottom" width="9%" align="right">0.14</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="bottom" width="1%">$</td><td id="ffcell" valign="bottom" width="9%" align="right">0.46</td><td valign="bottom" width="1%"><p style="MARGIN: 0px">&nbsp;</p></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">This resulted in a warrant value of $869,990 as of September 30, 2016. The change in fair market value at the re-measurement date was recorded as non-operating expense totaling $27,665 for the three months ended September 30, 2016. and non-operating income totaling $1,584,969 for the nine months ended September 30, 2016.</p><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><b><table id="pagebreak2dd7e98c-6651-4d07-8794-42c6d18b4bec" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">    <tr><td class="hpbhr">&nbsp;</td></tr><tr><td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">20</td></tr><tr></tr><tr><td><div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr><tr><td><a href="#toc">Table of Contents</a></td></tr></table></b><p style="MARGIN: 0px"><b></b>&nbsp;</p><p style="MARGIN: 0px"><b>7. Income Taxes</b></p><p style="COLOR: black; MARGIN: 0px" align="justify"><strong></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The Company records a valuation allowance against deferred tax assets to the extent that it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Due to the substantial doubt related to the Company's ability to utilize its deferred tax assets, a valuation allowance for the full amount of the deferred tax assets has been established at September 30, 2016. As a result of this valuation allowance there are no income tax benefits reflected in the accompanying statement of operations to offset pre-tax losses.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The Company has no uncertain tax positions as of September 30, 2016.</p><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><b>8. Subsequent Events</b></p><p style="COLOR: black; MARGIN: 0px" align="justify"><strong></strong>&nbsp;</p><p style="MARGIN: 0px"><b><i>Convertible Preferred Stock Issuance</i></b></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">In October 2016, the Company sold 500 shares of convertible preferred stock with a purchase price of $1,000 per share for gross proceeds of $500,000 to a healthcare investment fund under the Series C Preferred Stock Agreement. Each share of Preferred Stock is convertible into 2,500 shares of common stock which results in an effective conversion price of $0.40 per common share. This results in the reduction of the conversion price of the Series B Preferred Stock to $ 0.40 and a reduction in the exercise price of the Series B warrants to $ 0.40. As part of the terms of the Series&nbsp;C Preferred Stock agreement, the Company entered into a Registration Rights Agreement with the purchaser to file a registration statement to register for resale the shares of common stock underlying the preferred shares within 30 days following the closing of the agreement.</p><p style="MARGIN: 0px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><b style="MARGIN: 0px"><i>Technology License Agreement</i></b></p><p style="COLOR: black; MARGIN: 0px" align="justify"><strong><em></em></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">In October 2016, the Company entered into a technology license agreement with a third-party manufacturing company in order to biosynthetically manufacture cannabinoids. The terms of the agreement call for an initial payment of $50,000 along with a common stock issuance equal to $50,000 of the Company&rsquo;s common stock based on the 10 -day volume-weighted average closing price calculated from the effective date of the agreement.</p><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><table id="pagebreak2c5b5555-820e-45da-a450-586ffc3473c9" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">    <tr><td class="hpbhr">&nbsp;</td></tr><tr><td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">21</td></tr><tr></tr><tr><td><div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr><tr><td><a href="#toc">Table of Contents</a></td></tr></table></p><p style="MARGIN: 0px">&nbsp;&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b style="MARGIN: 0px"><u><a name="Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.">Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.</a></u></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><strong><u></u></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><i>The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements for the three and nine months ended September 30, 2016, the year ended December 31, 2015, and the year ended December 31, 2014 together with notes thereto. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors, including, but not limited, to those set forth under "Risk Factors" and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2015 and this Quarterly Report on Form 10-Q.</i></p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><em></em>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><i>Unless otherwise provided in this Quarterly Report, references to "we," "us," "our" and "Nemus" in this discussion and analysis refer to Nemus Bioscience, Inc., a Nevada corporation formerly known as Load Guard Logistics, Inc. ("LGL"), together with its wholly-owned subsidiary, Nemus, a California corporation ("Nemus"). Nemus became the wholly owned subsidiary of Nemus Bioscience, Inc. through the closing of a reverse merger transaction (the "Merger") pursuant to which a wholly owned subsidiary of LGL formed solely for the purpose of the Merger merged with and into Nemus and LGL changed its name to Nemus Bioscience, Inc.</i></p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><em></em>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><i>The Merger is accounted for as a reverse merger and recapitalization, with Nemus as the acquirer and LGL as the acquired company for financial reporting purposes. As a result, the assets and liabilities and the operations that will be reflected in the historical financial statements prior to the Merger will be those of Nemus and will be recorded at the historical cost basis of Nemus, and the consolidated financial statements after completion of the Merger will include the assets and liabilities of LGL and Nemus, the historical operations of Nemus and the operations of the combined enterprise of LGL and Nemus from and after the closing date of the Merger.</i></p><p style="COLOR: black; MARGIN: 0px" align="justify"><em></em>&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><b>Overview</b></p><p style="COLOR: black; MARGIN: 0px" align="justify"><strong></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We are a biopharmaceutical company focused on the discovery, development, and the commercialization of cannabis-based therapeutics, or cannabinoids, through our partnership with the University of Mississippi, or UM. UM has held the only contract to cultivate cannabis for research purposes on behalf of the Federal Government since 1968, and it has significant expertise in cannabis cultivation and the extraction, separation, process and manufacture of cannabis extracts. We are currently UM's sole partner for the development and commercialization of drugs derived from cannabis extracts, or cannabinoids, and the realization of this partnership will depend on the successful navigation of the complex regulatory framework for the cultivation and handling of cannabis in the United States.</p><p style="COLOR: black; MARGIN: 0px" align="justify"><b></b>&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><b>Recent Events</b></p><p style="COLOR: black; MARGIN: 0px" align="justify"><strong></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><u>UM 5050 pro-drug agreements</u>:</p><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">On September 29, 2014, the Company executed three license agreements with UM pursuant to which UM granted us exclusive, perpetual, worldwide licenses, including the right to sublicense, to intellectual property related to UM 5050, a pro-drug formulation of tetrahydrocannabinol, or THC for products administered through each of ocular, oral or rectal delivery. The license agreement for the field of oral delivery also includes rights to UM 1250, a bio-adhesive hot melt extruded film for topical and mucosal adhesion application and drug delivery. The license agreements contain certain milestone and royalty payments, as defined therein. There is an annual fee of $25,000 per license agreement, payable on the anniversary of each effective date. The aggregate milestone payments under the license agreements if the milestones are achieved is $2.1 million. These licenses also require the Company to reimburse UM for patent costs incurred related to these products under license. The agreements will terminate upon expiration of the patents, breach or default of the license agreements, or upon 60 days&rsquo; written notice by the Company to UM.</p><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">On October 15, 2014, we signed a renewable option agreement for the rights to explore other routes of delivery of UM5050 not yet agreed upon and/or in combination with other cannabinoids or other compatible compounds. There was a one-time up-front option payment of $10,000 for a six-month option period. This option was subsequently renewed for the period October 1, 2016 to December 14, 2016 to coincide with the UM8930 annual license renewal. The option payment for this shortened period is $2,500 due and payable on October 31, 2016.</p><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><table id="pagebreak1a1d3028-ab63-4e3a-a9fd-99bf9dbba15c" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">    <tr><td class="hpbhr">&nbsp;</td></tr><tr><td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">22</td></tr><tr></tr><tr><td><div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr><tr><td><a href="#toc">Table of Contents</a></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><u>UM 8930 pro-drug agreements:</u></p><p style="COLOR: black; MARGIN: 0px" align="justify"><u></u>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">On December 14, 2015, the Company executed two license agreements with UM pursuant to which UM granted us exclusive, perpetual, worldwide licenses, including the right to sublicense, to intellectual property related to UM 8930, a pro-drug formulation of cannabidiol, or CBD for products administered through each of ocular or rectal delivery. The license agreements contain certain milestone and royalty payments, as defined therein. There is a one-time upfront payment of $65,000 per license agreement, payable in four equal monthly installments that started on December 15, 2015. There is an annual fee of $25,000 per license agreement, payable on the anniversary of each effective date. The aggregate milestone payments under the license agreements if the milestones are achieved is $1.4 million. These licenses also require the Company to reimburse UM for patent costs incurred related to these products under license. These license agreements will terminate upon expiration of the patents, breach or default of the license agreements, or upon 60 days&rsquo; written notice by the Company to UM.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">On December 14, 2015, we signed a renewable option agreement for the rights to explore other routes of delivery of UM8930 not yet agreed upon and/or in combination with other cannabinoids or other compatible compounds. There was a one-time up-front option payment of $10,000 for an option period ending March 31, 2016. This option was subsequently renewed for the period from October 1, 2016 to December 14, 2016 to coincide with the UM8930 annual license renewal. The option payment for this shortened period is $2,500 due and payable on October 31, 2016.</p><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b>Critical Accounting Policies and Estimates</b></p><strong></strong><p style="COLOR: black; MARGIN: 0px" align="justify"><strong></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Our Management's Discussion and Analysis of Financial Condition and Results of Operations section discusses our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments, including those related to revenue recognition, accrued expenses, financing operations, and contingencies and litigation. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The most significant accounting estimates inherent in the preparation of our financial statements include estimates as to the appropriate carrying value of certain assets and liabilities which are not readily apparent from other sources.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">During the quarter ended September 30, 2016, there were no significant changes to the items that were disclosed as our critical accounting policies and estimates in Note 1 to our financial statements for the year ended December 31, 2015 contained in our Annual Report on Form 10-K as filed with the SEC on March 21, 2016.</p><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><b>Results of Operations</b></p><p style="COLOR: black; MARGIN: 0px" align="justify"><strong></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><b style="MARGIN: 0px"><i>For the three months ended September 30, 2016 and 2015</i></b></p><p style="COLOR: black; MARGIN: 0px" align="justify"><strong><em></em></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><b>Revenues.</b> To date, we have not generated any revenues, and do not expect to generate any revenue from the sale of products in the near future.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><b>Operating expenses.</b> For the three months ended September 30, 2016, our total operating expenses were $856,148 as compared to $896,292 for the three months ended September 30, 2015. The slight decrease in operating expenses was due to the items noted below:</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><u>Research and development.</u> Research and development expenses for the three months ended September 30, 2016 were $80,525 which consisted of license renewal fees with the University of Mississippi and contract research and development fees for several projects completed during the quarter. </p><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><table id="pagebreak8c9e81d9-626b-4d17-87cc-59ddf96ee56d" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">    <tr><td class="hpbhr">&nbsp;</td></tr><tr><td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">23</td></tr><tr></tr><tr><td><div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr><tr><td><a href="#toc">Table of Contents</a></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify">Research and development expenses for the three months ended September 30, 2015, were $152,288 which consisted of license renewal fees and contract research and development fees incurred by UM to begin studies concerning the medical utility of cannabinoids as anti-infective therapeutics for MRSA and glaucoma.</p><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><u>General and administrative</u>. General and administrative expenses for the three months ended September 30, 2016 were $775,623 which primarily consisted of salaries, stock compensation expense, consulting fees and professional fees. By comparison, general and administrative expenses for the three months ended September 30, 2015 were $744,004 which primarily consisted of the same components. However, stock compensation expense for the three months ended September 30, 2015 was $4,286 as compared to $181,608 for the three months ended September 30, 2016 due to the cancellation of stock options related to the company&rsquo;s former chief executive officer in August 2015.</p><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><b>Other income and expenses.</b> For the three months ended September 30, 2016, the Company had non-operating expense of $88,723 which consisted of the following components:</p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0" >    <tr height="15"><td width="4%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p></td><td valign="top" width="4%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">$27,665 represented a change in the fair value of the Series B warrant liability as determined by a third party independent valuation conducted as of September 30, 2016; the increase in the warrant value was primarily attributable to the decline in the fair value of the company's common stock.</p></td></tr><tr height="15"><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr height="15"><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">$61,058 represented a change in the fair value of the conversion right related to the Series B preferred stock issuance as estimated from the same valuation referenced above.</p></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify">For the three months ended September 30, 2015, the Company had non-operating expenses of $286,000 which represented a change in the fair value of the conversion right related to the Series A preferred stock issuance. This loss was estimated by determining the highest probability of a per share price in the next anticipated round of financing after considering all discussions with bankers, potential investors and preliminary term sheets. This amount represents the incremental value of shares that would be required to be issued to the preferred stockholders in the event of a subsequent down-round financing.</p><p style="COLOR: black; MARGIN: 0px" align="justify"><b></b>&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><b>Net loss.</b> For the three months ended September 30, 2016, we had a net loss of $945,271 as compared to a net loss of $1,182,792 for the three months ended September 30, 2015. We expect to incur net losses for the foreseeable future.</p><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b><i>For the nine months ended September 30, 2016 and 2015</i></b></p><p style="COLOR: black; MARGIN: 0px" align="justify"><b></b>&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><b>Revenues.</b> To date, we have not generated any revenues, and do not expect to generate any revenue from the sale of products in the near future.</p><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><b>Operating expenses.</b> For the nine months ended September 30, 2016, our total operating expenses were $3,558,522 as compared to $3,162,661 for the nine months ended September 30, 2015. The increase in operating expenses was due primarily to an increase in research and development costs as the company advances its drug development programs offset somewhat by a decline in general and administrative expenses, as discussed below.</p><p style="COLOR: black; MARGIN: 0px" align="justify"><u></u>&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><u>Research and development.</u> Research and development expenses for the nine months ended September 30, 2016 were $675,840 which consisted of contract R&amp;D fees incurred by the University of Mississippi for various research projects, process development fees incurred by the Company's contract manufacturer that were not present in 2015, and consulting and professional services fees.</p><p style="COLOR: black; MARGIN: 0px" align="justify">Research and development expenses for the nine months ended September 30, 2015, were $232,862 which consisted of option fees and contract research and development fees incurred by UM to begin studies concerning the medical utility of cannabinoids as anti-infective therapeutics for MRSA.</p><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><u>General and administrative</u>. General and administrative expenses for the nine months ended September 30, 2016 were $2,882,682 which primarily consisted of salaries, stock compensation expense, consulting fees and professional fees. By comparison, general and administrative expenses for the nine months ended September 30, 2015 were $2,929,799 which primarily consisted of consulting fees and professional fees associated with our costs of becoming a public company.</p><p style="COLOR: black; MARGIN: 0px" align="justify"><b></b>&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><table id="pagebreakb4a83216-9f41-4909-beb1-55e3a7432c4a" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">    <tr><td class="hpbhr">&nbsp;</td></tr><tr><td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">24</td></tr><tr></tr><tr><td><div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr><tr><td><a href="#toc">Table of Contents</a></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><b>Other income and expenses.</b> For the nine months ended September 30, 2016, the Company had non-operating income of $1,502,097 which consisted of the following components:</p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0" >    <tr height="15"><td width="4%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p></td><td valign="top" width="4%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">$1,584,969 of income from the cumulative change in the fair value of the Series B warrant liability as determined by third party independent appraisal conducted as of March 31, 2016, June 30, 2016, and September 30, 2016; the decrease in the warrant value was primarily attributable to the decline in the fair value of the company's common stock.</p></td></tr><tr height="15"><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr height="15"><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">$82,872 of expense from the cumulative change in the fair value of the conversion right related to the Series B preferred stock issuance as estimated from the same valuation referenced above.</p></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify">For the nine months ended September 30, 2015, the Company had non-operating expenses of $986,000 which represented a change in the fair value of the conversion right related to the Series A preferred stock issuance. This loss was estimated by determining the highest probability of a per share price in the next anticipated round of financing after considering all discussions with bankers, potential investors and preliminary term sheets.</p><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><b>Net loss.</b> For the nine months ended September 30, 2016, we had a net loss of $2,057,625 as compared to a net loss of $4,149,977 for the nine months ended September 30, 2015. We expect to incur net losses for the foreseeable future.</p><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><b>Liquidity and Capital Resources</b></p><p style="COLOR: black; MARGIN: 0px" align="justify"><strong></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We had cash and cash equivalents of $319,930 as of September 30, 2016, as compared to $3,221,209 as of December 31, 2015. This decrease is primarily attributable to the funding of operating expenses as previously discussed. We anticipate that we will continue to incur net losses into the foreseeable future as we continue to advance and develop a number of potential drug candidates into preclinical development activities and expand our corporate infrastructure which includes the costs associated with being a public company. In October 2016, we raised an additional $500,000 (see note 8) to be utilized to fund operations. Without additional funding, management believes that we will not have sufficient funds to meet its obligations within one year after the date the consolidated financial statements are issued. These conditions give rise to substantial doubt as to our ability to continue as a going concern.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We have been, and intend to continue, working toward identifying and obtaining new sources of financing. No assurances can be given that we will be successful in obtaining additional financing in the future. Any future financing that we may obtain may cause significant dilution to existing stockholders. Any debt financing or other financing of securities senior to common stock that we are able to obtain will likely include financial and other covenants that will restrict our flexibility. Any failure to comply with these covenants would have a negative impact on our business, prospects, financial condition, results of operations and cash flows.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">If adequate funds are not available, we may be required to delay, scale back or eliminate portions of our operations or obtain funds through arrangements with strategic partners or others that may require us to relinquish rights to certain of our assets. Accordingly, the inability to obtain such financing could result in a significant loss of ownership and/or control of our assets and could also adversely affect our ability to fund our continued operations and our expansion efforts.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">During the next twelve months, we expect to incur significant research and development expenses with respect to our products. The majority of our research and development activity is focused on development of potential drug candidates and preclinical trials.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We also expect to incur significant legal and accounting costs in connection with being a public company. We expect those fees will be significant and will continue to impact our liquidity. Those fees will be higher as our business volume and activity increases.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We anticipate that we will need to hire additional employees or independent contractors for our new laboratory at UM. We also anticipate that we will need to purchase or lease additional equipment for the Company's headquarters and laboratory facilities.<b style="MARGIN: 0px"><u>   <p style="MARGIN: 0px"><p style="MARGIN: 0px"><p style="COLOR: black; MARGIN: 0px" align="justify"></u></b><table id="pagebreak5cc21e94-d3fe-4bdb-8d6f-59878ea4d19b" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">    <tr><td class="hpbhr">&nbsp;</td></tr><tr><td style="BORDER-BOTTOM: black 1px solid"><p style="MARGIN: 0px" align="center">25</p></td></tr><tr></tr><tr><td><div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr><tr><td><a href="#toc">Table of Contents</a></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><strong><u>Off-Balance Sheet Arrangements</u></strong></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><strong><u></u></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">There are no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 0.5in" align="justify">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b style="MARGIN: 0px"><u><a name="Item 3. Quantitative and Qualitative Disclosures about Market Risk.">Item 3. Quantitative and Qualitative Disclosures about Market Risk.</a></u></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><strong><u></u></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Not applicable.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b style="MARGIN: 0px"><u><a name="Item 4. Controls and Procedures.">Item 4. Controls and Procedures.</a></u></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><strong><u></u></strong>&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b>Evaluation of disclosure controls and procedures.</b> We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management including our principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosures. In designing and evaluating the disclosure controls and procedures, management recognizes that any control and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</p><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify">We conducted an evaluation, under the supervision and with the participation of our principal executive and financial officers, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based upon that evaluation and subject to the foregoing, the principal executive and financial officers have concluded that, as of the end of the period covered by this report, the disclosure controls and procedures were effective at a reasonable assurance level.</p><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><b>Changes in internal controls over financial reporting.</b> There were no changes in our internal control over financial reporting that occurred during the fiscal quarter covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><table id="pagebreak46126cb5-ddaa-4219-9d58-83ab099bd4af" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">    <tr><td class="hpbhr">&nbsp;</td></tr><tr><td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">26</td></tr><tr></tr><tr><td><div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr><tr><td><a href="#toc">Table of Contents</a></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="center"><b><a name="PART II - OTHER INFORMATION">PART II&nbsp;- OTHER INFORMATION</a></b></p><p style="COLOR: black; MARGIN: 0px" align="justify"><strong></strong>&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b style="MARGIN: 0px"><u><a name="Item 1. Legal Proceeding">Item 1. Legal Proceeding</a></u></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><strong><u></u></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify">On August 3, 2016, John B. Hollister, the Company&rsquo;s former Chief Executive Officer, filed to dismiss his complaint against the Company and its Executive Chairman, and the Company and its Executive Chairman filed to dismiss their complaint against Hollister filed on January 25, 2016 containing claims against him for defamation, false light, unfair competition, breach of contract, breach of fiduciary duty and fraud.</p><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify">Hollister's employment as the Company's Chief Executive Officer was terminated by the Company on August 24, 2015 for good and lawful reasons by the Company's Board of Directors as the Company decided to go in a different direction. As stated in the Company's December 28, 2015 Form 8-K, the Company maintains that Hollister's complaint and subsequent pleadings were grossly inaccurate and his claims were entirely without merit alleging various causes of action arising out of his termination, including a breach of contract claim.</p><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify">Neither the Company nor its Executive Chairman made any payment to Hollister to resolve the lawsuit or otherwise.</p><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify">According to the Orange County Superior Court's online case records posted on August 11, 2016, the court entered the order for dismissal of the entire action with prejudice effective as of the&nbsp;August 3, 2016 filing date. </p><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b style="MARGIN: 0px"><u><a name="Item 1A. Risk Factors.">Item 1A. Risk Factors.</a></u></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><strong><u></u></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Investing in our common stock involves a high degree of risk. Our Annual Report on Form 10-K for the year ended December 31, 2015 includes a detailed discussion of risk factors that could affect our financial performance and could cause our actual results for future periods to differ materially from our anticipated results or other expectations, including those expressed in any forward-looking statements made in this Form 10-Q, under the heading "Part I, Item 1A-Risk Factors." There are no changes from the risk factors previously disclosed in our Annual Report on Form 10-K. You should carefully consider the risk factors discussed in our Annual Report on Form 10-K as well as the other information in this report before deciding whether to invest in shares of our common stock. The occurrence of any of the risks discussed in the Annual Report on Form 10-K could harm our business, financial condition, results of operations or growth prospects. In that case, the trading price of our common stock could decline, and you may lose all or part of your investment.</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b style="MARGIN: 0px"><u><a name="Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</a></u></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><strong><u></u></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">None</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b style="MARGIN: 0px"><u><a name="Item 3. Defaults Upon Senior Securities.">Item 3. Defaults Upon Senior Securities.</a></u></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><strong><u></u></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px 0px 0px 45px" align="justify">None.</p><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><b style="MARGIN: 0px"><u><a name="Item 4. Mine Safety Disclosures.">Item 4. Mine Safety Disclosures.</a></u></b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><strong><u></u></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Not applicable.</p><p style="COLOR: black; MARGIN: 0px" align="justify">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><b style="MARGIN: 0px"><u><a name="Item 5. Other Information.">Item 5. Other Information.</a></u></b></p><p style="COLOR: black; MARGIN: 0px" align="justify"><strong><u></u></strong>&nbsp;</p><p style="COLOR: black; MARGIN: 0px; TEXT-INDENT: 45px" align="justify">None.</p><p style="COLOR: black; MARGIN: 0px" align="justify"><table id="pagebreakd6c08ce3-b88a-4b20-873c-9131b982c923" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">    <tr><td class="hpbhr">&nbsp;</td></tr><tr><td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">27</td></tr><tr></tr><tr><td><div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr><tr><td><a href="#toc">Table of Contents</a></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="COLOR: black; MARGIN: 0px" align="justify"><b style="MARGIN: 0px"><u><a name="Item 6. Exhibits.">Item 6. Exhibits.</a></u></b></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0" >    <tr height="15" bgcolor="#cceeff"><td valign="top" width="8%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><a href="nmus_ex311.htm">31.1</a></p></td><td width="2%"></td><td valign="top" width="90%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><a href="nmus_ex311.htm">Certification of Principal Executive Officer, pursuant to Rule 13a-14 or 15d-14 of the Securities Exchange Act of 1934</a></p></td></tr><tr height="15" bgcolor="#ffffff"><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr height="15" bgcolor="#cceeff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><a href="nmus_ex312.htm">31.2</a></p></td><td></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><a href="nmus_ex312.htm">Certification of Principal Financial Officer, pursuant to Rule 13a-14 or 15d-14 of the Securities Exchange Act of 1934</a></p></td></tr><tr height="15" bgcolor="#ffffff"><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr height="15" bgcolor="#cceeff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><a href="nmus_ex321.htm">32.1+</a></p></td><td></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><a href="nmus_ex321.htm">Certification of Principal Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></p></td></tr><tr height="15" bgcolor="#ffffff"><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr height="15" bgcolor="#cceeff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><a href="nmus_ex322.htm">32.2+</a></p></td><td></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><a href="nmus_ex322.htm">Certification of Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></p></td></tr><tr height="15" bgcolor="#ffffff"><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr height="15" bgcolor="#cceeff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">101.ins</p></td><td></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">Instance Document</p></td></tr><tr height="15" bgcolor="#ffffff"><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr height="15" bgcolor="#cceeff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">101.sch</p></td><td></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">XBRL Taxonomy Schema Document</p></td></tr><tr height="15" bgcolor="#ffffff"><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr height="15" bgcolor="#cceeff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">101.cal</p></td><td></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">XBRL Taxonomy Calculation Linkbase Document</p></td></tr><tr height="15" bgcolor="#ffffff"><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr height="15" bgcolor="#cceeff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">101.def</p></td><td></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">XBRL Taxonomy Definition Linkbase Document</p></td></tr><tr height="15" bgcolor="#ffffff"><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr height="15" bgcolor="#cceeff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">101.lab</p></td><td></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">XBRL Taxonomy Label Linkbase Document</p></td></tr><tr height="15" bgcolor="#ffffff"><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr height="15" bgcolor="#cceeff"><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">101.pre</p></td><td></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">XBRL Taxonomy Presentation Linkbase Document</p></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><b>&nbsp;+ </b>Furnished herewith and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.</p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><table id="pagebreakc8178a2f-9853-40b1-b19c-9848c239aa03" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">    <tr><td class="hpbhr">&nbsp;</td></tr><tr><td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">28</td></tr><tr></tr><tr><td><div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr><tr><td>&nbsp;</td></tr></table></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b><a name="SIGNATURES">SIGNATURES</a></b></p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p><p style="MARGIN: 0px">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized</p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0" >    <tr height="15"><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p></td><td valign="top" colspan="2"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><b>Nemus Bioscience, Inc.,</b></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><b>a Nevada corporation</b></p></td><td valign="top"></td></tr><tr height="15"><td valign="top" width="50%"></td><td valign="top" width="3%"></td><td valign="top" width="35%"></td><td valign="top" width="12%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p></td></tr><tr height="15"><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">November 9, 2016</p></td><td><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">By:</p></td><td style="BORDER-BOTTOM: 1px solid"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;<i>/s/ Brian Murphy</i></p></td><td valign="top"></td></tr><tr height="15"><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">Brian Murphy</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr height="15"><td valign="top"></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">Its:</p></td><td valign="bottom"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">Chief Executive Officer</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">(Principal Executive Officer)</p></td><td valign="top"></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0" >    <tr height="15"><td valign="top" width="50%">November 9, 2016</td><td width="3%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">By:</p></td><td style="BORDER-BOTTOM: 1px solid" width="35%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;<i>/s/ Elizabeth Berecz</i></p></td><td width="12%"></td></tr><tr height="15"><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">Elizabeth Berecz</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr height="15"><td valign="top"></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">Its:</p></td><td valign="bottom"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">Chief Financial Officer</p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">(Principal Financial and Accounting Officer)</p></td><td valign="bottom"></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cols="1" cellpadding="0" width="100%" align="center" border="0" >    <tr><td style="BORDER-BOTTOM: black 1px solid"><p style="MARGIN: 0px" align="center">29</p></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p></BODY></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>nmus_ex311.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>nmus_ex311.htm</title><!--Document Created by EDGARMaster--></head><BODY spellcheck="true" style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN; MARGIN: 0px 7%" scroll="yes"><p style="MARGIN: 0px" align="right"><strong>EXHIBIT 31.1</strong></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>Certification of Principal Executive Officer,</b></p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>Required By Rule 13a-14(A) of the Securities Exchange Act of 1934, As Amended,</b></p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>As Adopted Pursuant To Section&nbsp;302 of the Sarbanes-Oxley Act of 2002</b></p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">I, Brian Murphy, certify that:</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p><p style="MARGIN: 0px" align="left"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0" >    <tr><td valign="top" width="3%">1.</td><td valign="top">I have reviewed this quarterly report on Form 10-Q of Nemus Bioscience, Inc.;</td></tr><tr><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><tr><td valign="top" width="3%">2.</td><td valign="top">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</td></tr><tr><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><tr><td valign="top" width="3%">3.</td><td valign="top">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</td></tr><tr><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><tr><td valign="top" width="3%">4.</td><td valign="top">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</td></tr></tr></tr></tr></table></p><p style="MARGIN: 0px">&nbsp;&nbsp;</p><p style="MARGIN: 0px" align="left"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0" >    <tr><td valign="top" width="3%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="top" width="3%">(a)</td><td valign="top">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</td></tr><tr><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><tr><td valign="top" width="3%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="top" width="3%">(b)</td><td valign="top">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</td></tr><tr><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><tr><td valign="top" width="3%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="top" width="3%">(c)</td><td valign="top">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</td></tr><tr><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><tr><td valign="top" width="3%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="top" width="3%">(d)</td><td valign="top">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</td></tr></tr></tr></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px" align="left"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0" >    <tr><td valign="top" width="3%">5.</td><td valign="top">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px" align="left"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0" >    <tr><td valign="top" width="3%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="top" width="3%">(a)</td><td valign="top">All significant deficiencies and material weaknesses <b></b>in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</td></tr><tr><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><tr><td valign="top" width="3%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="top" width="3%">(b)</td><td valign="top">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</td></tr></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px" align="left">&nbsp;</p><p style="MARGIN: 0px"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0" >    <tr height="15"><td width="50%"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">Date: November 9, 2016</p></td><td width="3%">By:</td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="35%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><em>&nbsp;/s/ Brian Murphy</em></p></td><td valign="top" width="12%"></td></tr><tr height="15"><td></td><td></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">Brian Murphy</p></td><td></td></tr><tr height="15"><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">Chief Executive Officer</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td></tr></table></p></BODY></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>nmus_ex312.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>nmus_ex312.htm</title><!--Document Created by EDGARMaster--></head><BODY spellcheck="true" style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN; MARGIN: 0px 7%" scroll="yes"><p style="MARGIN: 0px" align="right"><b>EXHIBIT 31.2</b></p><p style="MARGIN: 0px" align="right">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>Certification of Principal Financial Officer,</b></p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>Required By Rule 13a-14(A) of the Securities Exchange Act of 1934, As Amended,</b></p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>As Adopted Pursuant To Section&nbsp;302 of the Sarbanes-Oxley Act of 2002</b></p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">I, Elizabeth Berecz, certify that:</p><p style="MARGIN: 0px" align="center">&nbsp;</p><p style="MARGIN: 0px" align="center"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0" >    <tr height="15"><td valign="top" width="3%"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">1.</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">I have reviewed this quarterly report on Form 10-Q of Nemus Bioscience, Inc.;</p></td></tr><tr height="15"><td></td><td><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr height="15"><td valign="top" width="3%"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">2.</p><p style="MARGIN: 0px">&nbsp;</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr><tr height="15"><td></td><td><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr height="15"><td valign="top" width="3%"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">3.</p><p style="MARGIN: 0px">&nbsp;</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr><tr height="15"><td></td><td><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr height="15"><td valign="top" width="3%"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">4.</p><p style="MARGIN: 0px">&nbsp;</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px" align="left"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0" >    <tr><td valign="top" width="3%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="top" width="3%">(a)</td><td valign="top">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</td></tr><tr><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><tr><td valign="top" width="3%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="top" width="3%">(b)</td><td valign="top">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</td></tr><tr><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><tr><td valign="top" width="3%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="top" width="3%">(c)</td><td valign="top">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and<b></b></td></tr><tr><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><tr><td valign="top" width="3%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="top" width="3%">(d)</td><td valign="top">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</td></tr></tr></tr></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px" align="left"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0" >    <tr><td valign="top" width="3%">5.</td><td valign="top">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</td></tr></table></p><p style="MARGIN: 0px" align="left">&nbsp;</p><p style="MARGIN: 0px"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0" >    <tr><td valign="top" width="3%"><p style="MARGIN: 0px">&nbsp;</p></td><td valign="top" width="3%">(a)</td><td valign="top">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0" >    <tr height="15"><td valign="top" width="3%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p></td><td valign="top" width="3%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">(b)</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</p></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0" >    <tr height="15"><td width="50%"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">Date: November 9, 2016</p></td><td width="3%">By:</td><td style="BORDER-BOTTOM: 1px solid" valign="top" width="35%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><i>/s/ Elizabeth Berecz</i></p></td><td width="12%"></td></tr><tr height="15"><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">Elizabeth Berecz</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr height="15"><td></td><td></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">Chief&nbsp;Financial Officer</p></td><td></td></tr></table></p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p></BODY></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>nmus_ex321.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>nmus_ex321.htm</title><!--Document Created by EDGARMaster--></head><BODY spellcheck="true" style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN; MARGIN: 0px 7%" scroll="yes"><p style="MARGIN: 0px" align="right"><b>EXHIBIT 32.1</b></p><p style="MARGIN: 0px" align="right">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>Certification of Principal Executive Officer, pursuant to 18 U.S.C. Section&nbsp;1350,</b></p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002</b></p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p><p style="MARGIN: 0px">In connection with the Quarterly Report of Nemus Bioscience, Inc. a Nevada corporation (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended September 30, 2016, as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), Brian Murphy, Chief Executive Officer of the Company, certifies to the best of his knowledge, pursuant to 18&nbsp;U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that</p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0" >    <tr height="15"><td valign="top" width="3%"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">(1)</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr><tr height="15"><td></td><td><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr height="15"><td valign="top" width="3%"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">(2)</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p></td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0" >    <tr height="15"><td width="50%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">Date: November 9, 2016</p></td><td width="3%">By:</td><td style="BORDER-BOTTOM: 1px solid" valign="top" width="35%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><i>/s/ Brian Murphy</i></p></td><td width="12%"></td></tr><tr height="15"><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">Brian Murphy</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr height="15"><td></td><td></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">Chief Executive Officer</p></td><td></td></tr></table><br></p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p></BODY></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>nmus_ex322.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>nmus_ex322.htm</title><!--Document Created by EDGARMaster--></head><BODY spellcheck="true" style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN; MARGIN: 0px 7%" scroll="yes"><p style="MARGIN: 0px" align="right"><b>EXHIBIT 32.2</b></p><p style="MARGIN: 0px" align="right">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>Certification of Principal&nbsp;Financial Officer, pursuant to 18 U.S.C. Section&nbsp;1350,</b></p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002</b></p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p><p style="MARGIN: 0px">In connection with the Quarterly Report of Nemus Bioscience, Inc. a Nevada corporation (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended September 30, 2016, as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;),&nbsp;Elizabeth Berecz, Chief Financial Officer of the Company, certifies to the best of her knowledge, pursuant to 18&nbsp;U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p><p style="MARGIN: 0px" align="left"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0" >    <tr><td valign="top" width="3%">(1)</td><td valign="top">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</td></tr><tr><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><tr><td valign="top" width="3%">(2)</td><td valign="top">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</td></tr></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0" >    <tr height="15"><td width="50%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">Date: November 9, 2016</p></td><td width="3%">By:</td><td style="BORDER-BOTTOM: 1px solid" valign="top" width="35%"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><em>/s/ Elizabeth Berecz</em></p></td><td width="12%"></td></tr><tr height="15"><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td><td><p style="MARGIN: 0px">Elizabeth Berecz</p></td><td><p style="MARGIN: 0px">&nbsp;</p></td></tr><tr height="15"><td></td><td></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">Chief&nbsp;Financial Officer</p></td><td></td></tr></table></p><p style="MARGIN-BOTTOM: 0px; COLOR: black; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p></BODY></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>nmus-20160930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!-- Generated using Ez-XBRL version 8.0.0.0 [11/06/2016 07:25:59 PM] -->
<!-- Based on XBRL 2.1 -->
<!--XBRL Document Modified with Ez-Editor Version 1.6.0.0 on Wednesday, November 09, 2016 01:08:12 AM -->
<xbrli:xbrl xmlns:nmus="http://www.nemusbioscience.com/20160930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:country="http://xbrl.sec.gov/country/2016-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr">
<link:schemaRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:type="simple" xlink:href="nmus-20160930.xsd"/>
<!-- Context Section  -->
<xbrli:context id="Context_As_Of_17_Jul_2012T00_00_00_TO_17_Jul_2012T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-07-17
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jul_2013T00_00_00_TO_31_Jul_2013T00_00_00_LegalEntityAxis_UniversityOfMississippiMember_AgreementAxis_UniversityOfMississippiAgreementsMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:UniversityOfMississippiMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:UniversityOfMississippiAgreementsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-07-01
</xbrli:startDate>
<xbrli:endDate>
2013-07-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AgreementAxis_StockPurchaseAgreementJune2014Member_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:StockPurchaseAgreementJune2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Aug_2014T00_00_00_TO_31_Aug_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-08-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Aug_2014T00_00_00_TO_31_Aug_2014T00_00_00_AgreementAxis_StockPurchaseAgreementJune2014Member_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:StockPurchaseAgreementJune2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-08-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Aug_2014T00_00_00_TO_31_Aug_2014T00_00_00_AgreementAxis_StockPurchaseAgreementJune2014Member_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:StockPurchaseAgreementJune2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-08-01
</xbrli:startDate>
<xbrli:endDate>
2014-08-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Sep_2014T00_00_00_TO_29_Sep_2014T00_00_00_LegalEntityAxis_UniversityOfMississippiMember_AgreementAxis_OptionAgreementMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:UniversityOfMississippiMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:OptionAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-09-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-29
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-09-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2014T00_00_00_TO_15_Oct_2014T00_00_00_LegalEntityAxis_UniversityOfMississippiMember_MonthAndYearOfAgreementAxis_OctoberTwoThousandFifteenMember_AgreementAxis_OptionAgreementMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:UniversityOfMississippiMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="nmus:MonthAndYearOfAgreementAxis">nmus:OctoberTwoThousandFifteenMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:OptionAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-10-01
</xbrli:startDate>
<xbrli:endDate>
2014-10-15
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_BusinessAcquisitionAxis_NemusAcquisitionCorpMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nmus:NemusAcquisitionCorpMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-10-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_AgreementAxis_LeaseAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:LeaseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-10-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-10-01
</xbrli:startDate>
<xbrli:endDate>
2014-10-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_BusinessAcquisitionAxis_NemusAcquisitionCorpMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nmus:NemusAcquisitionCorpMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-10-01
</xbrli:startDate>
<xbrli:endDate>
2014-10-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_AgreementAxis_LeaseAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:LeaseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-10-01
</xbrli:startDate>
<xbrli:endDate>
2014-10-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Oct_2014T00_00_00_TO_31_Dec_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-10-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Jan_2015T00_00_00_TO_31_Jan_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-01-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2015T00_00_00_TO_31_Jan_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2015T00_00_00_TO_31_Mar_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-03-01
</xbrli:startDate>
<xbrli:endDate>
2015-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-03-01
</xbrli:startDate>
<xbrli:endDate>
2015-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-04-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-04-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-04-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-04-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-04-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-04-01
</xbrli:startDate>
<xbrli:endDate>
2015-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-04-01
</xbrli:startDate>
<xbrli:endDate>
2015-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-04-01
</xbrli:startDate>
<xbrli:endDate>
2015-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-04-01
</xbrli:startDate>
<xbrli:endDate>
2015-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_May_2015T00_00_00_TO_31_May_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-05-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_May_2015T00_00_00_TO_31_May_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-05-01
</xbrli:startDate>
<xbrli:endDate>
2015-05-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_May_2015T00_00_00_TO_31_May_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-05-01
</xbrli:startDate>
<xbrli:endDate>
2015-05-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-06-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Jul_2015T00_00_00_TO_31_Jul_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-07-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jul_2015T00_00_00_TO_31_Jul_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-07-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jul_2015T00_00_00_TO_31_Jul_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-07-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_21_Aug_2015T00_00_00_TO_21_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-08-21
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_21_Aug_2015T00_00_00_TO_21_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-08-21
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Aug_2015T00_00_00_TO_21_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-08-01
</xbrli:startDate>
<xbrli:endDate>
2015-08-21
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Aug_2015T00_00_00_TO_21_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-08-01
</xbrli:startDate>
<xbrli:endDate>
2015-08-21
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-08-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-08-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-08-01
</xbrli:startDate>
<xbrli:endDate>
2015-08-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-08-01
</xbrli:startDate>
<xbrli:endDate>
2015-08-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-08-01
</xbrli:startDate>
<xbrli:endDate>
2015-08-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-08-01
</xbrli:startDate>
<xbrli:endDate>
2015-08-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:SeriesBWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementClassOfStockAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2015T00_00_00_TO_20_Oct_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_RestrictedStockMember_RangeAxis_MinimumMember_TitleOfIndividualAxis_ManagementAndBoardOfDirectorsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmus:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">nmus:ManagementAndBoardOfDirectorsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-10-01
</xbrli:startDate>
<xbrli:endDate>
2015-10-20
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2015T00_00_00_TO_20_Oct_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_RestrictedStockMember_RangeAxis_MaximumMember_TitleOfIndividualAxis_ManagementAndBoardOfDirectorsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmus:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">nmus:ManagementAndBoardOfDirectorsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-10-01
</xbrli:startDate>
<xbrli:endDate>
2015-10-20
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2015T00_00_00_TO_20_Oct_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_RestrictedStockMember_TitleOfIndividualAxis_ManagementAndBoardOfDirectorsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmus:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">nmus:ManagementAndBoardOfDirectorsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-10-01
</xbrli:startDate>
<xbrli:endDate>
2015-10-20
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Nov_2015T00_00_00_TO_30_Nov_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-11-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Nov_2015T00_00_00_TO_30_Nov_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-11-01
</xbrli:startDate>
<xbrli:endDate>
2015-11-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Nov_2015T00_00_00_TO_30_Nov_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-11-01
</xbrli:startDate>
<xbrli:endDate>
2015-11-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Dec_2015T00_00_00_TO_14_Dec_2015T00_00_00_AgreementAxis_LicenseAgreementMember_LegalEntityAxis_UniversityOfMississippiMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:LicenseAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:UniversityOfMississippiMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-12-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-14
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Dec_2015T00_00_00_TO_14_Dec_2015T00_00_00_MonthAndYearOfAgreementAxis_December2015Member_AgreementAxis_LicenseAgreementMember_LegalEntityAxis_UniversityOfMississippiMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="nmus:MonthAndYearOfAgreementAxis">nmus:December2015Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:LicenseAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:UniversityOfMississippiMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-12-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-14
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmus:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_OmnibusIncentivePlan2014Member_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmus:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_OmnibusIncentivePlan2014Member_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmus:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-12-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Feb_2016T00_00_00_TO_05_Feb_2016T00_00_00_AgreementAxis_LetterAgreementMember_LegalEntityAxis_ContractManufacturingOrganizationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:LetterAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:ContractManufacturingOrganizationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-02-01
</xbrli:startDate>
<xbrli:endDate>
2016-02-05
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Feb_2016T00_00_00_TO_05_Feb_2016T00_00_00_AgreementAxis_LetterAgreementMember_LegalEntityAxis_ContractManufacturingOrganizationMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:LetterAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:ContractManufacturingOrganizationMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-02-01
</xbrli:startDate>
<xbrli:endDate>
2016-02-05
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Feb_2016T00_00_00_TO_05_Feb_2016T00_00_00_AgreementAxis_LetterAgreementMember_LegalEntityAxis_ContractManufacturingOrganizationMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:LetterAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:ContractManufacturingOrganizationMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-02-01
</xbrli:startDate>
<xbrli:endDate>
2016-02-05
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>


<xbrli:context id="Context_Custom_01_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-03-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>

<xbrli:context id="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_AgreementAxis_LetterAgreementMember_LegalEntityAxis_ContractManufacturingOrganizationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:LetterAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:ContractManufacturingOrganizationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_RestrictedStockMember_TitleOfIndividualAxis_ManagementAndBoardOfDirectorsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmus:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">nmus:ManagementAndBoardOfDirectorsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>

<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_AgreementAxis_StockPurchaseAgreementJune2014Member_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:StockPurchaseAgreementJune2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:SeriesBWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_AgreementAxis_LetterAgreementMember_LegalEntityAxis_ContractManufacturingOrganizationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:LetterAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:ContractManufacturingOrganizationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_RestrictedStockMember_TitleOfIndividualAxis_ManagementAndBoardOfDirectorsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmus:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">nmus:ManagementAndBoardOfDirectorsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmus:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:SeriesBWarrantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:SeriesBWarrantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_LegalEntityAxis_UniversityOfMississippiMember_AgreementAxis_UniversityOfMississippiAgreementsMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:UniversityOfMississippiMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:UniversityOfMississippiAgreementsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_AgreementAxis_StockPurchaseAgreementJune2014Member_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:StockPurchaseAgreementJune2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_LegalEntityAxis_UniversityOfMississippiMember_AgreementAxis_OptionAgreementMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:UniversityOfMississippiMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:OptionAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:SeriesBWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmus:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_OmnibusIncentivePlan2014Member_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmus:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_OmnibusIncentivePlan2014Member_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmus:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-10-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_MajorTypesOfDebtAndEquitySecuritiesAxis_ConvertiblePreferredStockMember_StatementClassOfStockAxis_SeriesCPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-10-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-10-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_StatementClassOfStockAxis_SeriesCWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nmus:SeriesCWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-10-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_MajorTypesOfDebtAndEquitySecuritiesAxis_ConvertiblePreferredStockMember_StatementClassOfStockAxis_SeriesCPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-10-01
</xbrli:startDate>
<xbrli:endDate>
2016-10-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_LicenseAgreementTermsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-10-01
</xbrli:startDate>
<xbrli:endDate>
2016-10-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_08-Nov-2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2016-11-08</xbrli:instant>
</xbrli:period>
</xbrli:context>






<!-- Unit Section  -->
<!--
I~1\FVPHexeD5678YReqi>MrlsywiI~\FVP645:c444c555cT{h><:;89E<I1;5;F18HHH1<E;E1;IE:96G6H8<H -->
<xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="Segments"><xbrli:measure>nmus:Segments</xbrli:measure></xbrli:unit>
<xbrli:unit id="License_agreements"><xbrli:measure>nmus:License_agreements</xbrli:measure></xbrli:unit>
<xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit>
<xbrli:unit id="pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:unit id="Advisors"><xbrli:measure>nmus:Advisors</xbrli:measure></xbrli:unit>
<xbrli:unit id="Investors"><xbrli:measure>nmus:Investors</xbrli:measure></xbrli:unit>
<!-- Element Section  --><dei:EntityRegistrantName contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">Nemus Bioscience, Inc.</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">0001516551</dei:EntityCentralIndexKey>
<dei:TradingSymbol contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">nmus</dei:TradingSymbol>
<dei:CurrentFiscalYearEndDate contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">--12-31</dei:CurrentFiscalYearEndDate>
<dei:EntityFilerCategory contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">Smaller Reporting Company</dei:EntityFilerCategory>
<dei:EntityCommonStockSharesOutstanding contextRef="Context_As_Of_08-Nov-2016T00_00_00" unitRef="shares" decimals="INF">20798163</dei:EntityCommonStockSharesOutstanding>
<dei:DocumentType contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">10-Q</dei:DocumentType>
<dei:DocumentPeriodEndDate contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">2016-09-30</dei:DocumentPeriodEndDate>
<dei:AmendmentFlag contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">false</dei:AmendmentFlag>
<dei:DocumentFiscalYearFocus contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">2016</dei:DocumentFiscalYearFocus>
<dei:DocumentFiscalPeriodFocus contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">Q3</dei:DocumentFiscalPeriodFocus>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">207330</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">4342722</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">3221209</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">319930</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">37500</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">37500</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
<us-gaap:PrepaidExpenseCurrent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">158946</us-gaap:PrepaidExpenseCurrent>
<us-gaap:PrepaidExpenseCurrent contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">249193</us-gaap:PrepaidExpenseCurrent>
<us-gaap:OtherAssetsCurrent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">36126</us-gaap:OtherAssetsCurrent>
<us-gaap:OtherAssetsCurrent contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">28626</us-gaap:OtherAssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">3453781</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">635249</us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">13383</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">12994</us-gaap:PropertyPlantAndEquipmentNet>
<nmus:DepositsAndOtherAssets contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">43884</nmus:DepositsAndOtherAssets>
<nmus:DepositsAndOtherAssets contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">43884</nmus:DepositsAndOtherAssets>
<us-gaap:OtherAssetsNoncurrent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">43884</us-gaap:OtherAssetsNoncurrent>
<us-gaap:OtherAssetsNoncurrent contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">43884</us-gaap:OtherAssetsNoncurrent>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">3511048</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">692127</us-gaap:Assets>
<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">125357</us-gaap:AccountsPayableCurrent>
<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">387373</us-gaap:AccountsPayableCurrent>
<us-gaap:AccruedSalariesCurrent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">46268</us-gaap:AccruedSalariesCurrent>
<us-gaap:AccruedSalariesCurrent contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">71802</us-gaap:AccruedSalariesCurrent>
<nmus:AccruedLicenseAndPatentReimbursementFees contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">97500</nmus:AccruedLicenseAndPatentReimbursementFees>
<nmus:AccruedLicenseAndPatentReimbursementFees contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">80000</nmus:AccruedLicenseAndPatentReimbursementFees>
<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">228645</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">135381</us-gaap:AccruedLiabilitiesCurrent>
<nmus:ProvisionForConversionOfPreferredStock contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">700000</nmus:ProvisionForConversionOfPreferredStock>
<nmus:ProvisionForConversionOfPreferredStock contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">84090</nmus:ProvisionForConversionOfPreferredStock>
<nmus:ProvisionForConversionOfPreferredStock contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">166718</nmus:ProvisionForConversionOfPreferredStock>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">581860</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">841274</us-gaap:LiabilitiesCurrent>
<us-gaap:DeferredRentCreditNoncurrent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">3233</us-gaap:DeferredRentCreditNoncurrent>
<us-gaap:DeferredRentCreditNoncurrent contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilitiesNoncurrent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">2454959</us-gaap:DerivativeLiabilitiesNoncurrent>
<us-gaap:DerivativeLiabilitiesNoncurrent contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">869990</us-gaap:DerivativeLiabilitiesNoncurrent>
<us-gaap:LiabilitiesNoncurrent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">2458192</us-gaap:LiabilitiesNoncurrent>
<us-gaap:LiabilitiesNoncurrent contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">869990</us-gaap:LiabilitiesNoncurrent>
<us-gaap:Liabilities contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">3040052</us-gaap:Liabilities>
<us-gaap:Liabilities contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">1711264</us-gaap:Liabilities>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">1363200</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">1359899</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
<us-gaap:CommonStockValue contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">19903</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">19913</us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">6086987</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">6635345</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:WarrantsAndRightsOutstanding contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">759386</us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:WarrantsAndRightsOutstanding contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">781811</us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:WarrantsAndRightsOutstanding contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="USD" decimals="0">2935800</us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">-7758480</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-9816105</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">-892204</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-2379036</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">3511048</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">692127</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
<us-gaap:TemporaryEquitySharesAuthorized contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="shares" decimals="-6">20000000</us-gaap:TemporaryEquitySharesAuthorized>
<us-gaap:TemporaryEquitySharesAuthorized contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" decimals="-6">20000000</us-gaap:TemporaryEquitySharesAuthorized>
<us-gaap:TemporaryEquitySharesIssued contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="shares" decimals="INF">4500</us-gaap:TemporaryEquitySharesIssued>
<us-gaap:TemporaryEquitySharesIssued contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" decimals="INF">4492</us-gaap:TemporaryEquitySharesIssued>
<us-gaap:TemporaryEquitySharesOutstanding contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="shares" decimals="INF">4500</us-gaap:TemporaryEquitySharesOutstanding>
<us-gaap:TemporaryEquitySharesOutstanding contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" decimals="INF">4492</us-gaap:TemporaryEquitySharesOutstanding>
<nmus:StockIssuanceCosts contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">493770</nmus:StockIssuanceCosts>
<nmus:StockIssuanceCosts contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">493770</nmus:StockIssuanceCosts>
<us-gaap:TemporaryEquityLiquidationPreference contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="-5">4500000</us-gaap:TemporaryEquityLiquidationPreference>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Jan_2015T00_00_00_TO_31_Jan_2015T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="shares" decimals="-6">236000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" decimals="-6">236000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="shares" decimals="INF">19903163</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" decimals="INF">19913163</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_BusinessAcquisitionAxis_NemusAcquisitionCorpMember" unitRef="shares" decimals="INF">16000000</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="shares" decimals="INF">19903163</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" decimals="INF">19913163</us-gaap:CommonStockSharesOutstanding>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">152288</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">232862</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">80525</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_AgreementAxis_LetterAgreementMember_LegalEntityAxis_ContractManufacturingOrganizationMember" unitRef="USD" decimals="0">18896</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">675840</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_AgreementAxis_LetterAgreementMember_LegalEntityAxis_ContractManufacturingOrganizationMember" unitRef="USD" decimals="0">225244</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_01_Oct_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">466200</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">744004</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">2929799</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">775623</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">2882682</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:OperatingExpenses contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">896292</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">3162661</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">856148</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">3558522</us-gaap:OperatingExpenses>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-896292</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-3162661</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-856148</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-3558522</us-gaap:OperatingIncomeLoss>
<nmus:ChangeInFairValueOfWarrantLiability contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">27665</nmus:ChangeInFairValueOfWarrantLiability>
<nmus:ChangeInFairValueOfWarrantLiability contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-1584969</nmus:ChangeInFairValueOfWarrantLiability>
<nmus:GainLossOnConversionRightPreferredStock contextRef="Context_Custom_01_Aug_2015T00_00_00_TO_21_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD" decimals="0">-986000</nmus:GainLossOnConversionRightPreferredStock>
<nmus:GainLossOnConversionRightPreferredStock contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">-286000</nmus:GainLossOnConversionRightPreferredStock>
<nmus:GainLossOnConversionRightPreferredStock contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true"/>
<nmus:GainLossOnConversionRightPreferredStock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">-986000</nmus:GainLossOnConversionRightPreferredStock>
<nmus:GainLossOnConversionRightPreferredStock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true"/>
<nmus:GainLossOnConversionRightPreferredStock contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" xsi:nil="true"/>
<nmus:GainLossOnConversionRightPreferredStock contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD" decimals="0">-61058</nmus:GainLossOnConversionRightPreferredStock>
<nmus:GainLossOnConversionRightPreferredStock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" xsi:nil="true"/>
<nmus:GainLossOnConversionRightPreferredStock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD" decimals="0">-82872</nmus:GainLossOnConversionRightPreferredStock>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-1182292</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-4148661</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-944871</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-2056425</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">500</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">1316</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">400</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">1200</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-1182792</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-4149977</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-945271</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-2057625</us-gaap:NetIncomeLoss>
<us-gaap:Depreciation contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">7290</us-gaap:Depreciation>
<us-gaap:Depreciation contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">11505</us-gaap:Depreciation>
<us-gaap:ShareBasedCompensation contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">263985</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">544823</us-gaap:ShareBasedCompensation>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0" id="Footnote-2_1">529016</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0" id="Footnote-2_2">51539</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0" id="Footnote-1_3">-25800</us-gaap:IncreaseDecreaseInPrepaidExpense>
<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0" id="Footnote-1_4">119361</us-gaap:IncreaseDecreaseInPrepaidExpense>
<us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-5470</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
<us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-7500</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0" id="Footnote-2_3">-267264</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0" id="Footnote-2_4">262016</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">99157</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
<us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">25534</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
<nmus:IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">29212</nmus:IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees>
<nmus:IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">17500</nmus:IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees>
<nmus:IncreaseDecreaseInStockSubscriptionLiability contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">100000</nmus:IncreaseDecreaseInStockSubscriptionLiability>
<nmus:IncreaseDecreaseInStockSubscriptionLiability contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">52899</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
<us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-96497</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-2614336</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-2890163</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">1982</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">11116</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-1982</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-11116</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">721069</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">1442302</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD" decimals="0">4588339</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">6751710</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">4135392</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-2901279</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:InterestPaid contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:InterestPaid contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxesPaid contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">116</us-gaap:IncomeTaxesPaid>
<us-gaap:IncomeTaxesPaid contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<nmus:NoncashValueOfWarrantsIssued contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">417875</nmus:NoncashValueOfWarrantsIssued>
<nmus:NoncashValueOfWarrantsIssued contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">22425</nmus:NoncashValueOfWarrantsIssued>
<us-gaap:StockIssued1 contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">168000</us-gaap:StockIssued1>
<nmus:NoncashValueOfWarrantsIssuedInExchangeForExtinguishmentOfTradeAccountsPayable contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">10000</nmus:NoncashValueOfWarrantsIssuedInExchangeForExtinguishmentOfTradeAccountsPayable>
<us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;1.&amp;#160;Nature of Operations, Business Activities and Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Nature of Operations and Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;Nemus Bioscience, Inc. is a biopharmaceutical company that plans to develop and commercialize therapeutics from cannabinoids through a partnership with the University of Mississippi. The University of Mississippi ("UM") is federally permitted and licensed to cultivate cannabis for research and commercial purposes. Unless otherwise specified, references in these Notes to the Unaudited Consolidated Financial Statements to the "Company," "we" or "our" refer to Nemus Bioscience, Inc., a Nevada corporation formerly known as Load Guard Logistics, Inc. ("LGL"), together with its wholly-owned subsidiary, Nemus, a California corporation ("Nemus"). Nemus became the wholly owned subsidiary of Nemus Bioscience, Inc. through the Merger (as defined below).&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;Nemus Bioscience, Inc. (formerly LGL) was incorporated in Nevada on March 16, 2011. Nemus was incorporated in California on July 17, 2012. Our headquarters are located in Costa Mesa, California.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;As of September 30, 2016, the Company has devoted substantially all of its efforts to securing product licenses, raising capital, and building infrastructure, and has not realized revenue from its planned principal operations.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0.5in; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Business Activities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;On October 31, 2014, pursuant to an Agreement and Plan of Merger, dated October 17, 2014 (the "Merger Agreement"), LGL, Nemus Acquisition Corp. ("Acquisition Sub"), Nemus Bioscience, Inc. ("Name Change Merger Sub"), and Nemus Acquisition Sub merged with and into Nemus and Nemus survived as a wholly-owned subsidiary of LGL (the "Merger"). Immediately after the Merger, LGL changed its name to "Nemus Bioscience, Inc." by merging with Name Change Merger Sub. At the closing of the Merger and pursuant to the Merger Agreement, Nemus issued an aggregate of 3,120,000 shares of its common stock to the former stockholders of LGL in exchange for all of the outstanding shares of LGL's capital stock, which when combined with the 12,880,000 shares of Nemus common stock outstanding, amounted to 16,000,000 total shares outstanding upon completion of the merger.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;The Merger is being accounted for as a reverse-merger and recapitalization. Nemus is the acquirer for financial reporting purposes and LGL is the acquired company. Consequently, the assets and liabilities and the operations that will be reflected in the historical consolidated financial statements prior to the Merger will be those of Nemus and will be recorded at the historical cost basis of Nemus, and the consolidated financial statements after completion of the Merger will include the assets and liabilities of LGL and Nemus, the historical operations of Nemus and the operations of the Nemus from and after the closing date of the Merger.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0.5in; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles ("U.S. GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of our financial statements include estimates as to the appropriate carrying value of certain assets and liabilities which are not readily apparent from other sources.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0.5in; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Liquidity and Going Concern&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;The Company has incurred operating losses and negative cash flows from operations since our inception. As of September 30, 2016, we had cash and cash equivalents of $319,930. In October 2016, we raised an additional $500,000 (see note 8) to be utilized to fund operations. The Company anticipates that it will continue to incur net losses into the foreseeable future as it continues to advance and develop a number of potential drug candidates into preclinical development activities and expands its corporate infrastructure which includes the costs associated with being a public company. Without additional funding, management believes that the Company will not have sufficient funds to meet its obligations within one year after the date the consolidated financial statements are issued. These conditions give rise to substantial doubt as to the Company's ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;The Company plans to continue to fund its operations and capital funding needs through public or private equity or debt financings, strategic collaborations, licensing arrangements, asset sales, government grants or other arrangements. However, the Company cannot be sure that such additional funds will be available on reasonable terms, or at all. If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result. If the Company is unable to secure adequate additional funding, the Company may be forced to make a reduction in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0.5in; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The carrying value of those investments approximates their fair market value due to their short maturity and liquidity. Cash and cash equivalents include cash on hand and amounts on deposit with financial institutions, which amounts may at times exceed federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0.5in; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Restricted Cash&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;A deposit of $37,500 as of September 30, 2016 and December 31, 2015 was restricted from withdrawal and held by a bank in the form of a certificate of deposit. This certificate serves as collateral for payment of the Company's credit cards.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 33.75pt; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Fair Value Measurements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last is considered unobservable, is used to measure fair value:&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align: justify; width: 100%; font: 10pt 'times new roman'; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td valign="top" width="4%"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top" width="6%"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Level 1:&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top" width="90%"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Level 2:&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin: 0px;"&gt;Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Level 3:&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;The carrying values of our financial instruments, including, cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses approximate their fair value due to the short maturities of these financial instruments. The Series B warrant liability and the conversion liability for the Series B preferred stock were valued utilizing Level 3 inputs primarily from a third party independent appraisal conducted as of September 30, 2016.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0.5in; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Property and Equipment, Net&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;As of September 30, 2016, property and equipment, net, was $12,994, consisting primarily of computers and equipment. The Company had $13,383 of property and equipment, net, as of December 31, 2015. Expenditures for additions, renewals and improvements will be capitalized at cost. Depreciation will generally be computed on a straight-line method based on the estimated useful life of the related assets currently ranging from two to three years. Maintenance and repairs that do not extend the life of assets are charged to expense when incurred. When properties are disposed of, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is reported in the period the transaction takes place.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount exceeds its estimated future undiscounted cash flows, an impairment charge is recognized by the amount by which the carrying amount exceeds the fair value of the asset.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;The costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, will be charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where there is an identified alternative future use. No cost associated with the use of licensed technologies has been capitalized to date.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0.5in; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;The Company accounts for our deferred income tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities, and net operating loss carry forwards (the "NOLs") and other tax credit carry forwards. These items are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period that includes the enactment date. Any interest or penalties would be recorded in the Company's statement of operations in the period incurred.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;The Company records a valuation allowance to reduce the deferred income tax assets to the amount that is more likely than not to be realized. In making such determinations, management considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. As a result, there are no income tax benefits reflected in the statement of operations to offset pre-tax losses.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;The Company recognizes a tax benefit from uncertain tax positions when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0.5in; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;The Company has not begun planned principal operations and has not generated any revenue since inception.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0.5in; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Research and Development Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;Research and development ("R&amp;amp;D") costs are expensed when incurred. These costs may consist of external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants; license fees; employee-related expenses, which include salaries, benefits and stock-based compensation for the personnel involved in our preclinical and clinical drug development activities; and facilities expense, depreciation and other allocated expenses; and equipment and laboratory supplies.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0.5in; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Stock-Based Compensation Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;Stock-based compensation cost is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period. We use the Black-Scholes option pricing model for estimating the grant date fair value of stock options and warrants using the following assumptions:&lt;/p&gt;
&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align: justify; width: 100%; font: 10pt 'times new roman'; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="4%"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top" width="4%"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Exercise price - We determined the exercise price based on valuations using the best information available to management at the time of the valuations.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Volatility&amp;#160;- We estimate the stock price volatility based on industry peers who are also in the early development stage given the limited market data available in the public arena.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Expected term - The expected term is based on a simplified method which defines the life as the average of the contractual term of the options and warrants and the weighted-average vesting period for all open awards.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Risk-free rate - The risk-free interest rate for the expected term of the option or warrant is based on the average market rate on U.S. treasury securities in effect during the period in which the awards were granted.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Dividends - The dividend yield assumption is based on our history and expectation of paying no dividends.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Stock-Based Compensation for Non-Employees&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 33.75pt; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;The Company accounts for warrants and options issued to non-employees under Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) No. 505-50,&amp;#160;&lt;i&gt;Equity - Equity Based Payments to Non-Employees,&lt;/i&gt;using the Black-Scholes option-pricing model. The value of such non-employee awards is periodically re-measured over the vesting terms and at each quarter end.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0.5in; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Segment Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 33.75pt; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;FASB ASC No. 280,&amp;#160;&lt;i&gt;Segment Reporting&lt;/i&gt;, establishes standards for reporting information about reportable segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group ("CODM"), in deciding how to allocate resources and in assessing performance. The CODM evaluates revenues and gross profits based on product lines and routes to market. Based on the early development stage of our operation, we operate in a single reportable segment.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Comprehensive Income (Loss)&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company is required to record all components of comprehensive income (loss) in the consolidated financial statements in the period in which they are recognized. Net income (loss) and other comprehensive income (loss), net of their related tax effect, arrived at a comprehensive income (loss). For the three and nine months ended September 30, 2016, the comprehensive income (loss) was equal to the net income (loss).&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0.5in; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Earnings per share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-indent: 33.75pt; margin: 0px;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;The Company applies FASB ASC No. 260, &lt;i&gt;Earnings per Share&lt;/i&gt;. Basic earnings (loss) per share is computed by dividing earnings (loss) available to common stockholders by the weighted-average number of shares of common stock outstanding. Diluted earnings or loss per share would include the dilutive effect of&amp;#160;outstanding warrants and awards granted to employees under stock-based compensation plans.&amp;#160; Potential shares of the Company's common stock are excluded from the calculation of diluted loss per common share because their effect would be anti-dilutive for the periods presented.&amp;#160; For the three and nine month period ending September 30, 2016, 10,879,500 warrants and 1,142,500 stock options outstanding at the end of the period are excluded from the calculation of diluted loss per common share.&amp;#160; For the three and nine month&amp;#160; period ended September 30, 2015, 10,759,500 warrants and 1,151,000 stock options outstanding at the end of the period are excluded from the calculation of diluted loss per common share.&lt;/font&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 33.75pt; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Recent accounting pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;In February 2016, the FASB issued ASU No. 2016-02&amp;#160;&lt;i&gt;Leases&lt;/i&gt;&amp;#160;(Topic 842) intended to improve financial reporting around leasing transactions. The ASU affects all companies and other organizations that lease assets such as real estate, airplanes, and manufacturing equipment. The ASU will require organizations that lease assets - referred to as "lessees"- to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. For public companies, the standard is effective for fiscal years beginning after December 15, 2018 and interim periods therein. Earlier adoption is permitted for any annual or interim period for which consolidated financial statements have not yet been issued. The Company is currently evaluating the potential impact that the adoption of ASU No. 2016-02 may have on its consolidated financial statements.&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
<nmus:UniversityOfMississippiAgreementsTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;2. University of Mississippi Agreements&lt;/b&gt;&lt;/p&gt;
&lt;div&gt;&amp;#160;&lt;/div&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;In July 2013, the Company entered into a Memorandum of Understanding (MOU) with UM to engage in joint research of extracting, manipulating, and studying cannabis in certain forms to develop intellectual property (IP) with the intention to create and commercialize therapeutic medicines. Nemus will own all IP developed solely by its employees and will jointly own all IP developed jointly between Nemus and UM employees. The term of the MOU agreement is five years and the parties agree to negotiate separate research agreements upon the identification of patentable technologies as well as any deemed to be a trade secret. The agreement may be terminated by either party with three months&amp;#8217; written notice to the other party.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0.5in; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;u&gt;UM 5050 pro-drug agreements&lt;/u&gt;:&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;On September 29, 2014, the Company executed three license agreements with UM pursuant to which UM granted us exclusive, perpetual, worldwide licenses, including the right to sublicense, to intellectual property related to UM 5050, a pro-drug formulation of tetrahydrocannabinol, or THC for products administered through each of ocular, oral or rectal delivery. The license agreement for the field of oral delivery also includes rights to UM 1250, a bio-adhesive hot melt extruded film for topical and mucosal adhesion application and drug delivery. The license agreements contain certain milestone and royalty payments, as defined therein. There is an annual fee of $25,000 per license agreement, payable on the anniversary of each effective date. The aggregate milestone payments under the license agreements, if the milestones are achieved, is $2.1 million. These licenses also require the Company to reimburse UM for patent costs incurred related to these products under license. The agreements will terminate upon expiration of the patents, breach or default of the license agreements, or upon 60 days&amp;#8217; written notice by the Company to UM.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 33.75pt; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;On October 15, 2014, we signed a renewable option agreement for the rights to explore other routes of delivery of UM5050 not yet agreed upon and/or in combination with other cannabinoids or other compatible compounds. There was a one-time up-front option payment of $10,000 for a six-month option period that has subsequently been renewed under the same financial terms and conditions. The most recent renewal occurred for the period from October 1, 2016 to December 14, 2016 to coincide with the renewals of the UM 8930 license discussed below. The option payment for this shortened period is $2,500 due and payable on October 31, 2016.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;u&gt;UM 8930 pro-drug agreements:&lt;/u&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;u&gt;&lt;/u&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;On December 14, 2015, the Company executed two license agreements with UM pursuant to which UM granted us exclusive, perpetual, worldwide licenses, including the right to sublicense, to intellectual property related to UM 8930, a pro-drug formulation of cannabidiol ("CBD") for products administered through each of ocular or rectal delivery. The license agreements contain certain milestone and royalty payments, as defined therein. There is a one-time upfront payment of $65,000 per license agreement, payable in four equal monthly installments that started on December 15, 2015. There is an annual fee of $25,000 per license agreement, payable on the anniversary of each effective date. The aggregate milestone payments under the license agreements, if the milestones are achieved, is $1.4 million. These licenses also require the Company to reimburse UM for patent costs incurred related to these products under license. These license agreements will terminate upon expiration of the patents, breach or default of the license agreements, or upon 60 days&amp;#8217; written notice by the Company to UM.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;On December 14, 2015, we signed a renewable option agreement for the rights to explore other routes of delivery of UM8930 not yet agreed upon and/or in combination with other cannabinoids or other compatible compounds. There was a one-time up-front option payment of $10,000 for an option period ending March 31, 2016. This option was subsequently renewed for the period October 1, 2016 to December 14, 2016 to coincide with the UM8930 annual license renewal. The option payment for this shortened period is $2,500 due and payable on October 31, 2016.&lt;/p&gt;</nmus:UniversityOfMississippiAgreementsTextBlock>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;3. Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Lease Commitments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;On September 1, 2014, the Company signed an operating lease for laboratory and office space at the Innovation Hub, Insight Park located on the University of Mississippi campus. The lease term commenced on October 1, 2014 and expires on December 31, 2017. There is annual escalating rent provisions and two months of free rent in the agreement. The total cash payments over the life of the lease are divided by the total number of months in the lease period and the average rent will be charged to expense each month during the lease period. The monthly amount charged to rent expense is $9,267.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;In October 2014, we signed a lease agreement for our corporate office headquarters that consists of approximately 4,087 square feet located at 650 Town Center Drive, Suite 1770, Costa Mesa, CA 92626. The lease expired on October 31, 2016 and our monthly rent was $5,373, payable in equal monthly installments with annual escalations. There was no subsequent renewal upon expiration of this lease.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;In November 2015, the Company entered into an operating lease for its office and lab furnishings both in Costa Mesa and the Innovation Hub laboratory. The lease expires on November 3, 2017 and the monthly lease payments are $7,559.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;Total net rent expense related to our operating leases for the three months ended September 30, 2016 and 2015, was $79,771 and $56,680, respectively. For the nine months ended September 30, 2016 and 2015, total net rent expense from operating leases was $240,746 and $170,931 respectively.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;Future minimum payments under the non-cancelable portion of our operating leases as of September 30, 2016 are as follows:&lt;/p&gt;
&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="text-align: justify; width: 85%; font: 10pt 'times new roman'; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;2016&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;
&lt;td align="right" valign="bottom" width="9%"&gt;56,671&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;2017&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="9%"&gt;161,963&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;2018&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="9%"&gt;-&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;2019&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="9%"&gt;-&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;2020&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="9%"&gt;-&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Thereafter&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: 1px solid;" valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" style="border-bottom: 1px solid;" valign="bottom" width="9%"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom: 1px;" valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Total&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: 3px double;" valign="bottom" width="1%"&gt;$&lt;/td&gt;
&lt;td align="right" style="border-bottom: 3px double;" valign="bottom" width="9%"&gt;218,634&lt;/td&gt;
&lt;td style="padding-bottom: 3px;" valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Legal Matters&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;General Litigation and Disputes&lt;/i&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;em&gt;&lt;/em&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;On August 3, 2016, John B. Hollister filed to dismiss his complaint against the Company and its Executive Chairman, and the Company and its Executive Chairman filed to dismiss their complaint against Hollister filed on January 25, 2016 containing claims against him for defamation, false light, unfair competition, breach of contract, breach of fiduciary duty and fraud.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;Hollister's employment as the Company's Chief Executive Officer was terminated by the Company on August 24, 2015 for good and lawful reasons by the Company's Board of Directors as the Company decided to go in a different direction. As stated in the Company's December 28, 2015 Form 8-K, the Company maintains that Hollister's complaint and subsequent pleadings were grossly inaccurate and his claims were entirely without merit alleging various causes of action arising out of his termination, including a breach of contract claim.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;Neither the Company nor its Executive Chairman made any payment to Hollister to resolve the lawsuit or otherwise.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;According to the Orange County Superior Court's online case records posted on August 11, 2016, the court entered the order for dismissal of the entire action with prejudice effective as of the&amp;#160;August 3, 2016 filing date.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0.5in; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;Government Proceedings&lt;/i&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;em&gt;&lt;/em&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;Like other companies in the pharmaceutical industry, we are subject to extensive regulation by national, state and local government agencies in the United States. As a result, interaction with government agencies occurs in the normal course of our operations. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from any government investigation or proceeding. As of September 30, 2016, the Company had no current proceedings or inquiries.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0.5in; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Change in Control Severance Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;In February 2015, we adopted a change in control severance plan, in which our named executive officers participate, that provides for the payment of severance benefits if the executive's service is terminated within twelve months following a change in control, either due to a termination without cause or upon a resignation for good reason (as each term is defined in the plan).&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;In either such event, and provided the executive timely executes and does not revoke a general release of claims against the Company, he or she will be entitled to receive: (i) a lump sum cash payment equal to at least six months of the executive's monthly compensation, plus an additional month for each full year of service over six years, (ii) Company-paid premiums for continued health insurance for a period equal to length of the cash severance period or, if earlier, when executive becomes covered under a subsequent employer's healthcare plan, and (iii) full vesting of all then-outstanding unvested stock options and restricted stock awards.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0.5in; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Contract Manufacturing Organization ("CMO") Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;On February 5, 2016, the Company entered into a letter agreement ("Agreement") with a third party contract manufacturing organization ("CMO") pursuant to which the CMO is to provide services to Nemus for process development and analytical method development and qualification for Nemus' prodrug of tetrahydrocannabinol, or THC, as well as for sample production and a stability study.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;Pursuant to the terms of the Agreement, Nemus will pay an estimated $154,000 to $183,000 in fees and expenses for the initial evaluation and development of a process for the production of Nemus' pro-drug of THC to ensure reproducibility, quality and safety and an estimated $142,900 for analytical method development and qualification. The Company recognized $18,896 and $225,244 respectively as research and development expense towards these fees for the three and nine months ended September 30, 2016. After the initial evaluation and development, Nemus has agreed to pay additional fees and expenses for sample production of Nemus' pro-drug of THC and a stability study, as well as possible extensions to or modifications of the aforementioned projects.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;Nemus may at any time cancel or delay any project under the Agreement prior to the scheduled start date. Nemus must reimburse the CMO for costs incurred prior to and including the date of cancellation plus any reasonable and foreseeable costs associated with stopping work on any project, including the CMO's loss of revenue incurred as the result of reserving production facilities for Nemus' exclusive use. Nemus may terminate the Agreement in whole or in part at any time upon 30 days' written notice.&lt;/div&gt;
&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;4. Stockholders' Deficit and Redeemable Convertible Series B Preferred Stock&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;In June 2014, the Company sold 1,800,000 shares of common stock with no par value and warrants for a purchase price of $900,000 (the "June 2014 Stock Purchase Agreement") to a group of private investors. See additional discussion on warrants below.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="left" style="widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;In August 2014, the Company sold 2,200,000 shares of common stock with no par value and warrants for a purchase price of $1,100,000 to a group of private investors. See additional discussion on warrants below.&lt;/p&gt;
&lt;p align="left" style="widows: 2; text-transform: none; font-style: normal; text-indent: 135px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="left" style="widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;In October 2014, the Company issued 1,110,000 shares of common stock with no par value to eighteen individual investors that had participated in a prior entity founded by Nemus' then current president. Such entity has been insolvent and not operating since the inception date of Nemus. The issuance of these shares was in exchange for the signing of a release of claims against the Company, its President, and the former entity. The Company recorded a general and administrative expense of $466,200 in the fourth quarter of 2014 to reflect the fair market value of the common stock issued in exchange for the release of claims. The fair market value of the common stock issued was determined via an independent third-party valuation conducted as of October 31, 2014.&lt;/p&gt;
&lt;p align="left" style="widows: 2; text-transform: none; font-style: normal; text-indent: 135px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="left" style="widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;In January 2015, the Company sold 241,663 shares of common stock with par value of $0.001 for a purchase price of $724,989 to a group of private investors.&lt;/p&gt;
&lt;p align="left" style="widows: 2; text-transform: none; font-style: normal; text-indent: 135px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="left" style="widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;In March 2015, the Company issued 24,000 shares of common stock with par value of $0.001 to a third party in exchange for services to be performed related to raising additional capital. The Company recorded a prepaid expense of $168,000 in the first quarter of 2015 to reflect the fair market value of the common stock issued and is amortizing this expense over the contract service period which is one year. The fair market value was determined utilizing the Company's closing stock price as of the commencement date of the contract service period. For three months ended March 31, 2016, the Company amortized $12,194 to general and administrative expense which represented the completion of this agreement.&lt;/p&gt;
&lt;p align="left" style="widows: 2; text-transform: none; font-style: normal; text-indent: 135px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="left" style="widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;In August 2015, in conjunction with the Series B Preferred Stock sale (discussed below), the Company raised $5.0 million at $1,000 per share resulting in the automatic conversion of the Series A Preferred Stock to common stock. This resulted in the conversion of 580,000 shares of Series A Preferred Stock at $2.50 per share to the equivalent of 1,812,500 shares of common stock.&lt;/p&gt;
&lt;p align="left" style="widows: 2; text-transform: none; font-style: normal; text-indent: 135px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="left" style="widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;In December 2015, a Series B Preferred Stockholder converted 500 shares of&amp;#160;its preferred stock to common stock as allowed under the Series B Stock Agreement (discussed below), resulting in the issuance of 625,000 shares of common stock at an effective price of $0.80 per share.&lt;/p&gt;
&lt;p align="left" style="widows: 2; text-transform: none; font-style: normal; text-indent: 135px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="left" style="widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;In March 2016, another Series B Preferred Stockholder converted 8 shares of&amp;#160;its preferred stock to common stock, resulting in the issuance of 10,000 shares of common stock at an effective price of $0.80 per share.&lt;/p&gt;
&lt;p align="left" style="widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;The Company has authorized 20,000,000 shares of preferred stock with a par value of $0.001 per share.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;u&gt;Series A Preferred Stock:&lt;/u&gt;&amp;#160;In April 2015, the Company sold 250,000 shares of Series A preferred stock with par value of $0.001 and 50,000 warrants to purchase the Company's common stock for an aggregate purchase price of $625,000, or $2.50 per share to a group of private investors. The shares of preferred stock automatically convert to shares of common stock either at (i) a subsequent equity financing of at least $1,000,000 or (ii) October 1, 2015, whichever is earlier. The warrants are exercisable at a price of $5.00 per share and expire five years from the issuance date. In May 2015, the Company sold 150,000 shares and 30,000 warrants and in July 2015, the Company sold 180,000 shares and 36,000 warrants under the same terms and conditions.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;The Series A preferred stock issued also has a "down-round" protection feature provided to the investors if the Company subsequently issues or sells any shares in a round of equity financing of at least $1,000,000 prior to October 1, 2015 in which the shares of common stock to be acquired are at a price less than $2.50 per share. The Company is required to issue additional shares of common stock to the investors in an amount such that the subscription price paid, when divided by the total number of shares issued will result in an actual price paid per share of common stock equal to such lower price. This conversion occurred as discussed above in conjunction with the Series B Preferred Stock financing totaling $5.0 million and resulted in the conversion of 580,000 shares of Series A Preferred Stock at to 1,812,500 shares of common stock.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;u&gt;Redeemable Convertible Series B Preferred Stock:&lt;/u&gt;&amp;#160;In August 2015, the Company sold 5,000 shares of Series B Convertible Preferred Stock and warrants to purchase 6,250,000 shares of the Company's common stock for an aggregate purchase price of $1,000 per share resulting in gross proceeds of $5.0 million. Each share of preferred stock is convertible into 1,250 shares of common stock which results in an effective conversion price of $0.80 per common share and can be converted by the holder at any time. The Series B preferred stock issued also has a "down-round" protection feature provided to the investors if the Company subsequently issues or sell any shares of common stock, stock options, or convertible securities at a price less than the conversion price of $0.80 per common share. The conversion price is automatically adjusted down to the price of the instrument being issued. See additional discussion in Note 5 below. The Series B shares have liquidation preference over other preferred shares and common stock and have voting rights equal to the number of common shares into which each holder's preferred stock is convertible as of the record date. The preferred stock has no dividend rights. If dividends are declared on the common stock, the holders of the preferred stock shall be entitled to participate in such dividends on an as-if converted basis. The warrants are exercisable at a price of $1.15 per share and expire five years from the issuance date. See additional discussion regarding these warrants in Note 6 below.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary, Series B preferred stockholders receive an amount per share equal to the conversion price of $0.80, subject to down-round adjustment, multiplied by the as-if converted share amount of 5,615,000 common shares, totaling $4.5 million. If upon the liquidation, the assets are insufficient to permit payments to the Series B holders, all assets legally available will be distributed in a pro rata basis among the Series B holders in proportion to the full amounts they would otherwise be entitled to receive. Any remaining assets are distributed pro rata among the common stockholders.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;Subject to certain trigger events occurring, the Series B preferred stock holders have the right to force the Company to redeem the shares of preferred stock at a price per preferred share equal to the greater of (A) 115% of the conversion amount and (B) the product of (1) the conversion rate in effect at such time and (2) the greatest closing sale price of the Common Stock during the period beginning on the date immediately preceding such triggering event and ending on the date such holder delivers the notice of redemption. Such triggering events include:&lt;/p&gt;
&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align: justify; width: 100%; font: 10pt 'times new roman'; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="4%"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top" width="4%"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top" width="92%"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Failure of the Series B Registration Statement to be declared effective by the SEC on or prior to the date that is ninety days after the Effectiveness Deadline;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Suspension of the Company's common stock from trading for a period of (2) consecutive trading days;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Failure of the Company to deliver all the shares of the common stock or make the appropriate cash payments in a timely manner upon conversion of the Series B Preferred;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Any default of indebtedness;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Any filing of voluntary or involuntary bankruptcy by the Company;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;A final judgment in excess of $100,000 rendered against the Company;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Breach of representations and warranties in the Stock Purchase Agreement;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Failure to comply with the Series B Certificate of Designation or Rule 144 requirements.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;As certain of these triggering events are considered to be outside the control of the Company, the Series B preferred stock is considered to be contingently redeemable convertible and as a result, has been classified as mezzanine equity in the Company's balance sheet.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;In December 2015, a Series B Preferred Stock holder converted 500 shares of its preferred stock to common stock at the conversion rate of 1,250:1 resulting in the issuance of 625,000 shares of common stock. In March 2016, another Series B Preferred Stockholder converted 8 shares of its preferred stock to common stock at the same ratio resulting in the issuance of 10,000 shares of common stock. As a result of these conversions, the liquidation preference for the Series B Preferred Stock has been reduced to $4.5 million at both September 30, 2016 and December 31, 2015.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;On July 17, 2012, the Company issued warrants to purchase up to 3,000,000 shares of our common stock to its founders and two advisors in consideration for services provided in the start-up of operations. The warrants are exercisable at a price of $1.00 per share and expire on June 20, 2023. The Company valued these warrants utilizing the Black-Scholes valuation model and they were determined to be of nominal value given the start-up nature of the Company's operations at the time of grant.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;In conjunction with the June 2014 Stock Purchase Agreement, the Company issued warrants to purchase up to 450,000 shares of common stock to a group of private investors. The warrants are exercisable at a price of $1.00 per share and expire on June 12, 2020. The Company valued these warrants at $85,500. This amount was recorded as warrants and was reclassified from the total consideration received for both the common stock and warrants purchased.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;In August 2014 as part of the June 2014 Stock Purchase Agreement, the Company issued warrants to purchase up to 550,000 shares of common stock with an exercise price of $1.00 per share that expire in August 2020. The Company valued these warrants at $104,500. This amount was recorded as warrants and was reclassified from the total consideration received for both the common stock and warrants purchased.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;In March 2015, the Company entered into an agreement with a financial advisory and public relations consulting firm which included the issuance of warrants to purchase up to 90,000 shares of common stock with an exercise price of $2.50 per share with a term of five years and vest quarterly over one year. These warrants were in exchange for services performed beginning in the first quarter and were subsequently issued in April 2015. The Company estimated the vested warrant value to be $85,950 utilizing the Black Scholes option pricing model and amortized $5,145 for services provided for the nine months ended September 30, 2016 and $46,810 for the nine months ended September 30, 2015.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;In April 2015, the Company entered into an agreement with one of its investors to provide advisory services on all matters including financing. In conjunction with this agreement, the Company issued warrants that vest immediately to purchase 100,000 shares of common stock with an exercise price of $5.00 per share with a term of ten years. The Company estimated the warrant value to be $326,000 utilizing the Black Scholes option pricing model and recorded this amount to general and administrative expense for the quarter due to the immediate vesting.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;In April 2015, the Company issued to a former service provider in exchange for payment of its outstanding invoice warrants that vest immediately to purchase 6,000 shares of common stock with an exercise price of $2.50 per share. The Company estimated the warrant value to be $10,000 which represented the value of the trade debt extinguished.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;In April 2015, the Company issued 50,000 warrants to purchase the Company's common stock in conjunction with its Series A Preferred Stock financing. The warrants are exercisable at a price of $5.00 per share and expire five years from the issuance date. In May 2015, the Company issued 30,000 warrants and in July 2015, 36,000 warrants under the same terms and conditions.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;In June 2015, the Company issued to a service provider in exchange for consulting services warrants that vest immediately to purchase 10,000 shares of common stock with an exercise price of $5.00 per share with a term of five years. The Company estimated the warrant value to be $14,700 utilizing the Black Scholes option pricing model.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;In August 2015, the Company issued 6,250,000 warrants to purchase common stock in conjunction with its Series B Preferred Stock financing. See further discussion in Note 6 below.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;In August 2015, the Company issued 187,500 warrants to purchase common stock to its investment banker in exchange for services rendered in conjunction with the Series B Preferred Stock financing. The warrants vest immediately and have an exercise price of $1.15 per share. The Company estimated the value of the warrants to be $86,250 utilizing the Black Scholes option pricing model and recorded this amount to offering costs.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;In November 2015, the Company entered into an agreement with a financial advisory and public relations consulting firm which included the issuance of warrants to purchase up to 120,000 shares of common stock with an exercise price of $1.15 per share with a term of five years. These warrants are in exchange for services to be performed from November 25, 2015 to May 25, 2016 and 60,000 shares vest immediately with the remainder in one quarter. The Company estimated the warrant value of vested warrants to be $42,000 utilizing the Black Scholes option pricing model and amortized $7,800 during the fiscal year ended December 31, 2015 and $34,200 in the nine months ended September 30, 2016.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;The Company's board of directors considered various objective and subjective factors, along with input from management, to determine the fair value of the warrants, including:&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align: justify; width: 100%; font: 10pt 'times new roman'; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="4%"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top" width="4%"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Contemporaneous valuation prepared by an independent third-party valuation specialist effective as of April 1, 2015, August 20, 2015, December 31, 2015, March 31, 2016, June 30, 2016, and September 30, 2016,&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Its results of operations, financial position and the status of research and development efforts and achievement of enterprise milestones,&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;The composition of, and changes to, the Company's management team and board of directors,&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;The lack of liquidity of its common stock as a newly public company,&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;The Company's stage of development, business strategy and the material risks related to its business and industry,&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;The valuation of publicly-traded companies in the biotechnology sectors,&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;External market conditions affecting the biotechnology industry sectors,&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;The likelihood of achieving a liquidity event for the holders of its common stock, such as an initial public offering, or IPO, or a sale of the Company, given prevailing market conditions, and&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;The state of the IPO market for similarly situated biotechnology companies,&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Discussions held with bankers, potential investors, and preliminary term sheets received as part of management's capital raise efforts.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;There are significant judgments and estimates inherent in the determination of the fair value of the Company's warrants. These judgments and estimates included the assumptions regarding its future operating performance, the time to completing an IPO or other liquidity event and the determination of the appropriate valuation methods. If the Company had made different assumptions, its warrant valuation could have been significantly different.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Stock Option Plans: 2014 Omnibus Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;The 2014 Omnibus Incentive Plan (the "2014 Plan") was adopted to provide a means by which officers, non-employee directors, and employees of and consultants to the Company and its affiliates could be given an opportunity to acquire an equity interest in the Company. All officers, non-employee directors, and employees of and consultants to the Company are eligible to participate in the 2014 Plan.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;On October 31, 2014, after the closing of the Merger, our Board of Directors approved the 2014 Plan. The 2014 Plan reserved 3,200,000 shares for future grants. As of September 30, 2016, options (net of canceled or expired options) covering an aggregate of 1,142,500 shares of the Company's common stock had been granted under the 2014 Plan, and the Company had 1,142,500 options outstanding and 857,500 shares available for future grants under the 2014 Plan.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;Options granted under the 2014 Plan expire no later than 10 years from the date of grant. Options granted under the 2014 Plan may be either incentive or non-qualified stock options. For incentive and non-qualified stock option grants, the option price shall be at least 100% of the fair value on the date of grants, as determined by the Company's Board of Directors. If at any time the Company grants an option, and the optionee directly or by attribution owns stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, the option price shall be at least 110% of the fair value and shall not be exercisable more than five years after the date of grant.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;Options granted under the 2014 Plan may be immediately exercisable if permitted in the specific grant approved by the Board of Directors and, if exercised early may be subject to repurchase provisions. The shares acquired generally vest over a period of five years from the date of grant. The Company granted options to purchase 1,142,500 shares net of cancellations through September 30, 2016, under the 2014 Plan.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;The following is a summary of activity under the 2014 Plan as of September 30, 2016:&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;table style="text-align: justify; width: 100%; font: 10pt 'times new roman'; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" id="hdcell" valign="bottom" colspan="2"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" style="border-bottom: black 1px solid;" valign="bottom" colspan="10"&gt;
&lt;p align="center" style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"&gt;&lt;b&gt;Options Outstanding&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" id="a76680571-b25a-46cf-adb5-0a5b90e79172" valign="bottom" colspan="2"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" id="afc6737b0-20f3-4128-9b88-0ce2c73b24e6" valign="bottom" colspan="2"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" id="a994652bc-25a0-4417-8050-76d260ea111d" valign="bottom" colspan="2"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" id="afe53c416-0afd-41ba-9444-3d0ab44e3204" valign="bottom" colspan="2"&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" id="afa874365-5607-419d-8579-0bb32ceeaa85" valign="bottom" colspan="2"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;strong&gt;&amp;#160;Available&lt;/strong&gt;&lt;/p&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;strong&gt;for Grant of&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" id="ac9842d75-5040-4102-bc96-70f1dddaf474" valign="bottom" colspan="2"&gt;
&lt;p align="center" style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"&gt;&lt;strong&gt;Number of&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" id="a6ca1f613-3c16-42b2-ab73-4e50d83a5f65" valign="bottom" colspan="2"&gt;
&lt;p align="center" style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"&gt;&lt;strong&gt;Price per&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" id="a3f44c511-0f2b-4243-87ae-237fae0727de" valign="bottom" colspan="2"&gt;
&lt;p align="center" style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"&gt;&lt;strong&gt;Average&lt;/strong&gt;&lt;/p&gt;
&lt;strong&gt;Exercise&lt;/strong&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" style="border-bottom: black 1px solid;" id="a860cc628-b6ed-4b0c-8425-c4ebf8b64b38" valign="bottom" width="9%" colspan="2"&gt;
&lt;p align="center" style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"&gt;&lt;strong&gt;Options &amp;amp; Shares&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" style="border-bottom: black 1px solid;" id="a6143ca92-0680-47a1-b75c-9276cdd2ad6d" valign="bottom" width="9%" colspan="2"&gt;
&lt;p align="center" style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" style="border-bottom: black 1px solid;" id="a5854f05c-db65-4bbe-a2f1-4064e1c3a94e" valign="bottom" width="9%" colspan="2"&gt;
&lt;p align="center" style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"&gt;&lt;strong&gt;Share&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" style="border-bottom: black 1px solid;" id="a1019efff-1f0b-4e3b-8305-3f78a4c73824" valign="bottom" width="9%" colspan="2"&gt;&lt;strong&gt;Price&lt;/strong&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"&gt;&lt;b&gt;Balance at December&amp;#160;31, 2015&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td align="right" id="ffcell" valign="bottom" width="9%"&gt;2,020,000&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td align="right" id="aa68043d3-4c6e-41e2-923a-3ea32f23491f" valign="bottom" width="9%"&gt;1,180,000&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;$&lt;/td&gt;
&lt;td&gt;
&lt;p align="right" style="margin: 0px;"&gt;0.42-3.00&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;
&lt;td align="right" id="a3ac2e0ee-3533-4107-bc1b-be817b691e31" valign="bottom" width="9%"&gt;0.63&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"&gt;Shares used for restricted stock awards (see discussion below)&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1px solid;" valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" style="border-bottom: black 1px solid;" id="af6282499-29f0-4366-8026-aad84c9cccf9" valign="bottom" width="9%"&gt;(1,200,000&lt;/td&gt;
&lt;td style="padding-bottom: 1px;" valign="bottom" width="1%"&gt;)&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="a3802741f-3c97-416f-9b7b-d473742c4d45" valign="bottom" width="9%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="a33d45ae7-5104-420f-bb23-ecabee3b4780" valign="bottom" width="9%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="af19a18f4-c640-4bb6-8dab-63b1a5ace68e" valign="bottom" width="9%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"&gt;&lt;b&gt;Subtotal&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="a2fea64e0-7816-4bca-b1b9-a1967a64dfdc" valign="bottom" width="9%"&gt;820,000&lt;/td&gt;
&lt;td style="padding-bottom: 3px;" valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="a09c554ec-af65-4d6a-bf86-49c087bba490" valign="bottom" width="9%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="ab0fed666-6caf-4e8e-b8af-ccbe2554b134" valign="bottom" width="9%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="a6496625f-1830-4cca-81b2-5feaa573e4e5" valign="bottom" width="9%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"&gt;Options granted&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="aeab8c37e-4d93-4d87-ac4c-19ad3d1e3e4b" valign="bottom" width="9%"&gt;-&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="aad543531-cb7d-4874-b6f3-fa51f2f60d42" valign="bottom" width="9%"&gt;-&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;
&lt;td align="right" id="a1c8dd8e3-5f02-491b-87bc-155884e23f5c" valign="bottom" width="9%"&gt;-&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;
&lt;td align="right" id="aa2779de5-c435-40dd-a35d-e1c39bc48abe" valign="bottom" width="9%"&gt;-&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"&gt;Options exercised&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="a80d77890-a888-441c-8740-76826013109d" valign="bottom" width="9%"&gt;-&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="ae409683e-9463-4f96-a6c5-babbcac5f0ba" valign="bottom" width="9%"&gt;-&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;
&lt;td align="right" id="a72c02b0e-b30d-4860-9836-e9163bd19cb7" valign="bottom" width="9%"&gt;-&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;
&lt;td align="right" id="a42b32d5f-a693-4a0a-861e-76035b64f9a3" valign="bottom" width="9%"&gt;-&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"&gt;Options cancelled&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1px solid;" valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" style="border-bottom: black 1px solid;" id="aa45a4ad7-4c57-4fa8-91ff-1790677360bb" valign="bottom" width="9%"&gt;37,500&lt;/td&gt;
&lt;td style="padding-bottom: 1px;" valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1px solid;" valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" style="border-bottom: black 1px solid;" id="a053bad77-79a0-4ec3-880f-f12d007048df" valign="bottom" width="9%"&gt;(37,500&lt;/td&gt;
&lt;td style="padding-bottom: 1px;" valign="bottom" width="1%"&gt;)&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;
&lt;td align="right" id="a9cf8c493-525d-4876-b79a-2d8d376ea8e5" valign="bottom" width="9%"&gt;1.15&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;
&lt;td align="right" id="a1cbb6319-d9f0-4463-a68f-35e5917237e8" valign="bottom" width="9%"&gt;1.15&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"&gt;&lt;b&gt;Balance at September 30, 2016&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 3px double;" valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" style="border-bottom: black 3px double;" id="ae97af3f1-dae5-4e42-8e09-2f66e2ffe5bf" valign="bottom" width="9%"&gt;857,500&lt;/td&gt;
&lt;td style="padding-bottom: 3px;" valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 3px double;" valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" style="border-bottom: black 3px double;" id="a687c36e5-ad50-4002-aedd-74d0845bfe95" valign="bottom" width="9%"&gt;1,142,500&lt;/td&gt;
&lt;td style="padding-bottom: 3px;" valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;$&lt;/td&gt;
&lt;td&gt;
&lt;p align="right" style="margin: 0px;"&gt;0.42-3.00&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;
&lt;td align="right" id="a6f9762c0-37b5-4eef-9783-e74792864859" valign="bottom" width="9%"&gt;0.61&lt;/td&gt;
&lt;td style="padding-bottom: 3px;" valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;The weighted average remaining contractual life in years of the options outstanding as of September 30, 2016 was 8.15 years.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;Aggregate intrinsic value is the sum of the amounts by which the quoted market price of the Company's stock exceeded the exercise price of the stock options at September 30, 2016 for those stock options for which the quoted market price was in excess of the exercise price ("in-the-money options"). As of September 30, 2016, the aggregate intrinsic value of options outstanding was $52,500. As of September 30, 2016, 238,500 options to purchase shares of common stock were exercisable.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Restricted Stock Awards&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;Restricted stock awards ("RSAs") are granted to our board of directors and members of senior management and are issued pursuant to the Company's 2014 Omnibus Incentive Plan. On October 20, 2015, a total of 1,200,000 RSAs were granted to members of the Company's senior management and board of directors with a fair market value of approximately $900,000. These RSAs vest from one to three years from the grant date as services are rendered to the Company. For the three and nine months ended September 30, 2016, the Company recorded $93,750 and $281,250 respectively in stock-based compensation expense related to these awards. (See discussion below).&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Stock Based Compensation Expense&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;The Company recognizes stock-based compensation expense based on the fair value of that portion of stock options that are ultimately expected to vest during the period. Stock-based compensation expense recognized in the consolidated statements of operations includes compensation expense for stock-based awards based on the estimated grant date fair value over the requisite service period. For the three and nine months ended September 30, 2016, the Company recognized stock-based compensation expense of $181,608 and $544,823 (including compensation expense for RSAs discussed above) which was recorded as a general and administrative expense in the consolidated statements of operations. For the three and nine months ended September 30, 2015, stock-based compensation expense was $4,286 and $263,985, respectively.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;The total amount of unrecognized compensation cost related to non-vested stock options was $1,109,963 as of September 30, 2016. This amount will be recognized over a weighted average period of 3.14 years.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Valuation Assumptions&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;The fair value of options was estimated at the date of grant using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company's common stock for similar terms. The expected term was estimated using the simplified method as permitted under SAB No. 110, since the Company has no recent exercise or forfeiture history that is representative of options granted during the year. The expected term represents the estimated period of time that stock options are expected to be outstanding, which is less than the contractual term which is generally ten years. The risk-free interest rate is based on the U.S. Treasury yield. The expected dividend yield is zero, as the Company does not anticipate paying dividends in the near future. There were no options granted in the nine months ended September 30, 2016; the assumptions for options granted in the nine months ended September 30, 2015 are as follows:&lt;/p&gt;
&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align: justify; width: 100%; font: 10pt 'times new roman'; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" style="border-bottom: 1px solid;" id="ab1e7c601-5a49-4f73-bd66-fd7b0d7c8462" valign="bottom" colspan="4"&gt;
&lt;p align="center" style="margin: 0px 0px 0px 1.9pt;"&gt;&lt;b&gt;Nine Months Ended September 30,&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" style="border-bottom: 1px solid;" id="accc5a3ce-8d0c-4e66-b78d-cf1f3bd013d1" valign="bottom" width="9%"&gt;
&lt;p align="center" style="margin: 0px 0px 0px 0.4pt;"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" style="border-bottom: 1px solid;" id="aed5d2e9f-3109-4425-88c1-45e53e9662c1" valign="bottom" width="9%" colspan="2"&gt;
&lt;p align="center" style="margin: 0px 0px 0px 0.9pt;"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1px;" valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Dividend yield&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p align="right" style="margin: 0px; color: black;"&gt;NA&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="a7832e1f6-078b-4820-a827-f22618578289" valign="bottom" width="9%"&gt;0.00&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Volatility factor&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p align="right" style="margin: 0px; color: black;"&gt;NA&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="right" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="af61ad908-d0ab-4dc9-a7c0-355a883d99a1" valign="bottom" width="9%"&gt;75.00&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Risk-free interest rate&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p align="right" style="margin: 0px; color: black;"&gt;NA&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2"&gt;
&lt;p align="right" style="margin: 0px;"&gt;1.65-1.85&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Expected term (years)&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p align="right" style="margin: 0px; color: black;"&gt;NA&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2"&gt;
&lt;p align="right" style="margin: 0px; color: black;"&gt;6.25-6.50&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Weighted-average fair value of options granted during the periods&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p align="right" style="margin: 0px; color: black;"&gt;NA&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;
&lt;td align="right" id="a34f935bf-cdd4-478b-92ef-8169b42ac679" valign="bottom" width="9%"&gt;2.69&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:PreferredStockTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;5. Provision for Conversion of Preferred Stock&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Series A Preferred Stock Conversion Liability&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;In connection with the Series A preferred stock financing, the Company recorded a liability related to down-round protection provided to the stockholders in the event that the Company does another offering of common stock greater than $1,000,000 at a price below $2.50 per share. The down-round provision expires at the closing of a subsequent financing round or October 1, 2015 whichever is earlier. With the assistance of a third-party valuation specialist, the Company valued the conversion liability pursuant to the accounting guidance of ASC 820-10,&amp;#160;&lt;i&gt;Fair Value Measurements&lt;/i&gt;, as of the closing date of the first round of financing which was April 1, 2015.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;As of June 30, 2015, the Company re-evaluated the likelihood and valuation of a potential down-round given that management has been actively pursuing capital raising efforts. In the absence of any definitive agreement, the Company calculated the fair value of the conversion feature to be $700,000 by determining the highest probability of a per share price in the next anticipated round of financing, after considering all discussions with bankers, potential investors, and preliminary term sheets. This amount was booked as a current liability as of June 30, 2015 and was charged as a non-operating expense for the period.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;In July 2015, the Company increased its down-round provision by $286,000 based on the closing of an additional round of 180,000 Series A shares by determining the highest probability of a per share price in the next anticipated round of financing, after considering all discussions with bankers, potential investors, and preliminary term sheets. This amount was charged to non-operating expense for the three months ended September 30, 2015.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;As of August 21, 2015, upon the closing of the Series B Preferred Stock sale with proceeds totaling $5.0 million, the Company issued 1,232,000 additional shares of common stock at $0.80 per share thereby eliminating this liability of $986,000 and offsetting it to Additional Paid-in-Capital. This amount was calculated by determining the difference in per share pricing between the Series A Preferred Stock financing of $2.50 per share and the Series B Preferred Stock Financing of $0.80 per share multiplied by the 580,000 total shares included in the Series A offering.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0.5in; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Series B Preferred Stock Conversion Liability&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;As of August 20, 2015, in connection with the Series B preferred stock financing, the Company recorded a liability related to down-round protection provided to the stockholders in the event that the Company does another sale or issuance of common stock, stock options or convertible securities where the share price is below $0.80 per share. With the assistance of a third-party valuation specialist, the Company valued the conversion liability pursuant to the accounting guidance of ASC 820-10,&amp;#160;&lt;i&gt;Fair Value Measurement&lt;/i&gt;s, as of the closing date of the financing. The Company also performed a review of the conversion liability in conjunction with ASC 815,&amp;#160;&lt;i&gt;Derivatives and Hedging/Contracts in Entity's Own Equity&lt;/i&gt;, and determined that the liability requires bifurcation and re-measurement to fair market value at the end of each reporting period. The value of this embedded derivative was determined utilizing a with and without method by valuing the preferred stock with and without the down round protection.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;As of September 30, 2016, the Company engaged a third-party valuation specialist to re-measure the conversion liability to fair market value as of that date utilizing the same methodology previously performed. The derivative which was classified as a current liability was adjusted to $166,718 as of September 30, 2016. The change in fair market value was recorded as non-operating expense of $61,058 for the three months ended September 30, 2016 and $82,872 as non-operating expense for the nine months ended September 30, 2016.&lt;/p&gt;</us-gaap:PreferredStockTextBlock>
<nmus:SeriesBWarrantsTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;6. Series B Warrants&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;In conjunction with the Series B Preferred Stock financing, the Company issued 6,437,500 common stock warrants that are exercisable at a price of $1.15 per share and expire five years from the issuance date. The warrants were initially valued at $2,935,800 utilizing the Black-Scholes pricing model. The warrants are exercisable in cash or through a cashless exercise provision. The Series B warrants also have a "down-round" protection feature provided to the investors if the Company subsequently issues or sells any shares of common stock, stock options, or convertible securities at a price less than the exercise price of $1.15 per each warrant. The conversion price is automatically adjusted down to the price of the instrument being issued. The Company reviewed the classification of the warrants as liabilities or equity under the guidance of ASC 480-10,&amp;#160;&lt;i&gt;Distinguishing Liabilities from Equity&lt;/i&gt;, and concluded that the Series B warrants should be classified as a liability. The Company then applied the fair value allocation methodology for allocating the proceeds of $5.0 million received from the Series B financing between the conversion liability and the warrants with the residual amount being allocated to the Preferred Stock. The Company also performed the same valuation as of September 30, 2016 utilizing the Black-Scholes pricing model and the following assumptions:&lt;/p&gt;
&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align: justify; width: 100%; font: 10pt 'times new roman'; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" style="border-bottom: 1px solid;" id="hdcell" valign="bottom" colspan="6"&gt;
&lt;p align="center" style="margin: 0px 0px 0px 2.4pt;"&gt;&lt;b&gt;Nine Months&lt;/b&gt;&lt;/p&gt;
&lt;p align="center" style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"&gt;&lt;b&gt;Ended September 30,&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" style="border-bottom: 1px solid;" id="a85319552-10b9-46fd-86ef-186ab0ebc38f" valign="bottom" width="9%" colspan="2"&gt;
&lt;p align="center" style="margin: 0px 0px 0px 0.9pt;"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1px;" valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" style="border-bottom: 1px solid;" id="ae4257b3b-5c4a-42c1-ae69-aed5df85e197" valign="bottom" width="9%" colspan="2"&gt;
&lt;p align="center" style="margin: 0px 0px 0px 0.4pt;"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1px;" valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Dividend yield&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="ffcell" valign="bottom" width="9%"&gt;0.00&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;%&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="a4bacfc70-3d2c-4b81-9d5e-aba330aa7aef" valign="bottom" width="9%"&gt;0.00&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Volatility factor&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="a1e9ca8cc-ec6f-4311-b554-1abf124df9fc" valign="bottom" width="9%"&gt;70.00&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;%&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="ae66c380e-73cf-4dd7-82b0-b6d14565deec" valign="bottom" width="9%"&gt;70.00&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Risk-free interest rate&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2"&gt;
&lt;p align="right" style="margin: 0px; color: black;"&gt;1.11 - 1.29&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="aec32d280-cd62-4d52-8c5b-ab6891500504" valign="bottom" width="9%"&gt;1.75&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Expected term (years)&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2"&gt;
&lt;p align="right" style="margin: 0px; color: black;"&gt;3.89-3.90&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="a4de46680-69c7-4ac0-8f49-5a85a6e9245c" valign="bottom" width="9%"&gt;4.61&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Weighted-average fair value of warrants&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;
&lt;td align="right" id="a635a5d17-e965-4939-95ef-46af09eeb328" valign="bottom" width="9%"&gt;0.14&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;
&lt;td align="right" id="a521176c9-5eeb-4083-875f-1db660f6290a" valign="bottom" width="9%"&gt;0.46&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;This resulted in a warrant value of $869,990 as of September 30, 2016. The change in fair market value at the re-measurement date was recorded as non-operating expense totaling $27,665 for the three months ended September 30, 2016. and non-operating income totaling $1,584,969 for the nine months ended September 30, 2016.&lt;/p&gt;</nmus:SeriesBWarrantsTextBlock>
<us-gaap:IncomeTaxDisclosureTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;7. Income Taxes&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;The Company records a valuation allowance against deferred tax assets to the extent that it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Due to the substantial doubt related to the Company's ability to utilize its deferred tax assets, a valuation allowance for the full amount of the deferred tax assets has been established at September 30, 2016. As a result of this valuation allowance there are no income tax benefits reflected in the accompanying statement of operations to offset pre-tax losses.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;The Company has no uncertain tax positions as of September 30, 2016.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
<us-gaap:SubsequentEventsTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;8. Subsequent Events&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Convertible Preferred Stock Issuance&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;In October 2016, the Company sold 500 shares of convertible preferred stock with a purchase price of $1,000 per share for gross proceeds of $500,000 to a healthcare investment fund under the Series C Preferred Stock Agreement. Each share of Preferred Stock is convertible into 2,500 shares of common stock which results in an effective conversion price of $0.40 per common share. This results in the reduction of the conversion price of the Series B Preferred Stock to $ 0.40 and a reduction in the exercise price of the Series B warrants to $ 0.40. As part of the terms of the Series&amp;#160;C Preferred Stock agreement, the Company entered into a Registration Rights Agreement with the purchaser to file a registration statement to register for resale the shares of common stock underlying the preferred shares within 30 days following the closing of the agreement.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Technology License Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;In October 2016, the Company entered into a technology license agreement with a third-party manufacturing company in order to biosynthetically manufacture cannabinoids. The terms of the agreement call for an initial payment of $50,000 along with a common stock issuance equal to $50,000 of the Company&amp;#8217;s common stock based on the 10 -day volume-weighted average closing price calculated from the effective date of the agreement.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
<us-gaap:UseOfEstimates contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles ("U.S. GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of our financial statements include estimates as to the appropriate carrying value of certain assets and liabilities which are not readily apparent from other sources.&lt;/div&gt;
&lt;/div&gt;</us-gaap:UseOfEstimates>
<nmus:LiquidityAndGoingConcernPolicyTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Liquidity and Going Concern&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;The Company has incurred operating losses and negative cash flows from operations since our inception. As of September 30, 2016, we had cash and cash equivalents of $319,930. In October 2016, we raised an additional $500,000 (see note 8) to be utilized to fund operations. The Company anticipates that it will continue to incur net losses into the foreseeable future as it continues to advance and develop a number of potential drug candidates into preclinical development activities and expands its corporate infrastructure which includes the costs associated with being a public company. Without additional funding, management believes that the Company will not have sufficient funds to meet its obligations within one year after the date the consolidated financial statements are issued. These conditions give rise to substantial doubt as to the Company's ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;The Company plans to continue to fund its operations and capital funding needs through public or private equity or debt financings, strategic collaborations, licensing arrangements, asset sales, government grants or other arrangements. However, the Company cannot be sure that such additional funds will be available on reasonable terms, or at all. If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result. If the Company is unable to secure adequate additional funding, the Company may be forced to make a reduction in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs&lt;/p&gt;</nmus:LiquidityAndGoingConcernPolicyTextBlock>
<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The carrying value of those investments approximates their fair market value due to their short maturity and liquidity. Cash and cash equivalents include cash on hand and amounts on deposit with financial institutions, which amounts may at times exceed federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk.&lt;/div&gt;
&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
<us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Restricted Cash&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;A deposit of $37,500 as of September 30, 2016 and December 31, 2015 was restricted from withdrawal and held by a bank in the form of a certificate of deposit. This certificate serves as collateral for payment of the Company's credit cards.&lt;/div&gt;
&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
<us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Fair Value Measurements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last is considered unobservable, is used to measure fair value:&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align: justify; width: 100%; font: 10pt 'times new roman'; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td valign="top" width="4%"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top" width="6%"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Level 1:&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top" width="90%"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Level 2:&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin: 0px;"&gt;Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Level 3:&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;The carrying values of our financial instruments, including, cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses approximate their fair value due to the short maturities of these financial instruments. The Series B warrant liability and the conversion liability for the Series B preferred stock were valued utilizing Level 3 inputs primarily from a third party independent appraisal conducted as of September 30, 2016.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Property and Equipment, Net&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;As of September 30, 2016, property and equipment, net, was $12,994, consisting primarily of computers and equipment. The Company had $13,383 of property and equipment, net, as of December 31, 2015. Expenditures for additions, renewals and improvements will be capitalized at cost. Depreciation will generally be computed on a straight-line method based on the estimated useful life of the related assets currently ranging from two to three years. Maintenance and repairs that do not extend the life of assets are charged to expense when incurred. When properties are disposed of, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is reported in the period the transaction takes place.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount exceeds its estimated future undiscounted cash flows, an impairment charge is recognized by the amount by which the carrying amount exceeds the fair value of the asset.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;The costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, will be charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where there is an identified alternative future use. No cost associated with the use of licensed technologies has been capitalized to date.&lt;/div&gt;
&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
<us-gaap:IncomeTaxPolicyTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;The Company accounts for our deferred income tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities, and net operating loss carry forwards (the "NOLs") and other tax credit carry forwards. These items are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period that includes the enactment date. Any interest or penalties would be recorded in the Company's statement of operations in the period incurred.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;The Company records a valuation allowance to reduce the deferred income tax assets to the amount that is more likely than not to be realized. In making such determinations, management considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. As a result, there are no income tax benefits reflected in the statement of operations to offset pre-tax losses.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;The Company recognizes a tax benefit from uncertain tax positions when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position.&lt;/div&gt;
&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;The Company has not begun planned principal operations and has not generated any revenue since inception.&lt;/div&gt;
&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Research and Development Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;Research and development ("R&amp;amp;D") costs are expensed when incurred. These costs may consist of external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants; license fees; employee-related expenses, which include salaries, benefits and stock-based compensation for the personnel involved in our preclinical and clinical drug development activities; and facilities expense, depreciation and other allocated expenses; and equipment and laboratory supplies.&lt;/div&gt;
&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
<us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;
&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Stock-Based Compensation Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;Stock-based compensation cost is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period. We use the Black-Scholes option pricing model for estimating the grant date fair value of stock options and warrants using the following assumptions:&lt;/p&gt;
&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;div style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;
&lt;table style="text-align: justify; width: 100%; font: 10pt 'times new roman'; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="4%"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top" width="4%"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Exercise price - We determined the exercise price based on valuations using the best information available to management at the time of the valuations.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Volatility&amp;#160;- We estimate the stock price volatility based on industry peers who are also in the early development stage given the limited market data available in the public arena.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Expected term - The expected term is based on a simplified method which defines the life as the average of the contractual term of the options and warrants and the weighted-average vesting period for all open awards.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Risk-free rate - The risk-free interest rate for the expected term of the option or warrant is based on the average market rate on U.S. treasury securities in effect during the period in which the awards were granted.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;div align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Dividends - The dividend yield assumption is based on our history and expectation of paying no dividends.&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
<nmus:StockBasedCompensationForNonEmployeesPolicyTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Stock-Based Compensation for Non-Employees&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 33.75pt; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;The Company accounts for warrants and options issued to non-employees under Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) No. 505-50,&amp;#160;&lt;i&gt;Equity - Equity Based Payments to Non-Employees,&lt;/i&gt;using the Black-Scholes option-pricing model. The value of such non-employee awards is periodically re-measured over the vesting terms and at each quarter end.&lt;/p&gt;</nmus:StockBasedCompensationForNonEmployeesPolicyTextBlock>
<us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Segment Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 33.75pt; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;FASB ASC No. 280,&amp;#160;&lt;i&gt;Segment Reporting&lt;/i&gt;, establishes standards for reporting information about reportable segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group ("CODM"), in deciding how to allocate resources and in assessing performance. The CODM evaluates revenues and gross profits based on product lines and routes to market. Based on the early development stage of our operation, we operate in a single reportable segment.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
<us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;&lt;b style="margin: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/b&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Comprehensive Income (Loss)&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;b style="margin: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/b&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;b style="margin: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/b&gt;
&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company is required to record all components of comprehensive income (loss) in the consolidated financial statements in the period in which they are recognized. Net income (loss) and other comprehensive income (loss), net of their related tax effect, arrived at a comprehensive income (loss). For the three and nine months ended September 30, 2016, the comprehensive income (loss) was equal to the net income (loss).&lt;/div&gt;
&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
<us-gaap:EarningsPerSharePolicyTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Earnings per share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-indent: 33.75pt; margin: 0px;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;The Company applies FASB ASC No. 260, &lt;i&gt;Earnings per Share&lt;/i&gt;. Basic earnings (loss) per share is computed by dividing earnings (loss) available to common stockholders by the weighted-average number of shares of common stock outstanding. Diluted earnings or loss per share would include the dilutive effect of&amp;#160;outstanding warrants and awards granted to employees under stock-based compensation plans.&amp;#160; Potential shares of the Company's common stock are excluded from the calculation of diluted loss per common share because their effect would be anti-dilutive for the periods presented.&amp;#160; For the three and nine month period ending September 30, 2016, 10,879,500 warrants and 1,142,500 stock options outstanding at the end of the period are excluded from the calculation of diluted loss per common share.&amp;#160; For the three and nine month&amp;#160; period ended September 30, 2015, 10,759,500 warrants and 1,151,000 stock options outstanding at the end of the period are excluded from the calculation of diluted loss per common share.&lt;/font&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b style="margin: 0px;"&gt;&lt;i&gt;Recent accounting pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;strong&gt;&lt;em&gt;&lt;/em&gt;&lt;/strong&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;In February 2016, the FASB issued ASU No. 2016-02&amp;#160;&lt;i&gt;Leases&lt;/i&gt;&amp;#160;(Topic 842) intended to improve financial reporting around leasing transactions. The ASU affects all companies and other organizations that lease assets such as real estate, airplanes, and manufacturing equipment. The ASU will require organizations that lease assets - referred to as "lessees"- to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. For public companies, the standard is effective for fiscal years beginning after December 15, 2018 and interim periods therein. Earlier adoption is permitted for any annual or interim period for which consolidated financial statements have not yet been issued. The Company is currently evaluating the potential impact that the adoption of ASU No. 2016-02 may have on its consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;
&lt;div style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;
&lt;table align="center" style="text-align: justify; width: 85%; font: 10pt 'times new roman'; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;2016&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;
&lt;td align="right"  valign="bottom" width="9%"&gt;56,671&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;2017&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right"  valign="bottom" width="9%"&gt;161,963&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;2018&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right"  valign="bottom" width="9%"&gt;-&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;2019&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right"  valign="bottom" width="9%"&gt;-&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;2020&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right"  valign="bottom" width="9%"&gt;-&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Thereafter&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: 1px solid;" valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" style="border-bottom: 1px solid;"  valign="bottom" width="9%"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom: 1px;" valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Total&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: 3px double;" valign="bottom" width="1%"&gt;$&lt;/td&gt;
&lt;td align="right" style="border-bottom: 3px double;"  valign="bottom" width="9%"&gt;218,634&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;
&lt;table style="text-align: justify; width: 100%; font: 10pt 'times new roman'; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" id="hdcell" valign="bottom" colspan="2"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" style="border-bottom: black 1px solid;" valign="bottom" colspan="10"&gt;
&lt;p align="center" style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"&gt;&lt;b&gt;Options Outstanding&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" id="a9c1c0c3d-601b-4b34-a06c-f3b715eb9c46" valign="bottom" colspan="2"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" id="ab1e58ec1-b4e9-47fe-a04f-3dcbdaa6f054" valign="bottom" colspan="2"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" id="aae7e6299-0811-4591-8b7e-0051acf1b3d6" valign="bottom" colspan="2"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" id="a3032682d-4917-4cbf-a972-44561b57977b" valign="bottom" colspan="2"&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" id="a48499af0-a4e5-43d2-a229-34781aa6daa7" valign="bottom" colspan="2"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;strong&gt;&amp;#160;Available&lt;/strong&gt;&lt;/p&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;strong&gt;for Grant of&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" id="a23cc0d7c-d151-42e1-b062-c76cd547dcf5" valign="bottom" colspan="2"&gt;
&lt;p align="center" style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"&gt;&lt;strong&gt;Number of&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" id="a8c9098f1-6d82-4278-a1b6-d3624e86743a" valign="bottom" colspan="2"&gt;
&lt;p align="center" style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"&gt;&lt;strong&gt;Price per&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" id="a3b170a80-a074-46c3-ac8a-cc808b53f311" valign="bottom" colspan="2"&gt;
&lt;p align="center" style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"&gt;&lt;strong&gt;Average&lt;/strong&gt;&lt;/p&gt;
&lt;strong&gt;Exercise&lt;/strong&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" style="border-bottom: black 1px solid;" id="a97273a83-1185-4d12-84af-f2230e078d78" valign="bottom" width="9%" colspan="2"&gt;
&lt;p align="center" style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"&gt;&lt;strong&gt;Options &amp;amp; Shares&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" style="border-bottom: black 1px solid;" id="a98ac3ec6-cd33-4c4d-8237-1c32f58d797e" valign="bottom" width="9%" colspan="2"&gt;
&lt;p align="center" style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" style="border-bottom: black 1px solid;" id="a6977c8ad-375c-4c64-a345-07b7b573f35a" valign="bottom" width="9%" colspan="2"&gt;
&lt;p align="center" style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"&gt;&lt;strong&gt;Share&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" style="border-bottom: black 1px solid;" id="a3bffaefa-c070-49d2-a8f3-70f443a96837" valign="bottom" width="9%" colspan="2"&gt;&lt;strong&gt;Price&lt;/strong&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"&gt;&lt;b&gt;Balance at December&amp;#160;31, 2015&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td align="right" id="ffcell" valign="bottom" width="9%"&gt;2,020,000&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td align="right" id="afc56a6ee-0003-48f7-be2b-994cc39e9ec8" valign="bottom" width="9%"&gt;1,180,000&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;$&lt;/td&gt;
&lt;td&gt;
&lt;p align="right" style="margin: 0px;"&gt;0.42-3.00&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;
&lt;td align="right" id="abd895ea5-68ad-4e1f-93f6-8f7518072754" valign="bottom" width="9%"&gt;0.63&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"&gt;Shares used for restricted stock awards (see discussion below)&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1px solid;" valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" style="border-bottom: black 1px solid;" id="aa47912fc-85e0-4545-8d9d-f4812dc020a9" valign="bottom" width="9%"&gt;(1,200,000&lt;/td&gt;
&lt;td style="padding-bottom: 1px;" valign="bottom" width="1%"&gt;)&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="a93a4e98f-7ce1-4240-8f2f-e35f79e2c87f" valign="bottom" width="9%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="a45874aba-3617-491d-a106-2b7a615824e7" valign="bottom" width="9%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="aa4964e5b-1be1-4cf2-a19e-d99b1ae1fc55" valign="bottom" width="9%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"&gt;&lt;b&gt;Subtotal&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="acc646180-f655-4e8b-a2a5-b30028795437" valign="bottom" width="9%"&gt;820,000&lt;/td&gt;
&lt;td style="padding-bottom: 3px;" valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="a33cf3d3e-009d-4872-9e28-eaa5dccfb4fe" valign="bottom" width="9%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="a50e97196-1fe7-482d-9730-a852311bed65" valign="bottom" width="9%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="a77f6ba51-2a31-48b1-bbdc-6cfe5512b292" valign="bottom" width="9%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"&gt;Options granted&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="a0970e4e9-b365-41eb-a412-2b535d786d21" valign="bottom" width="9%"&gt;-&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="a57312fe5-b4ad-4b62-80e5-aa1fdef1f917" valign="bottom" width="9%"&gt;-&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;
&lt;td align="right" id="a14c46776-7400-4a21-83a3-196d2593d887" valign="bottom" width="9%"&gt;-&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;
&lt;td align="right" id="afec4457e-7147-4c33-bf61-2f0fea7dfaf5" valign="bottom" width="9%"&gt;-&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"&gt;Options exercised&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="af5fa4d22-e63d-46bb-acb1-919d669ae0f1" valign="bottom" width="9%"&gt;-&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="a86a24e7f-980a-4e65-967a-5b7fbe922e0c" valign="bottom" width="9%"&gt;-&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;
&lt;td align="right" id="ae9770fbd-c81f-4479-a388-7055d39868a0" valign="bottom" width="9%"&gt;-&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;
&lt;td align="right" id="ae748cc22-57d8-40b1-90c6-7f9f24ad4d52" valign="bottom" width="9%"&gt;-&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"&gt;Options cancelled&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1px solid;" valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" style="border-bottom: black 1px solid;" id="ad3a45ec0-e872-41ee-a8a4-0f5361c9d1c0" valign="bottom" width="9%"&gt;37,500&lt;/td&gt;
&lt;td style="padding-bottom: 1px;" valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1px solid;" valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" style="border-bottom: black 1px solid;" id="a024bf5a9-68e7-4ae9-8d54-929ae0ab07f3" valign="bottom" width="9%"&gt;(37,500&lt;/td&gt;
&lt;td style="padding-bottom: 1px;" valign="bottom" width="1%"&gt;)&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;
&lt;td align="right" id="a79c5ff51-447c-4c8d-91b8-b4af82950757" valign="bottom" width="9%"&gt;1.15&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;
&lt;td align="right" id="ada723513-9fb7-42d6-a0c9-5bb20303124c" valign="bottom" width="9%"&gt;1.15&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"&gt;&lt;b&gt;Balance at September 30, 2016&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 3px double;" valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" style="border-bottom: black 3px double;" id="a59b9f2b0-0c39-4bc4-a2f9-6ad72a5b0e8a" valign="bottom" width="9%"&gt;857,500&lt;/td&gt;
&lt;td style="padding-bottom: 3px;" valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 3px double;" valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" style="border-bottom: black 3px double;" id="a1a28dff2-8b4a-4ff3-969c-e645ed2ea7d1" valign="bottom" width="9%"&gt;1,142,500&lt;/td&gt;
&lt;td style="padding-bottom: 3px;" valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;$&lt;/td&gt;
&lt;td&gt;
&lt;p align="right" style="margin: 0px;"&gt;0.42-3.00&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;
&lt;td align="right" id="aa118bbb2-6d9a-4c3a-b288-5b584a67903b" valign="bottom" width="9%"&gt;0.61&lt;/td&gt;
&lt;td style="padding-bottom: 3px;" valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;
&lt;div style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;
&lt;table style="text-align: justify; width: 100%; font: 10pt 'times new roman'; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" style="border-bottom: 1px solid;"  valign="bottom" colspan="4"&gt;
&lt;p align="center" style="margin: 0px 0px 0px 1.9pt;"&gt;&lt;b&gt;Nine Months Ended September 30,&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" style="border-bottom: 1px solid;"  valign="bottom" width="9%"&gt;
&lt;p align="center" style="margin: 0px 0px 0px 0.4pt;"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" style="border-bottom: 1px solid;"  valign="bottom" width="9%" colspan="2"&gt;
&lt;p align="center" style="margin: 0px 0px 0px 0.9pt;"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1px;" valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Dividend yield&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p align="right" style="margin: 0px; color: black;"&gt;NA&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right"  valign="bottom" width="9%"&gt;0.00&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Volatility factor&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p align="right" style="margin: 0px; color: black;"&gt;NA&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="right" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right"  valign="bottom" width="9%"&gt;75.00&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Risk-free interest rate&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p align="right" style="margin: 0px; color: black;"&gt;NA&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2"&gt;
&lt;p align="right" style="margin: 0px;"&gt;1.65-1.85&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Expected term (years)&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p align="right" style="margin: 0px; color: black;"&gt;NA&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2"&gt;
&lt;p align="right" style="margin: 0px; color: black;"&gt;6.25-6.50&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Weighted-average fair value of options granted during the periods&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p align="right" style="margin: 0px; color: black;"&gt;NA&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;
&lt;td align="right"  valign="bottom" width="9%"&gt;2.69&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
<us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;
&lt;div style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;
&lt;table style="text-align: justify; width: 100%; font: 10pt 'times new roman'; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" style="border-bottom: 1px solid;"  valign="bottom" colspan="6"&gt;
&lt;p align="center" style="margin: 0px 0px 0px 2.4pt;"&gt;&lt;b&gt;Nine Months&lt;/b&gt;&lt;/p&gt;
&lt;p align="center" style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"&gt;&lt;b&gt;Ended September 30,&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" style="border-bottom: 1px solid;"  valign="bottom" width="9%" colspan="2"&gt;
&lt;p align="center" style="margin: 0px 0px 0px 0.9pt;"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1px;" valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" style="border-bottom: 1px solid;"  valign="bottom" width="9%" colspan="2"&gt;
&lt;p align="center" style="margin: 0px 0px 0px 0.4pt;"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1px;" valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Dividend yield&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right"  valign="bottom" width="9%"&gt;0.00&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;%&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right"  valign="bottom" width="9%"&gt;0.00&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Volatility factor&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right"  valign="bottom" width="9%"&gt;70.00&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;%&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right"  valign="bottom" width="9%"&gt;70.00&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Risk-free interest rate&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2"&gt;
&lt;p align="right" style="margin: 0px; color: black;"&gt;1.11 - 1.29&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right"  valign="bottom" width="9%"&gt;1.75&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Expected term (years)&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2"&gt;
&lt;p align="right" style="margin: 0px; color: black;"&gt;3.89-3.90&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right"  valign="bottom" width="9%"&gt;4.61&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"&gt;Weighted-average fair value of warrants&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;
&lt;td align="right"  valign="bottom" width="9%"&gt;0.14&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;
&lt;td align="right"  valign="bottom" width="9%"&gt;0.46&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
<nmus:NumberOfSharesExchanged contextRef="Context_Custom_01_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_BusinessAcquisitionAxis_NemusAcquisitionCorpMember" unitRef="shares" decimals="INF">12880000</nmus:NumberOfSharesExchanged>
<us-gaap:PropertyPlantAndEquipmentDepreciationMethods contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">Straight-line method</us-gaap:PropertyPlantAndEquipmentDepreciationMethods>
<us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">Two to three years</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
<us-gaap:NumberOfReportableSegments contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="Segments" decimals="INF">1</us-gaap:NumberOfReportableSegments>
<nmus:StockIssuedDuringPeriodSharesReverseMerger contextRef="Context_Custom_01_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_BusinessAcquisitionAxis_NemusAcquisitionCorpMember" unitRef="shares" decimals="INF">3120000</nmus:StockIssuedDuringPeriodSharesReverseMerger>
<nmus:TermOfMemorandumOfUnderstandingAgreement contextRef="Context_Custom_01_Jul_2013T00_00_00_TO_31_Jul_2013T00_00_00_LegalEntityAxis_UniversityOfMississippiMember_AgreementAxis_UniversityOfMississippiAgreementsMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">P5Y</nmus:TermOfMemorandumOfUnderstandingAgreement>
<nmus:NumberOfLicenseAgreements contextRef="Context_Custom_01_Sep_2014T00_00_00_TO_29_Sep_2014T00_00_00_LegalEntityAxis_UniversityOfMississippiMember_AgreementAxis_OptionAgreementMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" unitRef="License_agreements" decimals="INF">3</nmus:NumberOfLicenseAgreements>
<nmus:NumberOfLicenseAgreements contextRef="Context_Custom_01_Dec_2015T00_00_00_TO_14_Dec_2015T00_00_00_AgreementAxis_LicenseAgreementMember_LegalEntityAxis_UniversityOfMississippiMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" unitRef="License_agreements" decimals="INF">2</nmus:NumberOfLicenseAgreements>
<nmus:NoticePeriodForTermination contextRef="Context_Custom_01_Jul_2013T00_00_00_TO_31_Jul_2013T00_00_00_LegalEntityAxis_UniversityOfMississippiMember_AgreementAxis_UniversityOfMississippiAgreementsMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">P3M</nmus:NoticePeriodForTermination>
<nmus:NoticePeriodForTermination contextRef="Context_Custom_01_Sep_2014T00_00_00_TO_29_Sep_2014T00_00_00_LegalEntityAxis_UniversityOfMississippiMember_AgreementAxis_OptionAgreementMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">P60D</nmus:NoticePeriodForTermination>
<nmus:NoticePeriodForTermination contextRef="Context_Custom_01_Dec_2015T00_00_00_TO_14_Dec_2015T00_00_00_AgreementAxis_LicenseAgreementMember_LegalEntityAxis_UniversityOfMississippiMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">P60D</nmus:NoticePeriodForTermination>
<nmus:OneTimeUpfrontPayment contextRef="Context_Custom_01_Oct_2014T00_00_00_TO_15_Oct_2014T00_00_00_LegalEntityAxis_UniversityOfMississippiMember_MonthAndYearOfAgreementAxis_OctoberTwoThousandFifteenMember_AgreementAxis_OptionAgreementMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" unitRef="USD" decimals="0">10000</nmus:OneTimeUpfrontPayment>
<nmus:OneTimeUpfrontPayment contextRef="Context_Custom_01_Dec_2015T00_00_00_TO_14_Dec_2015T00_00_00_AgreementAxis_LicenseAgreementMember_LegalEntityAxis_UniversityOfMississippiMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" unitRef="USD" decimals="0">65000</nmus:OneTimeUpfrontPayment>
<nmus:OneTimeUpfrontPayment contextRef="Context_Custom_01_Dec_2015T00_00_00_TO_14_Dec_2015T00_00_00_MonthAndYearOfAgreementAxis_December2015Member_AgreementAxis_LicenseAgreementMember_LegalEntityAxis_UniversityOfMississippiMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" unitRef="USD" decimals="0">10000</nmus:OneTimeUpfrontPayment>
<nmus:AnnualFeesForLicenseAgreement contextRef="Context_Custom_01_Sep_2014T00_00_00_TO_29_Sep_2014T00_00_00_LegalEntityAxis_UniversityOfMississippiMember_AgreementAxis_OptionAgreementMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" unitRef="USD" decimals="0">25000</nmus:AnnualFeesForLicenseAgreement>
<nmus:AnnualFeesForLicenseAgreement contextRef="Context_Custom_01_Dec_2015T00_00_00_TO_14_Dec_2015T00_00_00_AgreementAxis_LicenseAgreementMember_LegalEntityAxis_UniversityOfMississippiMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" unitRef="USD" decimals="0">25000</nmus:AnnualFeesForLicenseAgreement>
<nmus:AggregateMilestonePaymentsIfMilestonesAchieved contextRef="Context_Custom_01_Sep_2014T00_00_00_TO_29_Sep_2014T00_00_00_LegalEntityAxis_UniversityOfMississippiMember_AgreementAxis_OptionAgreementMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" unitRef="USD" decimals="-5">2100000</nmus:AggregateMilestonePaymentsIfMilestonesAchieved>
<nmus:AggregateMilestonePaymentsIfMilestonesAchieved contextRef="Context_Custom_01_Dec_2015T00_00_00_TO_14_Dec_2015T00_00_00_AgreementAxis_LicenseAgreementMember_LegalEntityAxis_UniversityOfMississippiMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" unitRef="USD" decimals="-5">1400000</nmus:AggregateMilestonePaymentsIfMilestonesAchieved>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">56671</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">161963</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">218634</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
<us-gaap:AreaOfLand contextRef="Context_As_Of_31_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_AgreementAxis_LeaseAgreementMember" unitRef="sqft" decimals="0">4087</us-gaap:AreaOfLand>
<us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_Custom_01_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">9267</us-gaap:OperatingLeasesRentExpenseNet>
<us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_Custom_01_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_AgreementAxis_LeaseAgreementMember" unitRef="USD" decimals="0">5373</us-gaap:OperatingLeasesRentExpenseNet>
<us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">56680</us-gaap:OperatingLeasesRentExpenseNet>
<us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">170931</us-gaap:OperatingLeasesRentExpenseNet>
<us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_Custom_01_Nov_2015T00_00_00_TO_30_Nov_2015T00_00_00" unitRef="USD" decimals="0">7559</us-gaap:OperatingLeasesRentExpenseNet>
<us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">79771</us-gaap:OperatingLeasesRentExpenseNet>
<us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">240746</us-gaap:OperatingLeasesRentExpenseNet>
<nmus:FeesAndExpensesForServicesProvided contextRef="Context_Custom_01_Feb_2016T00_00_00_TO_05_Feb_2016T00_00_00_AgreementAxis_LetterAgreementMember_LegalEntityAxis_ContractManufacturingOrganizationMember_RangeAxis_MinimumMember" unitRef="USD" decimals="0">154000</nmus:FeesAndExpensesForServicesProvided>
<nmus:FeesAndExpensesForServicesProvided contextRef="Context_Custom_01_Feb_2016T00_00_00_TO_05_Feb_2016T00_00_00_AgreementAxis_LetterAgreementMember_LegalEntityAxis_ContractManufacturingOrganizationMember_RangeAxis_MaximumMember" unitRef="USD" decimals="0">183000</nmus:FeesAndExpensesForServicesProvided>
<nmus:AnalyticalMethodDevelopmentAndQualificationExpense contextRef="Context_Custom_01_Feb_2016T00_00_00_TO_05_Feb_2016T00_00_00_AgreementAxis_LetterAgreementMember_LegalEntityAxis_ContractManufacturingOrganizationMember" unitRef="USD" decimals="0">142900</nmus:AnalyticalMethodDevelopmentAndQualificationExpense>
<nmus:SharesAvailableForGrantOfOptionsOpeningBalance contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">2020000</nmus:SharesAvailableForGrantOfOptionsOpeningBalance>
<nmus:SharesAvailableForGrantOfOptionsOpeningBalance contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">857500</nmus:SharesAvailableForGrantOfOptionsOpeningBalance>











<nmus:SharesAvailableForGrantOptionsExcludingRestrictedstock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">820000</nmus:SharesAvailableForGrantOptionsExcludingRestrictedstock>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="Context_Custom_01_Oct_2015T00_00_00_TO_20_Oct_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_RestrictedStockMember_TitleOfIndividualAxis_ManagementAndBoardOfDirectorsMember" unitRef="USD" decimals="INF">1200000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="Context_9ME_01-Jan-2016T00_00_00_TO_30-Sep-2016T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_RestrictedStockMember" unitRef="USD" decimals="INF">1200000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">1180000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">1142500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>




<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" xsi:nil="true"/>


<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" xsi:nil="true"/>


<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">37500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<nmus:OptionsOutstandingPricePerShareOpeningBalance contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_OmnibusIncentivePlan2014Member_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">0.42</nmus:OptionsOutstandingPricePerShareOpeningBalance>
<nmus:OptionsOutstandingPricePerShareOpeningBalance contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_OmnibusIncentivePlan2014Member_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">3.00</nmus:OptionsOutstandingPricePerShareOpeningBalance>
<nmus:OptionsOutstandingPricePerShareOpeningBalance contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_OmnibusIncentivePlan2014Member_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">0.42</nmus:OptionsOutstandingPricePerShareOpeningBalance>
<nmus:OptionsOutstandingPricePerShareOpeningBalance contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_OmnibusIncentivePlan2014Member_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">3.00</nmus:OptionsOutstandingPricePerShareOpeningBalance>






<nmus:OptionsOutstandingPricePerShareOptionsGranted contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" xsi:nil="true"/>


<nmus:OptionsOutstandingPricePerShareOptionsCancelled contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">1.15</nmus:OptionsOutstandingPricePerShareOptionsCancelled>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">0.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">0.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>








<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="2">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember" unitRef="pure" decimals="4">0.0165</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember" unitRef="pure" decimals="4">0.0185</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">2.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" xsi:nil="true"/>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_17_Jul_2012T00_00_00_TO_17_Jul_2012T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">3000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AgreementAxis_StockPurchaseAgreementJune2014Member_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">1800000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_31_Aug_2014T00_00_00_TO_31_Aug_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">2200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_31_Aug_2014T00_00_00_TO_31_Aug_2014T00_00_00_AgreementAxis_StockPurchaseAgreementJune2014Member_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">450000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_31_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">90000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_30_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00" unitRef="shares" decimals="INF">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_30_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">6000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_30_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">50000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_31_May_2015T00_00_00_TO_31_May_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">90000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">10000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_31_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">6250000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">10000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_30_Nov_2015T00_00_00_TO_30_Nov_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">120000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_AgreementAxis_StockPurchaseAgreementJune2014Member_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">550000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_17_Jul_2012T00_00_00_TO_17_Jul_2012T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Aug_2014T00_00_00_TO_31_Aug_2014T00_00_00_AgreementAxis_StockPurchaseAgreementJune2014Member_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">2.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00" unitRef="USD_per_Share" decimals="0">5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">2.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD_per_Share" decimals="2">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_May_2015T00_00_00_TO_31_May_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">2.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Nov_2015T00_00_00_TO_30_Nov_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_AgreementAxis_StockPurchaseAgreementJune2014Member_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="USD_per_Share" decimals="2">1.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<nmus:TermOfWarrant contextRef="Context_Custom_01_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">P5Y</nmus:TermOfWarrant>
<nmus:TermOfWarrant contextRef="Context_Custom_01_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00">P10Y</nmus:TermOfWarrant>
<nmus:TermOfWarrant contextRef="Context_Custom_01_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember_StatementClassOfStockAxis_SeriesAPreferredStockMember">P5Y</nmus:TermOfWarrant>
<nmus:TermOfWarrant contextRef="Context_Custom_01_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">P5Y</nmus:TermOfWarrant>
<nmus:TermOfWarrant contextRef="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">P5Y</nmus:TermOfWarrant>
<nmus:TermOfWarrant contextRef="Context_Custom_01_Nov_2015T00_00_00_TO_30_Nov_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">P5Y</nmus:TermOfWarrant>
<nmus:NumberOfAdvisors contextRef="Context_As_Of_17_Jul_2012T00_00_00_TO_17_Jul_2012T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="Advisors" decimals="INF">2</nmus:NumberOfAdvisors>
<nmus:ValueOfCommonStockCalledByWarrants contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AgreementAxis_StockPurchaseAgreementJune2014Member_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">900000</nmus:ValueOfCommonStockCalledByWarrants>
<nmus:ValueOfCommonStockCalledByWarrants contextRef="Context_As_Of_31_Aug_2014T00_00_00_TO_31_Aug_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">1100000</nmus:ValueOfCommonStockCalledByWarrants>
<nmus:ValueOfCommonStockCalledByWarrants contextRef="Context_As_Of_30_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">10000</nmus:ValueOfCommonStockCalledByWarrants>
<nmus:ValueOfCommonStockCalledByWarrants contextRef="Context_As_Of_30_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">326000</nmus:ValueOfCommonStockCalledByWarrants>
<nmus:ValueOfCommonStockCalledByWarrants contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">14700</nmus:ValueOfCommonStockCalledByWarrants>
<nmus:ValueOfCommonStockCalledByWarrants contextRef="Context_As_Of_31_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">86250</nmus:ValueOfCommonStockCalledByWarrants>
<nmus:ValueOfCommonStockCalledByWarrants contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">14700</nmus:ValueOfCommonStockCalledByWarrants>
<nmus:ValueOfCommonStockCalledByWarrants contextRef="Context_As_Of_30_Nov_2015T00_00_00_TO_30_Nov_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">42000</nmus:ValueOfCommonStockCalledByWarrants>
<nmus:ValueOfCommonStockCalledByWarrants contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">85950</nmus:ValueOfCommonStockCalledByWarrants>
<nmus:AmortizationOfWarrantServiceCost contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">46810</nmus:AmortizationOfWarrantServiceCost>
<nmus:AmortizationOfWarrantServiceCost contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">7800</nmus:AmortizationOfWarrantServiceCost>
<nmus:AmortizationOfWarrantServiceCost contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">5145</nmus:AmortizationOfWarrantServiceCost>
<nmus:AmortizationOfWarrantServiceCost contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">34200</nmus:AmortizationOfWarrantServiceCost>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Context_Custom_01_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00" unitRef="shares" decimals="INF">1110000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
<nmus:AmortizationOfGeneralAndAdministrativeExpenses contextRef="Context_3ME_01_Jan_2016T00_00_00_TO_31_Mar_2016T00_00_00" unitRef="USD" decimals="0">12194</nmus:AmortizationOfGeneralAndAdministrativeExpenses>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_3ME_01_Jan_2015T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">168000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_Custom_01_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_LicenseAgreementTermsMember" unitRef="USD" decimals="0">50000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<nmus:StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants contextRef="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="shares" decimals="INF">5000</nmus:StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01_Jan_2015T00_00_00_TO_31_Jan_2015T00_00_00" unitRef="shares" decimals="INF">241663</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="shares" decimals="INF">24000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">50000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01_May_2015T00_00_00_TO_31_May_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">30000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01_May_2015T00_00_00_TO_31_May_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">150000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01_Jul_2015T00_00_00_TO_31_Jul_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">36000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01_Jul_2015T00_00_00_TO_31_Jul_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">180000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">187500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_Custom_01_Jan_2015T00_00_00_TO_31_Jan_2015T00_00_00" unitRef="USD" decimals="0">724989</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<nmus:ValueOfWarrantsIssued contextRef="Context_Custom_01_Aug_2014T00_00_00_TO_31_Aug_2014T00_00_00_AgreementAxis_StockPurchaseAgreementJune2014Member_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">85500</nmus:ValueOfWarrantsIssued>
<nmus:ValueOfWarrantsIssued contextRef="Context_Custom_01_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">625000</nmus:ValueOfWarrantsIssued>
<nmus:ValueOfWarrantsIssued contextRef="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">1000</nmus:ValueOfWarrantsIssued>
<nmus:ValueOfWarrantsIssued contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_AgreementAxis_StockPurchaseAgreementJune2014Member_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">104500</nmus:ValueOfWarrantsIssued>
<nmus:NumberOfInvestor contextRef="Context_Custom_01_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00" unitRef="Investors" decimals="INF">18</nmus:NumberOfInvestor>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="Context_Custom_01_Nov_2015T00_00_00_TO_30_Nov_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">60000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" decimals="INF">20000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<nmus:MinimumIssuanceOfSharesInEquityFinancing contextRef="Context_Custom_01_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">1000000</nmus:MinimumIssuanceOfSharesInEquityFinancing>
<nmus:MinimumIssuanceOfSharesInEquityFinancing contextRef="Context_Custom_01_Jul_2015T00_00_00_TO_31_Jul_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">286000</nmus:MinimumIssuanceOfSharesInEquityFinancing>
<nmus:MinimumIssuanceOfSharesInEquityFinancing contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">1000000</nmus:MinimumIssuanceOfSharesInEquityFinancing>
<nmus:MinimumIssuanceOfSharesInEquityFinancing contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">1000000</nmus:MinimumIssuanceOfSharesInEquityFinancing>
<nmus:MaximumIssuancePricePerShareInEquityFinancing contextRef="Context_As_Of_30_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD_per_Share" decimals="2">2.50</nmus:MaximumIssuancePricePerShareInEquityFinancing>
<nmus:MaximumIssuancePricePerShareInEquityFinancing contextRef="Context_As_Of_31_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD_per_Share" decimals="0">1000</nmus:MaximumIssuancePricePerShareInEquityFinancing>
<nmus:MaximumIssuancePricePerShareInEquityFinancing contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">2.50</nmus:MaximumIssuancePricePerShareInEquityFinancing>
<nmus:MaximumIssuancePricePerShareInEquityFinancing contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD_per_Share" decimals="2">2.50</nmus:MaximumIssuancePricePerShareInEquityFinancing>
<nmus:ConversionPrice contextRef="Context_Custom_01_Aug_2015T00_00_00_TO_21_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD_per_Share" decimals="2">2.50</nmus:ConversionPrice>
<nmus:ConversionPrice contextRef="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD_per_Share" decimals="2">2.50</nmus:ConversionPrice>
<nmus:ConversionPrice contextRef="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.80</nmus:ConversionPrice>
<nmus:ConversionPrice contextRef="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD_per_Share" decimals="2">0.80</nmus:ConversionPrice>
<nmus:ConversionPrice contextRef="Context_Custom_01_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.80</nmus:ConversionPrice>
<nmus:ConversionPrice contextRef="Context_Custom_01_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.80</nmus:ConversionPrice>
<us-gaap:ConversionOfStockSharesConverted1 contextRef="Context_Custom_01_Aug_2015T00_00_00_TO_21_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">580000</us-gaap:ConversionOfStockSharesConverted1>
<us-gaap:ConversionOfStockSharesConverted1 contextRef="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">580000</us-gaap:ConversionOfStockSharesConverted1>
<us-gaap:ConversionOfStockSharesConverted1 contextRef="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="shares" decimals="INF">5615000</us-gaap:ConversionOfStockSharesConverted1>
<us-gaap:ConversionOfStockSharesConverted1 contextRef="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">1250</us-gaap:ConversionOfStockSharesConverted1>
<us-gaap:ConversionOfStockSharesConverted1 contextRef="Context_Custom_01_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="shares" decimals="INF">500</us-gaap:ConversionOfStockSharesConverted1>
<us-gaap:ConversionOfStockSharesConverted1 contextRef="Context_Custom_01_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="shares" decimals="INF">8</us-gaap:ConversionOfStockSharesConverted1>
<us-gaap:ConversionOfStockSharesIssued1 contextRef="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">1812500</us-gaap:ConversionOfStockSharesIssued1>
<us-gaap:ConversionOfStockSharesIssued1 contextRef="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="shares" decimals="INF">1812500</us-gaap:ConversionOfStockSharesIssued1>
<us-gaap:ConversionOfStockSharesIssued1 contextRef="Context_Custom_01_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="shares" decimals="INF">625000</us-gaap:ConversionOfStockSharesIssued1>
<us-gaap:ConversionOfStockSharesIssued1 contextRef="Context_Custom_01_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="shares" decimals="INF">10000</us-gaap:ConversionOfStockSharesIssued1>
<us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants contextRef="Context_Custom_01_Aug_2015T00_00_00_TO_21_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD" decimals="-5">5000000</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
<us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants contextRef="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD" decimals="-5">5000000</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
<us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="USD" decimals="-5">5000000</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
<us-gaap:PreferredStockRedemptionTerms contextRef="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">(A) 115% of the conversion amount and (B) the product of (1) the conversion rate in effect at such time and (2) the greatest closing sale price of the Common Stock during the period beginning on the date immediately preceding such triggering event and ending on the date such holder delivers the notice of redemption.</us-gaap:PreferredStockRedemptionTerms>
<us-gaap:PreferredStockConversionBasis contextRef="Context_Custom_01_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">1,250:1</us-gaap:PreferredStockConversionBasis>
<us-gaap:PreferredStockLiquidationPreferenceValue contextRef="Context_As_Of_31_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD" decimals="-5">4500000</us-gaap:PreferredStockLiquidationPreferenceValue>
<us-gaap:PreferredStockLiquidationPreferenceValue contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD" decimals="-5">4500000</us-gaap:PreferredStockLiquidationPreferenceValue>
<us-gaap:PreferredStockLiquidationPreferenceValue contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD" decimals="-5">4500000</us-gaap:PreferredStockLiquidationPreferenceValue>
<us-gaap:SharePrice contextRef="Context_As_Of_31_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD_per_Share" decimals="0">1000</us-gaap:SharePrice>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">3200000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">857500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
<nmus:PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="2">1.00</nmus:PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants>
<nmus:CommonStockVotingPercentage contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="2">0.10</nmus:CommonStockVotingPercentage>
<nmus:PercentageOfFairValueOptionPriceAtDateOfGrants contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="2">1.10</nmus:PercentageOfFairValueOptionPriceAtDateOfGrants>
<nmus:MaximumExercisablePeriodOfFairValueOfOption contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember">P5Y</nmus:MaximumExercisablePeriodOfFairValueOfOption>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_Custom_01_Oct_2015T00_00_00_TO_20_Oct_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_RestrictedStockMember_RangeAxis_MinimumMember_TitleOfIndividualAxis_ManagementAndBoardOfDirectorsMember">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_Custom_01_Oct_2015T00_00_00_TO_20_Oct_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_RestrictedStockMember_RangeAxis_MaximumMember_TitleOfIndividualAxis_ManagementAndBoardOfDirectorsMember">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember">P8Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">52500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">4286</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">263985</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">181608</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_RestrictedStockMember_TitleOfIndividualAxis_ManagementAndBoardOfDirectorsMember" unitRef="USD" decimals="0">93750</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">544823</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_RestrictedStockMember_TitleOfIndividualAxis_ManagementAndBoardOfDirectorsMember" unitRef="USD" decimals="0">281250</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">1109963</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">P3Y1M21D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">238500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<nmus:FairMarketValueOfSharesGranted contextRef="Context_Custom_01_Oct_2015T00_00_00_TO_20_Oct_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_RestrictedStockMember_TitleOfIndividualAxis_ManagementAndBoardOfDirectorsMember" unitRef="USD" decimals="0">900000</nmus:FairMarketValueOfSharesGranted>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">1142500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
<us-gaap:SharesIssued contextRef="Context_As_Of_31_Jul_2015T00_00_00_TO_31_Jul_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">180000</us-gaap:SharesIssued>
<us-gaap:SharesIssued contextRef="Context_As_Of_21_Aug_2015T00_00_00_TO_21_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="shares" decimals="INF">1232000</us-gaap:SharesIssued>
<us-gaap:SharesIssuedPricePerShare contextRef="Context_As_Of_21_Aug_2015T00_00_00_TO_21_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD_per_Share" decimals="2">2.50</us-gaap:SharesIssuedPricePerShare>
<us-gaap:SharesIssuedPricePerShare contextRef="Context_As_Of_21_Aug_2015T00_00_00_TO_21_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:SharesIssuedPricePerShare>
<us-gaap:SharesIssuedPricePerShare contextRef="Context_As_Of_31_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_MajorTypesOfDebtAndEquitySecuritiesAxis_ConvertiblePreferredStockMember_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="USD_per_Share" decimals="0">1000</us-gaap:SharesIssuedPricePerShare>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="pure" decimals="4">0.0000</us-gaap:FairValueAssumptionsExpectedDividendRate>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="pure" decimals="4">0.0000</us-gaap:FairValueAssumptionsExpectedDividendRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="pure" decimals="4">0.7000</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="pure" decimals="4">0.7000</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="pure" decimals="4">0.0175</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember_RangeAxis_MaximumMember" unitRef="pure" decimals="4">0.0129</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember_RangeAxis_MinimumMember" unitRef="pure" decimals="4">0.0111</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember">P4Y7M10D</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember_RangeAxis_MaximumMember">P3Y10M24D</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember_RangeAxis_MinimumMember">P3Y10M21D</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="USD_per_Share" decimals="2">0.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="USD_per_Share" decimals="2">0.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<nmus:NumberOfWarrantsIssued contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="shares" decimals="INF">6437500</nmus:NumberOfWarrantsIssued>
<nmus:ExpirationPeriodOfWarrants contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember">P5Y</nmus:ExpirationPeriodOfWarrants>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD_per_Share" decimals="2">-0.07</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD_per_Share" decimals="2">-0.25</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD_per_Share" decimals="2">-0.05</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD_per_Share" decimals="1">-0.1</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" decimals="0">17062366</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" decimals="0">16519854</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" decimals="0">19913163</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" decimals="0">19910426</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<nmus:OptionPaymentDueAndPayable contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_LegalEntityAxis_UniversityOfMississippiMember_AgreementAxis_UniversityOfMississippiAgreementsMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" unitRef="USD" decimals="0">2500</nmus:OptionPaymentDueAndPayable>
<nmus:OptionPaymentDueAndPayable contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_LegalEntityAxis_UniversityOfMississippiMember_AgreementAxis_OptionAgreementMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" unitRef="USD" decimals="0">2500</nmus:OptionPaymentDueAndPayable>
<us-gaap:IncreaseInRestrictedCash contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">37500</us-gaap:IncreaseInRestrictedCash>
<us-gaap:IncreaseInRestrictedCash contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_31_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="USD" decimals="0">500000</us-gaap:AdditionalPaidInCapital>





<nmus:OptionsOutstandingPricePerShareOptionsExercised contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" xsi:nil="true"/>
<us-gaap:PaymentsOfStockIssuanceCosts contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">7700</us-gaap:PaymentsOfStockIssuanceCosts>
<us-gaap:PaymentsOfStockIssuanceCosts contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD" decimals="0">411661</us-gaap:PaymentsOfStockIssuanceCosts>
<us-gaap:PaymentsOfStockIssuanceCosts contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementClassOfStockAxis_CommonStockMember" unitRef="USD" decimals="0">3920</us-gaap:PaymentsOfStockIssuanceCosts>
<nmus:ReductionInConversionPrice contextRef="Context_As_Of_31_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.40</nmus:ReductionInConversionPrice>
<nmus:ReductionInExcercisePrice contextRef="Context_As_Of_31_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_StatementClassOfStockAxis_SeriesCWarrantsMember" unitRef="USD_per_Share" decimals="2">0.40</nmus:ReductionInExcercisePrice>
<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="Context_Custom_01_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_MajorTypesOfDebtAndEquitySecuritiesAxis_ConvertiblePreferredStockMember_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="shares" decimals="INF">500</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="Context_Custom_01_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_MajorTypesOfDebtAndEquitySecuritiesAxis_ConvertiblePreferredStockMember_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="USD" decimals="0">500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
<us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="Context_As_Of_31_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_MajorTypesOfDebtAndEquitySecuritiesAxis_ConvertiblePreferredStockMember_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="shares" decimals="INF">2500</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="Context_Custom_01_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_LicenseAgreementTermsMember" unitRef="USD" decimals="0">50000</us-gaap:PaymentsToAcquireIntangibleAssets>
<nmus:CoversionPriceOfCovertibleSecurities contextRef="Context_As_Of_31_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_MajorTypesOfDebtAndEquitySecuritiesAxis_ConvertiblePreferredStockMember_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.40</nmus:CoversionPriceOfCovertibleSecurities>


<!-- Footnote Section -->
<link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<link:loc xlink:type="locator" xlink:href="#Footnote-2_1" xlink:label="lab_Footnote-2_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-1" xlink:from="lab_Footnote-2_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="2.0" xlink:to="Footnote-2" xlink:from="lab_Footnote-2_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-2_2" xlink:label="lab_Footnote-2_2"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-1" xlink:from="lab_Footnote-2_2"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="2.0" xlink:to="Footnote-2" xlink:from="lab_Footnote-2_2"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-1_3" xlink:label="lab_Footnote-1_3"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-1" xlink:from="lab_Footnote-1_3"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-1_4" xlink:label="lab_Footnote-1_4"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-1" xlink:from="lab_Footnote-1_4"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-2_3" xlink:label="lab_Footnote-2_3"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-2" xlink:from="lab_Footnote-2_3"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-2_4" xlink:label="lab_Footnote-2_4"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-2" xlink:from="lab_Footnote-2_4"/>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-1">During the nine months ended September 30, 2015, the Company issued warrants of our common stock for consulting services. The warrants were valued at $417,875 and were recorded as a Prepaid expense and are being amortized over the service period.During the nine months ended September 30, 2015, the Company also issued shares of common stock for consulting services valued at $168,000. Such amounts were recorded as a Prepaid expense and are being amortized over the service period.During the nine months ended September 30, 2016, warrants issued to service providers for consulting services were valued at $22,425 and recorded as a Prepaid expense and are being amortized over the service period.</link:footnote>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-2">During the nine months ended September 30, 2015, the Company issued warrants of our common stock to a service provider in exchange for extinguishment of $10,000 of trade accounts payable owed to this vendor.</link:footnote>
</link:footnoteLink>
<xbrli:context id="Context_3ME_01-Jul-2016T00_00_00_TO_30-Sep-2016T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-07-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME_01-Jul-2016T00_00_00_TO_30-Sep-2016T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="shares" decimals="0">10879500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<xbrli:context id="Context_9ME_01-Jan-2016T00_00_00_TO_30-Sep-2016T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME_01-Jan-2016T00_00_00_TO_30-Sep-2016T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="shares" decimals="0">10879500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<xbrli:context id="Context_3ME_01-Jul-2016T00_00_00_TO_30-Sep-2016T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-07-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME_01-Jul-2016T00_00_00_TO_30-Sep-2016T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="shares" decimals="0">1142500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<xbrli:context id="Context_9ME_01-Jan-2016T00_00_00_TO_30-Sep-2016T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME_01-Jan-2016T00_00_00_TO_30-Sep-2016T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="shares" decimals="0">1142500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<xbrli:context id="Context_3ME_01-Jul-2015T00_00_00_TO_30-Sep-2015T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-07-01</xbrli:startDate><xbrli:endDate>2015-09-30</xbrli:endDate></xbrli:period></xbrli:context>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME_01-Jul-2015T00_00_00_TO_30-Sep-2015T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="shares" decimals="0">10759500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<xbrli:context id="Context_9ME_01-Jan-2015T00_00_00_TO_30-Sep-2015T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-09-30</xbrli:endDate></xbrli:period></xbrli:context>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME_01-Jan-2015T00_00_00_TO_30-Sep-2015T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="shares" decimals="0">10759500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<xbrli:context id="Context_3ME_01-Jul-2015T00_00_00_TO_30-Sep-2015T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-07-01</xbrli:startDate><xbrli:endDate>2015-09-30</xbrli:endDate></xbrli:period></xbrli:context>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME_01-Jul-2015T00_00_00_TO_30-Sep-2015T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="shares" decimals="0">1151000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<xbrli:context id="Context_9ME_01-Jan-2015T00_00_00_TO_30-Sep-2015T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-09-30</xbrli:endDate></xbrli:period></xbrli:context>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME_01-Jan-2015T00_00_00_TO_30-Sep-2015T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="shares" decimals="0">1151000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<xbrli:context id="Context_9ME_01-Jan-2016T00_00_00_TO_30-Sep-2016T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmus:OmnibusIncentivePlan2014Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context>
	<nmus:SharesAvailableForGrantOptionsGranted contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" xsi:nil="true"/>
<nmus:SharesAvailableForGrantOptionsExercised contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" xsi:nil="true"/>
<nmus:SharesAvailableForGrantOptionsCancelled contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">37500</nmus:SharesAvailableForGrantOptionsCancelled>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">1.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>nmus-20160930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.6.0.0 on Wednesday, November 09, 2016 01:08:12 AM -->
<schema targetNamespace="http://www.nemusbioscience.com/20160930" elementFormDefault="qualified" xmlns:nmus="http://www.nemusbioscience.com/20160930" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:country="http://xbrl.sec.gov/country/2016-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric">
<annotation><appinfo>
<link:roleType roleURI="http://www.nemusbioscience.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
<link:definition>001 - Document - Document and Entity Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
<link:definition>002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/Consolidatedbalancesheetsparentheticals" id="Consolidatedbalancesheetsparentheticals">
<link:definition>003 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/ConsolidatedStatementsOfOperationsUnaudited" id="ConsolidatedStatementsOfOperationsUnaudited">
<link:definition>004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" id="ConsolidatedStatementsOfCashFlowsUnaudited">
<link:definition>005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/ConsolidatedStatementsOfCashFlowsUnauditedParentheticals" id="ConsolidatedStatementsOfCashFlowsUnauditedParentheticals">
<link:definition>006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (Parentheticals )</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPolicies" id="NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPolicies">
<link:definition>007 - Disclosure - Nature of Operations, Business Activities and Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/UniversityOfMississippiAgreements" id="UniversityOfMississippiAgreements">
<link:definition>008 - Disclosure - University of Mississippi Agreements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/COMMITMENTSANDCONTINGENCIES" id="COMMITMENTSANDCONTINGENCIES">
<link:definition>009 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemption" id="StockholdersDeficitAndPreferredStockSubjectToRedemption">
<link:definition>010 - Disclosure - Stockholders' Deficit and Redeemable Convertible Series B Preferred Stock</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/ProvisionForConversionOfPreferredStock" id="ProvisionForConversionOfPreferredStock">
<link:definition>011 - Disclosure - Provision for Conversion of Preferred Stock</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/SeriesBWarrants" id="SeriesBWarrants">
<link:definition>012 - Disclosure - Series B Warrants</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>013 - Disclosure - Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>014 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesPolicies" id="NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>015 - Disclosure - Nature of Operations, Business Activities and Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/CommitmentsandContingenciesTables" id="CommitmentsandContingenciesTables">
<link:definition>016 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockTables" id="StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockTables">
<link:definition>017 - Disclosure - Stockholders' Deficit and Redeemable Convertible Series B Preferred Stock (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/SeriesBWarrantsTables" id="SeriesBWarrantsTables">
<link:definition>018 - Disclosure - Series B Warrants (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesDetailTextuals" id="NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesDetailTextuals">
<link:definition>019 - Disclosure - Nature of Operations, Business Activities and Summary of Significant Accounting Policies (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/UniversityOfMississippiAgreementsDetailTextuals" id="UniversityOfMississippiAgreementsDetailTextuals">
<link:definition>021 - Disclosure - University of Mississippi Agreements (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsDetails" id="CommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsDetails">
<link:definition>022 - Disclosure - Commitments and Contingencies - Summary of Future minimum payments (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/CommitmentsAndContingenciesDetailTextuals" id="CommitmentsAndContingenciesDetailTextuals">
<link:definition>023 - Disclosure - Commitments and Contingencies (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockSummaryOfOptionActivityUnder2014PlanDetails" id="StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockSummaryOfOptionActivityUnder2014PlanDetails">
<link:definition>024 - Disclosure - Stockholders' Deficit and Redeemable Convertible Series B Preferred Stock - Summary of option activity under 2014 Plan (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockSummaryOfWeightedAverageAssumptionsForEmployeeOptionDetails1" id="StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockSummaryOfWeightedAverageAssumptionsForEmployeeOptionDetails1">
<link:definition>025 - Disclosure - Stockholders' Deficit and Redeemable Convertible Series B Preferred Stock - Summary of weighted average assumptions for employee option (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockDetailTextuals" id="StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockDetailTextuals">
<link:definition>026 - Disclosure - Stockholders' Deficit and Redeemable Convertible Series B Preferred Stock (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockDetailTextuals1" id="StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockDetailTextuals1">
<link:definition>027 - Disclosure - Stockholders' Deficit and Redeemable Convertible Series B Preferred Stock (Detail Textuals 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/ProvisionForConversionOfPreferredStockDetailTextuals" id="ProvisionForConversionOfPreferredStockDetailTextuals">
<link:definition>028 - Disclosure - Provision for Conversion of Preferred Stock (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/SeriesBWarrantsDetails" id="SeriesBWarrantsDetails">
<link:definition>029 - Disclosure - Series B Warrants (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/SeriesBWarrantsDetailTextuals" id="SeriesBWarrantsDetailTextuals">
<link:definition>030 - Disclosure - Series B Warrants (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/SubsequentEventsDetailTextuals" id="SubsequentEventsDetailTextuals">
<link:definition>031 - Disclosure - Subsequent Events (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="nmus-20160930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="nmus-20160930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="nmus-20160930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="nmus-20160930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:roleType roleURI="http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesDetailTextuals1" id="NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesDetailTextuals1"><link:definition>020 - Disclosure - Nature of Operations, Business Activities and Summary of Significant Accounting Policies (Detail Textuals 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
</appinfo></annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/country/2016-01-31" schemaLocation="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/currency/2016-01-31" schemaLocation="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/exch/2016-01-31" schemaLocation="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
<import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<import namespace="http://fasb.org/us-types/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd"/>
<element name="DocumentAndEntityInformationAbstract" id="nmus_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DepositsAndOtherAssets" id="nmus_DepositsAndOtherAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AccruedLicenseAndPatentReimbursementFees" id="nmus_AccruedLicenseAndPatentReimbursementFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ProvisionForConversionOfPreferredStock" id="nmus_ProvisionForConversionOfPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuanceCosts" id="nmus_StockIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ChangeInFairValueOfWarrantLiability" id="nmus_ChangeInFairValueOfWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GainLossOnConversionRightPreferredStock" id="nmus_GainLossOnConversionRightPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees" id="nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IncreaseDecreaseInStockSubscriptionLiability" id="nmus_IncreaseDecreaseInStockSubscriptionLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CashPaidDuringPeriodForAbstract" id="nmus_CashPaidDuringPeriodForAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NoncashValueOfWarrantsIssued" id="nmus_NoncashValueOfWarrantsIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NoncashValueOfWarrantsIssuedInExchangeForExtinguishmentOfTradeAccountsPayable" id="nmus_NoncashValueOfWarrantsIssuedInExchangeForExtinguishmentOfTradeAccountsPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="UniversityOfMississippiAgreementsAbstract" id="nmus_UniversityOfMississippiAgreementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="UniversityOfMississippiAgreementsTextBlock" id="nmus_UniversityOfMississippiAgreementsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ProvisionForConversionOfPreferredStockAbstract" id="nmus_ProvisionForConversionOfPreferredStockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SeriesBWarrantsAbstract" id="nmus_SeriesBWarrantsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SeriesBWarrantsTextBlock" id="nmus_SeriesBWarrantsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LiquidityAndGoingConcernPolicyTextBlock" id="nmus_LiquidityAndGoingConcernPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockBasedCompensationForNonEmployeesPolicyTextBlock" id="nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable" id="nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
<element name="NemusAcquisitionCorpMember" id="nmus_NemusAcquisitionCorpMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems" id="nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuedDuringPeriodSharesReverseMerger" id="nmus_StockIssuedDuringPeriodSharesReverseMerger" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NumberOfSharesExchanged" id="nmus_NumberOfSharesExchanged" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="UniversityOfMississippiAgreementsTable" id="nmus_UniversityOfMississippiAgreementsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
<element name="AgreementAxis" id="nmus_AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
<element name="AgreementDomain" id="nmus_AgreementDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="UniversityOfMississippiAgreementsMember" id="nmus_UniversityOfMississippiAgreementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OptionAgreementMember" id="nmus_OptionAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LicenseAgreementMember" id="nmus_LicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="UniversityOfMississippiMember" id="nmus_UniversityOfMississippiMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MonthAndYearOfAgreementAxis" id="nmus_MonthAndYearOfAgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
<element name="MonthAndYearOfAgreementDomain" id="nmus_MonthAndYearOfAgreementDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OctoberTwoThousandFifteenMember" id="nmus_OctoberTwoThousandFifteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="December2015Member" id="nmus_December2015Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="UniversityOfMississippiAgreementsLineItems" id="nmus_UniversityOfMississippiAgreementsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TermOfMemorandumOfUnderstandingAgreement" id="nmus_TermOfMemorandumOfUnderstandingAgreement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NumberOfLicenseAgreements" id="nmus_NumberOfLicenseAgreements" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NoticePeriodForTermination" id="nmus_NoticePeriodForTermination" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OneTimeUpfrontPayment" id="nmus_OneTimeUpfrontPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AnnualFeesForLicenseAgreement" id="nmus_AnnualFeesForLicenseAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AggregateMilestonePaymentsIfMilestonesAchieved" id="nmus_AggregateMilestonePaymentsIfMilestonesAchieved" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OptionPaymentDueAndPayable" id="nmus_OptionPaymentDueAndPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LeaseAgreementMember" id="nmus_LeaseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LetterAgreementMember" id="nmus_LetterAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ContractManufacturingOrganizationMember" id="nmus_ContractManufacturingOrganizationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FeesAndExpensesForServicesProvided" id="nmus_FeesAndExpensesForServicesProvided" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AnalyticalMethodDevelopmentAndQualificationExpense" id="nmus_AnalyticalMethodDevelopmentAndQualificationExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OmnibusIncentivePlan2014Member" id="nmus_OmnibusIncentivePlan2014Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SharesAvailableForGrantOfOptionsRollForward" id="nmus_SharesAvailableForGrantOfOptionsRollForward" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SharesAvailableForGrantOfOptionsOpeningBalance" id="nmus_SharesAvailableForGrantOfOptionsOpeningBalance" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SharesAvailableForGrantOptionsGranted" id="nmus_SharesAvailableForGrantOptionsGranted" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SharesAvailableForGrantOptionsExercised" id="nmus_SharesAvailableForGrantOptionsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SharesAvailableForGrantOptionsCancelled" id="nmus_SharesAvailableForGrantOptionsCancelled" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SharesAvailableForGrantOptionsExcludingRestrictedstock" id="nmus_SharesAvailableForGrantOptionsExcludingRestrictedstock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OptionsOutstandingPricePerShareRollForward" id="nmus_OptionsOutstandingPricePerShareRollForward" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OptionsOutstandingPricePerShareOpeningBalance" id="nmus_OptionsOutstandingPricePerShareOpeningBalance" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OptionsOutstandingPricePerShareOptionsGranted" id="nmus_OptionsOutstandingPricePerShareOptionsGranted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OptionsOutstandingPricePerShareOptionsExercised" id="nmus_OptionsOutstandingPricePerShareOptionsExercised" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OptionsOutstandingPricePerShareOptionsCancelled" id="nmus_OptionsOutstandingPricePerShareOptionsCancelled" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EquityTable" id="nmus_EquityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
<element name="StockPurchaseAgreementJune2014Member" id="nmus_StockPurchaseAgreementJune2014Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EquityLineItems" id="nmus_EquityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TermOfWarrant" id="nmus_TermOfWarrant" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NumberOfAdvisors" id="nmus_NumberOfAdvisors" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ValueOfCommonStockCalledByWarrants" id="nmus_ValueOfCommonStockCalledByWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AmortizationOfWarrantServiceCost" id="nmus_AmortizationOfWarrantServiceCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AmortizationOfGeneralAndAdministrativeExpenses" id="nmus_AmortizationOfGeneralAndAdministrativeExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" id="nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ValueOfWarrantsIssued" id="nmus_ValueOfWarrantsIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NumberOfInvestor" id="nmus_NumberOfInvestor" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MinimumIssuanceOfSharesInEquityFinancing" id="nmus_MinimumIssuanceOfSharesInEquityFinancing" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MaximumIssuancePricePerShareInEquityFinancing" id="nmus_MaximumIssuancePricePerShareInEquityFinancing" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConversionPrice" id="nmus_ConversionPrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ManagementAndBoardOfDirectorsMember" id="nmus_ManagementAndBoardOfDirectorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants" id="nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommonStockVotingPercentage" id="nmus_CommonStockVotingPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PercentageOfFairValueOptionPriceAtDateOfGrants" id="nmus_PercentageOfFairValueOptionPriceAtDateOfGrants" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MaximumExercisablePeriodOfFairValueOfOption" id="nmus_MaximumExercisablePeriodOfFairValueOfOption" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairMarketValueOfSharesGranted" id="nmus_FairMarketValueOfSharesGranted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SeriesBWarrantsMember" id="nmus_SeriesBWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NumberOfWarrantsIssued" id="nmus_NumberOfWarrantsIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ExpirationPeriodOfWarrants" id="nmus_ExpirationPeriodOfWarrants" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SeriesCWarrantsMember" id="nmus_SeriesCWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CoversionPriceOfCovertibleSecurities" id="nmus_CoversionPriceOfCovertibleSecurities" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ReductionInConversionPrice" id="nmus_ReductionInConversionPrice" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ReductionInExcercisePrice" id="nmus_ReductionInExcercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>nmus-20160930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.6.0.0 on Wednesday, November 09, 2016 01:08:12 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="nmus-20160930.xsd#ConsolidatedBalanceSheets" roleURI="http://www.nemusbioscience.com/role/ConsolidatedBalanceSheets"/>
<calculationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_OtherAssetsCurrent" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent"/><loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_DepositsAndOtherAssets" xlink:label="loc_nmus_DepositsAndOtherAssets"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="loc_nmus_DepositsAndOtherAssets" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" order="20" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedSalariesCurrent" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_AccruedLicenseAndPatentReimbursementFees" xlink:label="loc_nmus_AccruedLicenseAndPatentReimbursementFees"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_nmus_AccruedLicenseAndPatentReimbursementFees" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ProvisionForConversionOfPreferredStock" xlink:label="loc_nmus_ProvisionForConversionOfPreferredStock"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_nmus_ProvisionForConversionOfPreferredStock" order="50" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesNoncurrent" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_CommitmentsAndContingencies" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="30" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" order="40" use="optional" weight="1"/></calculationLink>







<roleRef xlink:type="simple" xlink:href="nmus-20160930.xsd#ConsolidatedStatementsOfOperationsUnaudited" roleURI="http://www.nemusbioscience.com/role/ConsolidatedStatementsOfOperationsUnaudited"/>
<calculationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/ConsolidatedStatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" order="10" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OperatingIncomeLoss" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ChangeInFairValueOfWarrantLiability" xlink:label="loc_nmus_ChangeInFairValueOfWarrantLiability"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_nmus_ChangeInFairValueOfWarrantLiability" order="20" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_GainLossOnConversionRightPreferredStock" xlink:label="loc_nmus_GainLossOnConversionRightPreferredStock"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_nmus_GainLossOnConversionRightPreferredStock" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" order="20" use="optional" weight="-1"/></calculationLink>



<roleRef xlink:type="simple" xlink:href="nmus-20160930.xsd#ConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.nemusbioscience.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"/>
<calculationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/ConsolidatedStatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_NetIncomeLoss" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_Depreciation" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ShareBasedCompensation" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_GainLossOnConversionRightPreferredStock" xlink:label="loc_nmus_GainLossOnConversionRightPreferredStock"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_nmus_GainLossOnConversionRightPreferredStock" order="50" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ChangeInFairValueOfWarrantLiability" xlink:label="loc_nmus_ChangeInFairValueOfWarrantLiability"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_nmus_ChangeInFairValueOfWarrantLiability" order="60" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseInRestrictedCash" xlink:label="loc_us-gaap_IncreaseInRestrictedCash"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseInRestrictedCash" order="70" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" order="80" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="90" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable" order="100" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="110" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees" xlink:label="loc_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees" order="120" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_IncreaseDecreaseInStockSubscriptionLiability" xlink:label="loc_nmus_IncreaseDecreaseInStockSubscriptionLiability"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_nmus_IncreaseDecreaseInStockSubscriptionLiability" order="130" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="140" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="20" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="30" use="optional" weight="1"/></calculationLink>



<roleRef xlink:type="simple" xlink:href="nmus-20160930.xsd#CommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsDetails" roleURI="http://www.nemusbioscience.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="50" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="60" use="optional" weight="1"/>
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>nmus-20160930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.6.0.0 on Wednesday, November 09, 2016 01:08:12 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
<roleRef xlink:type="simple" xlink:href="nmus-20160930.xsd#ConsolidatedStatementsOfOperationsUnaudited" roleURI="http://www.nemusbioscience.com/role/ConsolidatedStatementsOfOperationsUnaudited"/>
<roleRef xlink:type="simple" xlink:href="nmus-20160930.xsd#ConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.nemusbioscience.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"/>
<roleRef xlink:type="simple" xlink:href="nmus-20160930.xsd#ConsolidatedStatementsOfCashFlowsUnauditedParentheticals" roleURI="http://www.nemusbioscience.com/role/ConsolidatedStatementsOfCashFlowsUnauditedParentheticals"/>
<roleRef xlink:type="simple" xlink:href="nmus-20160930.xsd#NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesDetailTextuals" roleURI="http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesDetailTextuals"/>
<roleRef xlink:type="simple" roleURI="http://www.nemusbioscience.com/role/UniversityOfMississippiAgreementsDetailTextuals" xlink:href="nmus-20160930.xsd#UniversityOfMississippiAgreementsDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="nmus-20160930.xsd#CommitmentsAndContingenciesDetailTextuals" roleURI="http://www.nemusbioscience.com/role/CommitmentsAndContingenciesDetailTextuals"/>
<roleRef xlink:type="simple" roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockSummaryOfOptionActivityUnder2014PlanDetails" xlink:href="nmus-20160930.xsd#StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockSummaryOfOptionActivityUnder2014PlanDetails"/>
<roleRef xlink:type="simple" roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockSummaryOfWeightedAverageAssumptionsForEmployeeOptionDetails1" xlink:href="nmus-20160930.xsd#StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockSummaryOfWeightedAverageAssumptionsForEmployeeOptionDetails1"/>
<roleRef xlink:type="simple" roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockDetailTextuals" xlink:href="nmus-20160930.xsd#StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockDetailTextuals"/>
<roleRef xlink:type="simple" roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockDetailTextuals1" xlink:href="nmus-20160930.xsd#StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockDetailTextuals1"/>
<roleRef xlink:type="simple" xlink:href="nmus-20160930.xsd#ProvisionForConversionOfPreferredStockDetailTextuals" roleURI="http://www.nemusbioscience.com/role/ProvisionForConversionOfPreferredStockDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="nmus-20160930.xsd#SeriesBWarrantsDetails" roleURI="http://www.nemusbioscience.com/role/SeriesBWarrantsDetails"/>
<roleRef xlink:type="simple" xlink:href="nmus-20160930.xsd#SeriesBWarrantsDetailTextuals" roleURI="http://www.nemusbioscience.com/role/SeriesBWarrantsDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="nmus-20160930.xsd#SubsequentEventsDetailTextuals" roleURI="http://www.nemusbioscience.com/role/SubsequentEventsDetailTextuals"/>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/ConsolidatedStatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6" xlink:to="loc_us-gaap_OperatingExpenses_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OperatingIncomeLoss_10" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_11" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ChangeInFairValueOfWarrantLiability" xlink:label="loc_nmus_ChangeInFairValueOfWarrantLiability_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_11" xlink:to="loc_nmus_ChangeInFairValueOfWarrantLiability_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_GainLossOnConversionRightPreferredStock" xlink:label="loc_nmus_GainLossOnConversionRightPreferredStock_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_11" xlink:to="loc_nmus_GainLossOnConversionRightPreferredStock_13" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_14" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_15" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_16" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_17" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_18" order="80" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/ConsolidatedStatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_6" xlink:to="loc_us-gaap_NetIncomeLoss_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_6" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8" xlink:to="loc_us-gaap_Depreciation_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8" xlink:to="loc_us-gaap_ShareBasedCompensation_10" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_11" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_GainLossOnConversionRightPreferredStock" xlink:label="loc_nmus_GainLossOnConversionRightPreferredStock_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8" xlink:to="loc_nmus_GainLossOnConversionRightPreferredStock_12" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ChangeInFairValueOfWarrantLiability" xlink:label="loc_nmus_ChangeInFairValueOfWarrantLiability_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8" xlink:to="loc_nmus_ChangeInFairValueOfWarrantLiability_13" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_14" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseInRestrictedCash" xlink:label="loc_us-gaap_IncreaseInRestrictedCash_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_14" xlink:to="loc_us-gaap_IncreaseInRestrictedCash_15" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_14" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_16" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_14" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_17" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_14" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_18" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_14" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_19" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees" xlink:label="loc_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_14" xlink:to="loc_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees_20" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_IncreaseDecreaseInStockSubscriptionLiability" xlink:label="loc_nmus_IncreaseDecreaseInStockSubscriptionLiability_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_14" xlink:to="loc_nmus_IncreaseDecreaseInStockSubscriptionLiability_21" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_14" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_22" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_23" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_24" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_24" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_25" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_24" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_26" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_27" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_27" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_28" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_27" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_29" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_27" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_30" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_31" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_33" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_CashPaidDuringPeriodForAbstract" xlink:label="loc_nmus_CashPaidDuringPeriodForAbstract_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_33" xlink:to="loc_nmus_CashPaidDuringPeriodForAbstract_34" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_35"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_CashPaidDuringPeriodForAbstract_34" xlink:to="loc_us-gaap_InterestPaid_35" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_36"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_CashPaidDuringPeriodForAbstract_34" xlink:to="loc_us-gaap_IncomeTaxesPaid_36" order="10" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/ConsolidatedStatementsOfCashFlowsUnauditedParentheticals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_CommonStockMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_7" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_NoncashValueOfWarrantsIssued" xlink:label="loc_nmus_NoncashValueOfWarrantsIssued_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_nmus_NoncashValueOfWarrantsIssued_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssued1_9" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_NoncashValueOfWarrantsIssuedInExchangeForExtinguishmentOfTradeAccountsPayable" xlink:label="loc_nmus_NoncashValueOfWarrantsIssuedInExchangeForExtinguishmentOfTradeAccountsPayable_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_nmus_NoncashValueOfWarrantsIssuedInExchangeForExtinguishmentOfTradeAccountsPayable_10" order="40" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesDetailTextuals">
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_NemusAcquisitionCorpMember" xlink:label="loc_nmus_NemusAcquisitionCorpMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" xlink:to="loc_nmus_NemusAcquisitionCorpMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6" xlink:to="loc_us-gaap_SubsequentEventMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_StockIssuedDuringPeriodSharesReverseMerger" xlink:label="loc_nmus_StockIssuedDuringPeriodSharesReverseMerger_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_nmus_StockIssuedDuringPeriodSharesReverseMerger_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_NumberOfSharesExchanged" xlink:label="loc_nmus_NumberOfSharesExchanged_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_nmus_NumberOfSharesExchanged_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_10" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_11" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_AdditionalPaidInCapital_12" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_13" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_14" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDepreciationMethods_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDepreciationMethods_15" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_16" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_NumberOfReportableSegments_17" order="100" use="optional"/>


</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/UniversityOfMississippiAgreementsDetailTextuals">
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_UniversityOfMississippiAgreementsLineItems" xlink:label="loc_nmus_UniversityOfMississippiAgreementsLineItems_0"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_UniversityOfMississippiAgreementsTable" xlink:label="loc_nmus_UniversityOfMississippiAgreementsTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_nmus_UniversityOfMississippiAgreementsTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_AgreementAxis" xlink:label="loc_nmus_AgreementAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_nmus_AgreementAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_AgreementDomain" xlink:label="loc_nmus_AgreementDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nmus_AgreementAxis_2" xlink:to="loc_nmus_AgreementDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_AgreementDomain" xlink:label="loc_nmus_AgreementDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nmus_AgreementAxis_2" xlink:to="loc_nmus_AgreementDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_UniversityOfMississippiAgreementsMember" xlink:label="loc_nmus_UniversityOfMississippiAgreementsMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_AgreementDomain_3" xlink:to="loc_nmus_UniversityOfMississippiAgreementsMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_OptionAgreementMember" xlink:label="loc_nmus_OptionAgreementMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_AgreementDomain_3" xlink:to="loc_nmus_OptionAgreementMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_LicenseAgreementMember" xlink:label="loc_nmus_LicenseAgreementMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_AgreementDomain_3" xlink:to="loc_nmus_LicenseAgreementMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_dei_LegalEntityAxis_7" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_7" xlink:to="loc_dei_EntityDomain_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_8_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_7" xlink:to="loc_dei_EntityDomain_8_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_UniversityOfMississippiMember" xlink:label="loc_nmus_UniversityOfMississippiMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_8" xlink:to="loc_nmus_UniversityOfMississippiMember_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_10" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_10" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_11_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_10" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_11_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_11" xlink:to="loc_us-gaap_IntellectualPropertyMember_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_MonthAndYearOfAgreementAxis" xlink:label="loc_nmus_MonthAndYearOfAgreementAxis_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_nmus_MonthAndYearOfAgreementAxis_13" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_MonthAndYearOfAgreementDomain" xlink:label="loc_nmus_MonthAndYearOfAgreementDomain_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nmus_MonthAndYearOfAgreementAxis_13" xlink:to="loc_nmus_MonthAndYearOfAgreementDomain_14" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_MonthAndYearOfAgreementDomain" xlink:label="loc_nmus_MonthAndYearOfAgreementDomain_14_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nmus_MonthAndYearOfAgreementAxis_13" xlink:to="loc_nmus_MonthAndYearOfAgreementDomain_14_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_OctoberTwoThousandFifteenMember" xlink:label="loc_nmus_OctoberTwoThousandFifteenMember_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_MonthAndYearOfAgreementDomain_14" xlink:to="loc_nmus_OctoberTwoThousandFifteenMember_15" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_December2015Member" xlink:label="loc_nmus_December2015Member_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_MonthAndYearOfAgreementDomain_14" xlink:to="loc_nmus_December2015Member_16" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_TermOfMemorandumOfUnderstandingAgreement" xlink:label="loc_nmus_TermOfMemorandumOfUnderstandingAgreement_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_nmus_TermOfMemorandumOfUnderstandingAgreement_17" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_NumberOfLicenseAgreements" xlink:label="loc_nmus_NumberOfLicenseAgreements_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_nmus_NumberOfLicenseAgreements_18" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_NoticePeriodForTermination" xlink:label="loc_nmus_NoticePeriodForTermination_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_nmus_NoticePeriodForTermination_19" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_OneTimeUpfrontPayment" xlink:label="loc_nmus_OneTimeUpfrontPayment_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_nmus_OneTimeUpfrontPayment_20" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_AnnualFeesForLicenseAgreement" xlink:label="loc_nmus_AnnualFeesForLicenseAgreement_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_nmus_AnnualFeesForLicenseAgreement_21" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_AggregateMilestonePaymentsIfMilestonesAchieved" xlink:label="loc_nmus_AggregateMilestonePaymentsIfMilestonesAchieved_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_nmus_AggregateMilestonePaymentsIfMilestonesAchieved_22" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_OptionPaymentDueAndPayable" xlink:label="loc_nmus_OptionPaymentDueAndPayable_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_nmus_OptionPaymentDueAndPayable_23" order="70" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/CommitmentsAndContingenciesDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_AgreementAxis" xlink:label="loc_nmus_AgreementAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" xlink:to="loc_nmus_AgreementAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_AgreementDomain" xlink:label="loc_nmus_AgreementDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nmus_AgreementAxis_2" xlink:to="loc_nmus_AgreementDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_AgreementDomain" xlink:label="loc_nmus_AgreementDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nmus_AgreementAxis_2" xlink:to="loc_nmus_AgreementDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_LeaseAgreementMember" xlink:label="loc_nmus_LeaseAgreementMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_AgreementDomain_3" xlink:to="loc_nmus_LeaseAgreementMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_LetterAgreementMember" xlink:label="loc_nmus_LetterAgreementMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_AgreementDomain_3" xlink:to="loc_nmus_LetterAgreementMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" xlink:to="loc_dei_LegalEntityAxis_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_6" xlink:to="loc_dei_EntityDomain_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_7_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_6" xlink:to="loc_dei_EntityDomain_7_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ContractManufacturingOrganizationMember" xlink:label="loc_nmus_ContractManufacturingOrganizationMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_7" xlink:to="loc_nmus_ContractManufacturingOrganizationMember_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" xlink:to="loc_us-gaap_RangeAxis_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_9" xlink:to="loc_us-gaap_RangeMember_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_10_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_9" xlink:to="loc_us-gaap_RangeMember_10_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_10" xlink:to="loc_us-gaap_MinimumMember_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_10" xlink:to="loc_us-gaap_MaximumMember_12" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaap_AreaOfLand_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_us-gaap_AreaOfLand_13" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_14" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_15" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_FeesAndExpensesForServicesProvided" xlink:label="loc_nmus_FeesAndExpensesForServicesProvided_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_nmus_FeesAndExpensesForServicesProvided_16" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_AnalyticalMethodDevelopmentAndQualificationExpense" xlink:label="loc_nmus_AnalyticalMethodDevelopmentAndQualificationExpense_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_nmus_AnalyticalMethodDevelopmentAndQualificationExpense_17" order="50" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockSummaryOfOptionActivityUnder2014PlanDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_RestrictedStockMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_6" xlink:to="loc_us-gaap_PlanNameDomain_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_7_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_6" xlink:to="loc_us-gaap_PlanNameDomain_7_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_OmnibusIncentivePlan2014Member" xlink:label="loc_nmus_OmnibusIncentivePlan2014Member_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7" xlink:to="loc_nmus_OmnibusIncentivePlan2014Member_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_9" xlink:to="loc_us-gaap_RangeMember_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_10_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_9" xlink:to="loc_us-gaap_RangeMember_10_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_10" xlink:to="loc_us-gaap_MinimumMember_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_10" xlink:to="loc_us-gaap_MaximumMember_12" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_SharesAvailableForGrantOfOptionsRollForward" xlink:label="loc_nmus_SharesAvailableForGrantOfOptionsRollForward_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_nmus_SharesAvailableForGrantOfOptionsRollForward_13" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_SharesAvailableForGrantOfOptionsOpeningBalance" xlink:label="loc_nmus_SharesAvailableForGrantOfOptionsOpeningBalance_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_SharesAvailableForGrantOfOptionsRollForward_13" xlink:to="loc_nmus_SharesAvailableForGrantOfOptionsOpeningBalance_14" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_SharesAvailableForGrantOptionsGranted" xlink:label="loc_nmus_SharesAvailableForGrantOptionsGranted_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_SharesAvailableForGrantOfOptionsRollForward_13" xlink:to="loc_nmus_SharesAvailableForGrantOptionsGranted_15" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_SharesAvailableForGrantOptionsExercised" xlink:label="loc_nmus_SharesAvailableForGrantOptionsExercised_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_SharesAvailableForGrantOfOptionsRollForward_13" xlink:to="loc_nmus_SharesAvailableForGrantOptionsExercised_16" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_SharesAvailableForGrantOptionsCancelled" xlink:label="loc_nmus_SharesAvailableForGrantOptionsCancelled_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_SharesAvailableForGrantOfOptionsRollForward_13" xlink:to="loc_nmus_SharesAvailableForGrantOptionsCancelled_17" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_SharesAvailableForGrantOptionsExcludingRestrictedstock" xlink:label="loc_nmus_SharesAvailableForGrantOptionsExcludingRestrictedstock_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_SharesAvailableForGrantOfOptionsRollForward_13" xlink:to="loc_nmus_SharesAvailableForGrantOptionsExcludingRestrictedstock_18" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_SharesAvailableForGrantOfOptionsRollForward_13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_19" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_20" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_21" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_22" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_20" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_23" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_24" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_OptionsOutstandingPricePerShareRollForward" xlink:label="loc_nmus_OptionsOutstandingPricePerShareRollForward_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_nmus_OptionsOutstandingPricePerShareRollForward_25" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_OptionsOutstandingPricePerShareOpeningBalance" xlink:label="loc_nmus_OptionsOutstandingPricePerShareOpeningBalance_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_OptionsOutstandingPricePerShareRollForward_25" xlink:to="loc_nmus_OptionsOutstandingPricePerShareOpeningBalance_26" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_OptionsOutstandingPricePerShareOptionsGranted" xlink:label="loc_nmus_OptionsOutstandingPricePerShareOptionsGranted_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_OptionsOutstandingPricePerShareRollForward_25" xlink:to="loc_nmus_OptionsOutstandingPricePerShareOptionsGranted_27" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_OptionsOutstandingPricePerShareOptionsExercised" xlink:label="loc_nmus_OptionsOutstandingPricePerShareOptionsExercised_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_OptionsOutstandingPricePerShareRollForward_25" xlink:to="loc_nmus_OptionsOutstandingPricePerShareOptionsExercised_28" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_OptionsOutstandingPricePerShareOptionsCancelled" xlink:label="loc_nmus_OptionsOutstandingPricePerShareOptionsCancelled_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_OptionsOutstandingPricePerShareRollForward_25" xlink:to="loc_nmus_OptionsOutstandingPricePerShareOptionsCancelled_29" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_31" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_32" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_33" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_34" order="40" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockSummaryOfWeightedAverageAssumptionsForEmployeeOptionDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MinimumMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MaximumMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_10" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_11" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_12" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_13" order="50" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockDetailTextuals">
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_EquityLineItems" xlink:label="loc_nmus_EquityLineItems_0"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_EquityTable" xlink:label="loc_nmus_EquityTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_EquityTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_AgreementAxis" xlink:label="loc_nmus_AgreementAxis_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_nmus_AgreementAxis_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_AgreementDomain" xlink:label="loc_nmus_AgreementDomain_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nmus_AgreementAxis_6" xlink:to="loc_nmus_AgreementDomain_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_AgreementDomain" xlink:label="loc_nmus_AgreementDomain_7_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nmus_AgreementAxis_6" xlink:to="loc_nmus_AgreementDomain_7_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_StockPurchaseAgreementJune2014Member" xlink:label="loc_nmus_StockPurchaseAgreementJune2014Member_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_AgreementDomain_7" xlink:to="loc_nmus_StockPurchaseAgreementJune2014Member_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_10_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_10_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_10" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_12" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_12" xlink:to="loc_us-gaap_ClassOfStockDomain_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_13_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_12" xlink:to="loc_us-gaap_ClassOfStockDomain_13_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_13" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_14" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_13" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_15" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_16" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_17" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_TermOfWarrant" xlink:label="loc_nmus_TermOfWarrant_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_TermOfWarrant_18" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_NumberOfAdvisors" xlink:label="loc_nmus_NumberOfAdvisors_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_NumberOfAdvisors_19" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ValueOfCommonStockCalledByWarrants" xlink:label="loc_nmus_ValueOfCommonStockCalledByWarrants_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_ValueOfCommonStockCalledByWarrants_20" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_AmortizationOfWarrantServiceCost" xlink:label="loc_nmus_AmortizationOfWarrantServiceCost_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_AmortizationOfWarrantServiceCost_21" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_22" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_AmortizationOfGeneralAndAdministrativeExpenses" xlink:label="loc_nmus_AmortizationOfGeneralAndAdministrativeExpenses_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_AmortizationOfGeneralAndAdministrativeExpenses_23" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_24" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" xlink:label="loc_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants_25" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_26" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_27" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_28" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ValueOfWarrantsIssued" xlink:label="loc_nmus_ValueOfWarrantsIssued_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_ValueOfWarrantsIssued_29" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_NumberOfInvestor" xlink:label="loc_nmus_NumberOfInvestor_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_NumberOfInvestor_30" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_31" order="160" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_32" order="170" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_33" order="180" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_34" order="190" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_MinimumIssuanceOfSharesInEquityFinancing" xlink:label="loc_nmus_MinimumIssuanceOfSharesInEquityFinancing_35"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_MinimumIssuanceOfSharesInEquityFinancing_35" order="200" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_MaximumIssuancePricePerShareInEquityFinancing" xlink:label="loc_nmus_MaximumIssuancePricePerShareInEquityFinancing_36"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_MaximumIssuancePricePerShareInEquityFinancing_36" order="210" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ConversionPrice" xlink:label="loc_nmus_ConversionPrice_37"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_ConversionPrice_37" order="220" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_38"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_38" order="230" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_39"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_39" order="240" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_40"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_40" order="250" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_41"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_SharePrice_41" order="260" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockRedemptionTerms" xlink:label="loc_us-gaap_PreferredStockRedemptionTerms_42"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_PreferredStockRedemptionTerms_42" order="270" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="loc_us-gaap_PreferredStockConversionBasis_43"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_PreferredStockConversionBasis_43" order="280" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue_44"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_PreferredStockLiquidationPreferenceValue_44" order="290" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockDetailTextuals1">
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_EquityLineItems" xlink:label="loc_nmus_EquityLineItems_0"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_EquityTable" xlink:label="loc_nmus_EquityTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_EquityTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_PlanNameAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_2" xlink:to="loc_us-gaap_PlanNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_2" xlink:to="loc_us-gaap_PlanNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_OmnibusIncentivePlan2014Member" xlink:label="loc_nmus_OmnibusIncentivePlan2014Member_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3" xlink:to="loc_nmus_OmnibusIncentivePlan2014Member_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6" xlink:to="loc_us-gaap_RestrictedStockMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_RangeAxis_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_9" xlink:to="loc_us-gaap_RangeMember_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_10_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_9" xlink:to="loc_us-gaap_RangeMember_10_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_10" xlink:to="loc_us-gaap_MinimumMember_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_10" xlink:to="loc_us-gaap_MaximumMember_12" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_13" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_13" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_14" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_14_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_13" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_14_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_14" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_15" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_16" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_16" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_17" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_17_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_16" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_17_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ManagementAndBoardOfDirectorsMember" xlink:label="loc_nmus_ManagementAndBoardOfDirectorsMember_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_17" xlink:to="loc_nmus_ManagementAndBoardOfDirectorsMember_18" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_19" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_20" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_21" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_22" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants" xlink:label="loc_nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants_23" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_CommonStockVotingPercentage" xlink:label="loc_nmus_CommonStockVotingPercentage_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_CommonStockVotingPercentage_24" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_PercentageOfFairValueOptionPriceAtDateOfGrants" xlink:label="loc_nmus_PercentageOfFairValueOptionPriceAtDateOfGrants_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_PercentageOfFairValueOptionPriceAtDateOfGrants_25" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_MaximumExercisablePeriodOfFairValueOfOption" xlink:label="loc_nmus_MaximumExercisablePeriodOfFairValueOfOption_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_MaximumExercisablePeriodOfFairValueOfOption_26" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_27" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_28" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_29" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_30" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_31" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_32" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_33" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_34" order="160" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_35"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_35" order="170" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_36"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_36" order="180" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_FairMarketValueOfSharesGranted" xlink:label="loc_nmus_FairMarketValueOfSharesGranted_37"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_FairMarketValueOfSharesGranted_37" order="190" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/ProvisionForConversionOfPreferredStockDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockLineItems" xlink:label="loc_us-gaap_ConversionOfStockLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockTable" xlink:label="loc_us-gaap_ConversionOfStockTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConversionOfStockLineItems_0" xlink:to="loc_us-gaap_ConversionOfStockTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConversionOfStockTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_MinimumIssuanceOfSharesInEquityFinancing" xlink:label="loc_nmus_MinimumIssuanceOfSharesInEquityFinancing_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_0" xlink:to="loc_nmus_MinimumIssuanceOfSharesInEquityFinancing_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_MaximumIssuancePricePerShareInEquityFinancing" xlink:label="loc_nmus_MaximumIssuancePricePerShareInEquityFinancing_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_0" xlink:to="loc_nmus_MaximumIssuancePricePerShareInEquityFinancing_7" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ProvisionForConversionOfPreferredStock" xlink:label="loc_nmus_ProvisionForConversionOfPreferredStock_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_0" xlink:to="loc_nmus_ProvisionForConversionOfPreferredStock_8" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_9" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_0" xlink:to="loc_us-gaap_SharesIssued_10" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_11" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_GainLossOnConversionRightPreferredStock" xlink:label="loc_nmus_GainLossOnConversionRightPreferredStock_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_0" xlink:to="loc_nmus_GainLossOnConversionRightPreferredStock_12" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_0" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_13" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ConversionPrice" xlink:label="loc_nmus_ConversionPrice_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_0" xlink:to="loc_nmus_ConversionPrice_14" order="90" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/SeriesBWarrantsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_SeriesBWarrantsMember" xlink:label="loc_nmus_SeriesBWarrantsMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_nmus_SeriesBWarrantsMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_RangeAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MinimumMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MaximumMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_10" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_11" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_12" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_13" order="50" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/SeriesBWarrantsDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_SeriesBWarrantsMember" xlink:label="loc_nmus_SeriesBWarrantsMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_nmus_SeriesBWarrantsMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_NumberOfWarrantsIssued" xlink:label="loc_nmus_NumberOfWarrantsIssued_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_nmus_NumberOfWarrantsIssued_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_8" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_9" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ChangeInFairValueOfWarrantLiability" xlink:label="loc_nmus_ChangeInFairValueOfWarrantLiability_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_nmus_ChangeInFairValueOfWarrantLiability_10" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ExpirationPeriodOfWarrants" xlink:label="loc_nmus_ExpirationPeriodOfWarrants_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_nmus_ExpirationPeriodOfWarrants_11" order="70" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/SubsequentEventsDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_5" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_5" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_6" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8" xlink:to="loc_us-gaap_ClassOfStockDomain_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_9_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8" xlink:to="loc_us-gaap_ClassOfStockDomain_9_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_11" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_SeriesCWarrantsMember" xlink:label="loc_nmus_SeriesCWarrantsMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9" xlink:to="loc_nmus_SeriesCWarrantsMember_12" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_13" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_13" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_14" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_14_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_13" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_14_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_14" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_15" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_16" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_17" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_18" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_19" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_CoversionPriceOfCovertibleSecurities" xlink:label="loc_nmus_CoversionPriceOfCovertibleSecurities_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_nmus_CoversionPriceOfCovertibleSecurities_20" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ReductionInConversionPrice" xlink:label="loc_nmus_ReductionInConversionPrice_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_nmus_ReductionInConversionPrice_21" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ReductionInExcercisePrice" xlink:label="loc_nmus_ReductionInExcercisePrice_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_nmus_ReductionInExcercisePrice_22" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_23" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_24" order="90" use="optional"/>
</definitionLink>
<roleRef xlink:type="simple" xlink:href="nmus-20160930.xsd#NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesDetailTextuals1" roleURI="http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesDetailTextuals1"/>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesDetailTextuals1"><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaap_WarrantMember" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" order="1" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_Default" order="1"/>
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>nmus-20160930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.6.0.0 on Wednesday, November 09, 2016 01:08:12 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_DocumentAndEntityInformationAbstract" xlink:label="loc_2JF107H7I93I_nmus_DocumentAndEntityInformationAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_nmus_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_DocumentAndEntityInformationAbstract" xlink:to="lab_4LH329J9K15K_nmus_DocumentAndEntityInformationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_31290F3J262G9III3F2F_dei_EntityRegistrantName"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_dei_EntityRegistrantName" xlink:to="lab_53412H5L484I1KKK5H4H_dei_EntityRegistrantName"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_2JF107H7I93I_dei_EntityCentralIndexKey"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_dei_EntityCentralIndexKey" xlink:to="lab_4LH329J9K15K_dei_EntityCentralIndexKey"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_31290F3J262G9III3F2F_dei_TradingSymbol"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_dei_TradingSymbol" xlink:to="lab_53412H5L484I1KKK5H4H_dei_TradingSymbol"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_2JF107H7I93I_dei_CurrentFiscalYearEndDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_dei_CurrentFiscalYearEndDate" xlink:to="lab_4LH329J9K15K_dei_CurrentFiscalYearEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_31290F3J262G9III3F2F_dei_EntityFilerCategory"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_dei_EntityFilerCategory" xlink:to="lab_53412H5L484I1KKK5H4H_dei_EntityFilerCategory"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_2JF107H7I93I_dei_EntityCommonStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_4LH329J9K15K_dei_EntityCommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_31290F3J262G9III3F2F_dei_DocumentType"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_dei_DocumentType" xml:lang="en-US">Document Type</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_dei_DocumentType" xlink:to="lab_53412H5L484I1KKK5H4H_dei_DocumentType"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_2JF107H7I93I_dei_DocumentPeriodEndDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_dei_DocumentPeriodEndDate" xlink:to="lab_4LH329J9K15K_dei_DocumentPeriodEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_31290F3J262G9III3F2F_dei_AmendmentFlag"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_dei_AmendmentFlag" xlink:to="lab_53412H5L484I1KKK5H4H_dei_AmendmentFlag"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_2JF107H7I93I_dei_DocumentFiscalYearFocus"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_dei_DocumentFiscalYearFocus" xlink:to="lab_4LH329J9K15K_dei_DocumentFiscalYearFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_31290F3J262G9III3F2F_dei_DocumentFiscalPeriodFocus"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_dei_DocumentFiscalPeriodFocus" xlink:to="lab_53412H5L484I1KKK5H4H_dei_DocumentFiscalPeriodFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_2JF107H7I93I_us-gaap_StatementOfFinancialPositionAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement Of Financial Position [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_4LH329J9K15K_us-gaap_StatementOfFinancialPositionAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_AssetsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_AssetsAbstract" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_AssetsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_2JF107H7I93I_us-gaap_AssetsCurrentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_AssetsCurrentAbstract" xlink:to="lab_4LH329J9K15K_us-gaap_AssetsCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, At Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents, beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents, end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_2JF107H7I93I_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_4LH329J9K15K_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_PrepaidExpenseCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_PrepaidExpenseCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_2JF107H7I93I_us-gaap_OtherAssetsCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_OtherAssetsCurrent" xlink:to="lab_4LH329J9K15K_us-gaap_OtherAssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_AssetsCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_AssetsCurrent" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_2JF107H7I93I_us-gaap_PropertyPlantAndEquipmentNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Net equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4LH329J9K15K_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Net equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_4LH329J9K15K_us-gaap_PropertyPlantAndEquipmentNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_OtherAssetsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_OtherAssetsAbstract" xml:lang="en-US">Other Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_OtherAssetsAbstract" xml:lang="en-US">Other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_OtherAssetsAbstract" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_OtherAssetsAbstract"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_DepositsAndOtherAssets" xlink:label="loc_2JF107H7I93I_nmus_DepositsAndOtherAssets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_DepositsAndOtherAssets" xml:lang="en-US">Deposits And Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_nmus_DepositsAndOtherAssets" xml:lang="en-US">Deposits and other assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_DepositsAndOtherAssets" xml:lang="en-US">Represents aggregate carrying amount, as of the balance sheet date, of deposits and other assets.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_DepositsAndOtherAssets" xlink:to="lab_4LH329J9K15K_nmus_DepositsAndOtherAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_OtherAssetsNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Total other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_OtherAssetsNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_2JF107H7I93I_us-gaap_Assets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_Assets" xml:lang="en-US">Total Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4LH329J9K15K_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_Assets" xlink:to="lab_4LH329J9K15K_us-gaap_Assets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_2JF107H7I93I_us-gaap_LiabilitiesCurrentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_4LH329J9K15K_us-gaap_LiabilitiesCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_AccountsPayableCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_AccountsPayableCurrent" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_AccountsPayableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_2JF107H7I93I_us-gaap_AccruedSalariesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_AccruedSalariesCurrent" xml:lang="en-US">Accrued Salaries, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_AccruedSalariesCurrent" xml:lang="en-US">Accrued payroll and related expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_AccruedSalariesCurrent" xlink:to="lab_4LH329J9K15K_us-gaap_AccruedSalariesCurrent"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_AccruedLicenseAndPatentReimbursementFees" xlink:label="loc_31290F3J262G9III3F2F_nmus_AccruedLicenseAndPatentReimbursementFees"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_AccruedLicenseAndPatentReimbursementFees" xml:lang="en-US">Accrued License And Patent Reimbursement Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_AccruedLicenseAndPatentReimbursementFees" xml:lang="en-US">Accrued license and patent reimbursement fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_AccruedLicenseAndPatentReimbursementFees" xml:lang="en-US">Represents carrying value as of the balance sheet date of obligations incurred through that date and payable for accrued license and patent reimbursement fees.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_nmus_AccruedLicenseAndPatentReimbursementFees" xlink:to="lab_53412H5L484I1KKK5H4H_nmus_AccruedLicenseAndPatentReimbursementFees"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_2JF107H7I93I_us-gaap_AccruedLiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_4LH329J9K15K_us-gaap_AccruedLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ProvisionForConversionOfPreferredStock" xlink:label="loc_31290F3J262G9III3F2F_nmus_ProvisionForConversionOfPreferredStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_ProvisionForConversionOfPreferredStock" xml:lang="en-US">Provision For Conversion Of Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_ProvisionForConversionOfPreferredStock" xml:lang="en-US">Fair value of the conversion feature</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_ProvisionForConversionOfPreferredStock" xml:lang="en-US">Provision for conversion of Series B preferred stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_ProvisionForConversionOfPreferredStock" xml:lang="en-US">Represents the amount related to provision for conversion of preferred stock as of balance sheet date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_nmus_ProvisionForConversionOfPreferredStock" xlink:to="lab_53412H5L484I1KKK5H4H_nmus_ProvisionForConversionOfPreferredStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_2JF107H7I93I_us-gaap_LiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4LH329J9K15K_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_LiabilitiesCurrent" xlink:to="lab_4LH329J9K15K_us-gaap_LiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_LiabilitiesNoncurrentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_LiabilitiesNoncurrentAbstract" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_LiabilitiesNoncurrentAbstract" xml:lang="en-US">Noncurrent liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_LiabilitiesNoncurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_2JF107H7I93I_us-gaap_DeferredRentCreditNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_DeferredRentCreditNoncurrent" xml:lang="en-US">Deferred Rent Credit, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_DeferredRentCreditNoncurrent" xml:lang="en-US">Deferred rent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_DeferredRentCreditNoncurrent" xlink:to="lab_4LH329J9K15K_us-gaap_DeferredRentCreditNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_DerivativeLiabilitiesNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_DerivativeLiabilitiesNoncurrent" xml:lang="en-US">Derivative Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_DerivativeLiabilitiesNoncurrent" xml:lang="en-US">Series B warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_DerivativeLiabilitiesNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_2JF107H7I93I_us-gaap_LiabilitiesNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_LiabilitiesNoncurrent" xml:lang="en-US">Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_LiabilitiesNoncurrent" xml:lang="en-US">Total noncurrent liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4LH329J9K15K_us-gaap_LiabilitiesNoncurrent" xml:lang="en-US">Total noncurrent liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_4LH329J9K15K_us-gaap_LiabilitiesNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_Liabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_Liabilities" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_Liabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_2JF107H7I93I_us-gaap_CommitmentsAndContingencies"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies (Note 3)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_CommitmentsAndContingencies" xlink:to="lab_4LH329J9K15K_us-gaap_CommitmentsAndContingencies"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Redeemable Convertible Series B Preferred Stock, $0.001 par value, 20 million shares authorized; 4,492 issued and outstanding as of September 30, 2016 and 4,500 issued and outstanding as of December 31, 2015, net of $493,770 of issuance costs; $4.5 million liquidation preference as of September 30, 2016</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Series B preferred stock subject to redemption, $0.001 par value, 20 million shares authorized; 5,000 issued and outstanding as of September 30, 2015 and none issued and outstanding as of December 31, 2014. $5.0 million liquidation preference of Series B preferred stock as of September 30, 2014</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_2JF107H7I93I_us-gaap_StockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_StockholdersEquityAbstract" xlink:to="lab_4LH329J9K15K_us-gaap_StockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_CommonStockValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.001 par value; 236 million shares authorized; 19,913,163 issued and outstanding as of September 30, 2016 and 19,903,163 issued and outstanding as of December 31, 2015</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_CommonStockValue" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_CommonStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_2JF107H7I93I_us-gaap_AdditionalPaidInCapitalCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional paid-in-capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_4LH329J9K15K_us-gaap_AdditionalPaidInCapitalCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_WarrantsAndRightsOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Warrants and Rights Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_WarrantsAndRightsOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_2JF107H7I93I_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained earnings during the development stage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_4LH329J9K15K_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_4LH329J9K15K_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_StockholdersEquity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_StockholdersEquity" xml:lang="en-US">Total shareholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_StockholdersEquity" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_StockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_2JF107H7I93I_us-gaap_LiabilitiesAndStockholdersEquity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total Liabilities and Shareholders' Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4LH329J9K15K_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and stockholders' deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_4LH329J9K15K_us-gaap_LiabilitiesAndStockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_TemporaryEquityParOrStatedValuePerShare" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_TemporaryEquityParOrStatedValuePerShare" xml:lang="en-US">Redeemable Convertible Series B Preferred Stock, par value (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_2JF107H7I93I_us-gaap_TemporaryEquitySharesAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_TemporaryEquitySharesAuthorized" xml:lang="en-US">Temporary Equity, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_TemporaryEquitySharesAuthorized" xml:lang="en-US">Redeemable Convertible Series B Preferred Stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_TemporaryEquitySharesAuthorized" xlink:to="lab_4LH329J9K15K_us-gaap_TemporaryEquitySharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_TemporaryEquitySharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_TemporaryEquitySharesIssued" xml:lang="en-US">Temporary Equity, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_TemporaryEquitySharesIssued" xml:lang="en-US">Redeemable Convertible Series B Preferred Stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_TemporaryEquitySharesIssued" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_TemporaryEquitySharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_2JF107H7I93I_us-gaap_TemporaryEquitySharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Temporary Equity, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Redeemable Convertible Series B Preferred Stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_4LH329J9K15K_us-gaap_TemporaryEquitySharesOutstanding"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_StockIssuanceCosts" xlink:label="loc_31290F3J262G9III3F2F_nmus_StockIssuanceCosts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_StockIssuanceCosts" xml:lang="en-US">Stock Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_StockIssuanceCosts" xml:lang="en-US">Redeemable Convertible Series B Preferred Stock, issuance costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_StockIssuanceCosts" xml:lang="en-US">Represents amount of stock issuance costs.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_nmus_StockIssuanceCosts" xlink:to="lab_53412H5L484I1KKK5H4H_nmus_StockIssuanceCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_2JF107H7I93I_us-gaap_TemporaryEquityLiquidationPreference"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_TemporaryEquityLiquidationPreference" xml:lang="en-US">Temporary Equity, Liquidation Preference</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_TemporaryEquityLiquidationPreference" xml:lang="en-US">Redeemable Convertible Series B Preferred Stock, liquidation preference value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_TemporaryEquityLiquidationPreference" xlink:to="lab_4LH329J9K15K_us-gaap_TemporaryEquityLiquidationPreference"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_CommonStockParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Par value of common stock issued (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_CommonStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_2JF107H7I93I_us-gaap_CommonStockSharesAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_4LH329J9K15K_us-gaap_CommonStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_CommonStockSharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_CommonStockSharesIssued" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_CommonStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_2JF107H7I93I_us-gaap_CommonStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_4LH329J9K15K_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_4LH329J9K15K_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_4LH329J9K15K_us-gaap_CommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_IncomeStatementAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_IncomeStatementAbstract" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_IncomeStatementAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_2JF107H7I93I_us-gaap_StatementTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_StatementTable" xlink:to="lab_4LH329J9K15K_us-gaap_StatementTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_StatementClassOfStockAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_StatementClassOfStockAxis" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_StatementClassOfStockAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_2JF107H7I93I_us-gaap_ClassOfStockDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_ClassOfStockDomain" xlink:to="lab_4LH329J9K15K_us-gaap_ClassOfStockDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_SeriesAPreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Convertible Series A Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_SeriesAPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_2JF107H7I93I_us-gaap_SeriesBPreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_SeriesBPreferredStockMember" xml:lang="en-US">Series B Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_SeriesBPreferredStockMember" xml:lang="en-US">Redeemable Convertible Series B Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_SeriesBPreferredStockMember" xml:lang="en-US">Series B Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_4LH329J9K15K_us-gaap_SeriesBPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_StatementLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_StatementLineItems" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_StatementLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_2JF107H7I93I_us-gaap_OperatingExpensesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_OperatingExpensesAbstract" xlink:to="lab_4LH329J9K15K_us-gaap_OperatingExpensesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_ResearchAndDevelopmentExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_ResearchAndDevelopmentExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_2JF107H7I93I_us-gaap_GeneralAndAdministrativeExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_4LH329J9K15K_us-gaap_GeneralAndAdministrativeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_OperatingExpenses"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_OperatingExpenses" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_OperatingExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_2JF107H7I93I_us-gaap_OperatingIncomeLoss"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_4LH329J9K15K_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4LH329J9K15K_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_OperatingIncomeLoss" xlink:to="lab_4LH329J9K15K_us-gaap_OperatingIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_NonoperatingIncomeExpenseAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other expense (income)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_NonoperatingIncomeExpenseAbstract"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ChangeInFairValueOfWarrantLiability" xlink:label="loc_2JF107H7I93I_nmus_ChangeInFairValueOfWarrantLiability"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_ChangeInFairValueOfWarrantLiability" xml:lang="en-US">Change In Fair Value Of Warrant Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4LH329J9K15K_nmus_ChangeInFairValueOfWarrantLiability" xml:lang="en-US">Change in fair market value at the re-measurement date recorded as non-operating expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_nmus_ChangeInFairValueOfWarrantLiability" xml:lang="en-US">Change in fair value of warrant liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_ChangeInFairValueOfWarrantLiability" xml:lang="en-US">Represents the amount related to change in fair value of warrant liability.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_4LH329J9K15K_nmus_ChangeInFairValueOfWarrantLiability" xml:lang="en-US">Change in fair market value at the re-measurement date recorded as non-operating expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="lab_4LH329J9K15K_nmus_ChangeInFairValueOfWarrantLiability" xml:lang="en-US">Change in fair value of warrant liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_ChangeInFairValueOfWarrantLiability" xlink:to="lab_4LH329J9K15K_nmus_ChangeInFairValueOfWarrantLiability"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_GainLossOnConversionRightPreferredStock" xlink:label="loc_31290F3J262G9III3F2F_nmus_GainLossOnConversionRightPreferredStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_GainLossOnConversionRightPreferredStock" xml:lang="en-US">Gain Loss On Conversion Right Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_GainLossOnConversionRightPreferredStock" xml:lang="en-US">Change in fair value of conversion rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_GainLossOnConversionRightPreferredStock" xml:lang="en-US">Loss on conversion right of Series A preferred stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_GainLossOnConversionRightPreferredStock" xml:lang="en-US">Represents the amount related to gain or loss on conversion right of preferred stock during the period.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_GainLossOnConversionRightPreferredStock" xml:lang="en-US">Change in fair value of conversion rights of preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_nmus_GainLossOnConversionRightPreferredStock" xlink:to="lab_53412H5L484I1KKK5H4H_nmus_GainLossOnConversionRightPreferredStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_2JF107H7I93I_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Net loss before income taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4LH329J9K15K_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Net loss before income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_4LH329J9K15K_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_IncomeTaxExpenseBenefit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Provision for income taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax expense per books</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Provision for income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_IncomeTaxExpenseBenefit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_2JF107H7I93I_us-gaap_NetIncomeLoss"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_NetIncomeLoss" xml:lang="en-US">Net income (loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_4LH329J9K15K_us-gaap_NetIncomeLoss" xml:lang="en-US">Loss from operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4LH329J9K15K_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="lab_4LH329J9K15K_us-gaap_NetIncomeLoss" xml:lang="en-US">Net income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_NetIncomeLoss" xlink:to="lab_4LH329J9K15K_us-gaap_NetIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_EarningsPerShareBasicAndDiluted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Basic and diluted loss per common share (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_EarningsPerShareBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_2JF107H7I93I_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Shares used in computing basic and diluted loss per share (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_4LH329J9K15K_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_StatementOfCashFlowsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_StatementOfCashFlowsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_2JF107H7I93I_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Operating Activities, Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Cash flows from operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_4LH329J9K15K_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_2JF107H7I93I_us-gaap_Depreciation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_Depreciation" xlink:to="lab_4LH329J9K15K_us-gaap_Depreciation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_ShareBasedCompensation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_ShareBasedCompensation" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_2JF107H7I93I_us-gaap_AmortizationOfFinancingCosts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of Financing Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of warrants and stock issued for services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_4LH329J9K15K_us-gaap_AmortizationOfFinancingCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xml:lang="en-US">Increase (Decrease) In Operating Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xml:lang="en-US">Changes in assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseInRestrictedCash" xlink:label="loc_2JF107H7I93I_us-gaap_IncreaseInRestrictedCash"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_IncreaseInRestrictedCash" xml:lang="en-US">Increase in Restricted Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_IncreaseInRestrictedCash" xml:lang="en-US">Restricted cash</label>
<label xlink:type="resource" xlink:label="lab_4LH329J9K15K_us-gaap_IncreaseInRestrictedCash" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_IncreaseInRestrictedCash" xlink:to="lab_4LH329J9K15K_us-gaap_IncreaseInRestrictedCash"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_IncreaseDecreaseInPrepaidExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_IncreaseDecreaseInPrepaidExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_2JF107H7I93I_us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xml:lang="en-US">Increase (Decrease) in Other Current Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_4LH329J9K15K_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xml:lang="en-US">Other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="lab_4LH329J9K15K_us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_IncreaseDecreaseInAccountsPayable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_IncreaseDecreaseInAccountsPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_2JF107H7I93I_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xml:lang="en-US">Accrued payroll and related expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_4LH329J9K15K_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees" xlink:label="loc_31290F3J262G9III3F2F_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees" xml:lang="en-US">Increase Decrease In Accrued License And Patent Reimbursement Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees" xml:lang="en-US">Accrued license and patent reimbursement fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees" xml:lang="en-US">Represents amount of increase (decrease) in accrued license and patent reimbursement fees.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees" xml:lang="en-US">Accrued license and patent reimbursement fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees" xlink:to="lab_53412H5L484I1KKK5H4H_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_IncreaseDecreaseInStockSubscriptionLiability" xlink:label="loc_2JF107H7I93I_nmus_IncreaseDecreaseInStockSubscriptionLiability"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_IncreaseDecreaseInStockSubscriptionLiability" xml:lang="en-US">Increase Decrease In Stock Subscription Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4LH329J9K15K_nmus_IncreaseDecreaseInStockSubscriptionLiability" xml:lang="en-US">Stock subscription liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_IncreaseDecreaseInStockSubscriptionLiability" xml:lang="en-US">Represents amount of increase (decrease) in Increase Decrease in stock subscription liability.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_4LH329J9K15K_nmus_IncreaseDecreaseInStockSubscriptionLiability" xml:lang="en-US">Stock subscription liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_IncreaseDecreaseInStockSubscriptionLiability" xlink:to="lab_4LH329J9K15K_nmus_IncreaseDecreaseInStockSubscriptionLiability"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xml:lang="en-US">Accrued expenses and other liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_2JF107H7I93I_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided By (Used In) Operating Activities, Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Cash flows provided from operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4LH329J9K15K_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net cash used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_4LH329J9K15K_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Investing Activities, Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Cash flows from investing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_2JF107H7I93I_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments To Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_4LH329J9K15K_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_4LH329J9K15K_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided By (Used In) Investing Activities, Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net cash provided by (used in) financing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net cash used in investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_2JF107H7I93I_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Financing Activities, Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Cash flows from financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_4LH329J9K15K_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Additional raise of funds for operations and development of lead products</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Additional fund raised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from common stock issuance, net of $3,920 issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_2JF107H7I93I_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xml:lang="en-US">Proceeds from preferred stock issuance, net of issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="lab_4LH329J9K15K_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided By (Used In) Financing Activities, Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US">Net cash provided by financing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US">Net cash provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_2JF107H7I93I_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4LH329J9K15K_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_4LH329J9K15K_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_SupplementalCashFlowElementsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_SupplementalCashFlowElementsAbstract" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_SupplementalCashFlowElementsAbstract" xml:lang="en-US">Supplemental disclosures of cash-flow information:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_SupplementalCashFlowElementsAbstract"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_CashPaidDuringPeriodForAbstract" xlink:label="loc_2JF107H7I93I_nmus_CashPaidDuringPeriodForAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_CashPaidDuringPeriodForAbstract" xml:lang="en-US">Cash Paid During Period For Abstract</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_nmus_CashPaidDuringPeriodForAbstract" xml:lang="en-US">Cash paid during the period for:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_CashPaidDuringPeriodForAbstract" xlink:to="lab_4LH329J9K15K_nmus_CashPaidDuringPeriodForAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_InterestPaid"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_InterestPaid" xml:lang="en-US">Interest Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_InterestPaid" xml:lang="en-US">Interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_InterestPaid" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_InterestPaid"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_2JF107H7I93I_us-gaap_IncomeTaxesPaid"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Income Taxes Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_IncomeTaxesPaid" xlink:to="lab_4LH329J9K15K_us-gaap_IncomeTaxesPaid"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_CommonStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_CommonStockMember" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_CommonStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_2JF107H7I93I_us-gaap_PaymentsOfStockIssuanceCosts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of Stock Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Stock issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_4LH329J9K15K_us-gaap_PaymentsOfStockIssuanceCosts"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_NoncashValueOfWarrantsIssued" xlink:label="loc_31290F3J262G9III3F2F_nmus_NoncashValueOfWarrantsIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_NoncashValueOfWarrantsIssued" xml:lang="en-US">Noncash Value Of Warrants Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_NoncashValueOfWarrantsIssued" xml:lang="en-US">Value of warrants issued to purchase shares of common stock for consulting services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_NoncashValueOfWarrantsIssued" xml:lang="en-US">Represents noncash value of warrants issued to purchase shares of common stock for consulting services.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_nmus_NoncashValueOfWarrantsIssued" xlink:to="lab_53412H5L484I1KKK5H4H_nmus_NoncashValueOfWarrantsIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_2JF107H7I93I_us-gaap_StockIssued1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_StockIssued1" xml:lang="en-US">Stock Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_StockIssued1" xml:lang="en-US">Value of common stock issued for consulting services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_StockIssued1" xlink:to="lab_4LH329J9K15K_us-gaap_StockIssued1"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_NoncashValueOfWarrantsIssuedInExchangeForExtinguishmentOfTradeAccountsPayable" xlink:label="loc_31290F3J262G9III3F2F_nmus_NoncashValueOfWarrantsIssuedInExchangeForExtinguishmentOfTradeAccountsPayable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_NoncashValueOfWarrantsIssuedInExchangeForExtinguishmentOfTradeAccountsPayable" xml:lang="en-US">Noncash Value Of Warrants Issued In Exchange For Extinguishment Of Trade Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_NoncashValueOfWarrantsIssuedInExchangeForExtinguishmentOfTradeAccountsPayable" xml:lang="en-US">Value of warrants issued in exchange for extinguishment of trade accounts payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_NoncashValueOfWarrantsIssuedInExchangeForExtinguishmentOfTradeAccountsPayable" xml:lang="en-US">Represents noncash value of warrants issued exchange for extinguishment of trade accounts payable.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_nmus_NoncashValueOfWarrantsIssuedInExchangeForExtinguishmentOfTradeAccountsPayable" xlink:to="lab_53412H5L484I1KKK5H4H_nmus_NoncashValueOfWarrantsIssuedInExchangeForExtinguishmentOfTradeAccountsPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_2JF107H7I93I_us-gaap_AccountingPoliciesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_4LH329J9K15K_us-gaap_AccountingPoliciesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Nature of Operations, Business Activities and Summary of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_UniversityOfMississippiAgreementsAbstract" xlink:label="loc_2JF107H7I93I_nmus_UniversityOfMississippiAgreementsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_UniversityOfMississippiAgreementsAbstract" xml:lang="en-US">University Of Mississippi Agreements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_UniversityOfMississippiAgreementsAbstract" xlink:to="lab_4LH329J9K15K_nmus_UniversityOfMississippiAgreementsAbstract"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_UniversityOfMississippiAgreementsTextBlock" xlink:label="loc_31290F3J262G9III3F2F_nmus_UniversityOfMississippiAgreementsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_UniversityOfMississippiAgreementsTextBlock" xml:lang="en-US">University Of Mississippi Agreements [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_UniversityOfMississippiAgreementsTextBlock" xml:lang="en-US">University of Mississippi Agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_UniversityOfMississippiAgreementsTextBlock" xml:lang="en-US">Represents entire disclosure for University of Mississippi ("UM") Agreements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_nmus_UniversityOfMississippiAgreementsTextBlock" xlink:to="lab_53412H5L484I1KKK5H4H_nmus_UniversityOfMississippiAgreementsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_2JF107H7I93I_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_4LH329J9K15K_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_2JF107H7I93I_us-gaap_EquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_EquityAbstract" xlink:to="lab_4LH329J9K15K_us-gaap_EquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Deficit and Redeemable Convertible Series B Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ProvisionForConversionOfPreferredStockAbstract" xlink:label="loc_2JF107H7I93I_nmus_ProvisionForConversionOfPreferredStockAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_ProvisionForConversionOfPreferredStockAbstract" xml:lang="en-US">Provision For Conversion Of Preferred Stock [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_ProvisionForConversionOfPreferredStockAbstract" xlink:to="lab_4LH329J9K15K_nmus_ProvisionForConversionOfPreferredStockAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_PreferredStockTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_PreferredStockTextBlock" xml:lang="en-US">Preferred Stock [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_PreferredStockTextBlock" xml:lang="en-US">Provision for Conversion of Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_PreferredStockTextBlock" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_PreferredStockTextBlock"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_SeriesBWarrantsAbstract" xlink:label="loc_2JF107H7I93I_nmus_SeriesBWarrantsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_SeriesBWarrantsAbstract" xml:lang="en-US">Series B Warrants [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_SeriesBWarrantsAbstract" xlink:to="lab_4LH329J9K15K_nmus_SeriesBWarrantsAbstract"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_SeriesBWarrantsTextBlock" xlink:label="loc_31290F3J262G9III3F2F_nmus_SeriesBWarrantsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_SeriesBWarrantsTextBlock" xml:lang="en-US">Series B Warrants [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_SeriesBWarrantsTextBlock" xml:lang="en-US">Series B Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_SeriesBWarrantsTextBlock" xml:lang="en-US">The entire disclosure for series B warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_nmus_SeriesBWarrantsTextBlock" xlink:to="lab_53412H5L484I1KKK5H4H_nmus_SeriesBWarrantsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_2JF107H7I93I_us-gaap_IncomeTaxDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_4LH329J9K15K_us-gaap_IncomeTaxDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_IncomeTaxDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_IncomeTaxDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_2JF107H7I93I_us-gaap_SubsequentEventsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_SubsequentEventsAbstract" xlink:to="lab_4LH329J9K15K_us-gaap_SubsequentEventsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_SubsequentEventsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_SubsequentEventsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_2JF107H7I93I_us-gaap_UseOfEstimates"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_UseOfEstimates" xml:lang="en-US">Use Of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_UseOfEstimates" xlink:to="lab_4LH329J9K15K_us-gaap_UseOfEstimates"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_LiquidityAndGoingConcernPolicyTextBlock" xlink:label="loc_31290F3J262G9III3F2F_nmus_LiquidityAndGoingConcernPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_LiquidityAndGoingConcernPolicyTextBlock" xml:lang="en-US">Liquidity And Going Concern [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_LiquidityAndGoingConcernPolicyTextBlock" xml:lang="en-US">Liquidity and Going Concern</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_LiquidityAndGoingConcernPolicyTextBlock" xml:lang="en-US">Entire disclosure of policy for liquidity and going concern.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_nmus_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="lab_53412H5L484I1KKK5H4H_nmus_LiquidityAndGoingConcernPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_2JF107H7I93I_us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_4LH329J9K15K_us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Restricted Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_2JF107H7I93I_us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_4LH329J9K15K_us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property and Equipment, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_2JF107H7I93I_us-gaap_IncomeTaxPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_4LH329J9K15K_us-gaap_IncomeTaxPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_RevenueRecognitionPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_RevenueRecognitionPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_2JF107H7I93I_us-gaap_ResearchAndDevelopmentExpensePolicy"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_4LH329J9K15K_us-gaap_ResearchAndDevelopmentExpensePolicy"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_CompensationRelatedCostsPolicyTextBlock" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_CompensationRelatedCostsPolicyTextBlock" xml:lang="en-US">Stock-Based Compensation Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock" xlink:label="loc_2JF107H7I93I_nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock" xml:lang="en-US">Stock Based Compensation For Non Employees [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock" xml:lang="en-US">Stock-Based Compensation for Non-Employees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock" xml:lang="en-US">Represents policy for stock based compensation for Non Employees.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock" xlink:to="lab_4LH329J9K15K_nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_2JF107H7I93I_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Comprehensive Income (Loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_4LH329J9K15K_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_EarningsPerSharePolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_EarningsPerSharePolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_2JF107H7I93I_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recent accounting pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_4LH329J9K15K_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xml:lang="en-US">Schedule of future minimum payments under non-cancelable operating leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_2JF107H7I93I_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Schedule of summary of stock option activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_4LH329J9K15K_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of weighted average assumptions for employee options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_2JF107H7I93I_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xml:lang="en-US">Schedule of Series B Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_4LH329J9K15K_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_31290F3J262G9III3F2F_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Nature Of Operations Business Activities And Summary Of Significant Accounting Policies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Represents Tabular disclosure of nature of operations, business activities and Summary of significant accounting policies.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_53412H5L484I1KKK5H4H_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_2JF107H7I93I_us-gaap_BusinessAcquisitionAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_4LH329J9K15K_us-gaap_BusinessAcquisitionAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_BusinessAcquisitionAcquireeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_BusinessAcquisitionAcquireeDomain"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_NemusAcquisitionCorpMember" xlink:label="loc_2JF107H7I93I_nmus_NemusAcquisitionCorpMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_NemusAcquisitionCorpMember" xml:lang="en-US">Nemus Acquisition Corp [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_nmus_NemusAcquisitionCorpMember" xml:lang="en-US">Nemus Acquisition Corp</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_NemusAcquisitionCorpMember" xml:lang="en-US">Represents information of Nemus Acquisition Corp.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_NemusAcquisitionCorpMember" xlink:to="lab_4LH329J9K15K_nmus_NemusAcquisitionCorpMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_SubsequentEventTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_SubsequentEventTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_2JF107H7I93I_us-gaap_SubsequentEventTypeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_4LH329J9K15K_us-gaap_SubsequentEventTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_SubsequentEventMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent event</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_SubsequentEventMember" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_SubsequentEventMember"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_2JF107H7I93I_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Nature Of Operations Business Activities And Summary Of Significant Accounting Policies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Nature of Operations, Business Activities and Summary of Significant Accounting Policies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_4LH329J9K15K_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_StockIssuedDuringPeriodSharesReverseMerger" xlink:label="loc_31290F3J262G9III3F2F_nmus_StockIssuedDuringPeriodSharesReverseMerger"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_StockIssuedDuringPeriodSharesReverseMerger" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Merger</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_StockIssuedDuringPeriodSharesReverseMerger" xml:lang="en-US">Reverse merger common stock issuance with par value (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_StockIssuedDuringPeriodSharesReverseMerger" xml:lang="en-US">Represents number of shares issued during the period for reverse merger.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_nmus_StockIssuedDuringPeriodSharesReverseMerger" xlink:to="lab_53412H5L484I1KKK5H4H_nmus_StockIssuedDuringPeriodSharesReverseMerger"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_NumberOfSharesExchanged" xlink:label="loc_2JF107H7I93I_nmus_NumberOfSharesExchanged"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_NumberOfSharesExchanged" xml:lang="en-US">Number Of Shares Exchanged</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_nmus_NumberOfSharesExchanged" xml:lang="en-US">Number of shares exchanged</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_NumberOfSharesExchanged" xml:lang="en-US">This element represents number of shares exchanged.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_NumberOfSharesExchanged" xlink:to="lab_4LH329J9K15K_nmus_NumberOfSharesExchanged"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_AdditionalPaidInCapital"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid in Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional fund operations raised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_AdditionalPaidInCapital" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_AdditionalPaidInCapital"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:label="loc_2JF107H7I93I_us-gaap_PropertyPlantAndEquipmentDepreciationMethods"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xml:lang="en-US">Property, Plant and Equipment, Depreciation Methods</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xml:lang="en-US">Property, plant and equipment, depreciation methods</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:to="lab_4LH329J9K15K_us-gaap_PropertyPlantAndEquipmentDepreciationMethods"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Property plant and equipment estimated useful life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_2JF107H7I93I_us-gaap_NumberOfReportableSegments"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_NumberOfReportableSegments" xml:lang="en-US">Number of Reportable Segments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_NumberOfReportableSegments" xml:lang="en-US">Number of reportable segment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_NumberOfReportableSegments" xlink:to="lab_4LH329J9K15K_us-gaap_NumberOfReportableSegments"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Employee stock options and restricted stock awards excluded from computation of earnings per share</label>
<label xlink:type="resource" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Anti-dilutive excluded from the calculation of diluted loss per common share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_UniversityOfMississippiAgreementsTable" xlink:label="loc_2JF107H7I93I_nmus_UniversityOfMississippiAgreementsTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_UniversityOfMississippiAgreementsTable" xml:lang="en-US">University Of Mississippi Agreements [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_UniversityOfMississippiAgreementsTable" xml:lang="en-US">Tabular disclosure of information regarding University of Mississippi agreements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_UniversityOfMississippiAgreementsTable" xlink:to="lab_4LH329J9K15K_nmus_UniversityOfMississippiAgreementsTable"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_AgreementAxis" xlink:label="loc_31290F3J262G9III3F2F_nmus_AgreementAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_AgreementAxis" xml:lang="en-US">Agreement [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_AgreementAxis" xml:lang="en-US">Represents information regarding agreements of an entity.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_nmus_AgreementAxis" xlink:to="lab_53412H5L484I1KKK5H4H_nmus_AgreementAxis"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_AgreementDomain" xlink:label="loc_2JF107H7I93I_nmus_AgreementDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_AgreementDomain" xml:lang="en-US">Agreement [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_AgreementDomain" xml:lang="en-US">Represents information regarding agreement of an entity.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_AgreementDomain" xlink:to="lab_4LH329J9K15K_nmus_AgreementDomain"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_UniversityOfMississippiAgreementsMember" xlink:label="loc_31290F3J262G9III3F2F_nmus_UniversityOfMississippiAgreementsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_UniversityOfMississippiAgreementsMember" xml:lang="en-US">University Of Mississippi Agreements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_UniversityOfMississippiAgreementsMember" xml:lang="en-US">University of Mississippi Agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_UniversityOfMississippiAgreementsMember" xml:lang="en-US">Represents information regarding University of Mississippi ("UM") Agreements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_nmus_UniversityOfMississippiAgreementsMember" xlink:to="lab_53412H5L484I1KKK5H4H_nmus_UniversityOfMississippiAgreementsMember"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_OptionAgreementMember" xlink:label="loc_2JF107H7I93I_nmus_OptionAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_OptionAgreementMember" xml:lang="en-US">Option Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_nmus_OptionAgreementMember" xml:lang="en-US">UM 5050 pro-drug agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_OptionAgreementMember" xml:lang="en-US">Represents information regarding option agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_OptionAgreementMember" xlink:to="lab_4LH329J9K15K_nmus_OptionAgreementMember"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_LicenseAgreementMember" xlink:label="loc_31290F3J262G9III3F2F_nmus_LicenseAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_LicenseAgreementMember" xml:lang="en-US">License Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_LicenseAgreementMember" xml:lang="en-US">UM 8930 pro-drug agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_LicenseAgreementMember" xml:lang="en-US">Represents license agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_nmus_LicenseAgreementMember" xlink:to="lab_53412H5L484I1KKK5H4H_nmus_LicenseAgreementMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_2JF107H7I93I_dei_LegalEntityAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_dei_LegalEntityAxis" xlink:to="lab_4LH329J9K15K_dei_LegalEntityAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_31290F3J262G9III3F2F_dei_EntityDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_dei_EntityDomain" xlink:to="lab_53412H5L484I1KKK5H4H_dei_EntityDomain"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_UniversityOfMississippiMember" xlink:label="loc_2JF107H7I93I_nmus_UniversityOfMississippiMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_UniversityOfMississippiMember" xml:lang="en-US">University Of Mississippi [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_nmus_UniversityOfMississippiMember" xml:lang="en-US">University of Mississippi</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_UniversityOfMississippiMember" xml:lang="en-US">Represents information regarding university of mississippi.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_UniversityOfMississippiMember" xlink:to="lab_4LH329J9K15K_nmus_UniversityOfMississippiMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_2JF107H7I93I_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_4LH329J9K15K_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_IntellectualPropertyMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_IntellectualPropertyMember" xml:lang="en-US">Intellectual Property [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_IntellectualPropertyMember" xml:lang="en-US">Intellectual Property</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_IntellectualPropertyMember" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_IntellectualPropertyMember"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_MonthAndYearOfAgreementAxis" xlink:label="loc_2JF107H7I93I_nmus_MonthAndYearOfAgreementAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_MonthAndYearOfAgreementAxis" xml:lang="en-US">Month And Year Of Agreement [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_MonthAndYearOfAgreementAxis" xml:lang="en-US">Information regarding month and year of agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_MonthAndYearOfAgreementAxis" xlink:to="lab_4LH329J9K15K_nmus_MonthAndYearOfAgreementAxis"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_MonthAndYearOfAgreementDomain" xlink:label="loc_31290F3J262G9III3F2F_nmus_MonthAndYearOfAgreementDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_MonthAndYearOfAgreementDomain" xml:lang="en-US">Month And Year Of Agreement [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_MonthAndYearOfAgreementDomain" xml:lang="en-US">Represents month and year of agreement in which company entered into.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_nmus_MonthAndYearOfAgreementDomain" xlink:to="lab_53412H5L484I1KKK5H4H_nmus_MonthAndYearOfAgreementDomain"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_OctoberTwoThousandFifteenMember" xlink:label="loc_2JF107H7I93I_nmus_OctoberTwoThousandFifteenMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_OctoberTwoThousandFifteenMember" xml:lang="en-US">October Two Thousand Fifteen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_nmus_OctoberTwoThousandFifteenMember" xml:lang="en-US">October 2014</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_OctoberTwoThousandFifteenMember" xml:lang="en-US">Represents agreement date of the agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_OctoberTwoThousandFifteenMember" xlink:to="lab_4LH329J9K15K_nmus_OctoberTwoThousandFifteenMember"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_December2015Member" xlink:label="loc_31290F3J262G9III3F2F_nmus_December2015Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_December2015Member" xml:lang="en-US">December 2015 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_December2015Member" xml:lang="en-US">December 2015</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_December2015Member" xml:lang="en-US">Represents december 2015 as agreement month and year.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_nmus_December2015Member" xlink:to="lab_53412H5L484I1KKK5H4H_nmus_December2015Member"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_UniversityOfMississippiAgreementsLineItems" xlink:label="loc_2JF107H7I93I_nmus_UniversityOfMississippiAgreementsLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_UniversityOfMississippiAgreementsLineItems" xml:lang="en-US">University Of Mississippi Agreements [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_UniversityOfMississippiAgreementsLineItems" xml:lang="en-US">Line item represents information regarding University of Mississippi agreements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_UniversityOfMississippiAgreementsLineItems" xlink:to="lab_4LH329J9K15K_nmus_UniversityOfMississippiAgreementsLineItems"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_TermOfMemorandumOfUnderstandingAgreement" xlink:label="loc_31290F3J262G9III3F2F_nmus_TermOfMemorandumOfUnderstandingAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_TermOfMemorandumOfUnderstandingAgreement" xml:lang="en-US">Term Of Memorandum Of Understanding Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_TermOfMemorandumOfUnderstandingAgreement" xml:lang="en-US">Term of memorandum of understanding agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_TermOfMemorandumOfUnderstandingAgreement" xml:lang="en-US">This element represents duration of an agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but not limited to, weeks in a year or quarter.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_nmus_TermOfMemorandumOfUnderstandingAgreement" xlink:to="lab_53412H5L484I1KKK5H4H_nmus_TermOfMemorandumOfUnderstandingAgreement"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_NumberOfLicenseAgreements" xlink:label="loc_2JF107H7I93I_nmus_NumberOfLicenseAgreements"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_NumberOfLicenseAgreements" xml:lang="en-US">Number Of License Agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_nmus_NumberOfLicenseAgreements" xml:lang="en-US">Number of license agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_NumberOfLicenseAgreements" xml:lang="en-US">Represents number of license agreements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_NumberOfLicenseAgreements" xlink:to="lab_4LH329J9K15K_nmus_NumberOfLicenseAgreements"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_NoticePeriodForTermination" xlink:label="loc_31290F3J262G9III3F2F_nmus_NoticePeriodForTermination"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_NoticePeriodForTermination" xml:lang="en-US">Notice Period For Termination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_NoticePeriodForTermination" xml:lang="en-US">Notice period for termination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_NoticePeriodForTermination" xml:lang="en-US">This element represents written notice period for termination under agreement by either party.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_nmus_NoticePeriodForTermination" xlink:to="lab_53412H5L484I1KKK5H4H_nmus_NoticePeriodForTermination"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_OneTimeUpfrontPayment" xlink:label="loc_2JF107H7I93I_nmus_OneTimeUpfrontPayment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_OneTimeUpfrontPayment" xml:lang="en-US">One Time Upfront Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4LH329J9K15K_nmus_OneTimeUpfrontPayment" xml:lang="en-US">One-time up-front option payment under University of Mississippi option agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_nmus_OneTimeUpfrontPayment" xml:lang="en-US">One time up front payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_OneTimeUpfrontPayment" xml:lang="en-US">This element represents amount of one-time upfront payment.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_OneTimeUpfrontPayment" xlink:to="lab_4LH329J9K15K_nmus_OneTimeUpfrontPayment"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_AnnualFeesForLicenseAgreement" xlink:label="loc_31290F3J262G9III3F2F_nmus_AnnualFeesForLicenseAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_AnnualFeesForLicenseAgreement" xml:lang="en-US">Annual Fees For License Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_AnnualFeesForLicenseAgreement" xml:lang="en-US">Annual fees for license agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_AnnualFeesForLicenseAgreement" xml:lang="en-US">Represents annual fees for license agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_nmus_AnnualFeesForLicenseAgreement" xlink:to="lab_53412H5L484I1KKK5H4H_nmus_AnnualFeesForLicenseAgreement"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_AggregateMilestonePaymentsIfMilestonesAchieved" xlink:label="loc_2JF107H7I93I_nmus_AggregateMilestonePaymentsIfMilestonesAchieved"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_AggregateMilestonePaymentsIfMilestonesAchieved" xml:lang="en-US">Aggregate Milestone Payments If Milestones Achieved</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4LH329J9K15K_nmus_AggregateMilestonePaymentsIfMilestonesAchieved" xml:lang="en-US">Aggregate milestone payments if milestones achieved</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_AggregateMilestonePaymentsIfMilestonesAchieved" xml:lang="en-US">This element represents amount of aggregate milestone payments under the license agreements if the milestones are achieved.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_AggregateMilestonePaymentsIfMilestonesAchieved" xlink:to="lab_4LH329J9K15K_nmus_AggregateMilestonePaymentsIfMilestonesAchieved"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_OptionPaymentDueAndPayable" xlink:label="loc_31290F3J262G9III3F2F_nmus_OptionPaymentDueAndPayable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_OptionPaymentDueAndPayable" xml:lang="en-US">Option Payment Due And Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_OptionPaymentDueAndPayable" xml:lang="en-US">Option payment for shortened period due and payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_OptionPaymentDueAndPayable" xml:lang="en-US">Represents option payment for this shortened period due and payable on demand.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_nmus_OptionPaymentDueAndPayable" xlink:to="lab_53412H5L484I1KKK5H4H_nmus_OptionPaymentDueAndPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_2JF107H7I93I_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xml:lang="en-US">2016</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="lab_4LH329J9K15K_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xml:lang="en-US">2017</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_2JF107H7I93I_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xml:lang="en-US">2018</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="lab_4LH329J9K15K_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xml:lang="en-US">2019</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_2JF107H7I93I_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xml:lang="en-US">2020</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="lab_4LH329J9K15K_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xml:lang="en-US">Thereafter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_2JF107H7I93I_us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4LH329J9K15K_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="lab_4LH329J9K15K_us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_LeaseAgreementMember" xlink:label="loc_2JF107H7I93I_nmus_LeaseAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_LeaseAgreementMember" xml:lang="en-US">Lease Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_nmus_LeaseAgreementMember" xml:lang="en-US">Lease agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_LeaseAgreementMember" xml:lang="en-US">Represents information about name of agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_LeaseAgreementMember" xlink:to="lab_4LH329J9K15K_nmus_LeaseAgreementMember"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_LetterAgreementMember" xlink:label="loc_31290F3J262G9III3F2F_nmus_LetterAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_LetterAgreementMember" xml:lang="en-US">Letter Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_LetterAgreementMember" xml:lang="en-US">Letter agreement ("Agreement")</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_LetterAgreementMember" xml:lang="en-US">Represents letter agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_nmus_LetterAgreementMember" xlink:to="lab_53412H5L484I1KKK5H4H_nmus_LetterAgreementMember"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ContractManufacturingOrganizationMember" xlink:label="loc_2JF107H7I93I_nmus_ContractManufacturingOrganizationMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_ContractManufacturingOrganizationMember" xml:lang="en-US">Contract Manufacturing Organization [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_nmus_ContractManufacturingOrganizationMember" xml:lang="en-US">Contract manufacturing organization ("CMO")</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_ContractManufacturingOrganizationMember" xml:lang="en-US">Represents third party, contract manufacturing organization.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_ContractManufacturingOrganizationMember" xlink:to="lab_4LH329J9K15K_nmus_ContractManufacturingOrganizationMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_RangeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_RangeAxis" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_RangeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_2JF107H7I93I_us-gaap_RangeMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_RangeMember" xml:lang="en-US">Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_RangeMember" xlink:to="lab_4LH329J9K15K_us-gaap_RangeMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_MinimumMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_MinimumMember" xml:lang="en-US">Minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_MinimumMember" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_MinimumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_2JF107H7I93I_us-gaap_MaximumMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_MaximumMember" xml:lang="en-US">Maximum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_MaximumMember" xlink:to="lab_4LH329J9K15K_us-gaap_MaximumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_OperatingLeasedAssetsLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_OperatingLeasedAssetsLineItems" xml:lang="en-US">Operating Leased Assets [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_OperatingLeasedAssetsLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AreaOfLand" xlink:label="loc_2JF107H7I93I_us-gaap_AreaOfLand"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_AreaOfLand" xml:lang="en-US">Area of Land</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_AreaOfLand" xml:lang="en-US">Area of corporate office headquarters</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_AreaOfLand" xml:lang="en-US">Area of land</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_AreaOfLand" xlink:to="lab_4LH329J9K15K_us-gaap_AreaOfLand"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_OperatingLeasesRentExpenseNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_OperatingLeasesRentExpenseNet" xml:lang="en-US">Operating Leases, Rent Expense, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_OperatingLeasesRentExpenseNet" xml:lang="en-US">Rent expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_OperatingLeasesRentExpenseNet" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_OperatingLeasesRentExpenseNet"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_FeesAndExpensesForServicesProvided" xlink:label="loc_2JF107H7I93I_nmus_FeesAndExpensesForServicesProvided"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_FeesAndExpensesForServicesProvided" xml:lang="en-US">Fees And Expenses For Services Provided</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_nmus_FeesAndExpensesForServicesProvided" xml:lang="en-US">Fees and expenses for the initial evaluation and development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_FeesAndExpensesForServicesProvided" xml:lang="en-US">Represents amount of fees and expenses for services provided.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_FeesAndExpensesForServicesProvided" xlink:to="lab_4LH329J9K15K_nmus_FeesAndExpensesForServicesProvided"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_AnalyticalMethodDevelopmentAndQualificationExpense" xlink:label="loc_31290F3J262G9III3F2F_nmus_AnalyticalMethodDevelopmentAndQualificationExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_AnalyticalMethodDevelopmentAndQualificationExpense" xml:lang="en-US">Analytical Method Development And Qualification Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_AnalyticalMethodDevelopmentAndQualificationExpense" xml:lang="en-US">Estimated analytical method development and qualification</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_AnalyticalMethodDevelopmentAndQualificationExpense" xml:lang="en-US">Represents analytical method development and qualification expense.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_nmus_AnalyticalMethodDevelopmentAndQualificationExpense" xlink:to="lab_53412H5L484I1KKK5H4H_nmus_AnalyticalMethodDevelopmentAndQualificationExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_2JF107H7I93I_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_4LH329J9K15K_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_AwardTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_AwardTypeAxis" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_AwardTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_2JF107H7I93I_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_4LH329J9K15K_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_EmployeeStockOptionMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock Option</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_EmployeeStockOptionMember" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_EmployeeStockOptionMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_2JF107H7I93I_us-gaap_RestrictedStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted stock awards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_RestrictedStockMember" xlink:to="lab_4LH329J9K15K_us-gaap_RestrictedStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_PlanNameAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_PlanNameAxis" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_PlanNameAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_2JF107H7I93I_us-gaap_PlanNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_PlanNameDomain" xlink:to="lab_4LH329J9K15K_us-gaap_PlanNameDomain"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_OmnibusIncentivePlan2014Member" xlink:label="loc_31290F3J262G9III3F2F_nmus_OmnibusIncentivePlan2014Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_OmnibusIncentivePlan2014Member" xml:lang="en-US">Omnibus Incentive Plan 2014 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_OmnibusIncentivePlan2014Member" xml:lang="en-US">Omnibus Incentive Plan 2014</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_OmnibusIncentivePlan2014Member" xml:lang="en-US">Represents information of Omnibus Incentive Plan 2014.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_nmus_OmnibusIncentivePlan2014Member" xlink:to="lab_53412H5L484I1KKK5H4H_nmus_OmnibusIncentivePlan2014Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_2JF107H7I93I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_4LH329J9K15K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_SharesAvailableForGrantOfOptionsRollForward" xlink:label="loc_31290F3J262G9III3F2F_nmus_SharesAvailableForGrantOfOptionsRollForward"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_SharesAvailableForGrantOfOptionsRollForward" xml:lang="en-US">Shares Available For Grant Of Options [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_SharesAvailableForGrantOfOptionsRollForward" xml:lang="en-US">Shares Available For Grant Of Options &amp; Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_SharesAvailableForGrantOfOptionsRollForward" xml:lang="en-US">A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_nmus_SharesAvailableForGrantOfOptionsRollForward" xlink:to="lab_53412H5L484I1KKK5H4H_nmus_SharesAvailableForGrantOfOptionsRollForward"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_SharesAvailableForGrantOfOptionsOpeningBalance" xlink:label="loc_2JF107H7I93I_nmus_SharesAvailableForGrantOfOptionsOpeningBalance"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_SharesAvailableForGrantOfOptionsOpeningBalance" xml:lang="en-US">Shares Available For Grant Of Options Opening Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_nmus_SharesAvailableForGrantOfOptionsOpeningBalance" xml:lang="en-US">Balance at the beginning</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_4LH329J9K15K_nmus_SharesAvailableForGrantOfOptionsOpeningBalance" xml:lang="en-US">Balance at the beginning</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_4LH329J9K15K_nmus_SharesAvailableForGrantOfOptionsOpeningBalance" xml:lang="en-US">Balance at the ending</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_SharesAvailableForGrantOfOptionsOpeningBalance" xml:lang="en-US">This element represents shares available for grant of options.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_SharesAvailableForGrantOfOptionsOpeningBalance" xlink:to="lab_4LH329J9K15K_nmus_SharesAvailableForGrantOfOptionsOpeningBalance"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_SharesAvailableForGrantOptionsGranted" xlink:label="loc_31290F3J262G9III3F2F_nmus_SharesAvailableForGrantOptionsGranted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_SharesAvailableForGrantOptionsGranted" xml:lang="en-US">Shares Available For Grant Options Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_SharesAvailableForGrantOptionsGranted" xml:lang="en-US">Options granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_SharesAvailableForGrantOptionsGranted" xml:lang="en-US">This element represents number of Options granted.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_SharesAvailableForGrantOptionsGranted" xml:lang="en-US">Options granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_nmus_SharesAvailableForGrantOptionsGranted" xlink:to="lab_53412H5L484I1KKK5H4H_nmus_SharesAvailableForGrantOptionsGranted"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_SharesAvailableForGrantOptionsExercised" xlink:label="loc_2JF107H7I93I_nmus_SharesAvailableForGrantOptionsExercised"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_SharesAvailableForGrantOptionsExercised" xml:lang="en-US">Shares Available For Grant Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_nmus_SharesAvailableForGrantOptionsExercised" xml:lang="en-US">Options exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_SharesAvailableForGrantOptionsExercised" xml:lang="en-US">This element represents number of Options exercised.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_SharesAvailableForGrantOptionsExercised" xlink:to="lab_4LH329J9K15K_nmus_SharesAvailableForGrantOptionsExercised"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_SharesAvailableForGrantOptionsCancelled" xlink:label="loc_31290F3J262G9III3F2F_nmus_SharesAvailableForGrantOptionsCancelled"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_SharesAvailableForGrantOptionsCancelled" xml:lang="en-US">Shares Available For Grant Options Cancelled</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_SharesAvailableForGrantOptionsCancelled" xml:lang="en-US">Options cancelled</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_SharesAvailableForGrantOptionsCancelled" xml:lang="en-US">This element represents number of options cancelled.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_nmus_SharesAvailableForGrantOptionsCancelled" xlink:to="lab_53412H5L484I1KKK5H4H_nmus_SharesAvailableForGrantOptionsCancelled"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_SharesAvailableForGrantOptionsExcludingRestrictedstock" xlink:label="loc_2JF107H7I93I_nmus_SharesAvailableForGrantOptionsExcludingRestrictedstock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_SharesAvailableForGrantOptionsExcludingRestrictedstock" xml:lang="en-US">Shares Available For Grant Options Excluding Restricted stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_nmus_SharesAvailableForGrantOptionsExcludingRestrictedstock" xml:lang="en-US">Subtotal</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4LH329J9K15K_nmus_SharesAvailableForGrantOptionsExcludingRestrictedstock" xml:lang="en-US">Subtotal</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_SharesAvailableForGrantOptionsExcludingRestrictedstock" xml:lang="en-US">Represents total of number options granted, exercised and cancelled during the period excluding restricted stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_SharesAvailableForGrantOptionsExcludingRestrictedstock" xlink:to="lab_4LH329J9K15K_nmus_SharesAvailableForGrantOptionsExcludingRestrictedstock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xml:lang="en-US">Compensation expense from issuance of restricted common stock to employees and board members</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xml:lang="en-US">Number of restricted stock awards granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xml:lang="en-US">Shares used for restricted stock awards (see discussion below)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_2JF107H7I93I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Number of Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_4LH329J9K15K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Options outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Balance at the beginning</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Balance at the ending</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_2JF107H7I93I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Options granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Aggregate number of shares granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Options to purchase shares common stock granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_4LH329J9K15K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Options exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_2JF107H7I93I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Options cancelled</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_4LH329J9K15K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Options cancelled</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_4LH329J9K15K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_OptionsOutstandingPricePerShareRollForward" xlink:label="loc_31290F3J262G9III3F2F_nmus_OptionsOutstandingPricePerShareRollForward"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_OptionsOutstandingPricePerShareRollForward" xml:lang="en-US">Options Outstanding Price Per Share [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_OptionsOutstandingPricePerShareRollForward" xml:lang="en-US">Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_OptionsOutstandingPricePerShareRollForward" xml:lang="en-US">A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_nmus_OptionsOutstandingPricePerShareRollForward" xlink:to="lab_53412H5L484I1KKK5H4H_nmus_OptionsOutstandingPricePerShareRollForward"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_OptionsOutstandingPricePerShareOpeningBalance" xlink:label="loc_2JF107H7I93I_nmus_OptionsOutstandingPricePerShareOpeningBalance"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_OptionsOutstandingPricePerShareOpeningBalance" xml:lang="en-US">Options Outstanding Price Per Share Opening Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4LH329J9K15K_nmus_OptionsOutstandingPricePerShareOpeningBalance" xml:lang="en-US">Balance at the ending</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_nmus_OptionsOutstandingPricePerShareOpeningBalance" xml:lang="en-US">Balance at the beginning</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_4LH329J9K15K_nmus_OptionsOutstandingPricePerShareOpeningBalance" xml:lang="en-US">Balance at the beginning</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_4LH329J9K15K_nmus_OptionsOutstandingPricePerShareOpeningBalance" xml:lang="en-US">Balance at the ending</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_OptionsOutstandingPricePerShareOpeningBalance" xml:lang="en-US">This element represents options outstanding price per share.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_OptionsOutstandingPricePerShareOpeningBalance" xlink:to="lab_4LH329J9K15K_nmus_OptionsOutstandingPricePerShareOpeningBalance"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_OptionsOutstandingPricePerShareOptionsGranted" xlink:label="loc_31290F3J262G9III3F2F_nmus_OptionsOutstandingPricePerShareOptionsGranted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_OptionsOutstandingPricePerShareOptionsGranted" xml:lang="en-US">Options Outstanding Price Per Share Options Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_OptionsOutstandingPricePerShareOptionsGranted" xml:lang="en-US">Options granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_OptionsOutstandingPricePerShareOptionsGranted" xml:lang="en-US">This element represents options outstanding price per share.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_nmus_OptionsOutstandingPricePerShareOptionsGranted" xlink:to="lab_53412H5L484I1KKK5H4H_nmus_OptionsOutstandingPricePerShareOptionsGranted"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_OptionsOutstandingPricePerShareOptionsExercised" xlink:label="loc_2JF107H7I93I_nmus_OptionsOutstandingPricePerShareOptionsExercised"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_OptionsOutstandingPricePerShareOptionsExercised" xml:lang="en-US">Options Outstanding Price Per Share Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4LH329J9K15K_nmus_OptionsOutstandingPricePerShareOptionsExercised" xml:lang="en-US">Options exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_OptionsOutstandingPricePerShareOptionsExercised" xml:lang="en-US">Price per share at which option holders acquired shares when converting their stock options into shares.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_OptionsOutstandingPricePerShareOptionsExercised" xlink:to="lab_4LH329J9K15K_nmus_OptionsOutstandingPricePerShareOptionsExercised"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_OptionsOutstandingPricePerShareOptionsCancelled" xlink:label="loc_31290F3J262G9III3F2F_nmus_OptionsOutstandingPricePerShareOptionsCancelled"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_OptionsOutstandingPricePerShareOptionsCancelled" xml:lang="en-US">Options Outstanding Price Per Share Options Cancelled</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_OptionsOutstandingPricePerShareOptionsCancelled" xml:lang="en-US">Options cancelled</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_OptionsOutstandingPricePerShareOptionsCancelled" xml:lang="en-US">This element represents options outstanding price per share.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_nmus_OptionsOutstandingPricePerShareOptionsCancelled" xlink:to="lab_53412H5L484I1KKK5H4H_nmus_OptionsOutstandingPricePerShareOptionsCancelled"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_2JF107H7I93I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Weighted Average Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_4LH329J9K15K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Balance at the beginning</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Balance at the ending</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_2JF107H7I93I_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Options granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_4LH329J9K15K_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Options exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_2JF107H7I93I_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Options cancelled</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_4LH329J9K15K_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_2JF107H7I93I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Volatility factor</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_4LH329J9K15K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_2JF107H7I93I_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Contractual term of option outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected term (years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_4LH329J9K15K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted-average fair value of options granted during the periods</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_EquityTable" xlink:label="loc_2JF107H7I93I_nmus_EquityTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_EquityTable" xml:lang="en-US">Equity [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_EquityTable" xml:lang="en-US">Represents tabular disclosure of Equity.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_EquityTable" xlink:to="lab_4LH329J9K15K_nmus_EquityTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_StatementEquityComponentsAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_StatementEquityComponentsAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_2JF107H7I93I_us-gaap_EquityComponentDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_EquityComponentDomain" xlink:to="lab_4LH329J9K15K_us-gaap_EquityComponentDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_WarrantMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_WarrantMember" xml:lang="en-US">Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_WarrantMember" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_WarrantMember"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_StockPurchaseAgreementJune2014Member" xlink:label="loc_2JF107H7I93I_nmus_StockPurchaseAgreementJune2014Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_StockPurchaseAgreementJune2014Member" xml:lang="en-US">Stock Purchase Agreement June 2014 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_nmus_StockPurchaseAgreementJune2014Member" xml:lang="en-US">June 2014 Stock Purchase Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_StockPurchaseAgreementJune2014Member" xml:lang="en-US">Represents information of Stock Purchase Agreement June 2014.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_StockPurchaseAgreementJune2014Member" xlink:to="lab_4LH329J9K15K_nmus_StockPurchaseAgreementJune2014Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_IncomeStatementLocationAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_IncomeStatementLocationAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_2JF107H7I93I_us-gaap_IncomeStatementLocationDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_4LH329J9K15K_us-gaap_IncomeStatementLocationDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_GeneralAndAdministrativeExpenseMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and administrative expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_GeneralAndAdministrativeExpenseMember"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_EquityLineItems" xlink:label="loc_2JF107H7I93I_nmus_EquityLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_EquityLineItems" xml:lang="en-US">Equity [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_EquityLineItems" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_EquityLineItems" xlink:to="lab_4LH329J9K15K_nmus_EquityLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Warrants to purchase shares of common stock issued and outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Number of shares called by warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_2JF107H7I93I_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">common stock par value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Warrant exercise price (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_4LH329J9K15K_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_TermOfWarrant" xlink:label="loc_31290F3J262G9III3F2F_nmus_TermOfWarrant"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_TermOfWarrant" xml:lang="en-US">Term Of Warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_TermOfWarrant" xml:lang="en-US">Term of warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_TermOfWarrant" xml:lang="en-US">Represents term of warrant.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_nmus_TermOfWarrant" xlink:to="lab_53412H5L484I1KKK5H4H_nmus_TermOfWarrant"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_NumberOfAdvisors" xlink:label="loc_2JF107H7I93I_nmus_NumberOfAdvisors"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_NumberOfAdvisors" xml:lang="en-US">Number Of Advisors</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_nmus_NumberOfAdvisors" xml:lang="en-US">Number of advisors</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_NumberOfAdvisors" xml:lang="en-US">Represents number of advisors.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_NumberOfAdvisors" xlink:to="lab_4LH329J9K15K_nmus_NumberOfAdvisors"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ValueOfCommonStockCalledByWarrants" xlink:label="loc_31290F3J262G9III3F2F_nmus_ValueOfCommonStockCalledByWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_ValueOfCommonStockCalledByWarrants" xml:lang="en-US">Value Of Common Stock Called By Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_ValueOfCommonStockCalledByWarrants" xml:lang="en-US">Value of common stock called by warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_ValueOfCommonStockCalledByWarrants" xml:lang="en-US">Represents amount of common stock called by warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_nmus_ValueOfCommonStockCalledByWarrants" xlink:to="lab_53412H5L484I1KKK5H4H_nmus_ValueOfCommonStockCalledByWarrants"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_AmortizationOfWarrantServiceCost" xlink:label="loc_2JF107H7I93I_nmus_AmortizationOfWarrantServiceCost"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_AmortizationOfWarrantServiceCost" xml:lang="en-US">Amortization Of Warrant Service Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_nmus_AmortizationOfWarrantServiceCost" xml:lang="en-US">Amortization of warrant service cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_AmortizationOfWarrantServiceCost" xml:lang="en-US">Represents amortization of warrant service cost.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_AmortizationOfWarrantServiceCost" xlink:to="lab_4LH329J9K15K_nmus_AmortizationOfWarrantServiceCost"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Number of shares issued for services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Number of common shares issued to founders and one board member</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_AmortizationOfGeneralAndAdministrativeExpenses" xlink:label="loc_2JF107H7I93I_nmus_AmortizationOfGeneralAndAdministrativeExpenses"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_AmortizationOfGeneralAndAdministrativeExpenses" xml:lang="en-US">Amortization Of General And Administrative Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4LH329J9K15K_nmus_AmortizationOfGeneralAndAdministrativeExpenses" xml:lang="en-US">Amortized general and administrative expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_AmortizationOfGeneralAndAdministrativeExpenses" xml:lang="en-US">Represents amortization of general and administrative expenses during the period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_AmortizationOfGeneralAndAdministrativeExpenses" xlink:to="lab_4LH329J9K15K_nmus_AmortizationOfGeneralAndAdministrativeExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Fair market value of common stock issued recorded as prepaid expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Value of common shares issued to founders and one board member</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Value of common shares issued to services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" xlink:label="loc_2JF107H7I93I_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" xml:lang="en-US">Stock And Warrants Issued During Period Shares Preferred Stock And Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" xml:lang="en-US">Number of preferred stock and warrants sold</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" xml:lang="en-US">Number of preferred stock and warrants for common stock issued.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" xlink:to="lab_4LH329J9K15K_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Number of shares issued to group of private investors</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of common stock to investors in prior entity (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Number of common shares issued to individual investors</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_2JF107H7I93I_us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Value of shares issued to group of private investors</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issuance of common stock to investors in prior entity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_4LH329J9K15K_us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ValueOfWarrantsIssued" xlink:label="loc_31290F3J262G9III3F2F_nmus_ValueOfWarrantsIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_ValueOfWarrantsIssued" xml:lang="en-US">Value of warrants issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_ValueOfWarrantsIssued" xml:lang="en-US">Additional fund raised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_ValueOfWarrantsIssued" xml:lang="en-US">Value of warrants issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_ValueOfWarrantsIssued" xml:lang="en-US">This element represents value of warrants issued.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_nmus_ValueOfWarrantsIssued" xlink:to="lab_53412H5L484I1KKK5H4H_nmus_ValueOfWarrantsIssued"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_NumberOfInvestor" xlink:label="loc_2JF107H7I93I_nmus_NumberOfInvestor"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_NumberOfInvestor" xml:lang="en-US">Number Of Investor</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_nmus_NumberOfInvestor" xml:lang="en-US">Number of individual investor</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_NumberOfInvestor" xml:lang="en-US">This element represents number of individual investors.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_NumberOfInvestor" xlink:to="lab_4LH329J9K15K_nmus_NumberOfInvestor"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Number of shares vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_2JF107H7I93I_us-gaap_PreferredStockSharesAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_4LH329J9K15K_us-gaap_PreferredStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_PreferredStockParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_PreferredStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_MinimumIssuanceOfSharesInEquityFinancing" xlink:label="loc_2JF107H7I93I_nmus_MinimumIssuanceOfSharesInEquityFinancing"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_MinimumIssuanceOfSharesInEquityFinancing" xml:lang="en-US">Minimum Issuance Of Shares In Equity Financing</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_nmus_MinimumIssuanceOfSharesInEquityFinancing" xml:lang="en-US">Minimum equity financing under down-round protection feature</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_MinimumIssuanceOfSharesInEquityFinancing" xml:lang="en-US">Represents value of minimum issuance of shares under equity financing.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_MinimumIssuanceOfSharesInEquityFinancing" xlink:to="lab_4LH329J9K15K_nmus_MinimumIssuanceOfSharesInEquityFinancing"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_MaximumIssuancePricePerShareInEquityFinancing" xlink:label="loc_31290F3J262G9III3F2F_nmus_MaximumIssuancePricePerShareInEquityFinancing"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_MaximumIssuancePricePerShareInEquityFinancing" xml:lang="en-US">Maximum Issuance Price Per Share In Equity Financing</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_MaximumIssuancePricePerShareInEquityFinancing" xml:lang="en-US">Maximum common stock issuance price per share (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_MaximumIssuancePricePerShareInEquityFinancing" xml:lang="en-US">Represents maximum issuance price per share under equity financing.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_nmus_MaximumIssuancePricePerShareInEquityFinancing" xlink:to="lab_53412H5L484I1KKK5H4H_nmus_MaximumIssuancePricePerShareInEquityFinancing"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ConversionPrice" xlink:label="loc_2JF107H7I93I_nmus_ConversionPrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_ConversionPrice" xml:lang="en-US">Conversion Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_nmus_ConversionPrice" xml:lang="en-US">Conversion price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_ConversionPrice" xml:lang="en-US">Represents conversion price per share.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_ConversionPrice" xlink:to="lab_4LH329J9K15K_nmus_ConversionPrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_ConversionOfStockSharesConverted1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ConversionOfStockSharesConverted1" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ConversionOfStockSharesConverted1" xml:lang="en-US">Number of shares converted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_ConversionOfStockSharesConverted1" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_ConversionOfStockSharesConverted1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_2JF107H7I93I_us-gaap_ConversionOfStockSharesIssued1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_ConversionOfStockSharesIssued1" xml:lang="en-US">Conversion of Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_ConversionOfStockSharesIssued1" xml:lang="en-US">Number of shares issued in conversion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_ConversionOfStockSharesIssued1" xlink:to="lab_4LH329J9K15K_us-gaap_ConversionOfStockSharesIssued1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xml:lang="en-US">Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xml:lang="en-US">Proceeds received from the Series B financing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_2JF107H7I93I_us-gaap_SharePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_SharePrice" xml:lang="en-US">Share price (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_SharePrice" xlink:to="lab_4LH329J9K15K_us-gaap_SharePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockRedemptionTerms" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_PreferredStockRedemptionTerms"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_PreferredStockRedemptionTerms" xml:lang="en-US">Preferred Stock, Redemption Terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_PreferredStockRedemptionTerms" xml:lang="en-US">Preferred stock, redemption terms</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_PreferredStockRedemptionTerms" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_PreferredStockRedemptionTerms"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="loc_2JF107H7I93I_us-gaap_PreferredStockConversionBasis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_PreferredStockConversionBasis" xml:lang="en-US">Preferred Stock, Conversion Basis</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_PreferredStockConversionBasis" xml:lang="en-US">Preferred stock, conversion rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_PreferredStockConversionBasis" xlink:to="lab_4LH329J9K15K_us-gaap_PreferredStockConversionBasis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_PreferredStockLiquidationPreferenceValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_PreferredStockLiquidationPreferenceValue" xml:lang="en-US">Preferred Stock, Liquidation Preference, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_PreferredStockLiquidationPreferenceValue" xml:lang="en-US">Liquidation preference value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_PreferredStockLiquidationPreferenceValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_2JF107H7I93I_us-gaap_TitleOfIndividualAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_TitleOfIndividualAxis" xlink:to="lab_4LH329J9K15K_us-gaap_TitleOfIndividualAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Relationship to Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ManagementAndBoardOfDirectorsMember" xlink:label="loc_2JF107H7I93I_nmus_ManagementAndBoardOfDirectorsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_ManagementAndBoardOfDirectorsMember" xml:lang="en-US">Management And Board Of Directors [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_nmus_ManagementAndBoardOfDirectorsMember" xml:lang="en-US">Senior management and board of directors</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_ManagementAndBoardOfDirectorsMember" xml:lang="en-US">Person or persons controlling and directing the affairs of an entity and person serving on the board of directors.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_ManagementAndBoardOfDirectorsMember" xlink:to="lab_4LH329J9K15K_nmus_ManagementAndBoardOfDirectorsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Number of shares reserved for future grants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_2JF107H7I93I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xml:lang="en-US">Aggregate number of shares granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_4LH329J9K15K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Subtotal</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Number of shares available for future grant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Subtotal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_2JF107H7I93I_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Expiry period of options granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_4LH329J9K15K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants" xlink:label="loc_31290F3J262G9III3F2F_nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants" xml:lang="en-US">Percentage Of Option Price At Least Of Fair Value On Date Of Grants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants" xml:lang="en-US">Percentage of option price at least of fair value on date of grants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants" xml:lang="en-US">This element represents percentage of option price least of fair value on the date of grants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants" xlink:to="lab_53412H5L484I1KKK5H4H_nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_CommonStockVotingPercentage" xlink:label="loc_2JF107H7I93I_nmus_CommonStockVotingPercentage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_CommonStockVotingPercentage" xml:lang="en-US">Common Stock Voting Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_nmus_CommonStockVotingPercentage" xml:lang="en-US">Voting percentage of common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_CommonStockVotingPercentage" xml:lang="en-US">Percentage of vesting of share-based compensation awards.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_CommonStockVotingPercentage" xlink:to="lab_4LH329J9K15K_nmus_CommonStockVotingPercentage"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_PercentageOfFairValueOptionPriceAtDateOfGrants" xlink:label="loc_31290F3J262G9III3F2F_nmus_PercentageOfFairValueOptionPriceAtDateOfGrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_PercentageOfFairValueOptionPriceAtDateOfGrants" xml:lang="en-US">Percentage Of Fair Value Option Price At Date Of Grants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_PercentageOfFairValueOptionPriceAtDateOfGrants" xml:lang="en-US">Percentage of fair value option price at date of grants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_PercentageOfFairValueOptionPriceAtDateOfGrants" xml:lang="en-US">This element represents percentage of option price least of fair value on the date of grants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_nmus_PercentageOfFairValueOptionPriceAtDateOfGrants" xlink:to="lab_53412H5L484I1KKK5H4H_nmus_PercentageOfFairValueOptionPriceAtDateOfGrants"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_MaximumExercisablePeriodOfFairValueOfOption" xlink:label="loc_2JF107H7I93I_nmus_MaximumExercisablePeriodOfFairValueOfOption"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_MaximumExercisablePeriodOfFairValueOfOption" xml:lang="en-US">Maximum Exercisable Period Of Fair Value Of Option</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_nmus_MaximumExercisablePeriodOfFairValueOfOption" xml:lang="en-US">Maximum exercisable period of fair value of option</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_MaximumExercisablePeriodOfFairValueOfOption" xml:lang="en-US">This element represents maximum exercisable period of fair value of option.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_MaximumExercisablePeriodOfFairValueOfOption" xlink:to="lab_4LH329J9K15K_nmus_MaximumExercisablePeriodOfFairValueOfOption"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Vested period of shares granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Vested period of shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_2JF107H7I93I_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Remaining contractual life of options outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_4LH329J9K15K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xml:lang="en-US">Aggregate intrinsic value of options outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_2JF107H7I93I_us-gaap_AllocatedShareBasedCompensationExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Recognized stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_4LH329J9K15K_us-gaap_AllocatedShareBasedCompensationExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Total amount of unrecognized compensation cost related to non-vested stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_2JF107H7I93I_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Recognized period of non-vested stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_4LH329J9K15K_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Options to purchase shares of common stock, exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_FairMarketValueOfSharesGranted" xlink:label="loc_2JF107H7I93I_nmus_FairMarketValueOfSharesGranted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_FairMarketValueOfSharesGranted" xml:lang="en-US">Fair Market Value Of Shares Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_nmus_FairMarketValueOfSharesGranted" xml:lang="en-US">Fair market value of shares granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_FairMarketValueOfSharesGranted" xml:lang="en-US">Fair value of shares granted.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_FairMarketValueOfSharesGranted" xlink:to="lab_4LH329J9K15K_nmus_FairMarketValueOfSharesGranted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockTable" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_ConversionOfStockTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ConversionOfStockTable" xml:lang="en-US">Conversion of Stock [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_ConversionOfStockTable" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_ConversionOfStockTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockLineItems" xlink:label="loc_2JF107H7I93I_us-gaap_ConversionOfStockLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_ConversionOfStockLineItems" xml:lang="en-US">Conversion of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_ConversionOfStockLineItems" xlink:to="lab_4LH329J9K15K_us-gaap_ConversionOfStockLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_SharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_SharesIssued" xml:lang="en-US">Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_SharesIssued" xml:lang="en-US">Number of additional shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_SharesIssued" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_SharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_2JF107H7I93I_us-gaap_SharesIssuedPricePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares Issued, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares issued, price per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares issued, price per share (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_4LH329J9K15K_us-gaap_SharesIssuedPricePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_ClassOfWarrantOrRightTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ClassOfWarrantOrRightTable" xml:lang="en-US">Class of Warrant or Right [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_ClassOfWarrantOrRightTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_2JF107H7I93I_us-gaap_ClassOfWarrantOrRightAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_4LH329J9K15K_us-gaap_ClassOfWarrantOrRightAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_ClassOfWarrantOrRightDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_ClassOfWarrantOrRightDomain"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_SeriesBWarrantsMember" xlink:label="loc_2JF107H7I93I_nmus_SeriesBWarrantsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_SeriesBWarrantsMember" xml:lang="en-US">Series B Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_nmus_SeriesBWarrantsMember" xml:lang="en-US">Series B Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_SeriesBWarrantsMember" xml:lang="en-US">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_SeriesBWarrantsMember" xlink:to="lab_4LH329J9K15K_nmus_SeriesBWarrantsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_ClassOfWarrantOrRightLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ClassOfWarrantOrRightLineItems" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_ClassOfWarrantOrRightLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_2JF107H7I93I_us-gaap_FairValueAssumptionsExpectedDividendRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:to="lab_4LH329J9K15K_us-gaap_FairValueAssumptionsExpectedDividendRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_FairValueAssumptionsExpectedVolatilityRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Volatility factor</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_FairValueAssumptionsExpectedVolatilityRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_2JF107H7I93I_us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_4LH329J9K15K_us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_FairValueAssumptionsExpectedTerm"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Expected term (years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_FairValueAssumptionsExpectedTerm"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_2JF107H7I93I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted-average fair value of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_4LH329J9K15K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_NumberOfWarrantsIssued" xlink:label="loc_31290F3J262G9III3F2F_nmus_NumberOfWarrantsIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_NumberOfWarrantsIssued" xml:lang="en-US">Number Of Warrants Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_NumberOfWarrantsIssued" xml:lang="en-US">Number of warrants issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_NumberOfWarrantsIssued" xml:lang="en-US">Represents number of warrants issued during period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_nmus_NumberOfWarrantsIssued" xlink:to="lab_53412H5L484I1KKK5H4H_nmus_NumberOfWarrantsIssued"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ExpirationPeriodOfWarrants" xlink:label="loc_2JF107H7I93I_nmus_ExpirationPeriodOfWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_ExpirationPeriodOfWarrants" xml:lang="en-US">Expiration Period Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4LH329J9K15K_nmus_ExpirationPeriodOfWarrants" xml:lang="en-US">Warrants, expiration period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_ExpirationPeriodOfWarrants" xml:lang="en-US">Represents expiration period of warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_ExpirationPeriodOfWarrants" xlink:to="lab_4LH329J9K15K_nmus_ExpirationPeriodOfWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_SubsequentEventTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_SubsequentEventTable" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_SubsequentEventTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_2JF107H7I93I_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="lab_4LH329J9K15K_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_2JF107H7I93I_us-gaap_ConvertiblePreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_ConvertiblePreferredStockMember" xml:lang="en-US">Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_ConvertiblePreferredStockMember" xml:lang="en-US">Convertible preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_4LH329J9K15K_us-gaap_ConvertiblePreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_SeriesCPreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_SeriesCPreferredStockMember" xml:lang="en-US">Series C Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_SeriesCPreferredStockMember" xml:lang="en-US">Series C preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_SeriesCPreferredStockMember" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_SeriesCPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_SeriesCWarrantsMember" xlink:label="loc_2JF107H7I93I_nmus_SeriesCWarrantsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_SeriesCWarrantsMember" xml:lang="en-US">Series C Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4LH329J9K15K_nmus_SeriesCWarrantsMember" xml:lang="en-US">Series C warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_SeriesCWarrantsMember" xlink:to="lab_4LH329J9K15K_nmus_SeriesCWarrantsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_2JF107H7I93I_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_4LH329J9K15K_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_LicenseAgreementTermsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_LicenseAgreementTermsMember" xml:lang="en-US">License Agreement Terms [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_LicenseAgreementTermsMember" xml:lang="en-US">Technology license agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_LicenseAgreementTermsMember" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_LicenseAgreementTermsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_2JF107H7I93I_us-gaap_SubsequentEventLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_SubsequentEventLineItems" xlink:to="lab_4LH329J9K15K_us-gaap_SubsequentEventLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Number of shares sold</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_2JF107H7I93I_us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4LH329J9K15K_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Gross proceeds received</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_4LH329J9K15K_us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xml:lang="en-US">Each share of preferred stock convertible into</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_CoversionPriceOfCovertibleSecurities" xlink:label="loc_2JF107H7I93I_nmus_CoversionPriceOfCovertibleSecurities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_CoversionPriceOfCovertibleSecurities" xml:lang="en-US">Conversion Price Of Convertible Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4LH329J9K15K_nmus_CoversionPriceOfCovertibleSecurities" xml:lang="en-US">Conversion price, per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_CoversionPriceOfCovertibleSecurities" xml:lang="en-US">Represents per share value of each convertible security.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_CoversionPriceOfCovertibleSecurities" xlink:to="lab_4LH329J9K15K_nmus_CoversionPriceOfCovertibleSecurities"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ReductionInConversionPrice" xlink:label="loc_31290F3J262G9III3F2F_nmus_ReductionInConversionPrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_ReductionInConversionPrice" xml:lang="en-US">Reduction In Conversion Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_ReductionInConversionPrice" xml:lang="en-US">Reduction in conversion price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_53412H5L484I1KKK5H4H_nmus_ReductionInConversionPrice" xml:lang="en-US">Represents reduction in conversion price due to other series of shares transaction.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_nmus_ReductionInConversionPrice" xlink:to="lab_53412H5L484I1KKK5H4H_nmus_ReductionInConversionPrice"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ReductionInExcercisePrice" xlink:label="loc_2JF107H7I93I_nmus_ReductionInExcercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4LH329J9K15K_nmus_ReductionInExcercisePrice" xml:lang="en-US">Reduction In Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4LH329J9K15K_nmus_ReductionInExcercisePrice" xml:lang="en-US">Reduction in exercise price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4LH329J9K15K_nmus_ReductionInExcercisePrice" xml:lang="en-US">Represents reduction in exercise price due to other series of shares transaction.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2JF107H7I93I_nmus_ReductionInExcercisePrice" xlink:to="lab_4LH329J9K15K_nmus_ReductionInExcercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_31290F3J262G9III3F2F_us-gaap_PaymentsToAcquireIntangibleAssets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_PaymentsToAcquireIntangibleAssets" xml:lang="en-US">Payments to Acquire Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_53412H5L484I1KKK5H4H_us-gaap_PaymentsToAcquireIntangibleAssets" xml:lang="en-US">Intial payment to license agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_31290F3J262G9III3F2F_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_53412H5L484I1KKK5H4H_us-gaap_PaymentsToAcquireIntangibleAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
<label xlink:type="resource" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
<label xlink:type="resource" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain"/>
<label xlink:type="resource" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
<label xlink:type="resource" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
</labelLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>nmus-20160930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.6.0.0 on Wednesday, November 09, 2016 01:08:12 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="nmus-20160930.xsd#DocumentAndEntityInformation" roleURI="http://www.nemusbioscience.com/role/DocumentAndEntityInformation"/>
<roleRef xlink:type="simple" xlink:href="nmus-20160930.xsd#ConsolidatedBalanceSheets" roleURI="http://www.nemusbioscience.com/role/ConsolidatedBalanceSheets"/>
<roleRef xlink:type="simple" xlink:href="nmus-20160930.xsd#Consolidatedbalancesheetsparentheticals" roleURI="http://www.nemusbioscience.com/role/Consolidatedbalancesheetsparentheticals"/>
<roleRef xlink:type="simple" xlink:href="nmus-20160930.xsd#ConsolidatedStatementsOfOperationsUnaudited" roleURI="http://www.nemusbioscience.com/role/ConsolidatedStatementsOfOperationsUnaudited"/>
<roleRef xlink:type="simple" xlink:href="nmus-20160930.xsd#ConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.nemusbioscience.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"/>
<roleRef xlink:type="simple" xlink:href="nmus-20160930.xsd#ConsolidatedStatementsOfCashFlowsUnauditedParentheticals" roleURI="http://www.nemusbioscience.com/role/ConsolidatedStatementsOfCashFlowsUnauditedParentheticals"/>
<roleRef xlink:type="simple" xlink:href="nmus-20160930.xsd#NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPolicies"/>
<roleRef xlink:type="simple" roleURI="http://www.nemusbioscience.com/role/UniversityOfMississippiAgreements" xlink:href="nmus-20160930.xsd#UniversityOfMississippiAgreements"/>
<roleRef xlink:type="simple" xlink:href="nmus-20160930.xsd#COMMITMENTSANDCONTINGENCIES" roleURI="http://www.nemusbioscience.com/role/COMMITMENTSANDCONTINGENCIES"/>
<roleRef xlink:type="simple" xlink:href="nmus-20160930.xsd#StockholdersDeficitAndPreferredStockSubjectToRedemption" roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemption"/>
<roleRef xlink:type="simple" xlink:href="nmus-20160930.xsd#ProvisionForConversionOfPreferredStock" roleURI="http://www.nemusbioscience.com/role/ProvisionForConversionOfPreferredStock"/>
<roleRef xlink:type="simple" xlink:href="nmus-20160930.xsd#SeriesBWarrants" roleURI="http://www.nemusbioscience.com/role/SeriesBWarrants"/>
<roleRef xlink:type="simple" xlink:href="nmus-20160930.xsd#IncomeTaxes" roleURI="http://www.nemusbioscience.com/role/IncomeTaxes"/>
<roleRef xlink:type="simple" xlink:href="nmus-20160930.xsd#SubsequentEvents" roleURI="http://www.nemusbioscience.com/role/SubsequentEvents"/>
<roleRef xlink:type="simple" xlink:href="nmus-20160930.xsd#NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesPolicies"/>
<roleRef xlink:type="simple" xlink:href="nmus-20160930.xsd#CommitmentsandContingenciesTables" roleURI="http://www.nemusbioscience.com/role/CommitmentsandContingenciesTables"/>
<roleRef xlink:type="simple" roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockTables" xlink:href="nmus-20160930.xsd#StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockTables"/>
<roleRef xlink:type="simple" xlink:href="nmus-20160930.xsd#SeriesBWarrantsTables" roleURI="http://www.nemusbioscience.com/role/SeriesBWarrantsTables"/>
<roleRef xlink:type="simple" xlink:href="nmus-20160930.xsd#NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesDetailTextuals" roleURI="http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesDetailTextuals"/>
<roleRef xlink:type="simple" roleURI="http://www.nemusbioscience.com/role/UniversityOfMississippiAgreementsDetailTextuals" xlink:href="nmus-20160930.xsd#UniversityOfMississippiAgreementsDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="nmus-20160930.xsd#CommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsDetails" roleURI="http://www.nemusbioscience.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsDetails"/>
<roleRef xlink:type="simple" xlink:href="nmus-20160930.xsd#CommitmentsAndContingenciesDetailTextuals" roleURI="http://www.nemusbioscience.com/role/CommitmentsAndContingenciesDetailTextuals"/>
<roleRef xlink:type="simple" roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockSummaryOfOptionActivityUnder2014PlanDetails" xlink:href="nmus-20160930.xsd#StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockSummaryOfOptionActivityUnder2014PlanDetails"/>
<roleRef xlink:type="simple" roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockSummaryOfWeightedAverageAssumptionsForEmployeeOptionDetails1" xlink:href="nmus-20160930.xsd#StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockSummaryOfWeightedAverageAssumptionsForEmployeeOptionDetails1"/>
<roleRef xlink:type="simple" roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockDetailTextuals" xlink:href="nmus-20160930.xsd#StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockDetailTextuals"/>
<roleRef xlink:type="simple" roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockDetailTextuals1" xlink:href="nmus-20160930.xsd#StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockDetailTextuals1"/>
<roleRef xlink:type="simple" xlink:href="nmus-20160930.xsd#ProvisionForConversionOfPreferredStockDetailTextuals" roleURI="http://www.nemusbioscience.com/role/ProvisionForConversionOfPreferredStockDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="nmus-20160930.xsd#SeriesBWarrantsDetails" roleURI="http://www.nemusbioscience.com/role/SeriesBWarrantsDetails"/>
<roleRef xlink:type="simple" xlink:href="nmus-20160930.xsd#SeriesBWarrantsDetailTextuals" roleURI="http://www.nemusbioscience.com/role/SeriesBWarrantsDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="nmus-20160930.xsd#SubsequentEventsDetailTextuals" roleURI="http://www.nemusbioscience.com/role/SubsequentEventsDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/DocumentAndEntityInformation">
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_DocumentAndEntityInformationAbstract" xlink:label="loc_nmus_DocumentAndEntityInformationAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityRegistrantName_1" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCentralIndexKey_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_TradingSymbol_3" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_4" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityFilerCategory_5" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_6" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentType_7" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentPeriodEndDate_8" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_AmendmentFlag_9" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalYearFocus_10" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_11" order="100" use="optional"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_AssetsAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_OtherAssetsCurrent_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_AssetsCurrent_7" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaap_OtherAssetsAbstract_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_OtherAssetsAbstract_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_DepositsAndOtherAssets" xlink:label="loc_nmus_DepositsAndOtherAssets_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_9" xlink:to="loc_nmus_DepositsAndOtherAssets_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_9" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_Assets_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14" xlink:to="loc_us-gaap_AccountsPayableCurrent_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14" xlink:to="loc_us-gaap_AccruedSalariesCurrent_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_AccruedLicenseAndPatentReimbursementFees" xlink:label="loc_nmus_AccruedLicenseAndPatentReimbursementFees_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14" xlink:to="loc_nmus_AccruedLicenseAndPatentReimbursementFees_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_18" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ProvisionForConversionOfPreferredStock" xlink:label="loc_nmus_ProvisionForConversionOfPreferredStock_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14" xlink:to="loc_nmus_ProvisionForConversionOfPreferredStock_19" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14" xlink:to="loc_us-gaap_LiabilitiesCurrent_20" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_21" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_21" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_21" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_23" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_21" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_24" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_Liabilities_25" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_CommitmentsAndContingencies_26" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_27" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_StockholdersEquityAbstract_28" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_CommonStockValue_29" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_30" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_31" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_32" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_StockholdersEquity_33" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_34" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/Consolidatedbalancesheetsparentheticals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_StockIssuanceCosts" xlink:label="loc_nmus_StockIssuanceCosts_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_nmus_StockIssuanceCosts_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/ConsolidatedStatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_OperatingExpensesAbstract_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_us-gaap_OperatingExpenses_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_OperatingIncomeLoss_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ChangeInFairValueOfWarrantLiability" xlink:label="loc_nmus_ChangeInFairValueOfWarrantLiability_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_12" xlink:to="loc_nmus_ChangeInFairValueOfWarrantLiability_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_GainLossOnConversionRightPreferredStock" xlink:label="loc_nmus_GainLossOnConversionRightPreferredStock_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_12" xlink:to="loc_nmus_GainLossOnConversionRightPreferredStock_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_16" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_NetIncomeLoss_17" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_18" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_19" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/ConsolidatedStatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7" xlink:to="loc_us-gaap_NetIncomeLoss_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9" xlink:to="loc_us-gaap_Depreciation_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9" xlink:to="loc_us-gaap_ShareBasedCompensation_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_GainLossOnConversionRightPreferredStock" xlink:label="loc_nmus_GainLossOnConversionRightPreferredStock_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9" xlink:to="loc_nmus_GainLossOnConversionRightPreferredStock_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ChangeInFairValueOfWarrantLiability" xlink:label="loc_nmus_ChangeInFairValueOfWarrantLiability_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9" xlink:to="loc_nmus_ChangeInFairValueOfWarrantLiability_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_15" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseInRestrictedCash" xlink:label="loc_us-gaap_IncreaseInRestrictedCash_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_15" xlink:to="loc_us-gaap_IncreaseInRestrictedCash_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_15" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_15" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_18" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_15" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_19" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_15" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_20" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees" xlink:label="loc_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_15" xlink:to="loc_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees_21" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_IncreaseDecreaseInStockSubscriptionLiability" xlink:label="loc_nmus_IncreaseDecreaseInStockSubscriptionLiability_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_15" xlink:to="loc_nmus_IncreaseDecreaseInStockSubscriptionLiability_22" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_15" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_23" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_24" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_25" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_25" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_26" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_25" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_27" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_28" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_28" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_29" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_28" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_30" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_28" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_31" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_32" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_33" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_34" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_35" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_CashPaidDuringPeriodForAbstract" xlink:label="loc_nmus_CashPaidDuringPeriodForAbstract_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_35" xlink:to="loc_nmus_CashPaidDuringPeriodForAbstract_36" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_CashPaidDuringPeriodForAbstract_36" xlink:to="loc_us-gaap_InterestPaid_37" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_38"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_CashPaidDuringPeriodForAbstract_36" xlink:to="loc_us-gaap_IncomeTaxesPaid_38" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/ConsolidatedStatementsOfCashFlowsUnauditedParentheticals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_CommonStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_NoncashValueOfWarrantsIssued" xlink:label="loc_nmus_NoncashValueOfWarrantsIssued_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_nmus_NoncashValueOfWarrantsIssued_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssued1_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_NoncashValueOfWarrantsIssuedInExchangeForExtinguishmentOfTradeAccountsPayable" xlink:label="loc_nmus_NoncashValueOfWarrantsIssuedInExchangeForExtinguishmentOfTradeAccountsPayable_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_nmus_NoncashValueOfWarrantsIssuedInExchangeForExtinguishmentOfTradeAccountsPayable_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/UniversityOfMississippiAgreements">
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_UniversityOfMississippiAgreementsAbstract" xlink:label="loc_nmus_UniversityOfMississippiAgreementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_UniversityOfMississippiAgreementsTextBlock" xlink:label="loc_nmus_UniversityOfMississippiAgreementsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsAbstract_0" xlink:to="loc_nmus_UniversityOfMississippiAgreementsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/COMMITMENTSANDCONTINGENCIES">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemption">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/ProvisionForConversionOfPreferredStock">
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ProvisionForConversionOfPreferredStockAbstract" xlink:label="loc_nmus_ProvisionForConversionOfPreferredStockAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="loc_us-gaap_PreferredStockTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_ProvisionForConversionOfPreferredStockAbstract_0" xlink:to="loc_us-gaap_PreferredStockTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/SeriesBWarrants">
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_SeriesBWarrantsAbstract" xlink:label="loc_nmus_SeriesBWarrantsAbstract_0"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_SeriesBWarrantsTextBlock" xlink:label="loc_nmus_SeriesBWarrantsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_SeriesBWarrantsAbstract_0" xlink:to="loc_nmus_SeriesBWarrantsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_UseOfEstimates_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_LiquidityAndGoingConcernPolicyTextBlock" xlink:label="loc_nmus_LiquidityAndGoingConcernPolicyTextBlock_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_nmus_LiquidityAndGoingConcernPolicyTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock" xlink:label="loc_nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_13" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_14" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_15" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/CommitmentsandContingenciesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/SeriesBWarrantsTables">
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_SeriesBWarrantsAbstract" xlink:label="loc_nmus_SeriesBWarrantsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_SeriesBWarrantsAbstract_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_NemusAcquisitionCorpMember" xlink:label="loc_nmus_NemusAcquisitionCorpMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" xlink:to="loc_nmus_NemusAcquisitionCorpMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6" xlink:to="loc_us-gaap_SubsequentEventMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_StockIssuedDuringPeriodSharesReverseMerger" xlink:label="loc_nmus_StockIssuedDuringPeriodSharesReverseMerger_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_8" xlink:to="loc_nmus_StockIssuedDuringPeriodSharesReverseMerger_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_NumberOfSharesExchanged" xlink:label="loc_nmus_NumberOfSharesExchanged_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_8" xlink:to="loc_nmus_NumberOfSharesExchanged_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_8" xlink:to="loc_us-gaap_AdditionalPaidInCapital_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_8" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_14" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_15" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDepreciationMethods_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDepreciationMethods_16" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_17" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_8" xlink:to="loc_us-gaap_NumberOfReportableSegments_18" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>


</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/UniversityOfMississippiAgreementsDetailTextuals">
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_UniversityOfMississippiAgreementsAbstract" xlink:label="loc_nmus_UniversityOfMississippiAgreementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_UniversityOfMississippiAgreementsTable" xlink:label="loc_nmus_UniversityOfMississippiAgreementsTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsAbstract_0" xlink:to="loc_nmus_UniversityOfMississippiAgreementsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_AgreementAxis" xlink:label="loc_nmus_AgreementAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_nmus_AgreementAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_AgreementDomain" xlink:label="loc_nmus_AgreementDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_AgreementAxis_2" xlink:to="loc_nmus_AgreementDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_UniversityOfMississippiAgreementsMember" xlink:label="loc_nmus_UniversityOfMississippiAgreementsMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_AgreementDomain_3" xlink:to="loc_nmus_UniversityOfMississippiAgreementsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_OptionAgreementMember" xlink:label="loc_nmus_OptionAgreementMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_AgreementDomain_3" xlink:to="loc_nmus_OptionAgreementMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_LicenseAgreementMember" xlink:label="loc_nmus_LicenseAgreementMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_AgreementDomain_3" xlink:to="loc_nmus_LicenseAgreementMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_dei_LegalEntityAxis_7" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_7" xlink:to="loc_dei_EntityDomain_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_UniversityOfMississippiMember" xlink:label="loc_nmus_UniversityOfMississippiMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_8" xlink:to="loc_nmus_UniversityOfMississippiMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_10" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_11" xlink:to="loc_us-gaap_IntellectualPropertyMember_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_MonthAndYearOfAgreementAxis" xlink:label="loc_nmus_MonthAndYearOfAgreementAxis_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_nmus_MonthAndYearOfAgreementAxis_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_MonthAndYearOfAgreementDomain" xlink:label="loc_nmus_MonthAndYearOfAgreementDomain_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_MonthAndYearOfAgreementAxis_13" xlink:to="loc_nmus_MonthAndYearOfAgreementDomain_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_OctoberTwoThousandFifteenMember" xlink:label="loc_nmus_OctoberTwoThousandFifteenMember_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_MonthAndYearOfAgreementDomain_14" xlink:to="loc_nmus_OctoberTwoThousandFifteenMember_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_December2015Member" xlink:label="loc_nmus_December2015Member_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_MonthAndYearOfAgreementDomain_14" xlink:to="loc_nmus_December2015Member_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_UniversityOfMississippiAgreementsLineItems" xlink:label="loc_nmus_UniversityOfMississippiAgreementsLineItems_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_nmus_UniversityOfMississippiAgreementsLineItems_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_TermOfMemorandumOfUnderstandingAgreement" xlink:label="loc_nmus_TermOfMemorandumOfUnderstandingAgreement_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_17" xlink:to="loc_nmus_TermOfMemorandumOfUnderstandingAgreement_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_NumberOfLicenseAgreements" xlink:label="loc_nmus_NumberOfLicenseAgreements_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_17" xlink:to="loc_nmus_NumberOfLicenseAgreements_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_NoticePeriodForTermination" xlink:label="loc_nmus_NoticePeriodForTermination_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_17" xlink:to="loc_nmus_NoticePeriodForTermination_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_OneTimeUpfrontPayment" xlink:label="loc_nmus_OneTimeUpfrontPayment_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_17" xlink:to="loc_nmus_OneTimeUpfrontPayment_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_AnnualFeesForLicenseAgreement" xlink:label="loc_nmus_AnnualFeesForLicenseAgreement_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_17" xlink:to="loc_nmus_AnnualFeesForLicenseAgreement_22" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_AggregateMilestonePaymentsIfMilestonesAchieved" xlink:label="loc_nmus_AggregateMilestonePaymentsIfMilestonesAchieved_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_17" xlink:to="loc_nmus_AggregateMilestonePaymentsIfMilestonesAchieved_23" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_OptionPaymentDueAndPayable" xlink:label="loc_nmus_OptionPaymentDueAndPayable_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_17" xlink:to="loc_nmus_OptionPaymentDueAndPayable_24" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/CommitmentsAndContingenciesDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_AgreementAxis" xlink:label="loc_nmus_AgreementAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" xlink:to="loc_nmus_AgreementAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_AgreementDomain" xlink:label="loc_nmus_AgreementDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_AgreementAxis_2" xlink:to="loc_nmus_AgreementDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_LeaseAgreementMember" xlink:label="loc_nmus_LeaseAgreementMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_AgreementDomain_3" xlink:to="loc_nmus_LeaseAgreementMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_LetterAgreementMember" xlink:label="loc_nmus_LetterAgreementMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_AgreementDomain_3" xlink:to="loc_nmus_LetterAgreementMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" xlink:to="loc_dei_LegalEntityAxis_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_6" xlink:to="loc_dei_EntityDomain_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ContractManufacturingOrganizationMember" xlink:label="loc_nmus_ContractManufacturingOrganizationMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_7" xlink:to="loc_nmus_ContractManufacturingOrganizationMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" xlink:to="loc_us-gaap_RangeAxis_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_9" xlink:to="loc_us-gaap_RangeMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_10" xlink:to="loc_us-gaap_MinimumMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_10" xlink:to="loc_us-gaap_MaximumMember_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaap_AreaOfLand_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_13" xlink:to="loc_us-gaap_AreaOfLand_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_13" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_13" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_FeesAndExpensesForServicesProvided" xlink:label="loc_nmus_FeesAndExpensesForServicesProvided_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_13" xlink:to="loc_nmus_FeesAndExpensesForServicesProvided_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_AnalyticalMethodDevelopmentAndQualificationExpense" xlink:label="loc_nmus_AnalyticalMethodDevelopmentAndQualificationExpense_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_13" xlink:to="loc_nmus_AnalyticalMethodDevelopmentAndQualificationExpense_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockSummaryOfOptionActivityUnder2014PlanDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_RestrictedStockMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_6" xlink:to="loc_us-gaap_PlanNameDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_OmnibusIncentivePlan2014Member" xlink:label="loc_nmus_OmnibusIncentivePlan2014Member_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7" xlink:to="loc_nmus_OmnibusIncentivePlan2014Member_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_9" xlink:to="loc_us-gaap_RangeMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_10" xlink:to="loc_us-gaap_MinimumMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_10" xlink:to="loc_us-gaap_MaximumMember_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_SharesAvailableForGrantOfOptionsRollForward" xlink:label="loc_nmus_SharesAvailableForGrantOfOptionsRollForward_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13" xlink:to="loc_nmus_SharesAvailableForGrantOfOptionsRollForward_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_SharesAvailableForGrantOfOptionsOpeningBalance" xlink:label="loc_nmus_SharesAvailableForGrantOfOptionsOpeningBalance_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_SharesAvailableForGrantOfOptionsRollForward_14" xlink:to="loc_nmus_SharesAvailableForGrantOfOptionsOpeningBalance_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_SharesAvailableForGrantOptionsGranted" xlink:label="loc_nmus_SharesAvailableForGrantOptionsGranted_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_SharesAvailableForGrantOfOptionsRollForward_14" xlink:to="loc_nmus_SharesAvailableForGrantOptionsGranted_16" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_SharesAvailableForGrantOptionsExercised" xlink:label="loc_nmus_SharesAvailableForGrantOptionsExercised_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_SharesAvailableForGrantOfOptionsRollForward_14" xlink:to="loc_nmus_SharesAvailableForGrantOptionsExercised_17" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_SharesAvailableForGrantOptionsCancelled" xlink:label="loc_nmus_SharesAvailableForGrantOptionsCancelled_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_SharesAvailableForGrantOfOptionsRollForward_14" xlink:to="loc_nmus_SharesAvailableForGrantOptionsCancelled_18" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_SharesAvailableForGrantOptionsExcludingRestrictedstock" xlink:label="loc_nmus_SharesAvailableForGrantOptionsExcludingRestrictedstock_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_SharesAvailableForGrantOfOptionsRollForward_14" xlink:to="loc_nmus_SharesAvailableForGrantOptionsExcludingRestrictedstock_19" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_SharesAvailableForGrantOfOptionsRollForward_14" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_SharesAvailableForGrantOfOptionsOpeningBalance" xlink:label="loc_nmus_SharesAvailableForGrantOfOptionsOpeningBalance_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_SharesAvailableForGrantOfOptionsRollForward_14" xlink:to="loc_nmus_SharesAvailableForGrantOfOptionsOpeningBalance_21" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_23" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_24" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_22" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_25" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_26" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_27" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_OptionsOutstandingPricePerShareRollForward" xlink:label="loc_nmus_OptionsOutstandingPricePerShareRollForward_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13" xlink:to="loc_nmus_OptionsOutstandingPricePerShareRollForward_28" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_OptionsOutstandingPricePerShareOpeningBalance" xlink:label="loc_nmus_OptionsOutstandingPricePerShareOpeningBalance_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_OptionsOutstandingPricePerShareRollForward_28" xlink:to="loc_nmus_OptionsOutstandingPricePerShareOpeningBalance_29" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_OptionsOutstandingPricePerShareOptionsGranted" xlink:label="loc_nmus_OptionsOutstandingPricePerShareOptionsGranted_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_OptionsOutstandingPricePerShareRollForward_28" xlink:to="loc_nmus_OptionsOutstandingPricePerShareOptionsGranted_30" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_OptionsOutstandingPricePerShareOptionsExercised" xlink:label="loc_nmus_OptionsOutstandingPricePerShareOptionsExercised_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_OptionsOutstandingPricePerShareRollForward_28" xlink:to="loc_nmus_OptionsOutstandingPricePerShareOptionsExercised_31" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_OptionsOutstandingPricePerShareOptionsCancelled" xlink:label="loc_nmus_OptionsOutstandingPricePerShareOptionsCancelled_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_OptionsOutstandingPricePerShareRollForward_28" xlink:to="loc_nmus_OptionsOutstandingPricePerShareOptionsCancelled_32" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_OptionsOutstandingPricePerShareOpeningBalance" xlink:label="loc_nmus_OptionsOutstandingPricePerShareOpeningBalance_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_OptionsOutstandingPricePerShareRollForward_28" xlink:to="loc_nmus_OptionsOutstandingPricePerShareOpeningBalance_33" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_34" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_35" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_36" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_37" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_38"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_38" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_39"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_39" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockSummaryOfWeightedAverageAssumptionsForEmployeeOptionDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MinimumMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MaximumMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_EquityTable" xlink:label="loc_nmus_EquityTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_nmus_EquityTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_AgreementAxis" xlink:label="loc_nmus_AgreementAxis_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_nmus_AgreementAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_AgreementDomain" xlink:label="loc_nmus_AgreementDomain_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_AgreementAxis_6" xlink:to="loc_nmus_AgreementDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_StockPurchaseAgreementJune2014Member" xlink:label="loc_nmus_StockPurchaseAgreementJune2014Member_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_AgreementDomain_7" xlink:to="loc_nmus_StockPurchaseAgreementJune2014Member_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_10" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_12" xlink:to="loc_us-gaap_ClassOfStockDomain_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_13" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_13" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_EquityLineItems" xlink:label="loc_nmus_EquityLineItems_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_nmus_EquityLineItems_16" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_16" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_16" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_TermOfWarrant" xlink:label="loc_nmus_TermOfWarrant_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_16" xlink:to="loc_nmus_TermOfWarrant_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_NumberOfAdvisors" xlink:label="loc_nmus_NumberOfAdvisors_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_16" xlink:to="loc_nmus_NumberOfAdvisors_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ValueOfCommonStockCalledByWarrants" xlink:label="loc_nmus_ValueOfCommonStockCalledByWarrants_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_16" xlink:to="loc_nmus_ValueOfCommonStockCalledByWarrants_21" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_AmortizationOfWarrantServiceCost" xlink:label="loc_nmus_AmortizationOfWarrantServiceCost_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_16" xlink:to="loc_nmus_AmortizationOfWarrantServiceCost_22" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_16" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_23" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_AmortizationOfGeneralAndAdministrativeExpenses" xlink:label="loc_nmus_AmortizationOfGeneralAndAdministrativeExpenses_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_16" xlink:to="loc_nmus_AmortizationOfGeneralAndAdministrativeExpenses_24" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_16" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_25" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" xlink:label="loc_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_16" xlink:to="loc_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants_26" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_16" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_27" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_16" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_28" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_16" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_29" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ValueOfWarrantsIssued" xlink:label="loc_nmus_ValueOfWarrantsIssued_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_16" xlink:to="loc_nmus_ValueOfWarrantsIssued_30" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_NumberOfInvestor" xlink:label="loc_nmus_NumberOfInvestor_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_16" xlink:to="loc_nmus_NumberOfInvestor_31" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_16" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_32" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_33" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_16" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_34" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_16" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_35" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_MinimumIssuanceOfSharesInEquityFinancing" xlink:label="loc_nmus_MinimumIssuanceOfSharesInEquityFinancing_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_16" xlink:to="loc_nmus_MinimumIssuanceOfSharesInEquityFinancing_36" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_MaximumIssuancePricePerShareInEquityFinancing" xlink:label="loc_nmus_MaximumIssuancePricePerShareInEquityFinancing_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_16" xlink:to="loc_nmus_MaximumIssuancePricePerShareInEquityFinancing_37" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ConversionPrice" xlink:label="loc_nmus_ConversionPrice_38"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_16" xlink:to="loc_nmus_ConversionPrice_38" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_39"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_16" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_39" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_40"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_16" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_40" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_41"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_16" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_41" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_42"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_16" xlink:to="loc_us-gaap_SharePrice_42" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockRedemptionTerms" xlink:label="loc_us-gaap_PreferredStockRedemptionTerms_43"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_16" xlink:to="loc_us-gaap_PreferredStockRedemptionTerms_43" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="loc_us-gaap_PreferredStockConversionBasis_44"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_16" xlink:to="loc_us-gaap_PreferredStockConversionBasis_44" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue_45"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_16" xlink:to="loc_us-gaap_PreferredStockLiquidationPreferenceValue_45" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockDetailTextuals1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_EquityTable" xlink:label="loc_nmus_EquityTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_nmus_EquityTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_PlanNameAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_2" xlink:to="loc_us-gaap_PlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_OmnibusIncentivePlan2014Member" xlink:label="loc_nmus_OmnibusIncentivePlan2014Member_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3" xlink:to="loc_nmus_OmnibusIncentivePlan2014Member_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6" xlink:to="loc_us-gaap_RestrictedStockMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_RangeAxis_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_9" xlink:to="loc_us-gaap_RangeMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_10" xlink:to="loc_us-gaap_MinimumMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_10" xlink:to="loc_us-gaap_MaximumMember_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_13" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_14" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_16" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_16" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ManagementAndBoardOfDirectorsMember" xlink:label="loc_nmus_ManagementAndBoardOfDirectorsMember_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_17" xlink:to="loc_nmus_ManagementAndBoardOfDirectorsMember_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_EquityLineItems" xlink:label="loc_nmus_EquityLineItems_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_nmus_EquityLineItems_19" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_21" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_22" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_23" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants" xlink:label="loc_nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants_24" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_CommonStockVotingPercentage" xlink:label="loc_nmus_CommonStockVotingPercentage_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_nmus_CommonStockVotingPercentage_25" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_PercentageOfFairValueOptionPriceAtDateOfGrants" xlink:label="loc_nmus_PercentageOfFairValueOptionPriceAtDateOfGrants_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_nmus_PercentageOfFairValueOptionPriceAtDateOfGrants_26" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_MaximumExercisablePeriodOfFairValueOfOption" xlink:label="loc_nmus_MaximumExercisablePeriodOfFairValueOfOption_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_nmus_MaximumExercisablePeriodOfFairValueOfOption_27" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_28" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_29" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_30" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_31" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_32" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_33" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_34" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_35" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_36" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_37" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_FairMarketValueOfSharesGranted" xlink:label="loc_nmus_FairMarketValueOfSharesGranted_38"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_nmus_FairMarketValueOfSharesGranted_38" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/ProvisionForConversionOfPreferredStockDetailTextuals">
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ProvisionForConversionOfPreferredStockAbstract" xlink:label="loc_nmus_ProvisionForConversionOfPreferredStockAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockTable" xlink:label="loc_us-gaap_ConversionOfStockTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_ProvisionForConversionOfPreferredStockAbstract_0" xlink:to="loc_us-gaap_ConversionOfStockTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockLineItems" xlink:label="loc_us-gaap_ConversionOfStockLineItems_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockTable_1" xlink:to="loc_us-gaap_ConversionOfStockLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_MinimumIssuanceOfSharesInEquityFinancing" xlink:label="loc_nmus_MinimumIssuanceOfSharesInEquityFinancing_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_6" xlink:to="loc_nmus_MinimumIssuanceOfSharesInEquityFinancing_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_MaximumIssuancePricePerShareInEquityFinancing" xlink:label="loc_nmus_MaximumIssuancePricePerShareInEquityFinancing_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_6" xlink:to="loc_nmus_MaximumIssuancePricePerShareInEquityFinancing_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ProvisionForConversionOfPreferredStock" xlink:label="loc_nmus_ProvisionForConversionOfPreferredStock_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_6" xlink:to="loc_nmus_ProvisionForConversionOfPreferredStock_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_6" xlink:to="loc_us-gaap_SharesIssued_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_6" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_GainLossOnConversionRightPreferredStock" xlink:label="loc_nmus_GainLossOnConversionRightPreferredStock_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_6" xlink:to="loc_nmus_GainLossOnConversionRightPreferredStock_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_6" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_14" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ConversionPrice" xlink:label="loc_nmus_ConversionPrice_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_6" xlink:to="loc_nmus_ConversionPrice_15" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/SeriesBWarrantsDetails">
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_SeriesBWarrantsAbstract" xlink:label="loc_nmus_SeriesBWarrantsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_SeriesBWarrantsAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_SeriesBWarrantsMember" xlink:label="loc_nmus_SeriesBWarrantsMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_nmus_SeriesBWarrantsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_RangeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MinimumMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MaximumMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/SeriesBWarrantsDetailTextuals">
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_SeriesBWarrantsAbstract" xlink:label="loc_nmus_SeriesBWarrantsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_SeriesBWarrantsAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_SeriesBWarrantsMember" xlink:label="loc_nmus_SeriesBWarrantsMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_nmus_SeriesBWarrantsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_NumberOfWarrantsIssued" xlink:label="loc_nmus_NumberOfWarrantsIssued_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5" xlink:to="loc_nmus_NumberOfWarrantsIssued_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ChangeInFairValueOfWarrantLiability" xlink:label="loc_nmus_ChangeInFairValueOfWarrantLiability_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5" xlink:to="loc_nmus_ChangeInFairValueOfWarrantLiability_11" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ExpirationPeriodOfWarrants" xlink:label="loc_nmus_ExpirationPeriodOfWarrants_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5" xlink:to="loc_nmus_ExpirationPeriodOfWarrants_12" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/SubsequentEventsDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_5" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_6" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8" xlink:to="loc_us-gaap_ClassOfStockDomain_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_SeriesCWarrantsMember" xlink:label="loc_nmus_SeriesCWarrantsMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9" xlink:to="loc_nmus_SeriesCWarrantsMember_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_13" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_14" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventLineItems_16" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_16" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_16" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_16" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_16" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_CoversionPriceOfCovertibleSecurities" xlink:label="loc_nmus_CoversionPriceOfCovertibleSecurities_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_16" xlink:to="loc_nmus_CoversionPriceOfCovertibleSecurities_21" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ReductionInConversionPrice" xlink:label="loc_nmus_ReductionInConversionPrice_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_16" xlink:to="loc_nmus_ReductionInConversionPrice_22" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20160930.xsd#nmus_ReductionInExcercisePrice" xlink:label="loc_nmus_ReductionInExcercisePrice_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_16" xlink:to="loc_nmus_ReductionInExcercisePrice_23" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_16" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_24" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_16" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_25" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<roleRef xlink:type="simple" xlink:href="nmus-20160930.xsd#NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesDetailTextuals1" roleURI="http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesDetailTextuals1"/>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesDetailTextuals1"><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaap_WarrantMember" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6802480768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Nov. 08, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Nemus Bioscience, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001516551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">nmus<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,798,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6803001264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 319,930<span></span>
</td>
<td class="nump">$ 3,221,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">37,500<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">249,193<span></span>
</td>
<td class="nump">158,946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">28,626<span></span>
</td>
<td class="nump">36,126<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">635,249<span></span>
</td>
<td class="nump">3,453,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">12,994<span></span>
</td>
<td class="nump">13,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_DepositsAndOtherAssets', window );">Deposits and other assets</a></td>
<td class="nump">43,884<span></span>
</td>
<td class="nump">43,884<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total other assets</a></td>
<td class="nump">43,884<span></span>
</td>
<td class="nump">43,884<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">692,127<span></span>
</td>
<td class="nump">3,511,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">387,373<span></span>
</td>
<td class="nump">125,357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll and related expenses</a></td>
<td class="nump">71,802<span></span>
</td>
<td class="nump">46,268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_AccruedLicenseAndPatentReimbursementFees', window );">Accrued license and patent reimbursement fees</a></td>
<td class="nump">80,000<span></span>
</td>
<td class="nump">97,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">135,381<span></span>
</td>
<td class="nump">228,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ProvisionForConversionOfPreferredStock', window );">Provision for conversion of Series B preferred stock</a></td>
<td class="nump">166,718<span></span>
</td>
<td class="nump">84,090<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">841,274<span></span>
</td>
<td class="nump">581,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Series B warrants</a></td>
<td class="nump">869,990<span></span>
</td>
<td class="nump">2,454,959<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total noncurrent liabilities</a></td>
<td class="nump">869,990<span></span>
</td>
<td class="nump">2,458,192<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,711,264<span></span>
</td>
<td class="nump">3,040,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 3)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable Convertible Series B Preferred Stock, $0.001 par value, 20 million shares authorized; 4,492 issued and outstanding as of September 30, 2016 and 4,500 issued and outstanding as of December 31, 2015, net of $493,770 of issuance costs; $4.5 million liquidation preference as of September 30, 2016</a></td>
<td class="nump">1,359,899<span></span>
</td>
<td class="nump">1,363,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 236 million shares authorized; 19,913,163 issued and outstanding as of September 30, 2016 and 19,903,163 issued and outstanding as of December 31, 2015</a></td>
<td class="nump">19,913<span></span>
</td>
<td class="nump">19,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in-capital</a></td>
<td class="nump">6,635,345<span></span>
</td>
<td class="nump">6,086,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants</a></td>
<td class="nump">781,811<span></span>
</td>
<td class="nump">759,386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(9,816,105)<span></span>
</td>
<td class="num">(7,758,480)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="num">(2,379,036)<span></span>
</td>
<td class="num">(892,204)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' deficit</a></td>
<td class="nump">$ 692,127<span></span>
</td>
<td class="nump">$ 3,511,048<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_AccruedLicenseAndPatentReimbursementFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents carrying value as of the balance sheet date of obligations incurred through that date and payable for accrued license and patent reimbursement fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_AccruedLicenseAndPatentReimbursementFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_DepositsAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents aggregate carrying amount, as of the balance sheet date, of deposits and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_DepositsAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ProvisionForConversionOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount related to provision for conversion of preferred stock as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ProvisionForConversionOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13495-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Assets<br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6789987744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Redeemable Convertible Series B Preferred Stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Redeemable Convertible Series B Preferred Stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable Convertible Series B Preferred Stock, shares issued</a></td>
<td class="nump">4,492<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable Convertible Series B Preferred Stock, shares outstanding</a></td>
<td class="nump">4,492<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_StockIssuanceCosts', window );">Redeemable Convertible Series B Preferred Stock, issuance costs</a></td>
<td class="nump">$ 493,770<span></span>
</td>
<td class="nump">$ 493,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Redeemable Convertible Series B Preferred Stock, liquidation preference value</a></td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">236,000,000<span></span>
</td>
<td class="nump">236,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">19,913,163<span></span>
</td>
<td class="nump">19,903,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">19,913,163<span></span>
</td>
<td class="nump">19,903,163<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_StockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of stock issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_StockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6802992784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 80,525<span></span>
</td>
<td class="nump">$ 152,288<span></span>
</td>
<td class="nump">$ 675,840<span></span>
</td>
<td class="nump">$ 232,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">775,623<span></span>
</td>
<td class="nump">744,004<span></span>
</td>
<td class="nump">2,882,682<span></span>
</td>
<td class="nump">2,929,799<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">856,148<span></span>
</td>
<td class="nump">896,292<span></span>
</td>
<td class="nump">3,558,522<span></span>
</td>
<td class="nump">3,162,661<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(856,148)<span></span>
</td>
<td class="num">(896,292)<span></span>
</td>
<td class="num">(3,558,522)<span></span>
</td>
<td class="num">(3,162,661)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other expense (income)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ChangeInFairValueOfWarrantLiability', window );">Change in fair value of warrant liability</a></td>
<td class="nump">27,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,584,969)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="num">(944,871)<span></span>
</td>
<td class="num">(1,182,292)<span></span>
</td>
<td class="num">(2,056,425)<span></span>
</td>
<td class="num">(4,148,661)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">1,316<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (945,271)<span></span>
</td>
<td class="num">$ (1,182,792)<span></span>
</td>
<td class="num">$ (2,057,625)<span></span>
</td>
<td class="num">$ (4,149,977)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted loss per common share (in dollars per share)</a></td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares used in computing basic and diluted loss per share (in shares)</a></td>
<td class="nump">19,913,163<span></span>
</td>
<td class="nump">17,062,366<span></span>
</td>
<td class="nump">19,910,426<span></span>
</td>
<td class="nump">16,519,854<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other expense (income)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_GainLossOnConversionRightPreferredStock', window );">Change in fair value of conversion rights of preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 286,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 986,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other expense (income)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_GainLossOnConversionRightPreferredStock', window );">Change in fair value of conversion rights of preferred stock</a></td>
<td class="nump">$ 61,058<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 82,872<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ChangeInFairValueOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount related to change in fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ChangeInFairValueOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_GainLossOnConversionRightPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount related to gain or loss on conversion right of preferred stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_GainLossOnConversionRightPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6795778144">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (2,057,625)<span></span>
</td>
<td class="num">$ (4,149,977)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,505<span></span>
</td>
<td class="nump">7,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">544,823<span></span>
</td>
<td class="nump">263,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of warrants and stock issued for services</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">51,539<span></span>
</td>
<td class="nump">529,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ChangeInFairValueOfWarrantLiability', window );">Change in fair value of warrant liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,584,969)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseInRestrictedCash', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(37,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(119,361)<span></span>
</td>
<td class="nump">25,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,500<span></span>
</td>
<td class="nump">5,470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">262,016<span></span>
</td>
<td class="num">(267,264)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued payroll and related expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,534<span></span>
</td>
<td class="nump">99,157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees', window );">Accrued license and patent reimbursement fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(17,500)<span></span>
</td>
<td class="num">(29,212)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_IncreaseDecreaseInStockSubscriptionLiability', window );">Stock subscription liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(96,497)<span></span>
</td>
<td class="nump">52,899<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,890,163)<span></span>
</td>
<td class="num">(2,614,336)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(11,116)<span></span>
</td>
<td class="num">(1,982)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(11,116)<span></span>
</td>
<td class="num">(1,982)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock issuance, net of $3,920 issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">721,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from preferred stock issuance, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">6,751,710<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,901,279)<span></span>
</td>
<td class="nump">4,135,392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,221,209<span></span>
</td>
<td class="nump">207,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">319,930<span></span>
</td>
<td class="nump">4,342,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_CashPaidDuringPeriodForAbstract', window );"><strong>Cash paid during the period for:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_GainLossOnConversionRightPreferredStock', window );">Change in fair value of conversion rights of preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">986,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from preferred stock issuance, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,442,302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_GainLossOnConversionRightPreferredStock', window );">Change in fair value of conversion rights of preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">82,872<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from preferred stock issuance, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4,588,339<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">During the nine months ended September 30, 2015, the Company issued warrants of our common stock for consulting services. The warrants were valued at $417,875 and were recorded as a Prepaid expense and are being amortized over the service period.During the nine months ended September 30, 2015, the Company also issued shares of common stock for consulting services valued at $168,000. Such amounts were recorded as a Prepaid expense and are being amortized over the service period.During the nine months ended September 30, 2016, warrants issued to service providers for consulting services were valued at $22,425 and recorded as a Prepaid expense and are being amortized over the service period.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">During the nine months ended September 30, 2015, the Company issued warrants of our common stock to a service provider in exchange for extinguishment of $10,000 of trade accounts payable owed to this vendor.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_CashPaidDuringPeriodForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_CashPaidDuringPeriodForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ChangeInFairValueOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount related to change in fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ChangeInFairValueOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_GainLossOnConversionRightPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount related to gain or loss on conversion right of preferred stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_GainLossOnConversionRightPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of increase (decrease) in accrued license and patent reimbursement fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_IncreaseDecreaseInStockSubscriptionLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of increase (decrease) in Increase Decrease in stock subscription liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_IncreaseDecreaseInStockSubscriptionLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6802758256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (Parentheticals ) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NoncashValueOfWarrantsIssued', window );">Value of warrants issued to purchase shares of common stock for consulting services</a></td>
<td class="nump">$ 22,425<span></span>
</td>
<td class="nump">$ 417,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Value of common stock issued for consulting services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NoncashValueOfWarrantsIssuedInExchangeForExtinguishmentOfTradeAccountsPayable', window );">Value of warrants issued in exchange for extinguishment of trade accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,920<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 411,661<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_NoncashValueOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents noncash value of warrants issued to purchase shares of common stock for consulting services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_NoncashValueOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_NoncashValueOfWarrantsIssuedInExchangeForExtinguishmentOfTradeAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents noncash value of warrants issued exchange for extinguishment of trade accounts payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_NoncashValueOfWarrantsIssuedInExchangeForExtinguishmentOfTradeAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6793392960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations, Business Activities and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Nature of Operations, Business Activities and Summary of Significant Accounting Policies</a></td>
<td class="text"><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b>1.&#160;Nature of Operations, Business Activities and Summary of Significant Accounting Policies</b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Nature of Operations and Basis of Presentation</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">Nemus Bioscience, Inc. is a biopharmaceutical company that plans to develop and commercialize therapeutics from cannabinoids through a partnership with the University of Mississippi. The University of Mississippi ("UM") is federally permitted and licensed to cultivate cannabis for research and commercial purposes. Unless otherwise specified, references in these Notes to the Unaudited Consolidated Financial Statements to the "Company," "we" or "our" refer to Nemus Bioscience, Inc., a Nevada corporation formerly known as Load Guard Logistics, Inc. ("LGL"), together with its wholly-owned subsidiary, Nemus, a California corporation ("Nemus"). Nemus became the wholly owned subsidiary of Nemus Bioscience, Inc. through the Merger (as defined below).</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">Nemus Bioscience, Inc. (formerly LGL) was incorporated in Nevada on March 16, 2011. Nemus was incorporated in California on July 17, 2012. Our headquarters are located in Costa Mesa, California.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">As of September 30, 2016, the Company has devoted substantially all of its efforts to securing product licenses, raising capital, and building infrastructure, and has not realized revenue from its planned principal operations.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0.5in; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Business Activities</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">On October 31, 2014, pursuant to an Agreement and Plan of Merger, dated October 17, 2014 (the "Merger Agreement"), LGL, Nemus Acquisition Corp. ("Acquisition Sub"), Nemus Bioscience, Inc. ("Name Change Merger Sub"), and Nemus Acquisition Sub merged with and into Nemus and Nemus survived as a wholly-owned subsidiary of LGL (the "Merger"). Immediately after the Merger, LGL changed its name to "Nemus Bioscience, Inc." by merging with Name Change Merger Sub. At the closing of the Merger and pursuant to the Merger Agreement, Nemus issued an aggregate of 3,120,000 shares of its common stock to the former stockholders of LGL in exchange for all of the outstanding shares of LGL's capital stock, which when combined with the 12,880,000 shares of Nemus common stock outstanding, amounted to 16,000,000 total shares outstanding upon completion of the merger.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">The Merger is being accounted for as a reverse-merger and recapitalization. Nemus is the acquirer for financial reporting purposes and LGL is the acquired company. Consequently, the assets and liabilities and the operations that will be reflected in the historical consolidated financial statements prior to the Merger will be those of Nemus and will be recorded at the historical cost basis of Nemus, and the consolidated financial statements after completion of the Merger will include the assets and liabilities of LGL and Nemus, the historical operations of Nemus and the operations of the Nemus from and after the closing date of the Merger.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0.5in; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Use of Estimates</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles ("U.S. GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of our financial statements include estimates as to the appropriate carrying value of certain assets and liabilities which are not readily apparent from other sources.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0.5in; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Liquidity and Going Concern</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">The Company has incurred operating losses and negative cash flows from operations since our inception. As of September 30, 2016, we had cash and cash equivalents of $319,930. In October 2016, we raised an additional $500,000 (see note 8) to be utilized to fund operations. The Company anticipates that it will continue to incur net losses into the foreseeable future as it continues to advance and develop a number of potential drug candidates into preclinical development activities and expands its corporate infrastructure which includes the costs associated with being a public company. Without additional funding, management believes that the Company will not have sufficient funds to meet its obligations within one year after the date the consolidated financial statements are issued. These conditions give rise to substantial doubt as to the Company's ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">The Company plans to continue to fund its operations and capital funding needs through public or private equity or debt financings, strategic collaborations, licensing arrangements, asset sales, government grants or other arrangements. However, the Company cannot be sure that such additional funds will be available on reasonable terms, or at all. If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result. If the Company is unable to secure adequate additional funding, the Company may be forced to make a reduction in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0.5in; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Cash and Cash Equivalents</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The carrying value of those investments approximates their fair market value due to their short maturity and liquidity. Cash and cash equivalents include cash on hand and amounts on deposit with financial institutions, which amounts may at times exceed federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0.5in; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Restricted Cash</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">A deposit of $37,500 as of September 30, 2016 and December 31, 2015 was restricted from withdrawal and held by a bank in the form of a certificate of deposit. This certificate serves as collateral for payment of the Company's credit cards.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 33.75pt; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Fair Value Measurements</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last is considered unobservable, is used to measure fair value:&#160;</p>
<p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<table style="text-align: justify; width: 100%; font: 10pt 'times new roman'; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0">
<tr>
<td valign="top" width="4%">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">&#160;</p>
</td>
<td valign="top" width="6%">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Level 1:</p>
</td>
<td valign="top" width="90%">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities.</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top"></td>
<td valign="top"></td>
</tr>
<tr>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">&#160;</p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Level 2:</p>
</td>
<td valign="top">
<p style="margin: 0px;">Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top"></td>
<td valign="top"></td>
</tr>
<tr>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">&#160;</p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Level 3:</p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</p>
</td>
</tr>
</table>
<p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">The carrying values of our financial instruments, including, cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses approximate their fair value due to the short maturities of these financial instruments. The Series B warrant liability and the conversion liability for the Series B preferred stock were valued utilizing Level 3 inputs primarily from a third party independent appraisal conducted as of September 30, 2016.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0.5in; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Property and Equipment, Net</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">As of September 30, 2016, property and equipment, net, was $12,994, consisting primarily of computers and equipment. The Company had $13,383 of property and equipment, net, as of December 31, 2015. Expenditures for additions, renewals and improvements will be capitalized at cost. Depreciation will generally be computed on a straight-line method based on the estimated useful life of the related assets currently ranging from two to three years. Maintenance and repairs that do not extend the life of assets are charged to expense when incurred. When properties are disposed of, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is reported in the period the transaction takes place.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount exceeds its estimated future undiscounted cash flows, an impairment charge is recognized by the amount by which the carrying amount exceeds the fair value of the asset.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">The costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, will be charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where there is an identified alternative future use. No cost associated with the use of licensed technologies has been capitalized to date.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0.5in; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Income Taxes</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">The Company accounts for our deferred income tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities, and net operating loss carry forwards (the "NOLs") and other tax credit carry forwards. These items are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period that includes the enactment date. Any interest or penalties would be recorded in the Company's statement of operations in the period incurred.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">The Company records a valuation allowance to reduce the deferred income tax assets to the amount that is more likely than not to be realized. In making such determinations, management considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. As a result, there are no income tax benefits reflected in the statement of operations to offset pre-tax losses.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">The Company recognizes a tax benefit from uncertain tax positions when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0.5in; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Revenue Recognition</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">The Company has not begun planned principal operations and has not generated any revenue since inception.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0.5in; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Research and Development Expenses</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">Research and development ("R&amp;D") costs are expensed when incurred. These costs may consist of external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants; license fees; employee-related expenses, which include salaries, benefits and stock-based compensation for the personnel involved in our preclinical and clinical drug development activities; and facilities expense, depreciation and other allocated expenses; and equipment and laboratory supplies.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0.5in; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Stock-Based Compensation Expenses</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">Stock-based compensation cost is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period. We use the Black-Scholes option pricing model for estimating the grant date fair value of stock options and warrants using the following assumptions:</p>
<p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<table style="text-align: justify; width: 100%; font: 10pt 'times new roman'; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0">
<tr>
<td width="4%">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">&#160;</p>
</td>
<td valign="top" width="4%">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Exercise price - We determined the exercise price based on valuations using the best information available to management at the time of the valuations.</p>
</td>
</tr>
<tr>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
</tr>
<tr>
<td>
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">&#160;</p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Volatility&#160;- We estimate the stock price volatility based on industry peers who are also in the early development stage given the limited market data available in the public arena.</p>
</td>
</tr>
<tr>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
</tr>
<tr>
<td>
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">&#160;</p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Expected term - The expected term is based on a simplified method which defines the life as the average of the contractual term of the options and warrants and the weighted-average vesting period for all open awards.</p>
</td>
</tr>
<tr>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
</tr>
<tr>
<td>
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">&#160;</p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Risk-free rate - The risk-free interest rate for the expected term of the option or warrant is based on the average market rate on U.S. treasury securities in effect during the period in which the awards were granted.</p>
</td>
</tr>
<tr>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
</tr>
<tr>
<td>
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">&#160;</p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Dividends - The dividend yield assumption is based on our history and expectation of paying no dividends.</p>
</td>
</tr>
</table>
<p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Stock-Based Compensation for Non-Employees</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 33.75pt; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">The Company accounts for warrants and options issued to non-employees under Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) No. 505-50,&#160;<i>Equity - Equity Based Payments to Non-Employees,</i>using the Black-Scholes option-pricing model. The value of such non-employee awards is periodically re-measured over the vesting terms and at each quarter end.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0.5in; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Segment Information</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 33.75pt; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">FASB ASC No. 280,&#160;<i>Segment Reporting</i>, establishes standards for reporting information about reportable segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group ("CODM"), in deciding how to allocate resources and in assessing performance. The CODM evaluates revenues and gross profits based on product lines and routes to market. Based on the early development stage of our operation, we operate in a single reportable segment.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Comprehensive Income (Loss)</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company is required to record all components of comprehensive income (loss) in the consolidated financial statements in the period in which they are recognized. Net income (loss) and other comprehensive income (loss), net of their related tax effect, arrived at a comprehensive income (loss). For the three and nine months ended September 30, 2016, the comprehensive income (loss) was equal to the net income (loss).</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0.5in; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Earnings per share</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-indent: 33.75pt; margin: 0px;"><font style="font-family: times new roman,times;" size="2">The Company applies FASB ASC No. 260, <i>Earnings per Share</i>. Basic earnings (loss) per share is computed by dividing earnings (loss) available to common stockholders by the weighted-average number of shares of common stock outstanding. Diluted earnings or loss per share would include the dilutive effect of&#160;outstanding warrants and awards granted to employees under stock-based compensation plans.&#160; Potential shares of the Company's common stock are excluded from the calculation of diluted loss per common share because their effect would be anti-dilutive for the periods presented.&#160; For the three and nine month period ending September 30, 2016, 10,879,500 warrants and 1,142,500 stock options outstanding at the end of the period are excluded from the calculation of diluted loss per common share.&#160; For the three and nine month&#160; period ended September 30, 2015, 10,759,500 warrants and 1,151,000 stock options outstanding at the end of the period are excluded from the calculation of diluted loss per common share.</font></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 33.75pt; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Recent accounting pronouncements</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">In February 2016, the FASB issued ASU No. 2016-02&#160;<i>Leases</i>&#160;(Topic 842) intended to improve financial reporting around leasing transactions. The ASU affects all companies and other organizations that lease assets such as real estate, airplanes, and manufacturing equipment. The ASU will require organizations that lease assets - referred to as "lessees"- to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. For public companies, the standard is effective for fiscal years beginning after December 15, 2018 and interim periods therein. Earlier adoption is permitted for any annual or interim period for which consolidated financial statements have not yet been issued. The Company is currently evaluating the potential impact that the adoption of ASU No. 2016-02 may have on its consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6795831888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>University of Mississippi Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_UniversityOfMississippiAgreementsAbstract', window );"><strong>University Of Mississippi Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_UniversityOfMississippiAgreementsTextBlock', window );">University of Mississippi Agreements</a></td>
<td class="text"><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b>2. University of Mississippi Agreements</b></p>
<div>&#160;</div>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">In July 2013, the Company entered into a Memorandum of Understanding (MOU) with UM to engage in joint research of extracting, manipulating, and studying cannabis in certain forms to develop intellectual property (IP) with the intention to create and commercialize therapeutic medicines. Nemus will own all IP developed solely by its employees and will jointly own all IP developed jointly between Nemus and UM employees. The term of the MOU agreement is five years and the parties agree to negotiate separate research agreements upon the identification of patentable technologies as well as any deemed to be a trade secret. The agreement may be terminated by either party with three months&#8217; written notice to the other party.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0.5in; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><u>UM 5050 pro-drug agreements</u>:</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">On September 29, 2014, the Company executed three license agreements with UM pursuant to which UM granted us exclusive, perpetual, worldwide licenses, including the right to sublicense, to intellectual property related to UM 5050, a pro-drug formulation of tetrahydrocannabinol, or THC for products administered through each of ocular, oral or rectal delivery. The license agreement for the field of oral delivery also includes rights to UM 1250, a bio-adhesive hot melt extruded film for topical and mucosal adhesion application and drug delivery. The license agreements contain certain milestone and royalty payments, as defined therein. There is an annual fee of $25,000 per license agreement, payable on the anniversary of each effective date. The aggregate milestone payments under the license agreements, if the milestones are achieved, is $2.1 million. These licenses also require the Company to reimburse UM for patent costs incurred related to these products under license. The agreements will terminate upon expiration of the patents, breach or default of the license agreements, or upon 60 days&#8217; written notice by the Company to UM.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 33.75pt; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">On October 15, 2014, we signed a renewable option agreement for the rights to explore other routes of delivery of UM5050 not yet agreed upon and/or in combination with other cannabinoids or other compatible compounds. There was a one-time up-front option payment of $10,000 for a six-month option period that has subsequently been renewed under the same financial terms and conditions. The most recent renewal occurred for the period from October 1, 2016 to December 14, 2016 to coincide with the renewals of the UM 8930 license discussed below. The option payment for this shortened period is $2,500 due and payable on October 31, 2016.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><u>UM 8930 pro-drug agreements:</u></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><u></u>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">On December 14, 2015, the Company executed two license agreements with UM pursuant to which UM granted us exclusive, perpetual, worldwide licenses, including the right to sublicense, to intellectual property related to UM 8930, a pro-drug formulation of cannabidiol ("CBD") for products administered through each of ocular or rectal delivery. The license agreements contain certain milestone and royalty payments, as defined therein. There is a one-time upfront payment of $65,000 per license agreement, payable in four equal monthly installments that started on December 15, 2015. There is an annual fee of $25,000 per license agreement, payable on the anniversary of each effective date. The aggregate milestone payments under the license agreements, if the milestones are achieved, is $1.4 million. These licenses also require the Company to reimburse UM for patent costs incurred related to these products under license. These license agreements will terminate upon expiration of the patents, breach or default of the license agreements, or upon 60 days&#8217; written notice by the Company to UM.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">On December 14, 2015, we signed a renewable option agreement for the rights to explore other routes of delivery of UM8930 not yet agreed upon and/or in combination with other cannabinoids or other compatible compounds. There was a one-time up-front option payment of $10,000 for an option period ending March 31, 2016. This option was subsequently renewed for the period October 1, 2016 to December 14, 2016 to coincide with the UM8930 annual license renewal. The option payment for this shortened period is $2,500 due and payable on October 31, 2016.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_UniversityOfMississippiAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_UniversityOfMississippiAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_UniversityOfMississippiAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents entire disclosure for University of Mississippi ("UM") Agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_UniversityOfMississippiAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6794053872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b>3. Commitments and Contingencies</b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Lease Commitments</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">On September 1, 2014, the Company signed an operating lease for laboratory and office space at the Innovation Hub, Insight Park located on the University of Mississippi campus. The lease term commenced on October 1, 2014 and expires on December 31, 2017. There is annual escalating rent provisions and two months of free rent in the agreement. The total cash payments over the life of the lease are divided by the total number of months in the lease period and the average rent will be charged to expense each month during the lease period. The monthly amount charged to rent expense is $9,267.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">In October 2014, we signed a lease agreement for our corporate office headquarters that consists of approximately 4,087 square feet located at 650 Town Center Drive, Suite 1770, Costa Mesa, CA 92626. The lease expired on October 31, 2016 and our monthly rent was $5,373, payable in equal monthly installments with annual escalations. There was no subsequent renewal upon expiration of this lease.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">In November 2015, the Company entered into an operating lease for its office and lab furnishings both in Costa Mesa and the Innovation Hub laboratory. The lease expires on November 3, 2017 and the monthly lease payments are $7,559.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">Total net rent expense related to our operating leases for the three months ended September 30, 2016 and 2015, was $79,771 and $56,680, respectively. For the nine months ended September 30, 2016 and 2015, total net rent expense from operating leases was $240,746 and $170,931 respectively.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">Future minimum payments under the non-cancelable portion of our operating leases as of September 30, 2016 are as follows:</p>
<p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<table align="center" style="text-align: justify; width: 85%; font: 10pt 'times new roman'; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0">
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">2016</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td align="right" valign="bottom" width="9%">56,671</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">2017</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" valign="bottom" width="9%">161,963</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">2018</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" valign="bottom" width="9%">-</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">2019</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" valign="bottom" width="9%">-</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">2020</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" valign="bottom" width="9%">-</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Thereafter</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td style="border-bottom: 1px solid;" valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" style="border-bottom: 1px solid;" valign="bottom" width="9%">-</td>
<td style="padding-bottom: 1px;" valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Total</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td style="border-bottom: 3px double;" valign="bottom" width="1%">$</td>
<td align="right" style="border-bottom: 3px double;" valign="bottom" width="9%">218,634</td>
<td style="padding-bottom: 3px;" valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
</table>
<p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Legal Matters</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><i>General Litigation and Disputes</i></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><em></em>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">On August 3, 2016, John B. Hollister filed to dismiss his complaint against the Company and its Executive Chairman, and the Company and its Executive Chairman filed to dismiss their complaint against Hollister filed on January 25, 2016 containing claims against him for defamation, false light, unfair competition, breach of contract, breach of fiduciary duty and fraud.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">Hollister's employment as the Company's Chief Executive Officer was terminated by the Company on August 24, 2015 for good and lawful reasons by the Company's Board of Directors as the Company decided to go in a different direction. As stated in the Company's December 28, 2015 Form 8-K, the Company maintains that Hollister's complaint and subsequent pleadings were grossly inaccurate and his claims were entirely without merit alleging various causes of action arising out of his termination, including a breach of contract claim.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">Neither the Company nor its Executive Chairman made any payment to Hollister to resolve the lawsuit or otherwise.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">According to the Orange County Superior Court's online case records posted on August 11, 2016, the court entered the order for dismissal of the entire action with prejudice effective as of the&#160;August 3, 2016 filing date.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0.5in; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><i>Government Proceedings</i></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><em></em>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">Like other companies in the pharmaceutical industry, we are subject to extensive regulation by national, state and local government agencies in the United States. As a result, interaction with government agencies occurs in the normal course of our operations. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from any government investigation or proceeding. As of September 30, 2016, the Company had no current proceedings or inquiries.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0.5in; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Change in Control Severance Plan</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">In February 2015, we adopted a change in control severance plan, in which our named executive officers participate, that provides for the payment of severance benefits if the executive's service is terminated within twelve months following a change in control, either due to a termination without cause or upon a resignation for good reason (as each term is defined in the plan).</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">In either such event, and provided the executive timely executes and does not revoke a general release of claims against the Company, he or she will be entitled to receive: (i) a lump sum cash payment equal to at least six months of the executive's monthly compensation, plus an additional month for each full year of service over six years, (ii) Company-paid premiums for continued health insurance for a period equal to length of the cash severance period or, if earlier, when executive becomes covered under a subsequent employer's healthcare plan, and (iii) full vesting of all then-outstanding unvested stock options and restricted stock awards.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0.5in; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Contract Manufacturing Organization ("CMO") Agreement</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">On February 5, 2016, the Company entered into a letter agreement ("Agreement") with a third party contract manufacturing organization ("CMO") pursuant to which the CMO is to provide services to Nemus for process development and analytical method development and qualification for Nemus' prodrug of tetrahydrocannabinol, or THC, as well as for sample production and a stability study.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">Pursuant to the terms of the Agreement, Nemus will pay an estimated $154,000 to $183,000 in fees and expenses for the initial evaluation and development of a process for the production of Nemus' pro-drug of THC to ensure reproducibility, quality and safety and an estimated $142,900 for analytical method development and qualification. The Company recognized $18,896 and $225,244 respectively as research and development expense towards these fees for the three and nine months ended September 30, 2016. After the initial evaluation and development, Nemus has agreed to pay additional fees and expenses for sample production of Nemus' pro-drug of THC and a stability study, as well as possible extensions to or modifications of the aforementioned projects.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">Nemus may at any time cancel or delay any project under the Agreement prior to the scheduled start date. Nemus must reimburse the CMO for costs incurred prior to and including the date of cancellation plus any reasonable and foreseeable costs associated with stopping work on any project, including the CMO's loss of revenue incurred as the result of reserving production facilities for Nemus' exclusive use. Nemus may terminate the Agreement in whole or in part at any time upon 30 days' written notice.</div>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73718637&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6795831888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit and Redeemable Convertible Series B Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Deficit and Redeemable Convertible Series B Preferred Stock</a></td>
<td class="text"><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b>4. Stockholders' Deficit and Redeemable Convertible Series B Preferred Stock</b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Common Stock</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">In June 2014, the Company sold 1,800,000 shares of common stock with no par value and warrants for a purchase price of $900,000 (the "June 2014 Stock Purchase Agreement") to a group of private investors. See additional discussion on warrants below.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="left" style="widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">In August 2014, the Company sold 2,200,000 shares of common stock with no par value and warrants for a purchase price of $1,100,000 to a group of private investors. See additional discussion on warrants below.</p>
<p align="left" style="widows: 2; text-transform: none; font-style: normal; text-indent: 135px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="left" style="widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">In October 2014, the Company issued 1,110,000 shares of common stock with no par value to eighteen individual investors that had participated in a prior entity founded by Nemus' then current president. Such entity has been insolvent and not operating since the inception date of Nemus. The issuance of these shares was in exchange for the signing of a release of claims against the Company, its President, and the former entity. The Company recorded a general and administrative expense of $466,200 in the fourth quarter of 2014 to reflect the fair market value of the common stock issued in exchange for the release of claims. The fair market value of the common stock issued was determined via an independent third-party valuation conducted as of October 31, 2014.</p>
<p align="left" style="widows: 2; text-transform: none; font-style: normal; text-indent: 135px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="left" style="widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">In January 2015, the Company sold 241,663 shares of common stock with par value of $0.001 for a purchase price of $724,989 to a group of private investors.</p>
<p align="left" style="widows: 2; text-transform: none; font-style: normal; text-indent: 135px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="left" style="widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">In March 2015, the Company issued 24,000 shares of common stock with par value of $0.001 to a third party in exchange for services to be performed related to raising additional capital. The Company recorded a prepaid expense of $168,000 in the first quarter of 2015 to reflect the fair market value of the common stock issued and is amortizing this expense over the contract service period which is one year. The fair market value was determined utilizing the Company's closing stock price as of the commencement date of the contract service period. For three months ended March 31, 2016, the Company amortized $12,194 to general and administrative expense which represented the completion of this agreement.</p>
<p align="left" style="widows: 2; text-transform: none; font-style: normal; text-indent: 135px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="left" style="widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">In August 2015, in conjunction with the Series B Preferred Stock sale (discussed below), the Company raised $5.0 million at $1,000 per share resulting in the automatic conversion of the Series A Preferred Stock to common stock. This resulted in the conversion of 580,000 shares of Series A Preferred Stock at $2.50 per share to the equivalent of 1,812,500 shares of common stock.</p>
<p align="left" style="widows: 2; text-transform: none; font-style: normal; text-indent: 135px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="left" style="widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">In December 2015, a Series B Preferred Stockholder converted 500 shares of&#160;its preferred stock to common stock as allowed under the Series B Stock Agreement (discussed below), resulting in the issuance of 625,000 shares of common stock at an effective price of $0.80 per share.</p>
<p align="left" style="widows: 2; text-transform: none; font-style: normal; text-indent: 135px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="left" style="widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">In March 2016, another Series B Preferred Stockholder converted 8 shares of&#160;its preferred stock to common stock, resulting in the issuance of 10,000 shares of common stock at an effective price of $0.80 per share.</p>
<p align="left" style="widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Preferred Stock</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">The Company has authorized 20,000,000 shares of preferred stock with a par value of $0.001 per share.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><u>Series A Preferred Stock:</u>&#160;In April 2015, the Company sold 250,000 shares of Series A preferred stock with par value of $0.001 and 50,000 warrants to purchase the Company's common stock for an aggregate purchase price of $625,000, or $2.50 per share to a group of private investors. The shares of preferred stock automatically convert to shares of common stock either at (i) a subsequent equity financing of at least $1,000,000 or (ii) October 1, 2015, whichever is earlier. The warrants are exercisable at a price of $5.00 per share and expire five years from the issuance date. In May 2015, the Company sold 150,000 shares and 30,000 warrants and in July 2015, the Company sold 180,000 shares and 36,000 warrants under the same terms and conditions.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">The Series A preferred stock issued also has a "down-round" protection feature provided to the investors if the Company subsequently issues or sells any shares in a round of equity financing of at least $1,000,000 prior to October 1, 2015 in which the shares of common stock to be acquired are at a price less than $2.50 per share. The Company is required to issue additional shares of common stock to the investors in an amount such that the subscription price paid, when divided by the total number of shares issued will result in an actual price paid per share of common stock equal to such lower price. This conversion occurred as discussed above in conjunction with the Series B Preferred Stock financing totaling $5.0 million and resulted in the conversion of 580,000 shares of Series A Preferred Stock at to 1,812,500 shares of common stock.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><u>Redeemable Convertible Series B Preferred Stock:</u>&#160;In August 2015, the Company sold 5,000 shares of Series B Convertible Preferred Stock and warrants to purchase 6,250,000 shares of the Company's common stock for an aggregate purchase price of $1,000 per share resulting in gross proceeds of $5.0 million. Each share of preferred stock is convertible into 1,250 shares of common stock which results in an effective conversion price of $0.80 per common share and can be converted by the holder at any time. The Series B preferred stock issued also has a "down-round" protection feature provided to the investors if the Company subsequently issues or sell any shares of common stock, stock options, or convertible securities at a price less than the conversion price of $0.80 per common share. The conversion price is automatically adjusted down to the price of the instrument being issued. See additional discussion in Note 5 below. The Series B shares have liquidation preference over other preferred shares and common stock and have voting rights equal to the number of common shares into which each holder's preferred stock is convertible as of the record date. The preferred stock has no dividend rights. If dividends are declared on the common stock, the holders of the preferred stock shall be entitled to participate in such dividends on an as-if converted basis. The warrants are exercisable at a price of $1.15 per share and expire five years from the issuance date. See additional discussion regarding these warrants in Note 6 below.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary, Series B preferred stockholders receive an amount per share equal to the conversion price of $0.80, subject to down-round adjustment, multiplied by the as-if converted share amount of 5,615,000 common shares, totaling $4.5 million. If upon the liquidation, the assets are insufficient to permit payments to the Series B holders, all assets legally available will be distributed in a pro rata basis among the Series B holders in proportion to the full amounts they would otherwise be entitled to receive. Any remaining assets are distributed pro rata among the common stockholders.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">Subject to certain trigger events occurring, the Series B preferred stock holders have the right to force the Company to redeem the shares of preferred stock at a price per preferred share equal to the greater of (A) 115% of the conversion amount and (B) the product of (1) the conversion rate in effect at such time and (2) the greatest closing sale price of the Common Stock during the period beginning on the date immediately preceding such triggering event and ending on the date such holder delivers the notice of redemption. Such triggering events include:</p>
<p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<table style="text-align: justify; width: 100%; font: 10pt 'times new roman'; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0">
<tr>
<td width="4%">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">&#160;</p>
</td>
<td valign="top" width="4%">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top" width="92%">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Failure of the Series B Registration Statement to be declared effective by the SEC on or prior to the date that is ninety days after the Effectiveness Deadline;</p>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">&#160;</p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Suspension of the Company's common stock from trading for a period of (2) consecutive trading days;</p>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">&#160;</p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Failure of the Company to deliver all the shares of the common stock or make the appropriate cash payments in a timely manner upon conversion of the Series B Preferred;</p>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">&#160;</p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Any default of indebtedness;</p>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">&#160;</p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Any filing of voluntary or involuntary bankruptcy by the Company;</p>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">&#160;</p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">A final judgment in excess of $100,000 rendered against the Company;</p>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">&#160;</p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Breach of representations and warranties in the Stock Purchase Agreement;</p>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">&#160;</p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Failure to comply with the Series B Certificate of Designation or Rule 144 requirements.</p>
</td>
</tr>
</table>
<p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">As certain of these triggering events are considered to be outside the control of the Company, the Series B preferred stock is considered to be contingently redeemable convertible and as a result, has been classified as mezzanine equity in the Company's balance sheet.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">In December 2015, a Series B Preferred Stock holder converted 500 shares of its preferred stock to common stock at the conversion rate of 1,250:1 resulting in the issuance of 625,000 shares of common stock. In March 2016, another Series B Preferred Stockholder converted 8 shares of its preferred stock to common stock at the same ratio resulting in the issuance of 10,000 shares of common stock. As a result of these conversions, the liquidation preference for the Series B Preferred Stock has been reduced to $4.5 million at both September 30, 2016 and December 31, 2015.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Warrants</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">On July 17, 2012, the Company issued warrants to purchase up to 3,000,000 shares of our common stock to its founders and two advisors in consideration for services provided in the start-up of operations. The warrants are exercisable at a price of $1.00 per share and expire on June 20, 2023. The Company valued these warrants utilizing the Black-Scholes valuation model and they were determined to be of nominal value given the start-up nature of the Company's operations at the time of grant.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">In conjunction with the June 2014 Stock Purchase Agreement, the Company issued warrants to purchase up to 450,000 shares of common stock to a group of private investors. The warrants are exercisable at a price of $1.00 per share and expire on June 12, 2020. The Company valued these warrants at $85,500. This amount was recorded as warrants and was reclassified from the total consideration received for both the common stock and warrants purchased.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">In August 2014 as part of the June 2014 Stock Purchase Agreement, the Company issued warrants to purchase up to 550,000 shares of common stock with an exercise price of $1.00 per share that expire in August 2020. The Company valued these warrants at $104,500. This amount was recorded as warrants and was reclassified from the total consideration received for both the common stock and warrants purchased.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">In March 2015, the Company entered into an agreement with a financial advisory and public relations consulting firm which included the issuance of warrants to purchase up to 90,000 shares of common stock with an exercise price of $2.50 per share with a term of five years and vest quarterly over one year. These warrants were in exchange for services performed beginning in the first quarter and were subsequently issued in April 2015. The Company estimated the vested warrant value to be $85,950 utilizing the Black Scholes option pricing model and amortized $5,145 for services provided for the nine months ended September 30, 2016 and $46,810 for the nine months ended September 30, 2015.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">In April 2015, the Company entered into an agreement with one of its investors to provide advisory services on all matters including financing. In conjunction with this agreement, the Company issued warrants that vest immediately to purchase 100,000 shares of common stock with an exercise price of $5.00 per share with a term of ten years. The Company estimated the warrant value to be $326,000 utilizing the Black Scholes option pricing model and recorded this amount to general and administrative expense for the quarter due to the immediate vesting.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">In April 2015, the Company issued to a former service provider in exchange for payment of its outstanding invoice warrants that vest immediately to purchase 6,000 shares of common stock with an exercise price of $2.50 per share. The Company estimated the warrant value to be $10,000 which represented the value of the trade debt extinguished.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">In April 2015, the Company issued 50,000 warrants to purchase the Company's common stock in conjunction with its Series A Preferred Stock financing. The warrants are exercisable at a price of $5.00 per share and expire five years from the issuance date. In May 2015, the Company issued 30,000 warrants and in July 2015, 36,000 warrants under the same terms and conditions.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">In June 2015, the Company issued to a service provider in exchange for consulting services warrants that vest immediately to purchase 10,000 shares of common stock with an exercise price of $5.00 per share with a term of five years. The Company estimated the warrant value to be $14,700 utilizing the Black Scholes option pricing model.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">In August 2015, the Company issued 6,250,000 warrants to purchase common stock in conjunction with its Series B Preferred Stock financing. See further discussion in Note 6 below.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">In August 2015, the Company issued 187,500 warrants to purchase common stock to its investment banker in exchange for services rendered in conjunction with the Series B Preferred Stock financing. The warrants vest immediately and have an exercise price of $1.15 per share. The Company estimated the value of the warrants to be $86,250 utilizing the Black Scholes option pricing model and recorded this amount to offering costs.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">In November 2015, the Company entered into an agreement with a financial advisory and public relations consulting firm which included the issuance of warrants to purchase up to 120,000 shares of common stock with an exercise price of $1.15 per share with a term of five years. These warrants are in exchange for services to be performed from November 25, 2015 to May 25, 2016 and 60,000 shares vest immediately with the remainder in one quarter. The Company estimated the warrant value of vested warrants to be $42,000 utilizing the Black Scholes option pricing model and amortized $7,800 during the fiscal year ended December 31, 2015 and $34,200 in the nine months ended September 30, 2016.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">The Company's board of directors considered various objective and subjective factors, along with input from management, to determine the fair value of the warrants, including:&#160;</p>
<p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<table style="text-align: justify; width: 100%; font: 10pt 'times new roman'; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0">
<tr>
<td width="4%">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">&#160;</p>
</td>
<td valign="top" width="4%">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Contemporaneous valuation prepared by an independent third-party valuation specialist effective as of April 1, 2015, August 20, 2015, December 31, 2015, March 31, 2016, June 30, 2016, and September 30, 2016,</p>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">&#160;</p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Its results of operations, financial position and the status of research and development efforts and achievement of enterprise milestones,</p>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">&#160;</p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">The composition of, and changes to, the Company's management team and board of directors,</p>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">&#160;</p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">The lack of liquidity of its common stock as a newly public company,</p>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">&#160;</p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">The Company's stage of development, business strategy and the material risks related to its business and industry,</p>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">&#160;</p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">The valuation of publicly-traded companies in the biotechnology sectors,</p>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">&#160;</p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">External market conditions affecting the biotechnology industry sectors,</p>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">&#160;</p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">The likelihood of achieving a liquidity event for the holders of its common stock, such as an initial public offering, or IPO, or a sale of the Company, given prevailing market conditions, and</p>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">&#160;</p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">The state of the IPO market for similarly situated biotechnology companies,</p>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">&#160;</p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Discussions held with bankers, potential investors, and preliminary term sheets received as part of management's capital raise efforts.</p>
</td>
</tr>
</table>
<p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">There are significant judgments and estimates inherent in the determination of the fair value of the Company's warrants. These judgments and estimates included the assumptions regarding its future operating performance, the time to completing an IPO or other liquidity event and the determination of the appropriate valuation methods. If the Company had made different assumptions, its warrant valuation could have been significantly different.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Stock Option Plans: 2014 Omnibus Incentive Plan</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">The 2014 Omnibus Incentive Plan (the "2014 Plan") was adopted to provide a means by which officers, non-employee directors, and employees of and consultants to the Company and its affiliates could be given an opportunity to acquire an equity interest in the Company. All officers, non-employee directors, and employees of and consultants to the Company are eligible to participate in the 2014 Plan.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">On October 31, 2014, after the closing of the Merger, our Board of Directors approved the 2014 Plan. The 2014 Plan reserved 3,200,000 shares for future grants. As of September 30, 2016, options (net of canceled or expired options) covering an aggregate of 1,142,500 shares of the Company's common stock had been granted under the 2014 Plan, and the Company had 1,142,500 options outstanding and 857,500 shares available for future grants under the 2014 Plan.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">Options granted under the 2014 Plan expire no later than 10 years from the date of grant. Options granted under the 2014 Plan may be either incentive or non-qualified stock options. For incentive and non-qualified stock option grants, the option price shall be at least 100% of the fair value on the date of grants, as determined by the Company's Board of Directors. If at any time the Company grants an option, and the optionee directly or by attribution owns stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, the option price shall be at least 110% of the fair value and shall not be exercisable more than five years after the date of grant.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">Options granted under the 2014 Plan may be immediately exercisable if permitted in the specific grant approved by the Board of Directors and, if exercised early may be subject to repurchase provisions. The shares acquired generally vest over a period of five years from the date of grant. The Company granted options to purchase 1,142,500 shares net of cancellations through September 30, 2016, under the 2014 Plan.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">The following is a summary of activity under the 2014 Plan as of September 30, 2016:</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;&#160;</p>
<table style="text-align: justify; width: 100%; font: 10pt 'times new roman'; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0">
<tr>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="center" id="hdcell" valign="bottom" colspan="2">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="center" style="border-bottom: black 1px solid;" valign="bottom" colspan="10">
<p align="center" style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"><b>Options Outstanding</b></p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="center" id="a76680571-b25a-46cf-adb5-0a5b90e79172" valign="bottom" colspan="2"><strong>Shares</strong></td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="center" id="afc6737b0-20f3-4128-9b88-0ce2c73b24e6" valign="bottom" colspan="2"></td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="center" id="a994652bc-25a0-4417-8050-76d260ea111d" valign="bottom" colspan="2"></td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="center" id="afe53c416-0afd-41ba-9444-3d0ab44e3204" valign="bottom" colspan="2"><strong>Weighted</strong></td>
<td valign="bottom">
<p style="margin: 0px;"><strong>&#160;</strong></p>
</td>
</tr>
<tr>
<td valign="bottom">
<p style="margin: 0px;"><strong>&#160;</strong></p>
</td>
<td valign="bottom">
<p style="margin: 0px;"><strong>&#160;</strong></p>
</td>
<td align="center" id="afa874365-5607-419d-8579-0bb32ceeaa85" valign="bottom" colspan="2">
<p align="center" style="margin: 0px;"><strong>&#160;Available</strong></p>
<p align="center" style="margin: 0px;"><strong>for Grant of</strong></p>
</td>
<td valign="bottom">
<p style="margin: 0px;"><strong>&#160;</strong></p>
</td>
<td valign="bottom">
<p style="margin: 0px;"><strong>&#160;</strong></p>
</td>
<td align="center" id="ac9842d75-5040-4102-bc96-70f1dddaf474" valign="bottom" colspan="2">
<p align="center" style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"><strong>Number of</strong></p>
</td>
<td valign="bottom">
<p style="margin: 0px;"><strong>&#160;</strong></p>
</td>
<td valign="bottom">
<p style="margin: 0px;"><strong>&#160;</strong></p>
</td>
<td align="center" id="a6ca1f613-3c16-42b2-ab73-4e50d83a5f65" valign="bottom" colspan="2">
<p align="center" style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"><strong>Price per</strong></p>
</td>
<td valign="bottom">
<p style="margin: 0px;"><strong>&#160;</strong></p>
</td>
<td valign="bottom">
<p style="margin: 0px;"><strong>&#160;</strong></p>
</td>
<td align="center" id="a3f44c511-0f2b-4243-87ae-237fae0727de" valign="bottom" colspan="2">
<p align="center" style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"><strong>Average</strong></p>
<strong>Exercise</strong></td>
<td valign="bottom">
<p style="margin: 0px;"><strong>&#160;</strong></p>
</td>
</tr>
<tr>
<td valign="bottom">
<p style="margin: 0px;"><strong>&#160;</strong></p>
</td>
<td valign="bottom">
<p style="margin: 0px;"><strong>&#160;</strong></p>
</td>
<td align="center" style="border-bottom: black 1px solid;" id="a860cc628-b6ed-4b0c-8425-c4ebf8b64b38" valign="bottom" width="9%" colspan="2">
<p align="center" style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"><strong>Options &amp; Shares</strong></p>
</td>
<td valign="bottom">
<p style="margin: 0px;"><strong>&#160;</strong></p>
</td>
<td valign="bottom">
<p style="margin: 0px;"><strong>&#160;</strong></p>
</td>
<td align="center" style="border-bottom: black 1px solid;" id="a6143ca92-0680-47a1-b75c-9276cdd2ad6d" valign="bottom" width="9%" colspan="2">
<p align="center" style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"><strong>Shares</strong></p>
</td>
<td valign="bottom">
<p style="margin: 0px;"><strong>&#160;</strong></p>
</td>
<td valign="bottom">
<p style="margin: 0px;"><strong>&#160;</strong></p>
</td>
<td align="center" style="border-bottom: black 1px solid;" id="a5854f05c-db65-4bbe-a2f1-4064e1c3a94e" valign="bottom" width="9%" colspan="2">
<p align="center" style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"><strong>Share</strong></p>
</td>
<td valign="bottom">
<p style="margin: 0px;"><strong>&#160;</strong></p>
</td>
<td valign="bottom">
<p style="margin: 0px;"><strong>&#160;</strong></p>
</td>
<td align="center" style="border-bottom: black 1px solid;" id="a1019efff-1f0b-4e3b-8305-3f78a4c73824" valign="bottom" width="9%" colspan="2"><strong>Price</strong></td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"><b>Balance at December&#160;31, 2015</b></p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%"></td>
<td align="right" id="ffcell" valign="bottom" width="9%">2,020,000</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%"></td>
<td align="right" id="aa68043d3-4c6e-41e2-923a-3ea32f23491f" valign="bottom" width="9%">1,180,000</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td>$</td>
<td>
<p align="right" style="margin: 0px;">0.42-3.00</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td align="right" id="a3ac2e0ee-3533-4107-bc1b-be817b691e31" valign="bottom" width="9%">0.63</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;">Shares used for restricted stock awards (see discussion below)</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td style="border-bottom: black 1px solid;" valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" style="border-bottom: black 1px solid;" id="af6282499-29f0-4366-8026-aad84c9cccf9" valign="bottom" width="9%">(1,200,000</td>
<td style="padding-bottom: 1px;" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="a3802741f-3c97-416f-9b7b-d473742c4d45" valign="bottom" width="9%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="a33d45ae7-5104-420f-bb23-ecabee3b4780" valign="bottom" width="9%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="af19a18f4-c640-4bb6-8dab-63b1a5ace68e" valign="bottom" width="9%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"><b>Subtotal</b></p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="a2fea64e0-7816-4bca-b1b9-a1967a64dfdc" valign="bottom" width="9%">820,000</td>
<td style="padding-bottom: 3px;" valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="a09c554ec-af65-4d6a-bf86-49c087bba490" valign="bottom" width="9%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="ab0fed666-6caf-4e8e-b8af-ccbe2554b134" valign="bottom" width="9%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="a6496625f-1830-4cca-81b2-5feaa573e4e5" valign="bottom" width="9%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;">Options granted</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="aeab8c37e-4d93-4d87-ac4c-19ad3d1e3e4b" valign="bottom" width="9%">-</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="aad543531-cb7d-4874-b6f3-fa51f2f60d42" valign="bottom" width="9%">-</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td align="right" id="a1c8dd8e3-5f02-491b-87bc-155884e23f5c" valign="bottom" width="9%">-</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td align="right" id="aa2779de5-c435-40dd-a35d-e1c39bc48abe" valign="bottom" width="9%">-</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;">Options exercised</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="a80d77890-a888-441c-8740-76826013109d" valign="bottom" width="9%">-</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="ae409683e-9463-4f96-a6c5-babbcac5f0ba" valign="bottom" width="9%">-</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td align="right" id="a72c02b0e-b30d-4860-9836-e9163bd19cb7" valign="bottom" width="9%">-</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td align="right" id="a42b32d5f-a693-4a0a-861e-76035b64f9a3" valign="bottom" width="9%">-</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;">Options cancelled</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td style="border-bottom: black 1px solid;" valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" style="border-bottom: black 1px solid;" id="aa45a4ad7-4c57-4fa8-91ff-1790677360bb" valign="bottom" width="9%">37,500</td>
<td style="padding-bottom: 1px;" valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td style="border-bottom: black 1px solid;" valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" style="border-bottom: black 1px solid;" id="a053bad77-79a0-4ec3-880f-f12d007048df" valign="bottom" width="9%">(37,500</td>
<td style="padding-bottom: 1px;" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td align="right" id="a9cf8c493-525d-4876-b79a-2d8d376ea8e5" valign="bottom" width="9%">1.15</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td align="right" id="a1cbb6319-d9f0-4463-a68f-35e5917237e8" valign="bottom" width="9%">1.15</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"><b>Balance at September 30, 2016</b></p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td style="border-bottom: black 3px double;" valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" style="border-bottom: black 3px double;" id="ae97af3f1-dae5-4e42-8e09-2f66e2ffe5bf" valign="bottom" width="9%">857,500</td>
<td style="padding-bottom: 3px;" valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td style="border-bottom: black 3px double;" valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" style="border-bottom: black 3px double;" id="a687c36e5-ad50-4002-aedd-74d0845bfe95" valign="bottom" width="9%">1,142,500</td>
<td style="padding-bottom: 3px;" valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td>$</td>
<td>
<p align="right" style="margin: 0px;">0.42-3.00</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td align="right" id="a6f9762c0-37b5-4eef-9783-e74792864859" valign="bottom" width="9%">0.61</td>
<td style="padding-bottom: 3px;" valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
</table>
<p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">The weighted average remaining contractual life in years of the options outstanding as of September 30, 2016 was 8.15 years.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">Aggregate intrinsic value is the sum of the amounts by which the quoted market price of the Company's stock exceeded the exercise price of the stock options at September 30, 2016 for those stock options for which the quoted market price was in excess of the exercise price ("in-the-money options"). As of September 30, 2016, the aggregate intrinsic value of options outstanding was $52,500. As of September 30, 2016, 238,500 options to purchase shares of common stock were exercisable.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Restricted Stock Awards</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">Restricted stock awards ("RSAs") are granted to our board of directors and members of senior management and are issued pursuant to the Company's 2014 Omnibus Incentive Plan. On October 20, 2015, a total of 1,200,000 RSAs were granted to members of the Company's senior management and board of directors with a fair market value of approximately $900,000. These RSAs vest from one to three years from the grant date as services are rendered to the Company. For the three and nine months ended September 30, 2016, the Company recorded $93,750 and $281,250 respectively in stock-based compensation expense related to these awards. (See discussion below).</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Stock Based Compensation Expense</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">The Company recognizes stock-based compensation expense based on the fair value of that portion of stock options that are ultimately expected to vest during the period. Stock-based compensation expense recognized in the consolidated statements of operations includes compensation expense for stock-based awards based on the estimated grant date fair value over the requisite service period. For the three and nine months ended September 30, 2016, the Company recognized stock-based compensation expense of $181,608 and $544,823 (including compensation expense for RSAs discussed above) which was recorded as a general and administrative expense in the consolidated statements of operations. For the three and nine months ended September 30, 2015, stock-based compensation expense was $4,286 and $263,985, respectively.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">The total amount of unrecognized compensation cost related to non-vested stock options was $1,109,963 as of September 30, 2016. This amount will be recognized over a weighted average period of 3.14 years.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Valuation Assumptions</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">The fair value of options was estimated at the date of grant using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company's common stock for similar terms. The expected term was estimated using the simplified method as permitted under SAB No. 110, since the Company has no recent exercise or forfeiture history that is representative of options granted during the year. The expected term represents the estimated period of time that stock options are expected to be outstanding, which is less than the contractual term which is generally ten years. The risk-free interest rate is based on the U.S. Treasury yield. The expected dividend yield is zero, as the Company does not anticipate paying dividends in the near future. There were no options granted in the nine months ended September 30, 2016; the assumptions for options granted in the nine months ended September 30, 2015 are as follows:</p>
<p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<table style="text-align: justify; width: 100%; font: 10pt 'times new roman'; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0">
<tr>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="center" style="border-bottom: 1px solid;" id="ab1e7c601-5a49-4f73-bd66-fd7b0d7c8462" valign="bottom" colspan="4">
<p align="center" style="margin: 0px 0px 0px 1.9pt;"><b>Nine Months Ended September 30,</b></p>
</td>
<td valign="bottom">
<p align="center" style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr>
<td valign="bottom">
<p align="center" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p align="center" style="margin: 0px;">&#160;</p>
</td>
<td align="center" style="border-bottom: 1px solid;" id="accc5a3ce-8d0c-4e66-b78d-cf1f3bd013d1" valign="bottom" width="9%">
<p align="center" style="margin: 0px 0px 0px 0.4pt;"><b>2016</b></p>
</td>
<td valign="bottom">
<p align="center" style="margin: 0px;">&#160;</p>
</td>
<td align="center" style="border-bottom: 1px solid;" id="aed5d2e9f-3109-4425-88c1-45e53e9662c1" valign="bottom" width="9%" colspan="2">
<p align="center" style="margin: 0px 0px 0px 0.9pt;"><b>2015</b></p>
</td>
<td style="padding-bottom: 1px;" valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td colspan="2">
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Dividend yield</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p align="right" style="margin: 0px; color: black;">NA</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="a7832e1f6-078b-4820-a827-f22618578289" valign="bottom" width="9%">0.00</td>
<td valign="bottom" width="1%">%</td>
</tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Volatility factor</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p align="right" style="margin: 0px; color: black;">NA</p>
</td>
<td valign="bottom" width="1%">
<p align="right" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="af61ad908-d0ab-4dc9-a7c0-355a883d99a1" valign="bottom" width="9%">75.00</td>
<td valign="bottom" width="1%">%</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Risk-free interest rate</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p align="right" style="margin: 0px; color: black;">NA</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td colspan="2">
<p align="right" style="margin: 0px;">1.65-1.85</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">%</p>
</td>
</tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Expected term (years)</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p align="right" style="margin: 0px; color: black;">NA</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td colspan="2">
<p align="right" style="margin: 0px; color: black;">6.25-6.50</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Weighted-average fair value of options granted during the periods</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p align="right" style="margin: 0px; color: black;">NA</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td align="right" id="a34f935bf-cdd4-478b-92ef-8169b42ac679" valign="bottom" width="9%">2.69</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74567-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6626857088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision for Conversion of Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ProvisionForConversionOfPreferredStockAbstract', window );"><strong>Provision For Conversion Of Preferred Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Provision for Conversion of Preferred Stock</a></td>
<td class="text"><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b>5. Provision for Conversion of Preferred Stock</b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Series A Preferred Stock Conversion Liability</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">In connection with the Series A preferred stock financing, the Company recorded a liability related to down-round protection provided to the stockholders in the event that the Company does another offering of common stock greater than $1,000,000 at a price below $2.50 per share. The down-round provision expires at the closing of a subsequent financing round or October 1, 2015 whichever is earlier. With the assistance of a third-party valuation specialist, the Company valued the conversion liability pursuant to the accounting guidance of ASC 820-10,&#160;<i>Fair Value Measurements</i>, as of the closing date of the first round of financing which was April 1, 2015.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">As of June 30, 2015, the Company re-evaluated the likelihood and valuation of a potential down-round given that management has been actively pursuing capital raising efforts. In the absence of any definitive agreement, the Company calculated the fair value of the conversion feature to be $700,000 by determining the highest probability of a per share price in the next anticipated round of financing, after considering all discussions with bankers, potential investors, and preliminary term sheets. This amount was booked as a current liability as of June 30, 2015 and was charged as a non-operating expense for the period.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">In July 2015, the Company increased its down-round provision by $286,000 based on the closing of an additional round of 180,000 Series A shares by determining the highest probability of a per share price in the next anticipated round of financing, after considering all discussions with bankers, potential investors, and preliminary term sheets. This amount was charged to non-operating expense for the three months ended September 30, 2015.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">As of August 21, 2015, upon the closing of the Series B Preferred Stock sale with proceeds totaling $5.0 million, the Company issued 1,232,000 additional shares of common stock at $0.80 per share thereby eliminating this liability of $986,000 and offsetting it to Additional Paid-in-Capital. This amount was calculated by determining the difference in per share pricing between the Series A Preferred Stock financing of $2.50 per share and the Series B Preferred Stock Financing of $0.80 per share multiplied by the 580,000 total shares included in the Series A offering.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0.5in; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Series B Preferred Stock Conversion Liability</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">As of August 20, 2015, in connection with the Series B preferred stock financing, the Company recorded a liability related to down-round protection provided to the stockholders in the event that the Company does another sale or issuance of common stock, stock options or convertible securities where the share price is below $0.80 per share. With the assistance of a third-party valuation specialist, the Company valued the conversion liability pursuant to the accounting guidance of ASC 820-10,&#160;<i>Fair Value Measurement</i>s, as of the closing date of the financing. The Company also performed a review of the conversion liability in conjunction with ASC 815,&#160;<i>Derivatives and Hedging/Contracts in Entity's Own Equity</i>, and determined that the liability requires bifurcation and re-measurement to fair market value at the end of each reporting period. The value of this embedded derivative was determined utilizing a with and without method by valuing the preferred stock with and without the down round protection.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">As of September 30, 2016, the Company engaged a third-party valuation specialist to re-measure the conversion liability to fair market value as of that date utilizing the same methodology previously performed. The derivative which was classified as a current liability was adjusted to $166,718 as of September 30, 2016. The change in fair market value was recorded as non-operating expense of $61,058 for the three months ended September 30, 2016 and $82,872 as non-operating expense for the nine months ended September 30, 2016.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ProvisionForConversionOfPreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ProvisionForConversionOfPreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6793392160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Series B Warrants<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_SeriesBWarrantsAbstract', window );"><strong>Series B Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_SeriesBWarrantsTextBlock', window );">Series B Warrants</a></td>
<td class="text"><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b>6. Series B Warrants</b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">In conjunction with the Series B Preferred Stock financing, the Company issued 6,437,500 common stock warrants that are exercisable at a price of $1.15 per share and expire five years from the issuance date. The warrants were initially valued at $2,935,800 utilizing the Black-Scholes pricing model. The warrants are exercisable in cash or through a cashless exercise provision. The Series B warrants also have a "down-round" protection feature provided to the investors if the Company subsequently issues or sells any shares of common stock, stock options, or convertible securities at a price less than the exercise price of $1.15 per each warrant. The conversion price is automatically adjusted down to the price of the instrument being issued. The Company reviewed the classification of the warrants as liabilities or equity under the guidance of ASC 480-10,&#160;<i>Distinguishing Liabilities from Equity</i>, and concluded that the Series B warrants should be classified as a liability. The Company then applied the fair value allocation methodology for allocating the proceeds of $5.0 million received from the Series B financing between the conversion liability and the warrants with the residual amount being allocated to the Preferred Stock. The Company also performed the same valuation as of September 30, 2016 utilizing the Black-Scholes pricing model and the following assumptions:</p>
<p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<table style="text-align: justify; width: 100%; font: 10pt 'times new roman'; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0">
<tr>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="center" style="border-bottom: 1px solid;" id="hdcell" valign="bottom" colspan="6">
<p align="center" style="margin: 0px 0px 0px 2.4pt;"><b>Nine Months</b></p>
<p align="center" style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"><b>Ended September 30,</b></p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="center" style="border-bottom: 1px solid;" id="a85319552-10b9-46fd-86ef-186ab0ebc38f" valign="bottom" width="9%" colspan="2">
<p align="center" style="margin: 0px 0px 0px 0.9pt;"><b>2016</b></p>
</td>
<td style="padding-bottom: 1px;" valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="center" style="border-bottom: 1px solid;" id="ae4257b3b-5c4a-42c1-ae69-aed5df85e197" valign="bottom" width="9%" colspan="2">
<p align="center" style="margin: 0px 0px 0px 0.4pt;"><b>2015</b></p>
</td>
<td style="padding-bottom: 1px;" valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Dividend yield</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="ffcell" valign="bottom" width="9%">0.00</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="a4bacfc70-3d2c-4b81-9d5e-aba330aa7aef" valign="bottom" width="9%">0.00</td>
<td valign="bottom" width="1%">%</td>
</tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Volatility factor</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="a1e9ca8cc-ec6f-4311-b554-1abf124df9fc" valign="bottom" width="9%">70.00</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="ae66c380e-73cf-4dd7-82b0-b6d14565deec" valign="bottom" width="9%">70.00</td>
<td valign="bottom" width="1%">%</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Risk-free interest rate</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td colspan="2">
<p align="right" style="margin: 0px; color: black;">1.11 - 1.29</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="aec32d280-cd62-4d52-8c5b-ab6891500504" valign="bottom" width="9%">1.75</td>
<td valign="bottom" width="1%">%</td>
</tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Expected term (years)</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td colspan="2">
<p align="right" style="margin: 0px; color: black;">3.89-3.90</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="a4de46680-69c7-4ac0-8f49-5a85a6e9245c" valign="bottom" width="9%">4.61</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Weighted-average fair value of warrants</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td align="right" id="a635a5d17-e965-4939-95ef-46af09eeb328" valign="bottom" width="9%">0.14</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td align="right" id="a521176c9-5eeb-4083-875f-1db660f6290a" valign="bottom" width="9%">0.46</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
</table>
<p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">This resulted in a warrant value of $869,990 as of September 30, 2016. The change in fair market value at the re-measurement date was recorded as non-operating expense totaling $27,665 for the three months ended September 30, 2016. and non-operating income totaling $1,584,969 for the nine months ended September 30, 2016.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_SeriesBWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_SeriesBWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_SeriesBWarrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for series B warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_SeriesBWarrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6793531184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b>7. Income Taxes</b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">The Company records a valuation allowance against deferred tax assets to the extent that it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Due to the substantial doubt related to the Company's ability to utilize its deferred tax assets, a valuation allowance for the full amount of the deferred tax assets has been established at September 30, 2016. As a result of this valuation allowance there are no income tax benefits reflected in the accompanying statement of operations to offset pre-tax losses.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">The Company has no uncertain tax positions as of September 30, 2016.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6776647136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b>8. Subsequent Events</b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong></strong>&#160;</p>
<p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b><i>Convertible Preferred Stock Issuance</i></b></p>
<p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">In October 2016, the Company sold 500 shares of convertible preferred stock with a purchase price of $1,000 per share for gross proceeds of $500,000 to a healthcare investment fund under the Series C Preferred Stock Agreement. Each share of Preferred Stock is convertible into 2,500 shares of common stock which results in an effective conversion price of $0.40 per common share. This results in the reduction of the conversion price of the Series B Preferred Stock to $ 0.40 and a reduction in the exercise price of the Series B warrants to $ 0.40. As part of the terms of the Series&#160;C Preferred Stock agreement, the Company entered into a Registration Rights Agreement with the purchaser to file a registration statement to register for resale the shares of common stock underlying the preferred shares within 30 days following the closing of the agreement.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Technology License Agreement</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">In October 2016, the Company entered into a technology license agreement with a third-party manufacturing company in order to biosynthetically manufacture cannabinoids. The terms of the agreement call for an initial payment of $50,000 along with a common stock issuance equal to $50,000 of the Company&#8217;s common stock based on the 10 -day volume-weighted average closing price calculated from the effective date of the agreement.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6803794000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations, Business Activities and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Use of Estimates</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles ("U.S. GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of our financial statements include estimates as to the appropriate carrying value of certain assets and liabilities which are not readily apparent from other sources.</div>
</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_LiquidityAndGoingConcernPolicyTextBlock', window );">Liquidity and Going Concern</a></td>
<td class="text"><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Liquidity and Going Concern</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">The Company has incurred operating losses and negative cash flows from operations since our inception. As of September 30, 2016, we had cash and cash equivalents of $319,930. In October 2016, we raised an additional $500,000 (see note 8) to be utilized to fund operations. The Company anticipates that it will continue to incur net losses into the foreseeable future as it continues to advance and develop a number of potential drug candidates into preclinical development activities and expands its corporate infrastructure which includes the costs associated with being a public company. Without additional funding, management believes that the Company will not have sufficient funds to meet its obligations within one year after the date the consolidated financial statements are issued. These conditions give rise to substantial doubt as to the Company's ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">The Company plans to continue to fund its operations and capital funding needs through public or private equity or debt financings, strategic collaborations, licensing arrangements, asset sales, government grants or other arrangements. However, the Company cannot be sure that such additional funds will be available on reasonable terms, or at all. If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result. If the Company is unable to secure adequate additional funding, the Company may be forced to make a reduction in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Cash and Cash Equivalents</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The carrying value of those investments approximates their fair market value due to their short maturity and liquidity. Cash and cash equivalents include cash on hand and amounts on deposit with financial institutions, which amounts may at times exceed federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk.</div>
</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><div>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Restricted Cash</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">A deposit of $37,500 as of September 30, 2016 and December 31, 2015 was restricted from withdrawal and held by a bank in the form of a certificate of deposit. This certificate serves as collateral for payment of the Company's credit cards.</div>
</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Fair Value Measurements</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last is considered unobservable, is used to measure fair value:&#160;</p>
<p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<table style="text-align: justify; width: 100%; font: 10pt 'times new roman'; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0">
<tr>
<td valign="top" width="4%">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">&#160;</p>
</td>
<td valign="top" width="6%">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Level 1:</p>
</td>
<td valign="top" width="90%">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities.</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top"></td>
<td valign="top"></td>
</tr>
<tr>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">&#160;</p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Level 2:</p>
</td>
<td valign="top">
<p style="margin: 0px;">Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</p>
</td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top"></td>
<td valign="top"></td>
</tr>
<tr>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">&#160;</p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Level 3:</p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</p>
</td>
</tr>
</table>
<p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">The carrying values of our financial instruments, including, cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses approximate their fair value due to the short maturities of these financial instruments. The Series B warrant liability and the conversion liability for the Series B preferred stock were valued utilizing Level 3 inputs primarily from a third party independent appraisal conducted as of September 30, 2016.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Property and Equipment, Net</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">As of September 30, 2016, property and equipment, net, was $12,994, consisting primarily of computers and equipment. The Company had $13,383 of property and equipment, net, as of December 31, 2015. Expenditures for additions, renewals and improvements will be capitalized at cost. Depreciation will generally be computed on a straight-line method based on the estimated useful life of the related assets currently ranging from two to three years. Maintenance and repairs that do not extend the life of assets are charged to expense when incurred. When properties are disposed of, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is reported in the period the transaction takes place.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount exceeds its estimated future undiscounted cash flows, an impairment charge is recognized by the amount by which the carrying amount exceeds the fair value of the asset.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">The costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, will be charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where there is an identified alternative future use. No cost associated with the use of licensed technologies has been capitalized to date.</div>
</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Income Taxes</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">The Company accounts for our deferred income tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities, and net operating loss carry forwards (the "NOLs") and other tax credit carry forwards. These items are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period that includes the enactment date. Any interest or penalties would be recorded in the Company's statement of operations in the period incurred.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">The Company records a valuation allowance to reduce the deferred income tax assets to the amount that is more likely than not to be realized. In making such determinations, management considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. As a result, there are no income tax benefits reflected in the statement of operations to offset pre-tax losses.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">The Company recognizes a tax benefit from uncertain tax positions when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position.</div>
</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Revenue Recognition</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">The Company has not begun planned principal operations and has not generated any revenue since inception.</div>
</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Research and Development Expenses</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">Research and development ("R&amp;D") costs are expensed when incurred. These costs may consist of external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants; license fees; employee-related expenses, which include salaries, benefits and stock-based compensation for the personnel involved in our preclinical and clinical drug development activities; and facilities expense, depreciation and other allocated expenses; and equipment and laboratory supplies.</div>
</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation Expenses</a></td>
<td class="text"><div>
<p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Stock-Based Compensation Expenses</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">Stock-based compensation cost is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period. We use the Black-Scholes option pricing model for estimating the grant date fair value of stock options and warrants using the following assumptions:</p>
<p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<div style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">
<table style="text-align: justify; width: 100%; font: 10pt 'times new roman'; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0">
<tr>
<td width="4%">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">&#160;</p>
</td>
<td valign="top" width="4%">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Exercise price - We determined the exercise price based on valuations using the best information available to management at the time of the valuations.</p>
</td>
</tr>
<tr>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
</tr>
<tr>
<td>
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">&#160;</p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Volatility&#160;- We estimate the stock price volatility based on industry peers who are also in the early development stage given the limited market data available in the public arena.</p>
</td>
</tr>
<tr>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
</tr>
<tr>
<td>
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">&#160;</p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Expected term - The expected term is based on a simplified method which defines the life as the average of the contractual term of the options and warrants and the weighted-average vesting period for all open awards.</p>
</td>
</tr>
<tr>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
</tr>
<tr>
<td>
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">&#160;</p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Risk-free rate - The risk-free interest rate for the expected term of the option or warrant is based on the average market rate on U.S. treasury securities in effect during the period in which the awards were granted.</p>
</td>
</tr>
<tr>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
</tr>
<tr>
<td>
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">&#160;</p>
</td>
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<div align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Dividends - The dividend yield assumption is based on our history and expectation of paying no dividends.</div>
</td>
</tr>
</table>
</div>
</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock', window );">Stock-Based Compensation for Non-Employees</a></td>
<td class="text"><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Stock-Based Compensation for Non-Employees</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 33.75pt; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">The Company accounts for warrants and options issued to non-employees under Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) No. 505-50,&#160;<i>Equity - Equity Based Payments to Non-Employees,</i>using the Black-Scholes option-pricing model. The value of such non-employee awards is periodically re-measured over the vesting terms and at each quarter end.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Segment Information</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 33.75pt; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">FASB ASC No. 280,&#160;<i>Segment Reporting</i>, establishes standards for reporting information about reportable segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group ("CODM"), in deciding how to allocate resources and in assessing performance. The CODM evaluates revenues and gross profits based on product lines and routes to market. Based on the early development stage of our operation, we operate in a single reportable segment.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><div><b style="margin: 0px;"><b style="margin: 0px;"><i></i></b></b>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Comprehensive Income (Loss)</i></b></p>
<b style="margin: 0px;"><b style="margin: 0px;"><i></i></b></b>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<b style="margin: 0px;"><b style="margin: 0px;"><i></i></b></b>
<div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company is required to record all components of comprehensive income (loss) in the consolidated financial statements in the period in which they are recognized. Net income (loss) and other comprehensive income (loss), net of their related tax effect, arrived at a comprehensive income (loss). For the three and nine months ended September 30, 2016, the comprehensive income (loss) was equal to the net income (loss).</div>
</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per share</a></td>
<td class="text"><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Earnings per share</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-indent: 33.75pt; margin: 0px;"><font style="font-family: times new roman,times;" size="2">The Company applies FASB ASC No. 260, <i>Earnings per Share</i>. Basic earnings (loss) per share is computed by dividing earnings (loss) available to common stockholders by the weighted-average number of shares of common stock outstanding. Diluted earnings or loss per share would include the dilutive effect of&#160;outstanding warrants and awards granted to employees under stock-based compensation plans.&#160; Potential shares of the Company's common stock are excluded from the calculation of diluted loss per common share because their effect would be anti-dilutive for the periods presented.&#160; For the three and nine month period ending September 30, 2016, 10,879,500 warrants and 1,142,500 stock options outstanding at the end of the period are excluded from the calculation of diluted loss per common share.&#160; For the three and nine month&#160; period ended September 30, 2015, 10,759,500 warrants and 1,151,000 stock options outstanding at the end of the period are excluded from the calculation of diluted loss per common share.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting pronouncements</a></td>
<td class="text"><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b style="margin: 0px;"><i>Recent accounting pronouncements</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; margin-right: 0px; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong><em></em></strong>&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 45px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: black; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">In February 2016, the FASB issued ASU No. 2016-02&#160;<i>Leases</i>&#160;(Topic 842) intended to improve financial reporting around leasing transactions. The ASU affects all companies and other organizations that lease assets such as real estate, airplanes, and manufacturing equipment. The ASU will require organizations that lease assets - referred to as "lessees"- to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. For public companies, the standard is effective for fiscal years beginning after December 15, 2018 and interim periods therein. Earlier adoption is permitted for any annual or interim period for which consolidated financial statements have not yet been issued. The Company is currently evaluating the potential impact that the adoption of ASU No. 2016-02 may have on its consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_LiquidityAndGoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entire disclosure of policy for liquidity and going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_LiquidityAndGoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents policy for stock based compensation for Non Employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6793534624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of future minimum payments under non-cancelable operating leases</a></td>
<td class="text"><div>
<div style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">
<table align="center" style="text-align: justify; width: 85%; font: 10pt 'times new roman'; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0">
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">2016</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td align="right"  valign="bottom" width="9%">56,671</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">2017</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right"  valign="bottom" width="9%">161,963</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">2018</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right"  valign="bottom" width="9%">-</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">2019</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right"  valign="bottom" width="9%">-</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">2020</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right"  valign="bottom" width="9%">-</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Thereafter</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td style="border-bottom: 1px solid;" valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" style="border-bottom: 1px solid;"  valign="bottom" width="9%">-</td>
<td style="padding-bottom: 1px;" valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Total</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td style="border-bottom: 3px double;" valign="bottom" width="1%">$</td>
<td align="right" style="border-bottom: 3px double;"  valign="bottom" width="9%">218,634</td>
</tr>
</table>
</div>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6785244800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit and Redeemable Convertible Series B Preferred Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of summary of stock option activity</a></td>
<td class="text"><div style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">
<table style="text-align: justify; width: 100%; font: 10pt 'times new roman'; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0">
<tr>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="center" id="hdcell" valign="bottom" colspan="2">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="center" style="border-bottom: black 1px solid;" valign="bottom" colspan="10">
<p align="center" style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"><b>Options Outstanding</b></p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="center" id="a9c1c0c3d-601b-4b34-a06c-f3b715eb9c46" valign="bottom" colspan="2"><strong>Shares</strong></td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="center" id="ab1e58ec1-b4e9-47fe-a04f-3dcbdaa6f054" valign="bottom" colspan="2"></td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="center" id="aae7e6299-0811-4591-8b7e-0051acf1b3d6" valign="bottom" colspan="2"></td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="center" id="a3032682d-4917-4cbf-a972-44561b57977b" valign="bottom" colspan="2"><strong>Weighted</strong></td>
<td valign="bottom">
<p style="margin: 0px;"><strong>&#160;</strong></p>
</td>
</tr>
<tr>
<td valign="bottom">
<p style="margin: 0px;"><strong>&#160;</strong></p>
</td>
<td valign="bottom">
<p style="margin: 0px;"><strong>&#160;</strong></p>
</td>
<td align="center" id="a48499af0-a4e5-43d2-a229-34781aa6daa7" valign="bottom" colspan="2">
<p align="center" style="margin: 0px;"><strong>&#160;Available</strong></p>
<p align="center" style="margin: 0px;"><strong>for Grant of</strong></p>
</td>
<td valign="bottom">
<p style="margin: 0px;"><strong>&#160;</strong></p>
</td>
<td valign="bottom">
<p style="margin: 0px;"><strong>&#160;</strong></p>
</td>
<td align="center" id="a23cc0d7c-d151-42e1-b062-c76cd547dcf5" valign="bottom" colspan="2">
<p align="center" style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"><strong>Number of</strong></p>
</td>
<td valign="bottom">
<p style="margin: 0px;"><strong>&#160;</strong></p>
</td>
<td valign="bottom">
<p style="margin: 0px;"><strong>&#160;</strong></p>
</td>
<td align="center" id="a8c9098f1-6d82-4278-a1b6-d3624e86743a" valign="bottom" colspan="2">
<p align="center" style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"><strong>Price per</strong></p>
</td>
<td valign="bottom">
<p style="margin: 0px;"><strong>&#160;</strong></p>
</td>
<td valign="bottom">
<p style="margin: 0px;"><strong>&#160;</strong></p>
</td>
<td align="center" id="a3b170a80-a074-46c3-ac8a-cc808b53f311" valign="bottom" colspan="2">
<p align="center" style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"><strong>Average</strong></p>
<strong>Exercise</strong></td>
<td valign="bottom">
<p style="margin: 0px;"><strong>&#160;</strong></p>
</td>
</tr>
<tr>
<td valign="bottom">
<p style="margin: 0px;"><strong>&#160;</strong></p>
</td>
<td valign="bottom">
<p style="margin: 0px;"><strong>&#160;</strong></p>
</td>
<td align="center" style="border-bottom: black 1px solid;" id="a97273a83-1185-4d12-84af-f2230e078d78" valign="bottom" width="9%" colspan="2">
<p align="center" style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"><strong>Options &amp; Shares</strong></p>
</td>
<td valign="bottom">
<p style="margin: 0px;"><strong>&#160;</strong></p>
</td>
<td valign="bottom">
<p style="margin: 0px;"><strong>&#160;</strong></p>
</td>
<td align="center" style="border-bottom: black 1px solid;" id="a98ac3ec6-cd33-4c4d-8237-1c32f58d797e" valign="bottom" width="9%" colspan="2">
<p align="center" style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"><strong>Shares</strong></p>
</td>
<td valign="bottom">
<p style="margin: 0px;"><strong>&#160;</strong></p>
</td>
<td valign="bottom">
<p style="margin: 0px;"><strong>&#160;</strong></p>
</td>
<td align="center" style="border-bottom: black 1px solid;" id="a6977c8ad-375c-4c64-a345-07b7b573f35a" valign="bottom" width="9%" colspan="2">
<p align="center" style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"><strong>Share</strong></p>
</td>
<td valign="bottom">
<p style="margin: 0px;"><strong>&#160;</strong></p>
</td>
<td valign="bottom">
<p style="margin: 0px;"><strong>&#160;</strong></p>
</td>
<td align="center" style="border-bottom: black 1px solid;" id="a3bffaefa-c070-49d2-a8f3-70f443a96837" valign="bottom" width="9%" colspan="2"><strong>Price</strong></td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"><b>Balance at December&#160;31, 2015</b></p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%"></td>
<td align="right" id="ffcell" valign="bottom" width="9%">2,020,000</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%"></td>
<td align="right" id="afc56a6ee-0003-48f7-be2b-994cc39e9ec8" valign="bottom" width="9%">1,180,000</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td>$</td>
<td>
<p align="right" style="margin: 0px;">0.42-3.00</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td align="right" id="abd895ea5-68ad-4e1f-93f6-8f7518072754" valign="bottom" width="9%">0.63</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;">Shares used for restricted stock awards (see discussion below)</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td style="border-bottom: black 1px solid;" valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" style="border-bottom: black 1px solid;" id="aa47912fc-85e0-4545-8d9d-f4812dc020a9" valign="bottom" width="9%">(1,200,000</td>
<td style="padding-bottom: 1px;" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="a93a4e98f-7ce1-4240-8f2f-e35f79e2c87f" valign="bottom" width="9%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="a45874aba-3617-491d-a106-2b7a615824e7" valign="bottom" width="9%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="aa4964e5b-1be1-4cf2-a19e-d99b1ae1fc55" valign="bottom" width="9%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"><b>Subtotal</b></p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="acc646180-f655-4e8b-a2a5-b30028795437" valign="bottom" width="9%">820,000</td>
<td style="padding-bottom: 3px;" valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="a33cf3d3e-009d-4872-9e28-eaa5dccfb4fe" valign="bottom" width="9%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="a50e97196-1fe7-482d-9730-a852311bed65" valign="bottom" width="9%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="a77f6ba51-2a31-48b1-bbdc-6cfe5512b292" valign="bottom" width="9%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;">Options granted</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="a0970e4e9-b365-41eb-a412-2b535d786d21" valign="bottom" width="9%">-</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="a57312fe5-b4ad-4b62-80e5-aa1fdef1f917" valign="bottom" width="9%">-</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td align="right" id="a14c46776-7400-4a21-83a3-196d2593d887" valign="bottom" width="9%">-</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td align="right" id="afec4457e-7147-4c33-bf61-2f0fea7dfaf5" valign="bottom" width="9%">-</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;">Options exercised</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="af5fa4d22-e63d-46bb-acb1-919d669ae0f1" valign="bottom" width="9%">-</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="a86a24e7f-980a-4e65-967a-5b7fbe922e0c" valign="bottom" width="9%">-</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td align="right" id="ae9770fbd-c81f-4479-a388-7055d39868a0" valign="bottom" width="9%">-</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td align="right" id="ae748cc22-57d8-40b1-90c6-7f9f24ad4d52" valign="bottom" width="9%">-</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;">Options cancelled</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td style="border-bottom: black 1px solid;" valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" style="border-bottom: black 1px solid;" id="ad3a45ec0-e872-41ee-a8a4-0f5361c9d1c0" valign="bottom" width="9%">37,500</td>
<td style="padding-bottom: 1px;" valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td style="border-bottom: black 1px solid;" valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" style="border-bottom: black 1px solid;" id="a024bf5a9-68e7-4ae9-8d54-929ae0ab07f3" valign="bottom" width="9%">(37,500</td>
<td style="padding-bottom: 1px;" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td align="right" id="a79c5ff51-447c-4c8d-91b8-b4af82950757" valign="bottom" width="9%">1.15</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td align="right" id="ada723513-9fb7-42d6-a0c9-5bb20303124c" valign="bottom" width="9%">1.15</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"><b>Balance at September 30, 2016</b></p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td style="border-bottom: black 3px double;" valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" style="border-bottom: black 3px double;" id="a59b9f2b0-0c39-4bc4-a2f9-6ad72a5b0e8a" valign="bottom" width="9%">857,500</td>
<td style="padding-bottom: 3px;" valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td style="border-bottom: black 3px double;" valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" style="border-bottom: black 3px double;" id="a1a28dff2-8b4a-4ff3-969c-e645ed2ea7d1" valign="bottom" width="9%">1,142,500</td>
<td style="padding-bottom: 3px;" valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td>$</td>
<td>
<p align="right" style="margin: 0px;">0.42-3.00</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td align="right" id="aa118bbb2-6d9a-4c3a-b288-5b584a67903b" valign="bottom" width="9%">0.61</td>
<td style="padding-bottom: 3px;" valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
</table>
</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted average assumptions for employee options</a></td>
<td class="text"><div>
<div style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">
<table style="text-align: justify; width: 100%; font: 10pt 'times new roman'; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0">
<tr>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="center" style="border-bottom: 1px solid;"  valign="bottom" colspan="4">
<p align="center" style="margin: 0px 0px 0px 1.9pt;"><b>Nine Months Ended September 30,</b></p>
</td>
<td valign="bottom">
<p align="center" style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr>
<td valign="bottom">
<p align="center" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p align="center" style="margin: 0px;">&#160;</p>
</td>
<td align="center" style="border-bottom: 1px solid;"  valign="bottom" width="9%">
<p align="center" style="margin: 0px 0px 0px 0.4pt;"><b>2016</b></p>
</td>
<td valign="bottom">
<p align="center" style="margin: 0px;">&#160;</p>
</td>
<td align="center" style="border-bottom: 1px solid;"  valign="bottom" width="9%" colspan="2">
<p align="center" style="margin: 0px 0px 0px 0.9pt;"><b>2015</b></p>
</td>
<td style="padding-bottom: 1px;" valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td colspan="2">
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Dividend yield</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p align="right" style="margin: 0px; color: black;">NA</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right"  valign="bottom" width="9%">0.00</td>
<td valign="bottom" width="1%">%</td>
</tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Volatility factor</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p align="right" style="margin: 0px; color: black;">NA</p>
</td>
<td valign="bottom" width="1%">
<p align="right" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right"  valign="bottom" width="9%">75.00</td>
<td valign="bottom" width="1%">%</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Risk-free interest rate</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p align="right" style="margin: 0px; color: black;">NA</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td colspan="2">
<p align="right" style="margin: 0px;">1.65-1.85</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">%</p>
</td>
</tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Expected term (years)</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p align="right" style="margin: 0px; color: black;">NA</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td colspan="2">
<p align="right" style="margin: 0px; color: black;">6.25-6.50</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Weighted-average fair value of options granted during the periods</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p align="right" style="margin: 0px; color: black;">NA</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td align="right"  valign="bottom" width="9%">2.69</td>
</tr>
</table>
</div>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6793467584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Series B Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_SeriesBWarrantsAbstract', window );"><strong>Series B Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Series B Warrants</a></td>
<td class="text"><div>
<div style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">
<table style="text-align: justify; width: 100%; font: 10pt 'times new roman'; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0">
<tr>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="center" style="border-bottom: 1px solid;"  valign="bottom" colspan="6">
<p align="center" style="margin: 0px 0px 0px 2.4pt;"><b>Nine Months</b></p>
<p align="center" style="margin-top: 0px; margin-bottom: 0px; margin-right: 0px;"><b>Ended September 30,</b></p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="center" style="border-bottom: 1px solid;"  valign="bottom" width="9%" colspan="2">
<p align="center" style="margin: 0px 0px 0px 0.9pt;"><b>2016</b></p>
</td>
<td style="padding-bottom: 1px;" valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="center" style="border-bottom: 1px solid;"  valign="bottom" width="9%" colspan="2">
<p align="center" style="margin: 0px 0px 0px 0.4pt;"><b>2015</b></p>
</td>
<td style="padding-bottom: 1px;" valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Dividend yield</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right"  valign="bottom" width="9%">0.00</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right"  valign="bottom" width="9%">0.00</td>
<td valign="bottom" width="1%">%</td>
</tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Volatility factor</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right"  valign="bottom" width="9%">70.00</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right"  valign="bottom" width="9%">70.00</td>
<td valign="bottom" width="1%">%</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Risk-free interest rate</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td colspan="2">
<p align="right" style="margin: 0px; color: black;">1.11 - 1.29</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right"  valign="bottom" width="9%">1.75</td>
<td valign="bottom" width="1%">%</td>
</tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Expected term (years)</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td colspan="2">
<p align="right" style="margin: 0px; color: black;">3.89-3.90</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right"  valign="bottom" width="9%">4.61</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin-top: 0px; margin-bottom: 0px; color: black; margin-right: 0px;">Weighted-average fair value of warrants</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td align="right"  valign="bottom" width="9%">0.14</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td align="right"  valign="bottom" width="9%">0.46</td>
</tr>
</table>
</div>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_SeriesBWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_SeriesBWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the inputs and valuation techniques used to measure fair value, and a discussion of changes in valuation techniques and related inputs, if any, applied during the period to each separate class of assets, liabilities, and financial instruments classified in shareholders' equity that are measured on a recurring and/or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6803347104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations, Business Activities and Summary of Significant Accounting Policies (Detail Textuals)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2014 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($) </div>
<div>Segments </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Nature of Operations, Business Activities and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,913,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,903,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 319,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,221,209<span></span>
</td>
<td class="nump">$ 4,342,722<span></span>
</td>
<td class="nump">$ 207,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDepreciationMethods', window );">Property, plant and equipment, depreciation methods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Straight-line method<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property plant and equipment estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Two to three years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment | Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Nature of Operations, Business Activities and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional fund operations raised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=nmus_NemusAcquisitionCorpMember', window );">Nemus Acquisition Corp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Nature of Operations, Business Activities and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_StockIssuedDuringPeriodSharesReverseMerger', window );">Reverse merger common stock issuance with par value (in shares) | shares</a></td>
<td class="nump">3,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NumberOfSharesExchanged', window );">Number of shares exchanged | shares</a></td>
<td class="nump">12,880,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding | shares</a></td>
<td class="nump">16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_NumberOfSharesExchanged">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents number of shares exchanged.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_NumberOfSharesExchanged</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_StockIssuedDuringPeriodSharesReverseMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of shares issued during the period for reverse merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_StockIssuedDuringPeriodSharesReverseMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDepreciationMethods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the methodology for computing depreciation for classes of depreciable assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDepreciationMethods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68071081&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=nmus_NemusAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=nmus_NemusAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6790012512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations, Business Activities and Summary of Significant Accounting Policies (Detail Textuals 1) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive excluded from the calculation of diluted loss per common share</a></td>
<td class="nump">10,879,500<span></span>
</td>
<td class="nump">10,759,500<span></span>
</td>
<td class="nump">10,879,500<span></span>
</td>
<td class="nump">10,759,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive excluded from the calculation of diluted loss per common share</a></td>
<td class="nump">1,142,500<span></span>
</td>
<td class="nump">1,151,000<span></span>
</td>
<td class="nump">1,142,500<span></span>
</td>
<td class="nump">1,151,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6803759072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>University of Mississippi Agreements (Detail Textuals) - University of Mississippi - Intellectual Property<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 14, 2015 </div>
<div>USD ($) </div>
<div>License_agreements</div>
</th>
<th class="th">
<div>Oct. 15, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 29, 2014 </div>
<div>USD ($) </div>
<div>License_agreements</div>
</th>
<th class="th"><div>Jul. 31, 2013</div></th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_AgreementAxis=nmus_UniversityOfMississippiAgreementsMember', window );">University of Mississippi Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_TermOfMemorandumOfUnderstandingAgreement', window );">Term of memorandum of understanding agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NoticePeriodForTermination', window );">Notice period for termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_OptionPaymentDueAndPayable', window );">Option payment for shortened period due and payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_AgreementAxis=nmus_OptionAgreementMember', window );">UM 5050 pro-drug agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NumberOfLicenseAgreements', window );">Number of license agreements | License_agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NoticePeriodForTermination', window );">Notice period for termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_AnnualFeesForLicenseAgreement', window );">Annual fees for license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_AggregateMilestonePaymentsIfMilestonesAchieved', window );">Aggregate milestone payments if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_OptionPaymentDueAndPayable', window );">Option payment for shortened period due and payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_AgreementAxis=nmus_OptionAgreementMember', window );">UM 5050 pro-drug agreements | October 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_OneTimeUpfrontPayment', window );">One time up front payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_AgreementAxis=nmus_LicenseAgreementMember', window );">UM 8930 pro-drug agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NumberOfLicenseAgreements', window );">Number of license agreements | License_agreements</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NoticePeriodForTermination', window );">Notice period for termination</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_OneTimeUpfrontPayment', window );">One time up front payment</a></td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_AnnualFeesForLicenseAgreement', window );">Annual fees for license agreement</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_AggregateMilestonePaymentsIfMilestonesAchieved', window );">Aggregate milestone payments if milestones achieved</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_AgreementAxis=nmus_LicenseAgreementMember', window );">UM 8930 pro-drug agreements | December 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_OneTimeUpfrontPayment', window );">One time up front payment</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_AggregateMilestonePaymentsIfMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents amount of aggregate milestone payments under the license agreements if the milestones are achieved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_AggregateMilestonePaymentsIfMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_AnnualFeesForLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents annual fees for license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_AnnualFeesForLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_NoticePeriodForTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents written notice period for termination under agreement by either party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_NoticePeriodForTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_NumberOfLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_NumberOfLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_OneTimeUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents amount of one-time upfront payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_OneTimeUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_OptionPaymentDueAndPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents option payment for this shortened period due and payable on demand.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_OptionPaymentDueAndPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_TermOfMemorandumOfUnderstandingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents duration of an agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but not limited to, weeks in a year or quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_TermOfMemorandumOfUnderstandingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_UniversityOfMississippiAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line item represents information regarding University of Mississippi agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_UniversityOfMississippiAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_AgreementAxis=nmus_UniversityOfMississippiAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_AgreementAxis=nmus_UniversityOfMississippiAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nmus_UniversityOfMississippiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nmus_UniversityOfMississippiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_AgreementAxis=nmus_OptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_AgreementAxis=nmus_OptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_MonthAndYearOfAgreementAxis=nmus_OctoberTwoThousandFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_MonthAndYearOfAgreementAxis=nmus_OctoberTwoThousandFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_AgreementAxis=nmus_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_AgreementAxis=nmus_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_MonthAndYearOfAgreementAxis=nmus_December2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_MonthAndYearOfAgreementAxis=nmus_December2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6791711328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Future minimum payments (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2016</a></td>
<td class="nump">$ 56,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2017</a></td>
<td class="nump">161,963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2018</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2019</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2020</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">$ 218,634<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6791876240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Detail Textuals)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 05, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2014 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,267<span></span>
</td>
<td class="nump">$ 79,771<span></span>
</td>
<td class="nump">$ 56,680<span></span>
</td>
<td class="nump">$ 240,746<span></span>
</td>
<td class="nump">$ 170,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,525<span></span>
</td>
<td class="nump">$ 152,288<span></span>
</td>
<td class="nump">675,840<span></span>
</td>
<td class="nump">$ 232,862<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_AgreementAxis=nmus_LeaseAgreementMember', window );">Lease agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of corporate office headquarters | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_AgreementAxis=nmus_LetterAgreementMember', window );">Letter agreement ("Agreement") | Contract manufacturing organization ("CMO")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_AnalyticalMethodDevelopmentAndQualificationExpense', window );">Estimated analytical method development and qualification</a></td>
<td class="nump">$ 142,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_AgreementAxis=nmus_LetterAgreementMember', window );">Letter agreement ("Agreement") | Contract manufacturing organization ("CMO") | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_FeesAndExpensesForServicesProvided', window );">Fees and expenses for the initial evaluation and development</a></td>
<td class="nump">154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_AgreementAxis=nmus_LetterAgreementMember', window );">Letter agreement ("Agreement") | Contract manufacturing organization ("CMO") | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_FeesAndExpensesForServicesProvided', window );">Fees and expenses for the initial evaluation and development</a></td>
<td class="nump">$ 183,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_AnalyticalMethodDevelopmentAndQualificationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents analytical method development and qualification expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_AnalyticalMethodDevelopmentAndQualificationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_FeesAndExpensesForServicesProvided">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of fees and expenses for services provided.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_FeesAndExpensesForServicesProvided</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_AgreementAxis=nmus_LeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_AgreementAxis=nmus_LeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_AgreementAxis=nmus_LetterAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_AgreementAxis=nmus_LetterAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nmus_ContractManufacturingOrganizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nmus_ContractManufacturingOrganizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6802790160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit and Redeemable Convertible Series B Preferred Stock - Summary of option activity under 2014 Plan (Details) - Omnibus Incentive Plan 2014<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_SharesAvailableForGrantOfOptionsRollForward', window );"><strong>Shares Available For Grant Of Options &amp; Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_SharesAvailableForGrantOfOptionsOpeningBalance', window );">Balance at the beginning | shares</a></td>
<td class="nump">2,020,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_SharesAvailableForGrantOptionsExcludingRestrictedstock', window );">Subtotal | shares</a></td>
<td class="nump">820,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_SharesAvailableForGrantOptionsGranted', window );">Options granted | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_SharesAvailableForGrantOptionsExercised', window );">Options exercised | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_SharesAvailableForGrantOptionsCancelled', window );">Options cancelled | shares</a></td>
<td class="nump">37,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_SharesAvailableForGrantOfOptionsOpeningBalance', window );">Balance at the ending | shares</a></td>
<td class="nump">857,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the beginning | shares</a></td>
<td class="nump">1,180,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options cancelled | shares</a></td>
<td class="num">(37,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the ending | shares</a></td>
<td class="nump">1,142,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_OptionsOutstandingPricePerShareRollForward', window );"><strong>Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_OptionsOutstandingPricePerShareOptionsGranted', window );">Options granted | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_OptionsOutstandingPricePerShareOptionsExercised', window );">Options exercised | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_OptionsOutstandingPricePerShareOptionsCancelled', window );">Options cancelled | $ / shares</a></td>
<td class="nump">1.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the beginning | $ / shares</a></td>
<td class="nump">0.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options cancelled | $ / shares</a></td>
<td class="nump">1.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the ending | $ / shares</a></td>
<td class="nump">0.61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_OptionsOutstandingPricePerShareRollForward', window );"><strong>Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_OptionsOutstandingPricePerShareOpeningBalance', window );">Balance at the beginning | $ / shares</a></td>
<td class="nump">0.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_OptionsOutstandingPricePerShareOpeningBalance', window );">Balance at the ending | $ / shares</a></td>
<td class="nump">0.42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_OptionsOutstandingPricePerShareRollForward', window );"><strong>Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_OptionsOutstandingPricePerShareOpeningBalance', window );">Balance at the beginning | $ / shares</a></td>
<td class="nump">3.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_OptionsOutstandingPricePerShareOpeningBalance', window );">Balance at the ending | $ / shares</a></td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_SharesAvailableForGrantOfOptionsRollForward', window );"><strong>Shares Available For Grant Of Options &amp; Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Shares used for restricted stock awards (see discussion below) | $</a></td>
<td class="num">$ (1,200,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_OptionsOutstandingPricePerShareOpeningBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents options outstanding price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_OptionsOutstandingPricePerShareOpeningBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_OptionsOutstandingPricePerShareOptionsCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents options outstanding price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_OptionsOutstandingPricePerShareOptionsCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_OptionsOutstandingPricePerShareOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price per share at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_OptionsOutstandingPricePerShareOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_OptionsOutstandingPricePerShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents options outstanding price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_OptionsOutstandingPricePerShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_OptionsOutstandingPricePerShareRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_OptionsOutstandingPricePerShareRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_SharesAvailableForGrantOfOptionsOpeningBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents shares available for grant of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_SharesAvailableForGrantOfOptionsOpeningBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_SharesAvailableForGrantOfOptionsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_SharesAvailableForGrantOfOptionsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_SharesAvailableForGrantOptionsCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents number of options cancelled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_SharesAvailableForGrantOptionsCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_SharesAvailableForGrantOptionsExcludingRestrictedstock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents total of number options granted, exercised and cancelled during the period excluding restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_SharesAvailableForGrantOptionsExcludingRestrictedstock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_SharesAvailableForGrantOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents number of Options exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_SharesAvailableForGrantOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_SharesAvailableForGrantOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents number of Options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_SharesAvailableForGrantOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nmus_OmnibusIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nmus_OmnibusIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6795827520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit and Redeemable Convertible Series B Preferred Stock - Summary of weighted average assumptions for employee option (Details 1) - Stock Option - $ / shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility factor</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of options granted during the periods</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2.69<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.85%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6811655584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit and Redeemable Convertible Series B Preferred Stock (Detail Textuals)<br></strong></div></th>
<th class="th" colspan="13">1 Months Ended</th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 21, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2015 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2014 </div>
<div>Investors </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2014 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2014 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 17, 2012 </div>
<div>Advisors </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_TermOfWarrant', window );">Term of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ValueOfCommonStockCalledByWarrants', window );">Value of common stock called by warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_AmortizationOfWarrantServiceCost', window );">Amortization of warrant service cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,145<span></span>
</td>
<td class="nump">$ 46,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Number of shares issued for services | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_AmortizationOfGeneralAndAdministrativeExpenses', window );">Amortized general and administrative expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Fair market value of common stock issued recorded as prepaid expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 168,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued to group of private investors | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="nump">241,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Value of shares issued to group of private investors | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 724,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value of common stock issued (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NumberOfInvestor', window );">Number of individual investor | Investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 775,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 744,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 466,200<span></span>
</td>
<td class="nump">$ 2,882,682<span></span>
</td>
<td class="nump">$ 2,929,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued to group of private investors | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_MinimumIssuanceOfSharesInEquityFinancing', window );">Minimum equity financing under down-round protection feature | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 286,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_MaximumIssuancePricePerShareInEquityFinancing', window );">Maximum common stock issuance price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ConversionPrice', window );">Conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">580,000<span></span>
</td>
<td class="nump">580,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares issued in conversion | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,812,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants', window );">Number of preferred stock and warrants sold | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_MaximumIssuancePricePerShareInEquityFinancing', window );">Maximum common stock issuance price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ConversionPrice', window );">Conversion price | $ / shares</a></td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted | shares</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,615,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares issued in conversion | shares</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,812,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Proceeds received from the Series B financing | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionTerms', window );">Preferred stock, redemption terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(A) 115% of the conversion amount and (B) the product of (1) the conversion rate in effect at such time and (2) the greatest closing sale price of the Common Stock during the period beginning on the date immediately preceding such triggering event and ending on the date such holder delivers the notice of redemption.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConversionBasis', window );">Preferred stock, conversion rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1,250:1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Liquidation preference value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ValueOfCommonStockCalledByWarrants', window );">Value of common stock called by warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 326,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">6,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_TermOfWarrant', window );">Term of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NumberOfAdvisors', window );">Number of advisors | Advisors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ValueOfCommonStockCalledByWarrants', window );">Value of common stock called by warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,000<span></span>
</td>
<td class="nump">$ 86,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_AmortizationOfWarrantServiceCost', window );">Amortization of warrant service cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued to group of private investors | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ValueOfWarrantsIssued', window );">Value of warrants issued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares vested | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_MinimumIssuanceOfSharesInEquityFinancing', window );">Minimum equity financing under down-round protection feature | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_MaximumIssuancePricePerShareInEquityFinancing', window );">Maximum common stock issuance price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants | Series A preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_TermOfWarrant', window );">Term of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants | June 2014 Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ValueOfCommonStockCalledByWarrants', window );">Value of common stock called by warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ValueOfWarrantsIssued', window );">Value of warrants issued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ConversionPrice', window );">Conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_AmortizationOfGeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amortization of general and administrative expenses during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_AmortizationOfGeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_AmortizationOfWarrantServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amortization of warrant service cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_AmortizationOfWarrantServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents conversion price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_EquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_EquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_MaximumIssuancePricePerShareInEquityFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents maximum issuance price per share under equity financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_MaximumIssuancePricePerShareInEquityFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_MinimumIssuanceOfSharesInEquityFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents value of minimum issuance of shares under equity financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_MinimumIssuanceOfSharesInEquityFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_NumberOfAdvisors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of advisors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_NumberOfAdvisors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_NumberOfInvestor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents number of individual investors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_NumberOfInvestor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_TermOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents term of warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_TermOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ValueOfCommonStockCalledByWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of common stock called by warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ValueOfCommonStockCalledByWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ValueOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents value of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ValueOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConversionBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConversionBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The redemption terms of preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity. The redemption features of this capital stock are solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_AgreementAxis=nmus_StockPurchaseAgreementJune2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_AgreementAxis=nmus_StockPurchaseAgreementJune2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6792098048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit and Redeemable Convertible Series B Preferred Stock (Detail Textuals 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 20, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Recognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 263,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total amount of unrecognized compensation cost related to non-vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,109,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,109,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Recognized period of non-vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 1 month 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Recognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 181,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 544,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nmus_OmnibusIncentivePlan2014Member', window );">Omnibus Incentive Plan 2014 | Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Aggregate number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,142,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">857,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">857,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiry period of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants', window );">Percentage of option price at least of fair value on date of grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_CommonStockVotingPercentage', window );">Voting percentage of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_PercentageOfFairValueOptionPriceAtDateOfGrants', window );">Percentage of fair value option price at date of grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_MaximumExercisablePeriodOfFairValueOfOption', window );">Maximum exercisable period of fair value of option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vested period of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining contractual life of options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 1 month 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value of options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,142,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,142,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,180,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options to purchase shares of common stock, exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nmus_OmnibusIncentivePlan2014Member', window );">Omnibus Incentive Plan 2014 | Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Number of restricted stock awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nmus_OmnibusIncentivePlan2014Member', window );">Omnibus Incentive Plan 2014 | Restricted stock awards | Senior management and board of directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Number of restricted stock awards granted</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Recognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 281,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_FairMarketValueOfSharesGranted', window );">Fair market value of shares granted</a></td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nmus_OmnibusIncentivePlan2014Member', window );">Omnibus Incentive Plan 2014 | Restricted stock awards | Minimum | Senior management and board of directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vested period of shares</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nmus_OmnibusIncentivePlan2014Member', window );">Omnibus Incentive Plan 2014 | Restricted stock awards | Maximum | Senior management and board of directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vested period of shares</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_CommonStockVotingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_CommonStockVotingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_EquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_EquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_FairMarketValueOfSharesGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of shares granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_FairMarketValueOfSharesGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_MaximumExercisablePeriodOfFairValueOfOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents maximum exercisable period of fair value of option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_MaximumExercisablePeriodOfFairValueOfOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_PercentageOfFairValueOptionPriceAtDateOfGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents percentage of option price least of fair value on the date of grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_PercentageOfFairValueOptionPriceAtDateOfGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents percentage of option price least of fair value on the date of grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share instruments newly issued under a share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nmus_OmnibusIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nmus_OmnibusIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=nmus_ManagementAndBoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=nmus_ManagementAndBoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6803623264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision for Conversion of Preferred Stock (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Aug. 31, 2015</div></th>
<th class="th"><div>Aug. 21, 2015</div></th>
<th class="th"><div>Jul. 31, 2015</div></th>
<th class="th"><div>Apr. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ProvisionForConversionOfPreferredStock', window );">Fair value of the conversion feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_MinimumIssuanceOfSharesInEquityFinancing', window );">Minimum equity financing under down-round protection feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 286,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_MaximumIssuancePricePerShareInEquityFinancing', window );">Maximum common stock issuance price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ProvisionForConversionOfPreferredStock', window );">Fair value of the conversion feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of additional shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_GainLossOnConversionRightPreferredStock', window );">Change in fair value of conversion rights of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">286,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">986,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">580,000<span></span>
</td>
<td class="nump">580,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ConversionPrice', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_MaximumIssuancePricePerShareInEquityFinancing', window );">Maximum common stock issuance price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Proceeds received from the Series B financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of additional shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,232,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_GainLossOnConversionRightPreferredStock', window );">Change in fair value of conversion rights of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 986,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,058<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 82,872<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">5,615,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ConversionPrice', window );">Conversion price</a></td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents conversion price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_GainLossOnConversionRightPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount related to gain or loss on conversion right of preferred stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_GainLossOnConversionRightPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_MaximumIssuancePricePerShareInEquityFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents maximum issuance price per share under equity financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_MaximumIssuancePricePerShareInEquityFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_MinimumIssuanceOfSharesInEquityFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents value of minimum issuance of shares under equity financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_MinimumIssuanceOfSharesInEquityFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ProvisionForConversionOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount related to provision for conversion of preferred stock as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ProvisionForConversionOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6802555536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Series B Warrants (Details) - Series B Warrants - $ / shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility factor</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 7 months 10 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of warrants</a></td>
<td class="nump">$ 0.14<span></span>
</td>
<td class="nump">$ 0.46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_SeriesBWarrantsMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.11%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">3 years 10 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_SeriesBWarrantsMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.29%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nmus_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6785026896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Series B Warrants (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Apr. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants</a></td>
<td class="nump">$ 781,811<span></span>
</td>
<td class="nump">$ 781,811<span></span>
</td>
<td class="nump">$ 759,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Series B warrants</a></td>
<td class="nump">869,990<span></span>
</td>
<td class="nump">869,990<span></span>
</td>
<td class="nump">$ 2,454,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ChangeInFairValueOfWarrantLiability', window );">Change in fair market value at the re-measurement date recorded as non-operating expense</a></td>
<td class="nump">$ 27,665<span></span>
</td>
<td class="num">$ (1,584,969)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_SeriesBWarrantsMember', window );">Series B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NumberOfWarrantsIssued', window );">Number of warrants issued</a></td>
<td class="nump">6,437,500<span></span>
</td>
<td class="nump">6,437,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants</a></td>
<td class="nump">$ 2,935,800<span></span>
</td>
<td class="nump">$ 2,935,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Proceeds received from the Series B financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ExpirationPeriodOfWarrants', window );">Warrants, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ChangeInFairValueOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount related to change in fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ChangeInFairValueOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ExpirationPeriodOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents expiration period of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ExpirationPeriodOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_NumberOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of warrants issued during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_NumberOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13495-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nmus_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6811678560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Aug. 21, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Value of common shares issued to services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 168,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | Technology license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Value of common shares issued to services</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Intial payment to license agreement</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ReductionInConversionPrice', window );">Reduction in conversion price</a></td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | Series C warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ReductionInExcercisePrice', window );">Reduction in exercise price</a></td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | Convertible preferred stock | Series C preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross proceeds received</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Each share of preferred stock convertible into</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_CoversionPriceOfCovertibleSecurities', window );">Conversion price, per share</a></td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_CoversionPriceOfCovertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents per share value of each convertible security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_CoversionPriceOfCovertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ReductionInConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents reduction in conversion price due to other series of shares transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ReductionInConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ReductionInExcercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents reduction in exercise price due to other series of shares transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ReductionInExcercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nmus_SeriesCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nmus_SeriesCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>43
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M82$KPT)6AH6L# M9AUC(.OPD*VG^Z)Q^ %!+ P04    " !7AFE)2'4%[L4
M   K @  "P   %]R96QS+RYR96QSK9++;L) #$5_)9I]<4HE%A%AQ88=0OR
M.^,\E,QXY#$B_?N.V(#"0ZW$TJ][CZZ\#JFL#C2B]AQ2U\=43'X,J<K]VG2J
ML0)(MB./:<&10IXV+!XUE])"1#M@2[ LRQ7(K8[9K.?:Q<[51G;NTQ1'E):T
M-M,(9Y;AFWE89.D\^(GT%V-NFM[2ENW)4] '_K,- \]YEE<>QW8OG*\M"_V/
MZ'D4X$G1H>)%]2-F Q+M*;V"^GH A3&^.R6:E((C-Z."N[_8_ )02P,$%
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MB1FO=_]$X]3/$//KM]WA U!+ P04    " !7AFE)\*M1GI4"  !L"0  $
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M?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8.9_
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M?S7'5>Z?D< G1GZU%]DH;^,PN. KNA/YQH9O>#I#I@W6C CS#>J[D(P^*6%
MT<<XMIT9A_%/FDPT/P%.!#@38/Y?0C(1DIDPABX:/3/G^H(DJDK.AH"/E]$C
M?>=@EZC(U7K3!,K\4R<3:O=1Q67TT&8FQ'%$P 4"S(A(V9X%H$_@"!TZ_%?@
MY"(2OT#B/4%BZ,F"GOKIJ9>>&GJZH&=6 %Q$[A?(O *90]]8 B,B-XANC' &
M\BQ;B7/NE<D=F:TEXR(*O\#&*[!QZ,!.%0]DY0Q;K\36Y5O)<O1 5K*E\$H4
M+C^U\K%PK@/&FV(+\A4A_4SX*BMVI>S4\F%6D@NLU"]P+=CYY<-L5U2\17P
MT+50V"HN!L8K*OY*!HEK =@JB>=V5F/F+WG@5C2T\VS"9$N,??_1XI&EF-],
M\Q%!S>Z=Z76+W;G!':!YI#_A5=FC&_Z!^*WM1'!F4CWUYD&^,B:Q<B5^44XT
MJ@7/"X*O4D\W:L['IC0N).N?/79N]-5?4$L#!!0    ( %>&:4F+#3>Z& 0
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ML>I85:UUH9,'MV3.[JA^?\CML?6WRMW7_>&U?VBKR]M9_/Z#P.I_4$L#!!0
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MO]B]='U3OX8L%W7QZ_I[/(V_E^N;-)G"< !/ 7P+R-2' 7H*T+> FS$<8*8
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M<VAE970W+GAM;'U3P6[<(!#]%<0'!"_K3:N5UU(V5=4>*D4YM&?6'MLHP+B
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M?7C9U/\&T4.0DMW=4]*%_[,8"AH?CP_A;*>1F@R/_>V#++^T_ U02P,$%
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M$I:H7%I)V3N/^@JA1(OW<9<F[<-XL^<3;!W )P"? =^R)'Q,E&3>"R^*W.)
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MA?^S& H:'X\/X6RGD9H,C_WM@RR_M/P-4$L#!!0    ( %>&:4GL/!@ 70(
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MA-;ZZ6<WU\N]7186Q]LKW/X*JK]02P,$%     @ 5X9I2;EO=\RB 0  L0,
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M[+2Q%4)Q+0C=Z1O=ZQFY7Y1\J\PKT^]-.S6V"R4.YR&XG\2SOU!+ P04
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M-%)SWO7P;B%9<WN1AF<Q_0]02P,$%     @ 5X9I27E=2&G( @  F@P  !D
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M3T?FO*Q>G:L++8_7+X'F<V3Q%U!+ P04    " !7AFE)CYIPBN8!  "@!0
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M4&B4F>9Z+MP+XA:*#[?W<'Z4JW]02P,$%     @ 5X9I2;L(W_/; @  V@L
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MH+YO_9]*M%6C[RL:QUGPW@4:-.M>0R<:,BH"%7VTH,AB3:WI-$YP  9S9#I
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MRM;*KI?) I]_-*NBK'&-E\5RE>2M%W6KQ7()X+VNB]E/<71-9QY=K>NJAH.
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MUW=%F?W9I-]%Q_'Q^23*J@K/GVZ&H]V X7S"J]HL;^ V*&>F%X_CZ>'A\)=
MI.1#(51T:?')L^/SH_CT]!!_QB$28*D DJJNOH-GHZE=\@+DCRQE'LX8AMRW
M=V6M,T:HW!6+%!#VFR@U\VR6M:B&\+"J&X+?19.CDR$0CL_C\_%1/#XY^B(X
MXN>'6WS> F;K%J=IAG "/$2Z?)#E![-DE0%>-M_\L0?A@0ZLEVLF-#VP8CRO
MM@%KZTK0QK;Z=(@E[GU(\#+>F3H#7EOM]_/(ZQIV0D3O:@ZL.0<DRY [(QL8
ME@F??.TLMD1[61ZE0+63$N@[G!8AS,^_URV\^UHC,LY]K=&*?LGOR4.&=.%G
M#]=#2>C4ABG"4P\W_'KCR76^WGTLG:\.P#RX1]>?X)]WK][#';IZ'5U]>/7Q
MXM,;>"':6^?)&FB'20<NT]'6BEN+,%T!J!+2)?H$#) T0;B>L5B:FGNS*$C(
M:[[WO<D-*E;X6I(NLYQ4MCJ[;YV@"'$;9W9K6Q15CP@KW^+ISXIEQWG?)<#(
M(\"->9(IJ@#%%KG"DL"6#O4>F"%.&]T8$*QP!!P_JI//FV2PH3=UU.;?7R15
M-F,(9XLUTGB:&_%X)GB%"+4EDHNJMZY@'/@ 1EBM"8XW_=.X\1EUVX/R[;W8
M)$SV0=P33<OL]JXFQKEAK#Z*\82[='EQ_=OH]=NK'[>\2Z2!S1?%0Q7-RV+I
MH2DPH^R>F.7S-GO_X[H2 ;(N0.Z%S<Y ER>1BD ,?\6?2:W3<]EJ:%"-8+B,
M:&.G!'4 AXI:(!PRW 2FH7(KVHHVV@W^S.^X2^ Q?Q5S$(]1-@>-I86K?QC_
MC_@/DQ9?WO:F=<G?]&F%W[+B1@OR/FA!!=;0^E-[202?J%K?5+,R6]4LL_;<
M]Z:>Y:FB0PK1-F>Z"<4RN!C5)CSXL 8:G.#"Z-ITJ=T;%]<UT:;%S5DVV["X
MLI@9D\HG,X\36DG!J1='\?GD<(,$$0[8H!+M,8<'LW!8(9T&#AG=/';NJ^M#
MH.:E29##I(9_VB>:NJVAIM>B$P-GN<WR')> 1TIVJ2=\;1 _![\C"U"Z+G$&
M0&1Y%>]VZP#?Y#7(7%4+A=X,\+*7;F38A(F6+(,8E$':"A7HE_BF6"R5SE@*
M!#LIUF6(.F+0J-8+PEFE1Z/H$PQDOWR A3.U ;FC!@UU?!J?G4X):O0,J7&)
M:P)=+8D:EC$65^"M&T.XP!027BZ 6=&*95J!WNAG[1ITHD*WKA+B?*M-^SL<
MGYS%AX>'H^AZC6+9D@U6_\_W>A*[0Y$] M>S0_+= [FE;X?-@YQ,XN/)5"QL
M7W-;?W=$!C D+4 @%3&?9\PU$2;F,\)CG55WI!<CJ1P?XD'CCR!*I[#3AG4R
M*AX8RO5=!B@"*R[*UO:>+APUU/AH0%SZ?8/-^T>_$I;U1%3OG:+%5T10><H8
MS65N/H1NR/=H?YW2Z77 M'IX5%*O2UJA:#VPISAZL:X (4%\O+ \BK#]>KU<
M)N4C6:ZRVSR;PSG!:L5XC8#X4"RR6;]]VW]EP-8R'D6_U,(Z!Z8Q4!<B9/F
M]N&\9G&UV\D'4(6K=9,5*T"Q93(S:T)9DH;Q=M9W0$E6BR0G"5RT5['Q+I>F
M1*,3T J\T66RHJ]5B$GR',2^O,A "JGORF)]"[06[0TUZ+G57;:*'K+ZCFC!
M#WE&JDU-&W\')XW_7:TR9E6]CZ.]W1_>[>[C)N8F1>UY\8A$:IG5M=@:Q6=
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MX)]*!!'1$AK2L^"6H&XE5[E")*RJ OU5*CP(FP86>@."NF.4/\)#X/W^02"
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MM*+JG(CB2RA-T2043,3PQ\[)SG7S3IM90QX)]@R5&H7J'BKI[LN7"D)3V"*
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M9%FE@:<GB/[^AU0.!$5W$T:N@CJ0%ZB\\,& 8OG:W)1KS,)P6Z"QY5Y?7/_
M4\#3@\-)]!;3X5LIAOWI;C8K8NB;J[YO!O(4)Z.!)#MOA#>2V@0;. J#E RQ
M#LE<P5PFT-C@K-?$,'Y \F63%/;>7?VP+P';[\@RF]\F?''_6&2Y+\N3VH K
MUJC&;(4V=<Z-(/%YG7(8GR;TH9E:E$FD0T':(K*W!:JUB#36U;+WYL.^,[61
M0T$CO;!>06V&TQTCS*N9(:>WZ6&HA%*B'?S[YH-.C\XPD!G1@?+(1F)+WFT&
M >V?L^':7^M#-;2YV'P HQV,*9//J@'<3H>B7$F\3.1"L0(%!4[@2O ]+K9R
M6]09A[E0$+9O\74(0>HUP4TLG#./<R(D)4#/LU<FR+K1GE*1THJ5KJS)/9%L
MX0I+18BIVBU= N'47L.F<9,1-6--3H[1A8;][:__$CV4F Y*)H-L9AVDA?ML
MA  $QG>(2'% ZI.WQ:O<(T^3<\U'"Y#_,X@Q1"$Y8D/K5#845YC%3W=BN@U_
M%"$&Q' TX"_62.QBI#PK@Z@*JF11+M(' +&7JN?,&-9P+^&R\D[, =-=*&\)
M>J$[Q^1-NWF\.'3-Q+=BX%#N'M.RL#F]"XHT^/3;2XYWXCS"RI:M(DJ@$:DF
MX9M<S&#,$C_D2(82Q2R,HUX@X9&(V!;HK!0Z)R$.QRF]KU0C$%.G\U_ OL83
MWM=-5APDZ9TA'G)7 !Z9!?D%RW5*3':QY%F*E56FEVO0&/%G^@[E?&05,Z<>
MBY(]N'8*M"%2I"3)>3W(7E<\)@LX#N<!\=)8R427<<BR]2, _/$@YX;4AV>3
M*87=KZC&3F/RV-4X$'D\9PHO28)T+,S-$2YL%N;[IOEU;1^-"*)UYVX!)R7=
M3+]C8Q%,A-&!*847/9N,QEIP4NU%BM1\F"))!1>,A"JI](I'RU%V-1MI T^6
MA]H<[F"1DY<N<S5(BQ!M2UG4;+C*7/H)D\E:2L^4C-;D-DDPZEO>Z (+O$7C
MG1P"F!^[:)*X^+SM_O!NY.?!8M4,ICL/'#&#HI<X]^F,6;%I7QMW(V W"[2B
M,N&#NUD;,4;+54)&_8[(()H6'S%@!X<3&ZH$!&>:VZBA 4#71)[T$_YM'!*Y
M:;E\(<G"ZUQ<,9@"01'Z@"<'9$98KT ++=#"+$85%T:IA3Q(KX7]?SX@\F[?
M]-P>:!K%R&W-(63?&$'*6A3) H$9JT[ YC!IL?9)](27NR2F=8FF %K6<)SZ
M&H8],XE4!=C;H T\0?WCK$#K+A!U*WS88 U!)L#TL_.C0XM4Z$->5ZB(49([
MKZ\!+5X1W#2* #)D1A95 6\?!=6F:RVB;"E$(^'Z9&0G[^")SQ$UFWN:]O'$
MA^+?&T?$?0]Q1$'U-"L6T=[NY0LTCC^5$6[/ K\V&_%O'%\X_Z:=;,532+Q>
MEZ* T67D '/8S\)+C('?2XD3<O@RU<"E_V"L;3PZ_D=A;56/%/H/R>0Z*,DO
MS.6(L/UC<[F\P=PXO4<JDC@J35D)\N9#D_4IUVMPJ2]G4 (YN:N*!L*V?E%V
MM*GD_*5?<OY)+T<O71)VOX7D:!0-CT*VG."=0'$<=^F-BN)^V<L%C8-@\[QJ
M9+7#_$PL/91@M".[7][D>7'/./K;]0T6YZB([7U(RI]L@1DADOT&GEFR7*U%
MVN'IR7Q )@]*!/(.1/:AIG+*F/>)NQS8:4#<"5L,M@_A/982)\9%?\4* 6*"
MIG/-(_91>+G@]LZ+?8,[+G"51B'@UGOG!Y?R?CAHT]:NK.T(+O57YI;I^#/!
M5#62J$>#UM41K*;N1**:+*!ZK@Q_2)4LF6U*%$L0]N:%N.%%.8\G)Z?-E.R&
M-B!;#8@CE]+3%&1!H: 4$;%I\=-S&(2+,(>U'<>'9Z=1A:^3S[NV: 6?G8"N
M\ EM59=D_HM>EB2G7:\SF&Q\>@I"5%#:Z"(ZGYQ,3GQ,8QQ*N^X\8_VZM'!B
MN&/L]30^.CT*I)$!043R" ,D5.E>Z'->>(332OF=_!%.@U9.A_$>HZGE-)KR
M;V 0[;[A'"I"9R)N]&B^+D%PO"/;\TV!A;?\\E 6%<.+[Y&*-FSI?MJ%'O'U
MM ,IQ 0[]2[A:3\[C:?3<QB0;XJI0[3TQ!$\I,;^*LMT@DS-/G,_K4=8/Q[P
MZ7E\>CJFOSZ;GL0GZ#N"K:Q8I%L\.K?"-LX$;_2Z>S.-4M6R!5K*Y/@P/CWF
M,9Z- :?/C\;-M7"L%B5^K9==(B4ZD&;H4-((LM*O:M&:N#_KD>L:<$! ]7P'
M_[CS+$(0G8[QM].=\<DX/C\YPE_.=@[PGW/Z9W((_Q#*4\8^_H*P@*\GX[/X
MY.AXYRW(Q@N0,&HB#%J/_JV+?Z+PH:Q:D5 %[.UB?8NI<4?JLOE=<9='+S#?
M&X1@U'[0N";1J%FU!'X341(E%K'!T'T@5@E>U>#B))+V_HH42!3@+^\P/CK)
M73C'YG?;,[,OJSUW<[%8OBW)V8LS%;"+ D:>!O@:+07R]5W&QD.4D)<2848=
MMX + 2>. 0<HX(/B6^J,7U#!>FZ]__[?YAE(]53+*UU+]/Z\3-:I!]=OU'O
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MS'?)U5'XU[BW#JG6ZA?WC(=R[M2#E&(/C"&MBWVOKB,67F>(.%HBF<4$8Z^
MX$$V]V@WS^C*%4[CDS&S%04V03_V#OYX-'4QYF_F+@$S@"5/9JM<HK/&=O=
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M< 1T)J:3:Q<;?>VEM%TXV\R'8I%1E]T]_6F_.>4/K-2_TH2T3<_IX#C!URH
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MPJLML<XV['.:#4N K/)@^#.Q>#2(S#',0];J1$B./4*0VJY<0\'/#X9RP6A
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MN2%*618DD7(\FO>27"BX,(G"[NCYS@]M-'93H.C#9I,;E![J>B&E070P6T.
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MI3+JT4R=E],K!MI;IY7B!JJ E3L;V=P8%:^E3JMM_A<[BN0N97\U6+FMOG,
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MVP$  %]R96QS+RYR96QS4$L! A0#%     @ 5X9I262&T#=T 0  RA,  !H
M             ( !R0(  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ 5X9I2?"K49Z5 @  ; D  !               ( !=00  &1O
M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !7AFE)WC: L3X!  !I P  $0
M            @ $X!P  9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " !7
MAFE)F5R<(Q &  "<)P  $P              @ &E"   >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( %>&:4G2FN'Q4P(  &X+   -
M  "  >8.  !X;"]S='EL97,N>&UL4$L! A0#%     @ 5X9I2;5?*11H P
M/0L   \              ( !9!$  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0
M   ( %>&:4E#>T8R2@(  /0'   8              "  ?D4  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !7AFE)BPTWNA@$  !M$P
M&               @ %Y%P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L!
M A0#%     @ 5X9I29K-K6)1 @  G0@  !@              ( !QQL  'AL
M+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( %>&:4GR&>H6O0,
M !P0   8              "  4X>  !X;"]W;W)K<VAE971S+W-H965T-"YX
M;6Q02P$"% ,4    " !7AFE)\*[_--($  #R%P  &               @ %!
M(@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ 5X9I20 H
M2V K @  SP8  !@              ( !22<  'AL+W=O<FMS:&5E=',O<VAE
M970V+GAM;%!+ 0(4 Q0    ( %>&:4EK#FF@G0$  +$#   8
M  "  :HI  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !7
MAFE),T\$Y* !  "Q P  &               @ %]*P  >&PO=V]R:W-H965T
M<R]S:&5E=#@N>&UL4$L! A0#%     @ 5X9I2?@Q(3J> 0  L0,  !@
M         ( !4RT  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0
M   ( %>&:4E_1)A8H $  +$#   9              "  2<O  !X;"]W;W)K
M<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ 5X9I2:S""XF? 0  L0,
M !D              ( !_C   'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q0
M2P$"% ,4    " !7AFE)WZNEQJ !  "Q P  &0              @ '4,@
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( %>&:4D2:^!+
MGP$  +$#   9              "  :LT  !X;"]W;W)K<VAE971S+W-H965T
M,3,N>&UL4$L! A0#%     @ 5X9I2>>,\OJ@ 0  L0,  !D
M ( !@38  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " !7
MAFE)[#P8 %T"  !3"0  &0              @ %8.   >&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( %>&:4E+X5TTI $  +$#   9
M          "  >PZ  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#
M%     @ 5X9I27\2[AJJ 0  %@0  !D              ( !QSP  'AL+W=O
M<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " !7AFE)N6]WS*(!  "Q
M P  &0              @ &H/@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM
M;%!+ 0(4 Q0    ( %>&:4FO\WTY[0(  )4+   9              "  8%
M  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ 5X9I2:\N
MP: K @  (@<  !D              ( !I4,  'AL+W=O<FMS:&5E=',O<VAE
M970R,"YX;6Q02P$"% ,4    " !7AFE)>5U(:<@"  ":#   &0
M    @ $'1@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (
M %>&:4F/FG"*Y@$  * %   9              "  09)  !X;"]W;W)K<VAE
M971S+W-H965T,C(N>&UL4$L! A0#%     @ 5X9I2;L(W_/; @  V@L  !D
M             ( !(TL  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"
M% ,4    " !7AFE)-_D_L$0#  "X#P  &0              @ $U3@  >&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( %>&:4E$\>?K4 (
M %T(   9              "  ;!1  !X;"]W;W)K<VAE971S+W-H965T,C4N
M>&UL4$L! A0#%     @ 5X9I28*7_J;'!P  73   !D              ( !
M-U0  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " !7AFE)
M >E]?P<$  ">%   &0              @ $U7   >&PO=V]R:W-H965T<R]S
M:&5E=#(W+GAM;%!+ 0(4 Q0    ( %>&:4EFF,VGL0,  *,1   9
M      "  7-@  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%
M  @ 5X9I260\ZXEL @  R@@  !D              ( !6V0  'AL+W=O<FMS
M:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " !7AFE)ZUA1/Z<"  #8"0
M&0              @ '^9@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+
M 0(4 Q0    ( %>&:4E_3?:YL0(  #$+   9              "  =QI  !X
M;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ 5X9I26GTP05@
M6   +%0! !0              ( !Q&P  'AL+W-H87)E9%-T<FEN9W,N>&UL
64$L%!@     H "@ R@H  %;%      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.5.0.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>130</ContextCount>
  <ElementCount>217</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>32</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="nmus-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nmus-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nmus-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>003 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/Consolidatedbalancesheetsparentheticals</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nmus-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/ConsolidatedStatementsOfOperationsUnaudited</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nmus-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/ConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nmus-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (Parentheticals )</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/ConsolidatedStatementsOfCashFlowsUnauditedParentheticals</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (Parentheticals )</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nmus-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>007 - Disclosure - Nature of Operations, Business Activities and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Nature of Operations, Business Activities and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nmus-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>008 - Disclosure - University of Mississippi Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/UniversityOfMississippiAgreements</Role>
      <ShortName>University of Mississippi Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nmus-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>009 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nmus-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>010 - Disclosure - Stockholders' Deficit and Redeemable Convertible Series B Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemption</Role>
      <ShortName>Stockholders' Deficit and Redeemable Convertible Series B Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nmus-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>011 - Disclosure - Provision for Conversion of Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/ProvisionForConversionOfPreferredStock</Role>
      <ShortName>Provision for Conversion of Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nmus-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>012 - Disclosure - Series B Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/SeriesBWarrants</Role>
      <ShortName>Series B Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nmus-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>013 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nmus-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>014 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nmus-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>015 - Disclosure - Nature of Operations, Business Activities and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Nature of Operations, Business Activities and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="nmus-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>016 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="nmus-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>017 - Disclosure - Stockholders' Deficit and Redeemable Convertible Series B Preferred Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockTables</Role>
      <ShortName>Stockholders' Deficit and Redeemable Convertible Series B Preferred Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemption</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="nmus-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>018 - Disclosure - Series B Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/SeriesBWarrantsTables</Role>
      <ShortName>Series B Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/SeriesBWarrants</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="nmus-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>019 - Disclosure - Nature of Operations, Business Activities and Summary of Significant Accounting Policies (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesDetailTextuals</Role>
      <ShortName>Nature of Operations, Business Activities and Summary of Significant Accounting Policies (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="nmus-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>020 - Disclosure - Nature of Operations, Business Activities and Summary of Significant Accounting Policies (Detail Textuals 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesDetailTextuals1</Role>
      <ShortName>Nature of Operations, Business Activities and Summary of Significant Accounting Policies (Detail Textuals 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="nmus-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>021 - Disclosure - University of Mississippi Agreements (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/UniversityOfMississippiAgreementsDetailTextuals</Role>
      <ShortName>University of Mississippi Agreements (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/UniversityOfMississippiAgreements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="nmus-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>022 - Disclosure - Commitments and Contingencies - Summary of Future minimum payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Future minimum payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="nmus-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>023 - Disclosure - Commitments and Contingencies (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/CommitmentsAndContingenciesDetailTextuals</Role>
      <ShortName>Commitments and Contingencies (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="nmus-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>024 - Disclosure - Stockholders' Deficit and Redeemable Convertible Series B Preferred Stock - Summary of option activity under 2014 Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockSummaryOfOptionActivityUnder2014PlanDetails</Role>
      <ShortName>Stockholders' Deficit and Redeemable Convertible Series B Preferred Stock - Summary of option activity under 2014 Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="nmus-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>025 - Disclosure - Stockholders' Deficit and Redeemable Convertible Series B Preferred Stock - Summary of weighted average assumptions for employee option (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockSummaryOfWeightedAverageAssumptionsForEmployeeOptionDetails1</Role>
      <ShortName>Stockholders' Deficit and Redeemable Convertible Series B Preferred Stock - Summary of weighted average assumptions for employee option (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="nmus-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>026 - Disclosure - Stockholders' Deficit and Redeemable Convertible Series B Preferred Stock (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockDetailTextuals</Role>
      <ShortName>Stockholders' Deficit and Redeemable Convertible Series B Preferred Stock (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="nmus-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>027 - Disclosure - Stockholders' Deficit and Redeemable Convertible Series B Preferred Stock (Detail Textuals 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockDetailTextuals1</Role>
      <ShortName>Stockholders' Deficit and Redeemable Convertible Series B Preferred Stock (Detail Textuals 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBPreferredStockTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="nmus-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>028 - Disclosure - Provision for Conversion of Preferred Stock (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/ProvisionForConversionOfPreferredStockDetailTextuals</Role>
      <ShortName>Provision for Conversion of Preferred Stock (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/ProvisionForConversionOfPreferredStock</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="nmus-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>029 - Disclosure - Series B Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/SeriesBWarrantsDetails</Role>
      <ShortName>Series B Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/SeriesBWarrantsTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="nmus-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>030 - Disclosure - Series B Warrants (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/SeriesBWarrantsDetailTextuals</Role>
      <ShortName>Series B Warrants (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/SeriesBWarrantsTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="nmus-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>031 - Disclosure - Subsequent Events (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/SubsequentEventsDetailTextuals</Role>
      <ShortName>Subsequent Events (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/SubsequentEvents</ParentRole>
      <Position>31</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>nmus-20160930.xml</File>
    <File>nmus-20160930.xsd</File>
    <File>nmus-20160930_cal.xml</File>
    <File>nmus-20160930_def.xml</File>
    <File>nmus-20160930_lab.xml</File>
    <File>nmus-20160930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>49
<FILENAME>0001640334-16-001933-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001640334-16-001933-xbrl.zip
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M_OYS-D[XGQF:NF[@'_E16/C^-$AXQ6(TX;-J50?8;[NUWXKA>]KOKV2TP6=
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MO\("5*#58GXC)1O  X&HDZTE)HC6,'+L(O4P+QI(SOFB$ED9B-QP:?A W?B
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MR:9+GP0?PC-I;&#G1PG&!G8NW+FJB..83[)0*V*=%U$H5UE7CQ<1!N)B%QQ
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MKBQ%]01K2#U%F443C82<HHH+<F$'DLY<EL=,4-./HFE'HJ58R4X"E,)5ZA]
M+Z&=)[H-X3DIJY1[R5"\MRPI357*L(P9A6>4139GW7I"%2R21('OBJK\N?R6
M5]A:KCI8N*?O9-,$%7E^B6VP%J8I5KP&F(:H1^G)'H JJPYK"@D_>0-FBOT;
M$2_/U@UU:;V1OGS1/X:JHE&S&B"-:8)F+ABEJ@^0P,9JA&$K($ Z!M6(>F_A
MXF*/+W89^YD1O,[UFMU \'K-8BQ%2 9Q*YD"=S+RUOD1PF'DK24;5R79K0SB
M6=C !GW^!:8 -/]VT5[VF(D$:JML(>K#[51-W9_+U$TV!=]!8X)X1EY:^4%
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MU6'+[_L@U6RHOS[+DN:$L?ESU&V3:^^CT&=H6Z]"]S/P1@KG#-,BVO,CC.[
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M>4@^9[ )ECT8M!IP+R0I)O@D#/Z^LD;M?KNOLV7!<-TJPX&X(F !BJD()L6
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M.ZGOWKS)<#P+@YYFV:PJI@;KM3M8K$A43J5"3D*PKV0TC!2BJE./43?(B((
M=W&9%,[-H73"A1Q%40%Y-AV2-.\]FCCTL/<7 16LM#5/J[ J-RKFJ3/-P;T
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M"C9C^!Y,&[@2?)%9A[J%!K4?WO D]_*(8LB2T]':*]-YRG:/*7-AE:K!MC9
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M.+I7AC,GTYS,'W@/X&2^I]B/Y7,I[\1V]UZ)K.I@BAPP+7AP\<[6 __&E-=
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M6/O;%4#\=M']R\4&=\%2M%Q5:%N9VRX'I]V#MV>I6P+P1L("DUX<#5J8!K=
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M8(D]H.NM7=DUH3([-)OCQTY%+:PHB\L" U8'H"9U5-Q$& +3V\AB[HV?R!(
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M:T(<)[-#ITD;=LL><<_SFK;7 I&)=\;-8:?5:W:\P9!UG4%GV*Y0AE;31H5
MNR>!Y=%6ZQW.8@8S@YG!S&#G,M@"U[3&$XI;^.WB/QR'PW6AN]M75]W8I5/T
M!0NH61!+\_KJQ5I4H74"_2%N4G6AV7_9Y=US[SQK+G-"A+BC/:_:Z5]<PCA
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MJ0GUFTATOQ$#4I=$/\0F>V$Z32Q\RUTI?*E.6+!(-+NZ 'NG,>BU:)B?VD/
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M;K-?.](*%/.U1&%./&MD>(Y0-1USY'OPI*QKGEPO'&18?Q7#86^Z[A=N#_.
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M_S[^ @_DE!0SH--C3)-P;LUA_!##00[YESC ?VF>C7#+Y/T(,SS#&09/2N#
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M".)CY0U6Z?'W+K:A0GM97E.<PLN-T?RBY5I0!I7 344&2 ,&-HTBRN#/%PL
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M/RWG[*V/V(;[ [;A+I0WBVVW=[:XMIKAODK_CS>)([_KZ<S3G?&U.>^ KKG
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M36E.DNLTO [OXS0N2H1:?* "O&V#Y9N&<Y+U'\'47@#"<T]X> ]I-<\MU,,
MZO%W] @&<!]V]"BV[#S2M'&2,[H?[&_/]G=AQ^O[+"\%S&6M-PE@SU=9<03
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M0.PX36%.;N/,,Y%XAG-W.EM*VFM/M,Q&S=4']I8W'[D#I#.RE#V-36;SY"H
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M5%)T&%?8G"R"\DE^B%1#.P1%J"LW[A!QNKY**>YTYQ#+#6G*5LCZ9"BWC-K
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M;5!&>SZY+MG21GE&LC">4GR_(U;=!4V'"Y3256V,F 'H[\^2.$O#";NXR&Y
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M;(( ,V<ZVP/([F7),/ VIC+#Y*P5L2VW%8C0Q\9L$*QH<A# 3&23>QA"<,3
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MFD+<9O?,(L%?;?6^3>1P7022]P)P@=Q*<1D(G3-'[ 4/(4%__W]02P,$%
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M[NUC\62E.7#1Z0JT0;21.T<LLG'3\8;PQ[IJ*]J$L1?[(=$*+J80_/M1$>
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M,/2/CCX%;JH<BJDS9IIQ!%4)FKD)DM(#XB.;R3YJ];1O0M;-4#3@( O(7E$
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M@'/R/5E9#G8/()_LSG=K/OR!9[5F )-NT]P^P![9 B8I<S4',NQ3N(),7D"
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M&D=A9'L.H<VOB!;)0LZ$ "+[\0Q1I3'Y^:7O)5%8L>W2J.&S-EX7]6?3K_3
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H<RTR,#$V,#DS,%]P<F4N>&UL4$L%!@     &  8 B@$  )J! 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
